Anti-Cancer Combination Treatment and Kit-of-Parts

ABSTRACT

In one aspect the present invention relates to pharmaceutical kits of parts suitable for treating neoplastic diseases such as cancer comprising an anti-cancer medicament, a Basidiomycete bioactive agent in solid or liquid form, and, optionally instructions for a dosing regime.

All patent and non-patent references cited in the present applicationare hereby incorporated by reference in their entirety.

TECHNICAL FIELD OF THE INVENTION

The present invention relates to pharmaceutical kits of parts suitablefor treating neoplastic diseases such as cancer.

BACKGROUND OF THE INVENTION

Medicinal Mushrooms

Mushrooms have been used for medicinal purposes for centuries in manycultures. Several members of the Basidiomycete mushroom class, such asfor e.g. members of the Agaricus mushroom family have been used formedicinal and health-related purposes.

A number of researchers have suggested anticancer, antitumour orantimutagenic properties of e.g. Agaricus mushrooms (Kimura, Y: In Vivo2005, Vol 19, Iss 1, p37-60; Kim et al., Food Science and Biotechnology2004, vol 13, Iss 6, p852; Kim et al., Food Science and Biotechnology2004, vol 13, Iss 3, p 347-352; Guterrez et al., Texicology in Vitro2004, Vol 18, lss 3, p 301-309; Ribeiro et al., Mutation ResearchReviews in Mutation Research 2003, Vol 54, Iss 2-3, p 195.201; Pinheiroet al., Food and Chemical Toxicology 2003, Vol. 41, Iss 11, p 1543-1550;(Inhibiting tumour growth) Lee et al., Experimental Animals 2003, Vol.52, p371-375; Luiz et al., Mutation research—Fundamental and MolecularMechanisms of Mutagenesis 2003, Vol. 528, Iss 1-2, p 75-79; Bellini etal., Texicology in Vitro 2003, Vol 17, Iss 4, p465-469; Ashida et al.,Food Factors in Health Promotion and Disease Prevention 2003, Vol. 851,p235-248; (antigenotoxic effect) de Oliveira et al., Food and ChemicalToxicology 2002, Vol. 40, Iss 12, p1775-1780; Kuo et al., Journal ofLaboratory and clinical medicine 2002, Vol. 140, Iss 3, p 176-187;Oshiman et al., Planta Medica 2002, Vol. 68, lss 7, p 610-614; Meloni etal., Mutation Research—Genetic Toxicology and Environmental Mutagenesis2001, Vol. 496, Iss 1-2, p 5-13; Osaki et al., Yakugaku Zasshi—Journalof the Pharmaceutical Society of Japan 1994, Vol. 114, Iss 5, p342-350;Itoh et al., Japanese Journal of Pharmacology 1994, Vol. 66, Iss 2, p265-271.; Ito et al., Anticancer Research 1997, Vol. 17, Iss 1A, p277-284; Fujimiya et al., Cancer Immunology Immunotherapy 1998, Vol. 46,Iss 3, p 147-159; Fujimiya et al., Journal of the Japanese Society forFood Science and Technology—Nippon Shokuhin Kagaku Kogaku Kaishi 1998.,Vol 45, Iss 4, p 246-252; Ebina et al., Biotherapy 1998, Vol. 11, Iss 4,p 259-265; Fujimiya et al., Anticancer Research 1999, Vol. 19, Iss 1A, p113-118; Mizuno et al., Biochemistry and Molecular Biology International1999, Vol. 47, Iss 4, p 707-717; Takaku et al., Journal of Nutrition2001, Vol. 131, Iss 5, p 1409-1413; Ohno et al., Biological andPharmaceutical Bulletin 2001, Vol. 24, Iss 7, p 820-828; Delmanto etal., Mutation Research—Genetic Toxicology and Environmental Mutagenesis2001, Vol. 496, Iss 1-2, p 15-21).

There is however a surprising paucity of epidemiologic and experimentalstudies that address the biologic activities of mushrooms after oraladministration to animals or humans (Borchers et al., “Mushrooms, Tumorsand Immunity: an update”, Experimental Biology and Medicine229:393-406).

SUMMARY OF THE INVENTION

The present invention relates to a pharmaceutical kit of partscomprising

-   -   a) an anti-cancer medicament,    -   b) a Basidiomycete bioactive agent in solid or liquid form, and,        optionally    -   c) instructions for a dosage regime for said kits of parts.

In another aspect, the present invention relates to a method oftreatment comprising the step of administering said pharmaceutical kitof parts simultaneously (optionally in a co-formulation) or sequentiallyaccording to a set dosage regime.

Another aspect of the present invention relates to use of a medicament,such as an anti-cancer medicament, and a Basidiomycete bioactive agentin solid or liquid form in the manufacture of a kit of parts for thetreatment of an individual in need thereof, such as an individualsuffering from, or at risk of suffering from, a neoplastic disease suchas cancer.

Another aspect of the present invention relates to a method forenhancing a therapeutic effect of an anti-cancer drug, comprisingco-administering (simultaneously or in any order) with said anti-cancerdrug (such as any of the anti-cancer drugs described herein) aBasidiomycete bioactive agent (such as any of the Basidiomycetebioactive agents described herein).

Bioactive agents produced by Agaricus sp. (any basidiomycetous fungalspecies of the genus agaricus of the family agaricaceae and the orderagaricales and the subclass agaricomycetidae), Schizophyllum sp. (anybasidiomycetous fungal species of the genus schizophyllum of the familyschizophyllaceae and the order agaricales and the subclassagaricomycetidae), Lentinus sp. (any basidiomycetous fungal species ofthe genus lentinus of the family polyporaceae and the order polyporalesand the subclass agaricomycetidae (L. edodes is also termed Lentinulaedodes, which is placed in the family Marasmiaceae, in the orderAgaricales and the subclass agaricomycetidae)), Trametes sp. (anybasidiomycetous fungal species of the genus trametes of the familypolyporaceae and the order polyporales and the subclassagaricomycetidae), Ganoderma sp. (any basidiomycetous fungal species ofthe genus ganoderma of the family ganodermataceae and the orderpolyporales and the subclass agaricomycetidae), and Grifola sp. (anybasidiomycetous fungal species of the genus grifola of the familymeripilaceae and the order polyporales and the subclassagaricomycetidae) are preferred in one embodiment of the presentinvention.

FIGURE LEGENDS

FIG. 1: bacteriostatic effect of different dilutions (1:10, 1:20 and1:40) of the bioactive agent obtained by the method as described inexample 1 on E. coli K12. A culture without the bioactive agent was usedas control (Ref). The experiment is described in detail in Example 4.

FIG. 2: cancer-cell specific cytotoxicity of different concentrations ofLentinex—comprising an embodiment of the bioactive agent of the presentinvention—on 4 different human and mouse cancer cell lines. The MRC-5cell line from normal human fetal lung fibroblasts was used as control.The experiment is described in detail in Example 5.

DEFINITIONS

Mycelium: Mass of hyphae constituting the body (thallus) of the fungus.Agaricus sp.: A basidiomycetous fungal species of the genus agaricus ofthe family agaricaceae and the order agaricales and the subclassagaricomycetidae.

Schizophyllum sp.: A basidiomycetous fungal species of the genusschizophyllum of the family schizophyllaceae and the order agaricalesand the subclass agaricomycetidae.

Lentinus sp.: A basidiomycetous fungal species of the genus lentinus ofthe family polyporaceae and the order polyporales and the subclassagaricomycetidae. L. edodes is also termed Lentinula edodes, which isplaced in the family Marasmiaceae, in the order Agaricales and thesubclass agaricomycetidae.

Trametes sp.: A basidiomycetous fungal species of the genus trametes ofthe family polyporaceae and the order polyporales and the subclassagaricomycetidae.

Ganoderma sp.: A basidiomycetous fungal species of the genus ganodermaof the family ganodermataceae and the order polyporales and the subclassagaricomycetidae.

Grifola sp.: A basidiomycetous fungal species of the genus grifola ofthe family meripilaceae and the order polyporales and the subclassagaricomycetidae.

Fruiting bodies or fruit bodies: Any one of a variety of complex,spore-bearing fungal structures.

Basidiomycete cell: A cell from a fungus of the class Basidiomycete ofthe Phylum Basidiomycota, wherein the cell can be derived from any partof the fungus, such as fruiting body, hyphae, spores and mycelium. TheBasidiomycete cell can be a single hyphae, spores, aggregates ofmycelium, or partly differentiated mycelium, or comprised in fungalmycelium.

Bioactive agent: Any agent, drug, compound, composition of matter ormixture which provides some pharmacologic, often beneficial, effect thatcan be demonstrated in-vivo or in vitro. As used herein, this termfurther includes any physiologically or pharmacologically activesubstance that produces a localized or systemic effect in a patient.Further examples of bioactive agents include, but are not limited to,agents comprising or consisting of an oligosaccharide, agents comprisingor consisting of a polysaccharide, agents comprising or consisting of anoptionally glycosylated peptide, agents comprising or consisting of anoptionally glycosylated polypeptide, agents comprising or consisting ofan oligonucleotide, agents comprising or consisting of a polynucleotide,agents comprising or consisting of a lipid, agents comprising orconsisting of a fatty acid, agents comprising or consisting of a fattyacid ester and agents comprising or consisting of secondary metabolites.

Anti-cancer medicament: a medicament comprising an anti-cancer activityor anti-neoplastic activity, i.e. effective in treating or preventing acancer. Often the efficacy is tested in a clinical trial to test whethera new treatment has an anti-cancer effect, for example, whether itshrinks a tumour or improves blood test results, and whether it worksagainst a certain type of cancer.

Bioactive agents comprising an immune stimulating activity: Agentseffective in the stimulation or restoration of the ability of the immunesystem to fight infection and disease. Also included are agents capableof reducing or eliminating any side effect(s) that may be caused by somecancer treatments.

Neoplasm: tissue composed of cells that grow in an abnormal way.Neoplasms may be benign or malignant (metastatic). Benign tumors remainlocalized as a discrete mass. A system has been devised to classifymalignant tissue according to the degree of malignancy, from grade 1,barely malignant, to grade 4, highly malignant. One preferred neoplasmtype treated is a cancer. An individual suffering from a neoplasticdisease is defined as having at least one neoplasm. Neoplastic diseasesas used herein includes any abnormal and uncontrolled cell growth(mitosis) that results in the production of a tumour (i.e. a neoplasm).

Kit of parts: a kit of parts as used in the present invention providesthe Basidiomycete bioactive agent and anti-cancer medicament foradministration in combination. By the phrase “in combination” withanother substance(s) and/or therapeutic method(s) is meant herein theBasidiomycete bioactive agent is administered to the individual thustreated before, during (including concurrently with

-   -   preferably co-formulated with) and/or after treatment of an        individual with the anti-cancer medicament. The combined active        substances may be used for simultaneous, sequential or separate        administration. In all cases, it is preferred that any of the        herein-mentioned medicaments and bioactive agents are        administered in pharmaceutically effective amounts, i.e. an        administration involving a total amount of each active component        of the medicament or pharmaceutical composition or method that        is sufficient to show a meaningful patient benefit. The        formulations may conveniently be presented in unit dosage form        by methods known to those skilled in the art. It is preferred        that the kit may for example contain the active compounds in        dosage forms for administration. A dosage form contains a        sufficient amount of one or more of the active compound(s) such        that a desirable effect can be obtained when administered to a        subject. Thus, it is preferred that the medical packaging        comprises an amount of dosage units corresponding to the        relevant dosage regimen. Accordingly, in one embodiment, the        medical packaging comprises a pharmaceutical composition        comprising the compounds as defined above or a pharmaceutically        acceptable salt thereof and pharmaceutically acceptable        carriers, vehicles and/or excipients, said packaging having from        7 to 21 dosage units, or multiples thereof, thereby having        dosage units for one week of administration or several weeks of        administration. The medical packaging may be in any suitable        form    -   for example for oral or parenteral administration. In another        preferred embodiment the packaging is in the form of a        cartridge, such as a cartridge for an injection pen, the        injection pen being such as an injection pen known from insulin        treatment. Preferably, the kit-of-parts contains instructions        indicating the use of the dosage form to achieve a desirable        affect and the amount of dosage form to be taken over a        specified time period. Accordingly, in one embodiment the        medical packaging comprises instructions for administering the        pharmaceutical composition. It is envisaged that at least one        (such as 2 or 3) anti-cancer medicament(s) and at least one        (such as 2 or 3) Basidiomycete bioactive agents may be used for        the manufacture of any of the “kit of parts” described herein        for administration to an individual in need thereof. Preferably,        said kit of parts is for treatment or prophylaxis of a        neoplastic disease, such as cancer.

Polysaccharides: the term “polysaccharide” as used herein coverspolysaccharides as well as polysaccharides containing and/or covalentlylinked to peptides, polypeptides or the like, such asproteopolysaccharides.

Polysaccharides comprising monosaccharides: A polysaccharide is said tocomprise monosaccharides, wherein said monosaccharides are covalentlylinked to form said polysaccharide. Hydrolysing a polysaccharide willyield the monosaccharides that formed said polysaccharide in free form.The monosaccharide content of a polysaccharide can thus be determined byhydrolysing the polysaccharide and measuring the presence of individualmonosaccharides. The monosaccharide content of a mixture ofpolysaccharides is determined by determining the monosaccharide contentof the entire mixture.

Polypeptide: the term “polypeptide” as used herein covers proteins,peptides and polypeptides, wherein said proteins, peptides orpolypeptides may or may not have been post-translationally modified.Post-translational modification may for example be phosphorylation,methylation, glucosylation,

Ratio: A polysaccharide or a mixture of polysaccharides are said tocomprise e.g. galactose, mannose, and glucose in a given ratio, whenhydrolysation of said polysaccharide or said mixture of polysaccharideyields galactose, mannose and glucose in said given ratio. Galactose,mannose, and glucose in the ratio 1:a to b:c to d, means that for everypart galactose, mannose is present in the range of a to b parts andglucose is present in the range of c to d parts, wherein a, b, c and dindicates numerical values. Thus, by way of example a polysaccharidemixture comprising galactose, mannose, and glucose in the ratio 1:5 to25:1 to 50, means that for every part galactose, the polysaccharidemixture comprises in the range of 5 to 25 parts mannose and in the rangeif 1 to 50 part glucose

DETAILED DESCRIPTION OF THE INVENTION Anti-Cancer Medicament

In one aspect, the present invention relates to a kit of partscomprising:

-   -   a) an anti-cancer medicament,    -   b) a Basidiomycete bioactive agent in solid or liquid form, and,        optionally    -   c) instructions for a dosing regime.

Said anti-cancer medicament may be any medicament with an anti-cancereffect in the individual thus treated.

Thus, said anti-cancer medicament may for example be selected from thegroup consisting of:

-   -   Aldesleukin/Proleukin (Chiron Corp)    -   Alemtuzumab/Campath (Millennium and ILEX Partners, LP)    -   alitretinoin/Panretin (Ligand Pharmaceuticals)    -   allopurinol/Zyloprim (GlaxoSmithKline)    -   altretamine/Hexalen (US Bioscience)    -   amifostine/Ethyol (US Bioscience)    -   anastrozole/Arimidex (AstraZeneca)    -   arsenic trioxide/Trisenox (Cell Therapeutic)    -   Asparaginase/Elspar (Merck & Co, Inc)    -   BCG Live/TICE BCG (Organon Teknika Corp)    -   bexarotene capsules/Targretin (Ligand Pharmaceuticals)    -   bleomycin/Blenoxane (Bristol-Myers Squibb)    -   busulfan/Busulfex (GlaxoSmithKline)    -   calusterone/Methosarb (Pharmacia & Upjohn Company)    -   capecitabine/Xeloda (Roche)    -   carboplatin/Paraplatin (Bristol-Myers Squibb)    -   carmustine/BCNU, BiCNU (Bristol-Myers Squibb)    -   carmustine with Polifeprosan 20 Implant/Gliadel Wafer (Guilford    -   Pharmaceuticals Inc.)    -   celecoxib/Celebrex (Searle)    -   chlorambucil/Leukeran (GlaxoSmithKline)    -   cisplatin/Platinol (Bristol-Myers Squibb)    -   cladribine/Leustatin, 2-CdA (R. W. Johnson Pharmaceutical        Research Institute)    -   cyclophosphamide Cytoxan/Neosar (Bristol-Myers Squibb)    -   cytarabine/Cytosar-U (Pharmacia & Upjohn Company)    -   dacarbazine/DTIC-Dome (Bayer)    -   dactinomycin/actinomycin D Cosmegen (Merck)    -   Darbepoetin alfa/Aranesp (Amgen, Inc)    -   daunorubicin/daunomycin/Daunorubicin (Bedford Labs)    -   daunorubicin/daunomycin/Cerubidine (Wyeth Ayerst)    -   Denileukin/diftitox/Ontak (Seragen, Inc)    -   dexrazoxane/Zinecard (Pharmacia & Upjohn Company)    -   docetaxel/Taxotere (Aventis Pharmaceutical)    -   doxorubicin Adriamycin/Rubex (Pharmacia & Upjohn Company)    -   DROMOSTANOLONE PROPIONATE/MASTERONE INJECTION (SYNTEX)    -   Elliott's B Solution (Orphan Medical, Inc)    -   epirubicin/Ellence (Pharmacia & Upjohn Company)    -   etoposide phosphate (Bristol-Myers Squibb)    -   etoposide/VP-16/Vepesid (Bristol-Myers Squibb)    -   exemestane/Aromasin (Pharmacia & Upjohn Company)    -   Filgrastim/Neupogen (Amgen, Inc)    -   floxuridine/FUDR (Roche)    -   fludarabine/Fludara (Berlex Laboratories Inc.)    -   fluorouracil/5-FU/Adrucil (ICN Puerto Rico)    -   fulvestrant/Faslodex (IPR)    -   gemcitabine/Gemzar (Eli Lilly)    -   gemtuzumab/ozogamicin/Mylotarg (Wyeth Ayerst)    -   goserelin acetate/Zoladex Implant (AstraZeneca Pharmaceuticals)    -   hydroxyurea/Hydrea (Bristol-Myers Squibb)    -   Ibritumomab Tiuxetan/Zevalin (IDEC Pharmaceuticals Corp)    -   idarubicin/Idamycin (Adria Laboratories)    -   ifosfamide/IFEX (Bristol-Myers Squibb)    -   imatinib mesylate/Gleevec (Novartis)    -   Interferon alfa-2a/Roferon-A (Hoffmann-La Roche Inc)    -   Interferon alfa-2b/Intron A (Schering Corp)    -   irinotecan/Camptosar (Pharmacia & Upjohn Company)    -   letrozole/Femara (Novartis)    -   leucovorin Wellcovorin/Leucovorin (Immunex Corporation)    -   levamisole/Ergamisol (Janssen Research Foundation)    -   lomustine/CCNU/CeeBU (Bristol-Myers Squibb)    -   meclorethamine/nitrogen mustard/Mustargen (Merck)    -   megestrol acetate/Megace (Bristol-Myers Squibb)    -   melphalan/L-PAM/Alkeran (GlaxoSmithKline)    -   mercaptopurine/6-MP Purinethol (GlaxoSmithKline)    -   mesna/Mesnex (Asta Medica)    -   methotrexate (Lederle Laboratories)    -   methoxsalen/Uvadex (Therakos)    -   mitomycin C/Mutamycin (Bristol-Myers Squibb)    -   mitomycin C/Mitozytrex (Supergen)    -   mitotane/Lysodren (Bristol-Myers Squibb)    -   mitoxantrone/Novantrone (Lederle Laboratories)    -   nandrolone phenpropionate/Durabolin-50 (Organon)    -   Nofetumomab/Verluma (Boehringer Ingelheim Pharma KG (formerly        Dr. Karl    -   Thomae GmbH))    -   Oprelvekin/Neumega (Genetics Institute)    -   oxaliplatin/Eloxatin (Sanofi Synthelabo)    -   paclitaxel/Taxol (Bristol-Myers Squibb)    -   pamidronate/Aredia (Novartis)    -   pegademase/Adagen (Pegademase Bovine) (Enzon)    -   Pegaspargase/Oncaspar (Enzon, Inc)    -   Pegfilgrastim/Neulasta (Amgen, Inc)    -   pentostatin/Nipent (Parke-Davis Pharmaceutical Co.)    -   pipobroman/Vercyte (Abbott Labs)    -   plicamycin/mithramycin/Mithracin (Pfizer Labs)    -   porfimer sodium/Photofrin (QLT Phototherapeutics Inc.)    -   procarbazine/Matulane (Sigma Tau Pharms)    -   quinacrine/Atabrine (Abbott Labs)    -   Rasburicase/Elitek (Sanofi-Synthelabo, Inc)    -   Rituximab/Rituxan (Genentech, Inc)    -   Sargramostim/Prokine (Immunex Corp)    -   streptozocin/Zanosar (Pharmacia & Upjohn Company)    -   talc/Scierosol (Bryan)    -   tamoxifen/Nolvadex (AstraZeneca Pharmaceuticals)    -   temozolomide/Temodar (Schering)    -   teniposideNM-26/Vumon (Bristol-Myers Squibb)    -   testolactone/Teslac (Bristol-Myers Squibb)    -   thioguanine/6-TG/Thioguanine (GlaxoSmithKline)    -   thiotepa/Thioplex (Lederle Laboratories)    -   topotecan/Hycamtin (GlaxoSmithKline)    -   topotecan/Hycamtin (GlaxoSmithKline)    -   toremifene/Fareston (Orion Corp)    -   Tositumomab/Bexxar (Corixa Corporation)    -   Trastuzumab/Herceptin (Genentech, Inc)    -   tretinoin/ATRA/Vesanoid (Roche)    -   Uracil Mustard (Roberts Labs)    -   valrubicin/Valstar (Medeva)    -   vinblastine/Velban (Eli Lilly)    -   vincristine/Oncovin (Eli Lilly)    -   vinorelbine/Navelbine (GlaxoSmithKline), and    -   zoledronate/Zometa (Novartis)

In a preferred embodiment of the present invention, said anti-cancerdrug is Aldesleukin/Proleukin (Chiron Corp)

In another preferred embodiment of the present invention, saidanti-cancer drug is Alemtuzumab/Campath (Millennium and ILEX Partners,LP), such as for the treatment or prophylaxis of B-cell chroniclymphocytic leukaemia (B-CLL).

In another preferred embodiment of the present invention, saidanti-cancer drug is alitretinoin/Panretin (Ligand Pharmaceuticals), suchas for the treatment or prophylaxis of cutaneous lesions in sarcomapatients, such as in patients suffering from AIDS-related Kaposi'ssarcoma.

In another preferred embodiment of the present invention, saidanti-cancer drug is allopurinol/Zyloprim (GlaxoSmithKline), such as forthe treatment of patients with leukaemia and/or lymphoma and/or one ormore solid tumor malignancies who are receiving cancer therapy whichcauses elevations of serum and urinary uric acid levels.

In another preferred embodiment of the present invention, saidanti-cancer drug is altretamine/Hexalen (US Bioscience), such as fortreatment or prophylaxis of ovarian cancer.

In another preferred embodiment of the present invention, saidanti-cancer drug is amifostine/Ethyol (US Bioscience), such as fortreatment or prophylaxis of post-radiation xerostomia for e.g. head andneck cancer and/or ovarian cancer (preferably advanced) and/or non-smallcell lung cancer.

In another preferred embodiment of the present invention, saidanti-cancer drug is anastrozole/Arimidex (AstraZeneca), such as for thetreatment of breast cancer, for example hormone receptor positive earlybreast cancer, advanced breast cancer, locally advanced or metastaticbreast cancer.

In another preferred embodiment of the present invention, saidanti-cancer drug is trioxide/Trisenox (Cell Therapeutic).

In another preferred embodiment of the present invention, saidanti-cancer drug is Asparaginase/Elspar (Merck & Co, Inc), such as forthe treatment of pediatric patients.

In another preferred embodiment of the present invention, saidanti-cancer drug is Live/TICE BCG (Organon Teknika Corp).

In another preferred embodiment of the present invention, saidanti-cancer drug is bexarotene capsules/Targretin (LigandPharmaceuticals), such as for treatment of cutaneous manifestations ofcutaneous T-cell lymphoma, preferably via oral administration.

In another preferred embodiment of the present invention, saidanti-cancer drug is bleomycin/Blenoxane (Bristol-Myers Squibb), such asfor treatment of malignant pleural effusion (MPE) and prevention ofrecurrent pleural effusions.

In another preferred embodiment of the present invention, saidanti-cancer drug is busulfan/Busulfex (GlaxoSmithKline), such as priorto hematopoietic progenitor cell transplantation for chronic myelogenousleukemia, preferably via oral administration.

In another preferred embodiment of the present invention, saidanti-cancer drug is calusterone/Methosarb (Pharmacia & Upjohn Company).

In another preferred embodiment of the present invention, saidanti-cancer drug is capecitabine/Xeloda (Roche), such as for treatmentof breast cancer, preferably metastatic breast cancer, or colorectalcarcinoma, preferably metastatic colorectal carcinoma.

In another preferred embodiment of the present invention, saidanti-cancer drug is Carboplatin/Paraplatin (Bristol-Myers Squibb), suchas for treatment of ovarian carcinoma.

In another preferred embodiment of the present invention, saidanti-cancer drug is carmustine/BCNU, BiCNU (Bristol-Myers Squibb)

In another preferred embodiment of the present invention, saidanti-cancer drug is carmustine with Polifeprosan 20 Implant/GliadelWafer (Guilford Pharmaceuticals Inc.), such as to prolong survival inpatients with recurrent glioblastoma multiforme who qualify for surgery.

In another preferred embodiment of the present invention, saidanti-cancer drug is celecoxib/Celebrex (Searle), such as for treatmentof familial adenomatous polyposis.

In another preferred embodiment of the present invention, saidanti-cancer drug is chlorambucil/Leukeran (GlaxoSmithKline), such as fortreatment of chronic lymphocytic leukaemia.

In another preferred embodiment of the present invention, saidanti-cancer drug is cisplatin/Platinol (Bristol-Myers Squibb), such asfor treatment of ovarian tumour preferably metastatic ovarian tumour,testicular tumour, preferably testicular tumour, transitional cellbladder cancer.

In another preferred embodiment of the present invention, saidanti-cancer drug is cladribine/Leustatin, 2-CdA (R. W. JohnsonPharmaceutical Research Institute), such as for treatement of activehairy cell leukaemia.

In another preferred embodiment of the present invention, saidanti-cancer drug is cyclophosphamide Cytoxan/Neosar (Bristol-MyersSquibb)

In another preferred embodiment of the present invention, saidanti-cancer drug is cytarabine/Cytosar-U (Pharmacia & Upjohn Company)

In another preferred embodiment of the present invention, saidanti-cancer drug is dacarbazine/DTIC-Dome (Bayer).

In another preferred embodiment of the present invention, saidanti-cancer drug is dactinomycin/actinomycin D Cosmegen (Merck)

In another preferred embodiment of the present invention, saidanti-cancer drug is Darbepoetin alfa/Aranesp (Amgen, Inc), such as fortreatment of anemia associated with chemotherapeutic regimes.

In another preferred embodiment of the present invention, saidanti-cancer drug is daunorubicin/daunomycin/Daunorubicin (Bedford Labs),such as in liposomal form, for example for the treatment of HIV-relatedKaposi's sarcoma.

In another preferred embodiment of the present invention, saidanti-cancer drug is daunorubicin/daunomycin/Cerubidine (Wyeth Ayerst),such as for treatment of leukaemia.

In another preferred embodiment of the present invention, saidanti-cancer drug is Denileukin/diftitox/Ontak (Seragen, Inc), such asfor treatment of T-cell lymphoma, preferably of individuals whosemalignant cells express the CDC25 component of the IL-2 receptor.

In another preferred embodiment of the present invention, saidanti-cancer drug is dexrazoxane/Zinecard (Pharmacia & Upjohn Company),such as to aid in reducing the severity of cardiomyopathy associatedwith doxorubicin administration in women with metastatic breast cancer.

In another preferred embodiment of the present invention, saidanti-cancer drug is docetaxel/Taxotere (Aventis Pharmaceutical), such asfor treatment of breast cancer, preferably locally advanced ormetastatic breast cancer, or non-small cell lung cancer, preferablylocally advanced or metastatic non-small cell lung cancer.

In another preferred embodiment of the present invention, saidanti-cancer drug is doxorubicin/Adriamycin Rubex (Pharmacia & UpjohnCompany), such as for treatment of AIDS-related Kaposi's sarcoma ormetastatic carcinoma of the ovary.

In another preferred embodiment of the present invention, saidanti-cancer drug is Dromostanolone propionate/Masterone injection(SYNTEX).

In another preferred embodiment of the present invention, saidanti-cancer drug is Elliott's B Solution (Orphan Medical, Inc), such asfor treatment or prophylaxis of miningeal leukaemia or lymphocyticlymphoma.

In another preferred embodiment of the present invention, saidanti-cancer drug is Epirubicin/Ellence (Pharmacia & Upjohn Company),such as for treatment or prophylaxis of breast cancer.

In another preferred embodiment of the present invention, saidanti-cancer drug is etoposide phosphate (Bristol-Myers Squibb), such asfor treatment or prophylaxis of refractory testicular tumours, smallcell lung cancer.

In another preferred embodiment of the present invention, saidanti-cancer drug is etoposide/VP-16/Vepesid (Bristol-Myers Squibb), suchas for treatment or prophylaxis of refractory testicular tumours, smallcell lung cancer.

In another preferred embodiment of the present invention, saidanti-cancer drug is exemestane/Aromasin (Pharmacia & Upjohn Company),such as for treatment or prophylaxis of breast cancer, preferably fortreatment of advanced breast cancer.

In another preferred embodiment of the present invention, saidanti-cancer drug is Filgrastim/Neupogen (Amgen, Inc), such as fortreatment of nonmyeloid malignancies undergoing myeloablativechemotherapy followed by marrow transplantation.

In another preferred embodiment of the present invention, saidanti-cancer drug is floxuridine/FUDR (Roche)

In another preferred embodiment of the present invention, saidanti-cancer drug is fludarabine/Fludara (Berlex Laboratories Inc.), suchas for treatment or prophylaxis of B-cell lymphocytic leukaemia.

In another preferred embodiment of the present invention, saidanti-cancer drug is fluorouracil/5-FU/Adrucil (ICN Puerto Rico), such asto prolong survival.

In another preferred embodiment of the present invention, saidanti-cancer drug is fulvestrant/Faslodex (IPR), such as for treatment orprophylaxis of breast cancer, preferably in post-menopausal women.

In another preferred embodiment of the present invention, saidanti-cancer drug is gemcitabine/Gemzar (Eli Lilly), such as fortreatment or prophylaxis of adenocarcinoma of the pancreas or non-smallcell lung cancer, preferably locally advanced or metastaticadenocarcinoma of the pancreas or non-small cell lung cancer.

In another preferred embodiment of the present invention, saidanti-cancer drug is gemtuzumab/ozogamicin/Mylotarg (Wyeth Ayerst), suchas for treatment or prophylaxis of CD33 positive acute myeloid leukaemiain patients who are preferably 60 years of age or older.

In another preferred embodiment of the present invention, saidanti-cancer drug is goserelin acetate/Zoladex Implant (AstraZenecaPharmaceuticals), such as for treatment or prophylaxis of breast cancer,preferably advanced stage breast cancer.

In another preferred embodiment of the present invention, saidanti-cancer drug is hydroxyurea/Hydrea (Bristol-Myers Squibb).

In another preferred embodiment of the present invention, saidanti-cancer drug is Ibritumomab Tiuxetan/Zevalin (IDEC PharmaceuticalsCorp), such as for treatment or prophylaxis of non-Hodgkin's lymphoma,for example patients with Rituximab refractory follicular non-Hodgkin'slymphoma.

In another preferred embodiment of the present invention, saidanti-cancer drug is idarubicin/Idamycin (Adria Laboratories), such asfor treatment or prophylaxis of acute myeloid leukaemia, for example inadults.

In another preferred embodiment of the present invention, saidanti-cancer drug is ifosfamide/IFEX (Bristol-Myers Squibb), such as fortreatment of germ cell testicular cancer.

In another preferred embodiment of the present invention, saidanti-cancer drug is imatinib mesylate/Gleevec (Novartis), such as fortreatment of chronic myelogeneous leukaemia or gastrointestinal stromaltumours.

In another preferred embodiment of the present invention, saidanti-cancer drug is Interferon alfa-2a/Roferon-A (Hoffmann-La RocheInc), such as for treatment or prophylaxis of malignant melanoma,Non-Hodgkin's Lymphoma, condylomata acuminate, hairy cell leukaemia orAIDS-related Kaposi's sarcoma.

In another preferred embodiment of the present invention, saidanti-cancer drug is Interferon alfa-2b/Intron A (Schering Corp).

In another preferred embodiment of the present invention, saidanti-cancer drug is irinotecan/Camptosar (Pharmacia & Upjohn Company),such as for treatment or prophylaxis of carcinoma of the colon orrectum, preferably metastatic carcinoma of the colon or rectum.

In another preferred embodiment of the present invention, saidanti-cancer drug is letrozole/Femara (Novartis), carcinoma of the colonor rectum, such as for treatment or prophylaxis of breast cancer,preferably in post-menopausal women.

In another preferred embodiment of the present invention, saidanti-cancer drug is Leucovorin/Wellcovorin (Immunex Corporation), suchas for treatment or prophylaxis of colorectal cancer, preferablyadvanced colorectal cancer.

In another preferred embodiment of the present invention, saidanti-cancer drug is levamisole/Ergamisol (Janssen Research Foundation),such as for treatment or prophylaxis of colon cancer, preferably aftersurgical resection.

In another preferred embodiment of the present invention, saidanti-cancer drug is lomustine/CCNU/CeeBU (Bristol-Myers Squibb).

In another preferred embodiment of the present invention, saidanti-cancer drug is meclorethamine/nitrogen mustard/Mustargen (Merck)

In another preferred embodiment of the present invention, saidanti-cancer drug is megestrol acetate/Megace (Bristol-Myers Squibb)

In another preferred embodiment of the present invention, saidanti-cancer drug is melphalan/L-PAM/Alkeran (GlaxoSmithKline), such asfor treatment or prophylaxis of multiple myeloma.

In another preferred embodiment of the present invention, saidanti-cancer drug is mercaptopurine/6-MP Purinethol (GlaxoSmithKline)

In another preferred embodiment of the present invention, saidanti-cancer drug is mesna/Mesnex (Asta Medica) such as for treatment orprophylaxis of ifosfamide-indeuced hemorrhagic cystitis.

In another preferred embodiment of the present invention, saidanti-cancer drug is methotrexate (Lederle Laboratories), such as fortreatment or prophylaxis of osteosarcoma.

In another preferred embodiment of the present invention, saidanti-cancer drug is methoxsalen/Uvadex (Therakos), such as for treatmentor prophylaxis of skin manifestations of cutaneous T-cell lymphoma(CTCL).

In another preferred embodiment of the present invention, saidanti-cancer drug is mitomycin C/Mutamycin (Bristol-Myers Squibb).

In another preferred embodiment of the present invention, saidanti-cancer drug is mitomycin C/Mitozytrex (Supergen), such as fortreatment or prophylaxis of disseminated adenocarcinoma of the stomachor pancreas.

In another preferred embodiment of the present invention, saidanti-cancer drug is mitotane/Lysodren (Bristol-Myers Squibb)

In another preferred embodiment of the present invention, saidanti-cancer drug is mitoxantrone/Novantrone (Lederle Laboratories), suchas for treatment or prophylaxis of prostrate cancer or acutenonlymphocytic leukaemia (ANLL) in adults.

In another preferred embodiment of the present invention, saidanti-cancer drug is nandrolone phenpropionate/Durabolin-50 (Organon).

In another preferred embodiment of the present invention, saidanti-cancer drug is Nofetumomab/Verluma (Boehringer Ingelheim Pharma KG(formerly Dr. Karl Tomae GmbH).

In another preferred embodiment of the present invention, saidanti-cancer drug is doxorubicin/Adriamycin PFS.

In another preferred embodiment of the present invention, saidanti-cancer drug is Oprelvekin/Neumega (Genetics Institute), preferablyadministered after myelosuppressive chemotherapy in patients withnonmyeloid malignancies

In another preferred embodiment of the present invention, saidanti-cancer drug is oxaliplatin/Eloxatin (Sanofi Synthelabo), such asfor treatment or prophylaxis of carcinoma of the colon, preferablymetastatic carcinoma of the colon.

In another preferred embodiment of the present invention, saidanti-cancer drug is paclitaxel/Taxol/Paxene (Bristol-Myers Squibb), suchas for treatment or prophylaxis of advanced AIDS-related Kaposi'ssarcoma, breast cancer, metastatic breast cancer, carcinoma of theovary, AIDS-related Kaposi's sarcoma, metastatic carcinoma of the ovary,non-small cell lung cancer or node-positive breast cancer.

In another preferred embodiment of the present invention, saidanti-cancer drug is pamidronate/Aredia (Novartis), such as for treatmentor prophylaxis of osteolytic bone metastases of breast cancer.

In another preferred embodiment of the present invention, saidanti-cancer drug is pegademase/Adagen (Pegademase Bovine) (Enzon).

In another preferred embodiment of the present invention, saidanti-cancer drug is Pegaspargase/Oncaspar (Enzon, Inc).

In another preferred embodiment of the present invention, saidanti-cancer drug is Pegfilgrastim/Neulasta (Amgen, Inc), such as fortreatment or prophylaxis of non-myeloid malignancies.

In another preferred embodiment of the present invention, saidanti-cancer drug is pentostatin/Nipent (Parke-Davis Pharmaceutical Co.),such as for treatment or prophylaxis of hairy cell leukaemia, forexample alpha interferon refractory hairy cell leukaemia.

In another preferred embodiment of the present invention, saidanti-cancer drug is pipobroman/Vercyte (Abbott Labs)

In another preferred embodiment of the present invention, saidanti-cancer drug is plicamycin/mithramycin/Mithracin (Pfizer Labs)

In another preferred embodiment of the present invention, saidanti-cancer drug is porfimer sodium/Photofrin (QLT PhototherapeuticsInc.), such as for the treatment or prophylaxis of partially obstructingor completely obstructing esophogeal cancer.

In another preferred embodiment of the present invention, saidanti-cancer drug is procarbazine/Matulane (Sigma Tau Pharms)

In another preferred embodiment of the present invention, saidanti-cancer drug is quinacrine/Atabrine (Abbott Labs)

In another preferred embodiment of the present invention, saidanti-cancer drug is Rasburicase/Elitek (Sanofi-Synthelabo, Inc), such asfor the treatment or prophylaxis of patients suffering from leukaemia,lymphoma or solid tumor malignancies.

In another preferred embodiment of the present invention, saidanti-cancer drug is Rituximab/Rituxan (Genentech, Inc)

In another preferred embodiment of the present invention, saidanti-cancer drug is Sargramostim/Prokine (Immunex Corp)

In another preferred embodiment of the present invention, saidanti-cancer drug is streptozocin/Zanosar (Pharmacia & Upjohn Company)

In another preferred embodiment of the present invention, saidanti-cancer drug is talc/Sclerosol (Bryan), such as for the treatment orprophylaxis of malignant pleural effusion in symptomatic patients.

In another preferred embodiment of the present invention, saidanti-cancer drug is tamoxifen/Nolvadex (AstraZeneca Pharmaceuticals),such as for the treatment or prophylaxis of breast cancer, for examplefollowing mastectomy and axillary dissection in postmenopausal women, orfor metastatic breast cancer, for example in men.

In another preferred embodiment of the present invention, saidanti-cancer drug is temozolomide/Temodar (Schering), such as for thetreatment or prophylaxis of refractory anaplastic astrocytma.

In another preferred embodiment of the present invention, saidanti-cancer drug is teniposide/VM-26/Vumon (Bristol-Myers Squibb), suchas for the treatment or prophylaxis of refractory childhood acutelymphoblastic leukaemia.

In another preferred embodiment of the present invention, saidanti-cancer drug is testolactone/Teslac (Bristol-Myers Squibb)

In another preferred embodiment of the present invention, saidanti-cancer drug is thioguanine/6-TG/Thioguanine (GlaxoSmithKline)

In another preferred embodiment of the present invention, saidanti-cancer drug is thiotepa/Thioplex (Lederle Laboratories)

In another preferred embodiment of the present invention, saidanti-cancer drug is topotecan/Hycamtin (GlaxoSmithKline), such as forthe treatment or prophylaxis of metastatic carcinoma of the ovary, orsmall cell lung cancer.

In another preferred embodiment of the present invention, saidanti-cancer drug is toremifene/Fareston (Orion Corp), such as for thetreatment or prophylaxis of advanced breast cancer in postmenopausalwomen.

In another preferred embodiment of the present invention, saidanti-cancer drug is Tositumomab/Bexxar (Corixa Corporation), such as forthe treatment or prophylaxis of non-Hodgkin's lymphoma.

In another preferred embodiment of the present invention, saidanti-cancer drug is Trastuzumab/Herceptin (Genentech, Inc), such as forthe treatment or prophylaxis of metastatic breast cancer.

In another preferred embodiment of the present invention, saidanti-cancer drug is tretinoin/ATRA/Vesanoid (Roche), such as for thetreatment or prophylaxis of acute promyeocytic leukaemia.

In another preferred embodiment of the present invention, saidanti-cancer drug is Uracil Mustard (Roberts Labs)

In another preferred embodiment of the present invention, saidanti-cancer drug is vairubicin/Valstar (Medeva), such as for thetreatment or prophylaxis of BCG-refractory carcinoma in situ (CIS) ofthe urinary bladder.

In another preferred embodiment of the present invention, saidanti-cancer drug is vinblastine/Velban (Eli Lilly)

In another preferred embodiment of the present invention, saidanti-cancer drug is vincristine/Oncovin (Eli Lilly)

In another preferred embodiment of the present invention, saidanti-cancer drug is vinorelbine/Navelbine (GlaxoSmithKline), such as forthe treatment or prophylaxis of non-small cell lung cancer, such asunresectable, advanced non-small cell lung cancer.

In another preferred embodiment of the present invention, saidanti-cancer drug is zoledronate/Zometa (Novartis), such as for thetreatment or prophylaxis of multiple myeloma or patients with documentedbone metastases from solid tumours.

In one preferred embodiment of the present invention, the anti-cancerdrug is not carboplatin.

In one aspect of the present invention, the Basidiomycete bioactiveagent is administered in combination with a chemotherapeutic agent, suchas any of the following: an alkylating agent, a Nitrosourea, anantimetabolite, Anthracycline or a related drug, a topoisomerase IIinhibitor, a mitotic inhibitor, a corticosteroid hormone.

Thus, in one preferred embodiment, the Basidiomycete bioactive agent isadministered in combination with an alkylating agent, such as one ormore of the following: busulfan, cisplatin, carboplatin, chlorambucil,cyclophosphamide, ifosfamide, dacarbazine (DTIC), mechlorethamine(nitrogen mustard), melphalan, and temozolomide.

In another preferred embodiment, the Basidiomacete bioactive agent isadministered in combination with a Nitrosourea, such as one or more ofthe following: carmustine (BCNU) and lomustine (CCNU).

In another preferred embodiment, the Basidiomycete bioactive agent isadministered in combination with an antimetabolite, such as one or moreof the following: 5-fluorouracil, capecitabine, 6-mercaptopurine,methotrexate, gemcitabine, cytarabine (ara-C), fludarabine, andpemetrexed.

In another preferred embodiment, the Basidiomycete bioactive agent isadministered in combination with an Anthracycline or a related drug,such as one or more of the following: daunorubicin, doxorubicin(Adriamycin), epirubicin, idarubicin, and mitoxantrone.

In another preferred embodiment, the Basidiomycete bioactive agent isadministered in combination with a topoisomerase II inhibitor, such asone or more of the following: topotecan, irinotecan, etoposide (VP-16),and teniposide.

In another preferred embodiment, the Basidiomycete bioactive agent isadministered in combination with a mitotic inhibitor, such as one ormore of the following: a taxane (for example paclitaxel, docetaxel), avinca alkaloid (vinblastine, vincristine, and vinorelbine).

In another preferred embodiment, the Basidiomycete bioactive agent isadministered in combination with a corticosteroid hormone, such as oneor more of the following: prednisone or dexamethasone.

In another preferred embodiment, the Basidiomycete bioactive agent isadministered in combination with a targeted therapy, such as one or moreof the following: imatinib (Gleevec), gefitinib (Iressa), erlotinib(Tarceva), rituximab (Rituxan), and bevacizumab (Avastin).

In another preferred embodiment, the Basidiomycete bioactive agent isadministered in combination with a sexhormone, such as one or more ofthe following: anti-estrogens (such as tamoxifen, fulvestrant),aromatase inhibitors (such as anastrozole, exemestane, letrozole),progestins (such as megestrol acetate), anti-androgens (such asbicalutamide, flutamide), and LHRH agonists (such as leuprolide,goserelin).

In another preferred embodiment, the Basidiomycete bioactive agent isadministered in combination with one or more of the following:L-asparaginase, dactinomycin, thalidomide, and tretinoin.

Disease Treated

The methods, uses, and kit-of-parts described herein may be used totreat any individual suffering from, or at risk of suffering from, aneoplastic disease.

In one embodiment of the present invention, said neoplastic disease isbenign. In another embodiment of the present invention, said neoplasticdisease is metastatic, such as stage 3-4 metastatic disease,

In one preferred embodiment of the present invention, the neoplasticdisease is selected from the group consisting of: Acute LymphoblasticLeukemia, Acute Myeloid Leukemia, Adrenocortical Carcinoma, AIDS-RelatedCancers, AIDS-Related Lymphoma, Anal Cancer, Astrocytoma (e.g. ChildhoodCerebellar or Childhood Cerebral), Basal Cell Carcinoma, ExtrahepaticBile Duct Cancer, Bladder Cancer, Bone Cancer, Osteosarcoma/MalignantFibrous Histiocytoma, Brain Stem Glioma, Brain Tumor, Breast Cancer,Male Breast Cancer, Bronchial Adenomas/Carcinoids, Burkitt's Lymphoma,Carcinoid Tumor, Carcinoma of Unknown Primary, Primary Central NervousSystem Lymphoma, Cerebral Astrocytoma/Malignant Glioma, Cervical Cancer,Childhood Cancers, Chronic Lymphocytic Leukemia, Chronic MyelogenousLeukemia, Chronic Myeloproliferative Disorders, Colon Cancer, CutaneousT-Cell Lymphoma, Endometrial Cancer, Ependymoma (such as ChildhoodEpdndymoma), Esophageal Cancer, Ewing's Family of Tumors, ExtracranialGerm Cell Tumor (such as Childhood Extracranial Germ Cell Tumor),Extragonadal Germ Cell Tumor, Eye Cancer (Intraocular Melanoma orRetinoblastoma), Gallbladder Cancer, Gastric (Stomach) Cancer,Gastrointestinal Carcinoid Tumor, Gestational Trophoblastic Tumor,Glioma, Hairy Cell Leukemia, Head and Neck Cancer, Hepatocellular(Liver) Cancer, Hodgkin's Lymphoma, Hypopharyngeal Cancer, Hypothalamicand Visual Pathway Glioma (such as Childhood Hypothalamic and VisualPathway Glioma), Intraocular Melanoma, Islet Cell Carcinoma (EndocrinePancreas), Kaposi's Sarcoma, Kidney (Renal Cell) Cancer, LaryngealCancer, Lip and Oral Cavity Cancer, Lung Cancer (Non-Small Cell or SmallCell), Lymphoma (such as AIDS-Related Lymphoma, Burkitt's Lymphoma,Cutaneous T-Cell Lymphoma, Non-Hodgkin's Lymphoma), Macroglobulinemia(such as Waldenstrom's Macroglobulinemia), Malignant FibrousHistiocytoma of Bone/Osteosarcoma, Medulloblastoma (such as ChildhoodMedulloblastoma), Melanoma, Merkel Cell Carcinoma, Mesothelioma (such asAdult Malignant Mesothelioma or childhood Mesothelioma), MetastaticSquamous Neck Cancer with Occult Primary, Multiple Endocrine NeoplasiaSyndrome (such as occurring in childhood), Multiple Myeloma/Plasma CellNeoplasm, Mycosis Fungoides, Myelodysplastic Syndromes,Myelodysplastic/Myeloproliferative Diseases, Myeloma (such as MultipleMyeloma), Chronic myeloproliferative disorders, Nasal Cavity andParanasal Sinus Cancer, Nasopharyngeal Cancer, Nasopharyngeal Cancer(such as Childhood Nasopharyngeal Cancer), Neuroblastoma, OropharyngealCancer, Osteosarcoma/Malignant Fibrous Histiocytoma of Bone, OvarianCancer (such as Childhood Ovarian Cancer), Ovarian Epithelial Cancer,Ovarian Germ Cell Tumor, Ovarian Low Malignant Potential Tumor,Pancreatic Cancer, Pancreatic Cancer, Paranasal Sinus and Nasal CavityCancer, Parathyroid Cancer, Penile Cancer, Pheochromocytoma,Pineoblastoma and Supratentorial Primitive Neuroectodermal Tumors,Pituitary Tumor, Pleuropulmonary Blastoma, Prostate Cancer, Renal Pelvisand Ureter Transitional Cell Cancer, Retinoblastoma, Rhabdomyosarcoma(such as Childhood Rhabdomyosarcoma), Salivary Gland Cancer, Adult-onsetsoft tissue Sarcoma, Soft Tissue Sarcoma (such as Childhood Soft TissueSarcoma), uterine Sarcoma, Sezary Syndrome, Skin Cancer (such asnon-Melanoma skin cancer), Merkel Cell Skin Carcinoma, Small IntestineCancer, Supratentorial Primitive Neuroectodermal Tumors (such asoccurring in Childhood), Cutaneous T-Cell Lymphoma, Testicular Cancer,Thymoma and Thymic Carcinoma, Thyroid Cancer, Transitional Cell Cancerof the Renal Pelvis and Ureter, Trophoblastic Tumor (such as GestationalTrophoblastic Tumor), Urethral Cancer, Endometrial uterine cancer,Uterine Sarcoma, Vaginal Cancer, Visual Pathway and Hypothalamic Glioma(such as Childhood Visual Pathway and Hypothalamic Glioma),Waldenstrom's Macroglobulinemia or Wilms' Tumor.

One aspect of the present invention relates to the palliative treatmentof terminal cancer states in an individual in need thereof, such aswherein said individual is suffering from advanced-stage cancer,preferably terminal cancer.

In accordance with the above, in one aspect of the present invention,the kit-of-parts is suitable for treating or preventing any of thefollowing aerodigestive tract cancer forms:

-   -   Pancreatic cancer    -   cancer of the upper GI tract, such as stomach cancer and/or        esophagus cancer.    -   head and neck cancer, in particular cancer of the thyroid or        cancer of the salivary glands.    -   lung cancer, in particular small lung cell cancer.

In another preferred embodiment of the present invention, the kit ofparts according to the present invention is for the treatment orprevention of lower GI cancer, such as colorectal cancers, in particularcolon cancer.

In another preferred embodiment of the present invention, thekit-of-parts is for the treatment or prevention of an endocrine cancer,i.e. a cancer in an endocrine organ of an individual's body.

In one preferred embodiment, said cancer is liver cancer.

The invention is also useful for treating individuals suffering from thefollowing cancer forms:

-   -   cancer of the ovaries    -   breast cancer.

In a further preferred embodiment of the present invention, thetreatment with Basidiomycete bioactive agent is for the treatment orprevention of undesirable side-effects caused in whole or in part by ananti-cancer treatment, such as chemotherapy or radiotherapy orcombinations thereof.

In one embodiment it is preferred that the Basidiomycete bioactive agentis administered before the anti-cancer treatment (for exampleprophylactically). In this embodiment the treatment may be startedbefore any anti-cancer treatment initiates. It may be administeredcontinuously during the anti-cancer treatment or it may be administeredat intervals, for example between periods with anti-cancer therapy. Byadministering during and in particular between the periods ofanti-cancer therapy, the risk that the treated individual acquiresinfections and other complications may be reduced due to the betterhealth conditions.

Helicobacter pylori

Helicobacter is a gram-negative bacterium with polar flagella, usingoxygen as an electron acceptor, which cannot utilize carbohydrates as anenergy source.

Helicobacter is used herein interchangeably with “Helicobacter sp.”. Ina preferred embodiment the Helicobacter sp. is Helicobacter pylori.

In one embodiment, the present invention provides methods for preventingor inhibiting or reducing the growth of Helicobacter by administeringthe bioactive agent according to the present invention. The bioactiveagent can be administered to an individual in need thereof alone or incombination with other therapeutic agents like antibiotics andinhibitors of acid secretion. By the phrase “in combination” withtherapeutic agents is meant herein that one or more bioactive agent(s)according to the present invention is administered to the individualthus treated before and/or during (including concurrently with) and/orafter treatment of an individual with one or more therapeutic agents. Inall cases of combination treatment described herein, the bioactive agentcan be administered in the form of food. In all cases of combinationtreatment described herein, the combination may be in the form ofkit-in-part systems, wherein the combined active substances may be usedfor simultaneous, sequential or separate administration. In all cases,it is preferred that any of the herein-mentioned medicaments areadministered in pharmaceutically effective amounts, i.e. anadministration involving a total amount of each active component of themedicament or pharmaceutical composition or method that is sufficient toshow a meaningful patient benefit. The combination of a bioactive agentaccording to the present invention and therapeutic agents provideimprovements over therapy with the therapeutic agent alone, inparticular for patients that do not respond to therapy with thetherapeutic agent alone or in combination with other treatment regimes.

Thus, the present invention provides a method of treating an infectionwith Helicobacter in a subject, particularly human subjects, comprisingadministering a therapeutically effective amount of a bioactive agentaccording to the present invention alone or in combination with othertherapeutic agents.

In one embodiment, the other therapeutic agent is an antibiotic. Inanother embodiment the antibiotic is amoxicillin. In a furtherembodiment the antibiotic is clarithromycin. In yet another embodimentthe antibiotic is metronidazole. In another embodiment the therapeuticagent is an inhibitor of acid secretion like an H₂ inhibitor or a protonpump inhibitor. In a further embodiment the H₂ inhibitor is omeprazol.Further embodiments of the invention provide methods where one ore moreantibiotic is co-administered with an inhibitor of acid secretion.

In one embodiment of the invention the subject having a Helicobacterinfection is suffering from a peptic ulcer. Peptic ulcers, ascontemplated in the current invention include, but are not limited to,circumscribed breaks in the continuity of the mucosal layer of thegastrointestinal tract. These breaks in the continuity of the mucosallayer can include breaks that do not extend below the epithelium, alsoreferred to as “erosions” or breaks that do extend below the epithelium.The peptic ulcers may be acute, or chronic. Further, peptic ulcers canbe located in any part of the gastrointestinal tract that is exposed toacid-pepsin gastric juice, including esophagus, stomach, duodenum andafter gastroenterostomy, the jejunum.

In another embodiment the subject having the Helicobacter infection issuffering from, or at risk of developing, cancer of the gastrointestinaltract. As stated above, the portions of the gastrointestinal tract wherecancer may be present or may develop are any areas where thegastrointestinal tract is exposed to acid-pepsin gastric juice,including esophagus, stomach, duodenum and after gastroenterostomy, thejejunum. As used herein the term “cancer of the gastrointestinal tract”is used as one of ordinary skill in the art would recognize the term.Examples of “cancer of the gastrointestinal tract” include, but are notlimited to, neoplasias (or neoplasms), hyperplasias, dysplasias,metaplasias or hypertrophies. The neoplasms may be benign or malignant,and they may originate from any cell type, including but not limited toepithelial cells of various origin, muscle cells and endothelial cells.

The treatment can be used for patients with a pre-existing Helicobacterinfection, or for patients pre-disposed to a Helicobacter infection.Additionally, the bioactive agent of the present invention can be usedto alleviate symptoms of a Helicobacter infection in patients, or as apreventative measure in patients.

As used herein, the phrase Helicobacter infection is used to mean aninteraction between Helicobacter and the host organism (subject). Theinfections may be localized, meaning that the Helicobacter grows andremains near the point of initial interaction. The infection may also begeneralized, where the Helicobacter may become more widespread beyondthe initial point of interaction, including spreading to the surroundingtissue or organ and even being distributed and growing throughout theentire host organism. As used herein the term interaction (of a host andHelicobacter) is used to mean a process where the Helicobacter grows inor around a particular tissue. Helicobacter is considered to haveinfected the subject if the bacteria is able to penetrate the surface ofcells of a particular tissue and grow within the cells of the tissue. Anexample of this type of infection includes, but is not limited toHelicobacter penetrating and growing within the epithelial cells liningthe lumen of the stomach. Additionally, the Helicobacter can also besaid to have infected the host organism by growing extracellularly tothe tissue cells.

The method of the current invention comprises administering anantibacterially effective amount of the bioactive agent to treat aHelicobacter infection. As used herein, “an antibacterially effectiveamount to treat a Helicobacter infection” is intended to mean an amountaffective to prevent, inhibit, retard or reverse the growth ofHelicobacter, and/or reduce the number of viable Helicobacter cellswithin the stomach or at a site of infection. “Antibacterially effectiveamount to treat a Helicobacter infection” is also used to mean an amounteffective to kill, reduce or ameliorate any existing infections ofHelicobacter. Thus, according to the present invention, an“antibacterially effective amount to treat a Helicobacter infection” ofthe bioactive agent of the present invention can be used as a treatmentof a pre-existing Helicobacter infection. Effective amounts for use inthese treatments can completely or partially prevent a pre-existingHelicobacter infection from spreading to surrounding tissue and beyond,and they can also be used to slow the growth and/or spread rate of theHelicobacter in the subject. Furthermore, the “antibacterially effectiveamounts to treat a Helicobacter infection” of the bioactive agent of thecurrent invention can prevent a Helicobacter infection in subjects.Another aspect of an “antibacterially effective amount to treat aHelicobacter infection”, as used in the current invention, means thatthe bioactive agent administered to the subject is capable of preventingor reducing the cellular or physiological damage to the infected orsurrounding tissue, caused by the toxins produced by the Helicobacter.In still another aspect, the phrase “antibacterially effective amount totreat a Helicobacter infection” can be used to mean an amount of theadministered bioactive agent that can reduce or prevent the formation orefficacy of the virulence of the Helicobacter. By virulence is meant theability of the Helicobacter to combat the host organism's or cellsnatural defences to the Helicobacter infection.

Antibody Therapy

In one embodiment, the present invention provides methods for enhancingthe antitumor activity of antibody therapy by administering a bioactiveagent according to the present invention in combination with theantibody therapy. By the phrase “in combination” with antibody therapyis meant herein that one or more bioactive agent(s) according to thepresent invention is administered to the individual thus treated beforeand/or during (including concurrently with) and/or after treatment of anindividual with a therapeutic antibody. In all cases of combinationtreatment described herein, the bioactive agent can be administered inthe form of food. In all cases of combination treatment describedherein, the combination may be in the form of kit-in-part systems,wherein the combined active substances may be used for simultaneous,sequential or separate administration. In all cases, it is preferredthat any of the herein-mentioned medicaments are administered inpharmaceutically effective amounts, i.e. an administration involving atotal amount of each active component of the medicament orpharmaceutical composition or method that is sufficient to show ameaningful patient benefit. The combination of a bioactive agentaccording to the present invention and therapeutic monoclonal antibodiesprovide improvements over monoclonal antibody therapy alone, inparticular for patients that do not respond to monoclonal antibodytherapy alone or in combination with other treatment regimes.

Thus, the present invention provides a method of treating cancer in asubject, particularly human subjects, comprising co-administering atherapeutically effective amount of a monoclonal antibody and atherapeutically effective amount of a bioactive agent according to thepresent invention.

In one embodiment, the monoclonal antibody is an anti-CD20 monoclonalantibody. In another embodiment, the monoclonal antibody is rituximab.In another embodiment, methods of the present invention treatnon-Hodgkin's lymphoma. Further embodiments of the present inventionprovide methods where monoclonal antibody rituximab and a bioactiveagent according to the present invention are administered once weeklyfor e.g. up to eight consecutive weeks. In another embodiment, therituximab is administered once weekly and the a bioactive agentaccording to the present invention is administered up to five timesweekly for up to eight consecutive weeks. Another embodiment of presentinvention provides that the bioactive agent dose is from 10 to 500[mu]g/kg/dose. In certain embodiments of the present invention, thepatient has previously been treated with rituximab and showed noappreciable tumor remission or regression. In other embodiments, thepatient has relapsed after receiving rituximab therapy.

In another aspect, the present invention provides a method of treatingcancer in a subject comprising co-administering a therapeuticallyeffective amount of an anti-CD20 monoclonal antibody and atherapeutically effective amount of a bioactive agent according to thepresent invention, wherein administering the bioactive agent results inan optimal immunological response.

In another aspect, the present invention provides a method for treatingcancer in a subject comprising co-administering a monoclonal antibodythat binds to a Her-2/neu receptor and a bioactive agent according tothe present invention. In one embodiment, the subject is a humanpatient. The monoclonal antibody can e.g. be trastuzumab.

One aspect of the present invention provides a method of treating cancerin a subject comprising co-administering a monoclonal antibody thatbinds to a cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and abioactive agent according to the present invention. In certainembodiments, the subject is a human patient. In one embodiment of thepresent invention, the anti-CTLA-4 monoclonal antibody is administeredat a dose of 3 mg/kg every three weeks for four cycles and the bioactiveagent is administered one to five times weekly for up to eight weeks.The present invention also provides embodiments where the dose of hebioactive agent is from 10 to 500 [mu]g/kg/dose.

One of the mechanisms associated with the antitumor activity ofmonoclonal antibody therapy is antibody dependent cellular cytotoxicity(ADCC). In ADCC, monoclonal antibodies bind to a target cell (e.g.cancer cell) and specific effector cells expressing receptors for themonoclonal antibody (e.g. NK cells, monocytes and granulocytes) bind themonoclonal antibody/target cell complex resulting in target cell death.A bioactive agent according to the present invention is believed toenhance effector cell function, thereby increasing monoclonal antibodytherapy efficacy. Thus, the dose and schedule of bioactive agentadministration in combination with MAbs can be based on the ability ofthe bioactive agent to elevate parameters associated with differentationand functional activity of cell populations mediating ADCC, includingbut not limited to, NK cells, macrophages and neutrophils. Theseparameters can be evaluated using assays of NK, macrophage andneutrophil cell cytotoxicity, ADCC (NK cell fraction or totalmononuclear cells, or effector molecules essential to the ability ofcells to implement ADCC (e.g., FasL, granzymes and perforin).

Combination therapy with a bioactive agent according to the presentinvention and a monoclonal antibody may in one embodiment be indicatedwhen a first line treatment has failed and may be considered as a secondline treatment. However, based on the enhanced antitumor activity of thebioactive agent in combination with a monoclonal antibody, the presentinvention also provides using the combination as a first line treatmentin patient populations that are newly diagnosed and have not beenpreviously treated with anticancer agents “de novo patients” andpatients that have not previously received any monoclonal antibodytherapy “naive patients.”

A bioactive agent according to the present invention is also useful incombination therapy with monoclonal antibodies in the absence of anydirect antibody mediated ADCC of tumor cells. Antibodies that block aninhibitory signal in the immune system can lead to augmented immuneresponses. Examples include (1) antibodies against molecules of the B7Rfamily that have inhibitory function such as, cytotoxic Tlymphocyte-associated antigen 4 (CTLA-4), programmed death-1 (PD-1), Band T lymphocyte attenuator (BTLA); (2) antibodies against inhibitorycytokines like IL-10, TGFP; and (3) antibodies that deplete or inhibitfunctions of suppressive cells like anti-CD25 or CTLA-4. For example,anti-CTLA4 mAbs in both mice and humans are thought to either suppressfunction of immune-suppressive regulatory T cells (Tregs) or inhibit theinhibitory signal transmitted through binding of CTLA-4 on T cells toB7-1 or B7-2 molecules on APCs or tumor cells. CTLA-4 is expressedtransiently on the surface of activated T cells and constitutivelyexpressed on Treg cells. Cross-linking CTLA-4 leads to an inhibitorysignal on activated T cells, and antibodies against CTLA-4 block theinhibitory signal on T cells leading to sustained T cell activation(Phan et al., PNAS, 100:8372-8377, 2003.)

Preferred Antibodies for Use in the Combination Therapy:

Although monoclonal antibodies are preferred, any of the embodimentsdescribed herein may also use polyclonal antibodies instead of, or incombination with, monoclonal antibodies. In one embodiment of thecombination invention, naked antibodies (i.e. antibodies without anydrug or radioactive material attached to them) are used. In anotherembodiment of the present invention, conjugated antibodies are used(joined e.g. to one or more of: a chemotherapy drug, a radioactiveparticle, or a toxin). For example, the antibody used may be aconjugated monoclonal antibody. Another preferred embodiment uses one ormore of: a chemolabeled monoclonal antibody, a monoclonal antibody withradioactive particles attached, an immunotoxin.

Preferred immunotoxins include, but are not restricted to, an antibodyattached to one or more of: a bacterial toxins such as diphtherial toxin(DT) or pseudomonal exotoxin (PE40), a plant toxin such as ricin A orsaporin. Preferred is e.g. gemtuzumab ozogamicin (Mylotarg) or otherantibodies attached to calicheamicin, or BL22.

It is preferred that the antibody is targeted to a molecule known to beassociated with cancerous processes. For example, the antibody may bindspecifically one or more of the following targets: vascular endothelialgrowth factor-A (VEGF-A), epidermal growth factor receptor (EGFR), CD20antigen, the HER2 protein, the CD52 antigen, the VEGF protein, erbB-2,EGFR, erbB-2, cathepsin L, cyclin E, Ras, p53, BCR-ABL, Bcl-2,caspase-3.

Table 1 is a non-exclusive list of monoclonal antibodies approved orbeing tested for which combination therapy with a bioactive agentaccording to the present invention is possible. Other preferredantibodies may be selected from, but are not restricted to, the groupconsisting of:

Alemtuzumab (Campath), bevacizumab (Avastin, Genentech Inc.), OncoScint(such as for colorectal and ovarian cancer), ProstaScint (such as forprostate cancer), Tositumomab (Bexxar),Cetuximab (Erbitux, ImClone Systems Inc.), Gemtuzumab ozogamicin(Mylotarg), Rituximab (Rituxan, Roche/Genentech), anti-erbB-2 scFv,Ibritumomab tiuxetan (Zevalin), Panitumumab (formerly known as“ABX-EGF”, Abgenix, Fremont Calif.), Ibritumomab tiuxetan (Zevalin), EMD72000 (Vanhoefer et al., J Clin Oncol 2004; 22:175-184), IbritumomabTioxetan, and Trastuzumab (Herceptin).

Further suitable antibodies and protocols for use of any of theantibodies described herein can be found in e.g. US 2005/0244413 (Adolfet al.) and US 2005/0265966 (Wane et al.), U.S. Pat. No. 5,338,661(Jensenius), and “Recombinant Polyclonal Antibodies for Cancer Therapy”(Sharon et al., Journal of Cellular Biochemistry 96:305-313 (2005)), allof which are incorporated herein by reference.

TABLE 1 Target Drug Name Clinical Indication Company IL-2Rα(CD25)Zenapax transplant Roche IL-1R AMG108 osteoarthritis Amgen RANK-L AMG162osteoporosis Amgen Blys LympoSTAT-B SLE, RA HGS CD40L (CD39)InitiatedAID Celltech/IDEC TRAIL-R1 HGS-ETR1 cancers HGS TRAIL-R2HGS-ETR2 solid tumors HGS CD30 SGN30 NHL Seattle Genetics CD40 SGN40 MMSeattle Genetics HER2 Herceptin Breast cancer Genentech EGF-R ABX-EGFCRC, NSCLC, RCC Abgenix EMD72000 solid tumors Merck MDX-214EGF-R-positive Medarex tumors Erbitux CRC Imclone VEGF-R CDP791 solidtumors Celltech PDGF-R CDP860 solid tumors Celltech/ZymoGenetics CD11a(αL) Raptiva psoriasis Genentech α4-integrin Antegrin CD, MS PDL,Biogen-IDEC α4β7 integrin MLM02 CD, UC Millenium α5β3 integrin Vitaxinpsoriasis, prostate cancer AME/Lilly CD2 (LFA3/Fc) Amevive psoriasisBiogen/IDEC CD152 CTLA-4/lg RA Bristol Meyers CD152 CTLA-4 cancersMedarex CD49a Integrin α1 RA/Luous Biogen/IDEC CD49e Integrin α5 cancersProtein Design Labs MUC1 Theragyn MUC18 (TIM-like) ABX-MA1 melanomaTAG-72 Mucin Anatumomab cancers CD3 Ecromeximab melanoma Kyowa HakkoTRX4 type1 IDDM TolerRx Nuvion UC PDL OrthoCloneOKT3 organ transplantOrtho biotech CD4 HuMax-CD4 T-cell lymphoma GenMab CD19 MT103 NHLMedimmune CD64 (Fc GR1) AntiCD64 cancers Medarex CD33 MyloTarg AMLCelltch/Whyeth ZAmyl AML Protein Design Labs CD22 lymphocide NHL, AIDImmunomedics CEA CEA-Cide cancers Immunomedics CD20 Rituxan NHLGenentech CD52 Campath MS, NHL, T-cell lymph Genzyme, IDEX CD44Bivatuzumab cancers Boehringer Ingelheim CD23 (Fc Ep R) IDEC152 allerhicasthma, rhinitis Biogen/IDEC LRR: CD14 ICOSIC14 sepsis ICOS EpCAMPanorex colorectal cancer Centocor Lewis-Y—Ag SGN15 cancers SeattleGenetics CD80 B7.1 psoriasis/NHL Biogen/IDEC

Dosage of the bioactive agent may be varied as known to one skilled inthe art and as disclosed in detail elsewhere herein. Preferably,administration is intravenous administration or oral administration.Antibodies may also be given intravenously in one embodiment, forexample co-formulated with the bioactive agent.

For example, the antibody and/or bioactive agent may be given at adosage of 5 mg/kg, every other week, or may be administered with a 400mg/m² loading dose and weekly doses of 250 mg/m² over 1 hour.

Cytochrome P450

It has been shown, that the polysaccharide Lentinan from Lentinus edodesand polysaccharides from Agaricus blazei can suppress the expression ofcytochrome P450s (CYPs) and thus can prevent cancer (Hashimoto et al.Biosci. Biotechnol. Biochem. 2004, 66 (7) 1610-1614 and Okamoto et al.Biofactors 2004 21 (1-4) 407-09 both of which are incorporated herein byreference). P450s are a class of drug- and xenobiotic-metabolizingenzymes mainly expressed in the liver. Carcinogens such as polyaromatichydrocarbons and heterocyclic amines are metabolized to theircarcinogenic forms by CYPs. Moreover the suppression of P450 caused bypolysaccharides, such as Lentinan, is advantageous for chemotherapypatients, as it prolongs the duration and intensifies the action ofdrugs.

Thus in one embodiment the present invention is directed to a bioactiveagent capable of suppressing the expression of P450s. In a furtherembodiment the bioactive agent of the present invention is used in acombination therapy with a chemotherapeutic drug. In all cases ofcombination therapy described herein, the bioactive agent can beadministered in the form of food.

Dendritic Cells

It has been demonstrated that chemoimmunotherapy using S-1, an oralfluoropyrimidine anticancer drug, combined with lentinan is effective inmodifying dendritic cells (DCs) in vivo and in vitro (Mushiake et al.Cancer Immunol. Immunother. 2005 February; 54 (2) 120-128).

The survival period of Colon-26—bearing mice treated with S-1 andLentinan was significantly more prolonged than that of mice treated withS-1 alone (P<0.05). The frequency of CD86⁺ DCs infiltrated into Colon-26was increased in mice treated with S-1 and lentinan, and splenic DCsharvested from mice treated with S-1+LNT showed more potent T-cellproliferation activity than that of DCs from mice treated with S-1 alone(P<0.05).

Furthermore, the activity of cytotoxic T lymphocytes (CTLs) insplenocytes of mice treated with S-1 and Lentinan was specific and morepotent than that of CTLs from mice treated with S-1 alone (P<0.05).

The results suggest that modulation of specific immunity with Lentinanhas a significant role in enhanced anti-tumour effects through themodification of DC function. The combination therapy of S-1 andbioactive agents according to the invention presents a promisingchemoimmunotherapy, which may lead to better survival for cancerpatients. Thus in one embodiment the present invention is directed to acombination therapy of S-1 and the bioactive agent according to thisinvention in cancer patients. In all cases of combination therapydescribed herein, the bioactive agent can be administered in the form offood.

Bioactive Species According to the Invention

In one aspect there is provided a bioactive agent as disclosed in theitems herein below:

-   1. The bioactive agent according to a first item comprises or    consists of an agent selected from an oligosaccharide, a    polysaccharide and an optionally glycosylated polypeptide.-   2. The bioactive agent according to item 1, wherein the bioactive    agent comprises or consists of a polysaccharide.-   3. The bioactive agent according to item 1, wherein the bioactive    agent comprises or consists of an oligosaccharide.-   4. The bioactive agent according to item 1, wherein the bioactive    agent comprises or consists of an optionally glycosylated    polypeptide.-   5. The bioactive agent according to item 2, wherein the    polysaccharide is a homopolymer.-   6. The bioactive agent according to item 2, wherein the    polysaccharide is a heteropolymer.-   7. The bioactive agent according to items 2, wherein the    polysaccharide comprises glucose monosaccharide units, optionally in    combination with further monosaccharide units selected from the    group of units consisting of glucuronic acid, galactose, mannose,    arabinose and xylose, including any combination thereof.-   8. The bioactive agent according to item 7, wherein the further    monosaccharide units are all glucuronic acid.-   9. The bioactive agent according to item 7, wherein the further    monosaccharide units are all galactose.-   10. The bioactive agent according to item 7, wherein the further    monosaccharide units are all mannose.-   11. The bioactive agent according to item 7, wherein the further    monosaccharide units are all arabinose.-   12. The bioactive agent according to item 7, wherein the further    monosaccharide units are all xylose.-   13. The bioactive agent according to item 7, wherein the further    monosaccharide units are glucuronic acid and galactose.-   14. The bioactive agent according to item 7, wherein the further    monosaccharide units are glucuronic acid and mannose.-   15. The bioactive agent according to item 7, wherein the further    monosaccharide units are glucuronic acid and arabinose.-   16. The bioactive agent according to item 7, wherein the further    monosaccharide units are glucuronic acid and xylose.-   17. The bioactive agent according to item 7, wherein the further    monosaccharide units are galactose and mannose.-   18. The bioactive agent according to item 7, wherein the further    monosaccharide units are galactose and arabinose.-   19. The bioactive agent according to item 7, wherein the further    monosaccharide units are galactose and xylose.-   20. The bioactive agent according to item 7, wherein the further    monosaccharide units are mannose and arabinose.-   21. The bioactive agent according to item 7, wherein the further    monosaccharide units are mannose and xylose.-   22. The bioactive agent according to item 7, wherein the further    monosaccharide units are arabinose and xylose.-   23. The bioactive agent according to item 7, wherein the further    monosaccharide units are glucuronic acid, galactose and mannose.-   24. The bioactive agent according to item 7, wherein the further    monosaccharide units are glucuronic acid, galactose and arabinose.-   25. The bioactive agent according to item 7, wherein the further    monosaccharide units are glucuronic acid, galactose and xylose.-   26. The bioactive agent according to item 7, wherein the further    monosaccharide units are glucuronic acid, mannose and arabinose.-   27. The bioactive agent according to item 7, wherein the further    monosaccharide units are glucuronic acid mannose and xylose.-   28. The bioactive agent according to item 7, wherein the further    monosaccharide units are glucuronic acid, arabinose and xylose.-   29. The bioactive agent according to item 7, wherein the further    monosaccharide units are galactose, mannose and arabinose.-   30. The bioactive agent according to item 7, wherein the further    monosaccharide units are galactose, mannose and xylose.-   31. The bioactive agent according to item 7, wherein the further    monosaccharide units are galactose, arabinose and xylose.-   32. The bioactive agent according to item 7, wherein the further    monosaccharide units are mannose, arabinose and xylose.-   33. The bioactive agent according to item 7, wherein the further    monosaccharide units are glucuronic acid, galactose, mannose and    arabinose.-   34. The bioactive agent according to item 7, wherein the further    monosaccharide units are glucuronic acid, galactose, mannose and    xylose.-   35. The bioactive agent according to item 7, wherein the further    monosaccharide units are glucuronic acid, galactose, arabinose and    xylose.-   36. The bioactive agent according to item 7, wherein the further    monosaccharide units are glucuronic acid, mannose, arabinose and    xylose.-   37. The bioactive agent according to item 7, wherein the further    monosaccharide units are galactose, mannose, arabinose and xylose.-   38. The bioactive agent according to item 2, wherein the backbone of    the polysaccharide comprises glucose monosaccharide units in    combination with further monosaccharide units selected from the    group of units consisting of glucuronic acid, galactose, mannose,    arabinose and xylose, including any combination thereof.-   39. The bioactive agent according to item 38, wherein the further    monosaccharide units are all glucuronic acid.-   40. The bioactive agent according to item 38, wherein the further    monosaccharide units are all galactose.-   41. The bioactive agent according to item 38, wherein the further    monosaccharide units are all mannose.-   42. The bioactive agent according to item 38, wherein the further    monosaccharide units are all arabinose.-   43. The bioactive agent according to item 38, wherein the further    monosaccharide units are all xylose.-   44. The bioactive agent according to item 38, wherein the further    monosaccharide units are glucuronic acid and galactose.-   45. The bioactive agent according to item 38, wherein the further    monosaccharide units are glucuronic acid and mannose.-   46. The bioactive agent according to item 38, wherein the further    monosaccharide units are glucuronic acid and arabinose.-   47. The bioactive agent according to item 38, wherein the further    monosaccharide units are glucuronic acid and xylose.-   48. The bioactive agent according to item 38, wherein the further    monosaccharide units are galactose and mannose.-   49. The bioactive agent according to item 38, wherein the further    monosaccharide units are galactose and arabinose.-   50. The bioactive agent according to item 38, wherein the further    monosaccharide units are galactose and xylose.-   51. The bioactive agent according to item 38, wherein the further    monosaccharide units are mannose and arabinose.-   52. The bioactive agent according to item 38, wherein the further    monosaccharide units are mannose and xylose.-   53. The bioactive agent according to item 38, wherein the further    monosaccharide units are arabinose and xylose.-   54. The bioactive agent according to item 38, wherein the further    monosaccharide units are glucuronic acid, galactose and mannose.-   55. The bioactive agent according to item 38, wherein the further    monosaccharide units are glucuronic acid, galactose and arabinose.-   56. The bioactive agent according to item 38, wherein the further    monosaccharide units are glucuronic acid, galactose and xylose.-   57. The bioactive agent according to item 38, wherein the further    monosaccharide units are glucuronic acid, mannose and arabinose.-   58. The bioactive agent according to item 38, wherein the further    monosaccharide units are glucuronic acid mannose and xylose.-   59. The bioactive agent according to item 38, wherein the further    monosaccharide units are glucuronic acid, arabinose and xylose.-   60. The bioactive agent according to item 38, wherein the further    monosaccharide units are galactose, mannose and arabinose.-   61. The bioactive agent according to item 38, wherein the further    monosaccharide units are galactose, mannose and xylose.-   62. The bioactive agent according to item 38, wherein the further    monosaccharide units are galactose, arabinose and xylose.-   63. The bioactive agent according to item 38, wherein the further    monosaccharide units are mannose, arabinose and xylose.-   64. The bioactive agent according to item 38, wherein the further    monosaccharide units are glucuronic acid, galactose, mannose and    arabinose.-   65. The bioactive agent according to item 38, wherein the further    monosaccharide units are glucuronic acid, galactose, mannose and    xylose.-   66. The bioactive agent according to item 38, wherein the further    monosaccharide units are glucuronic acid, galactose, arabinose and    xylose.-   67. The bioactive agent according to item 38, wherein the further    monosaccharide units are glucuronic acid, mannose, arabinose and    xylose.-   68. The bioactive agent according to item 38, wherein the further    monosaccharide units are galactose, mannose, arabinose and xylose.-   69. The bioactive agent according to item 2, wherein the backbone of    the polysaccharide comprises a plurality of monosaccharide units,    and wherein the side chains of the polysaccharide comprises further    monosaccharide units selected from the group of units consisting of    glucuronic acid, galactose, mannose, arabinose xylose and glucose,    including any combination thereof.-   70. The bioactive agent according to item 69, wherein the further    monosaccharide units are all glucuronic acid.-   71. The bioactive agent according to item 69, wherein the further    monosaccharide units are all galactose.-   72. The bioactive agent according to item 69, wherein the further    monosaccharide units are all mannose.-   73. The bioactive agent according to item 69, wherein the further    monosaccharide units are all arabinose.-   74. The bioactive agent according to item 69, wherein the further    monosaccharide units are all xylose.-   75. The bioactive agent according to item 69, wherein the further    monosaccharide units are all glucose.-   76. The bioactive agent according to item 69, wherein the further    monosaccharide units are glucuronic acid and galactose.-   77. The bioactive agent according to item 69, wherein the further    monosaccharide units are glucuronic acid and mannose.-   78. The bioactive agent according to item 69, wherein the further    monosaccharide units are glucuronic acid and arabinose.-   79. The bioactive agent according to item 69, wherein the further    monosaccharide units are glucuronic acid and xylose.-   80. The bioactive agent according to item 69, wherein the further    monosaccharide units are glucuronic acid and glucose.-   81. The bioactive agent according to item 69, wherein the further    monosaccharide units are galactose and mannose.-   82. The bioactive agent according to item 69, wherein the further    monosaccharide units are galactose and arabinose.-   83. The bioactive agent according to item 69, wherein the further    monosaccharide units are galactose and xylose.-   84. The bioactive agent according to item 69, wherein the further    monosaccharide units are galactose and glucose.-   85. The bioactive agent according to item 69, wherein the further    monosaccharide units are mannose and arabinose.-   86. The bioactive agent according to item 69, wherein the further    monosaccharide units are mannose and xylose.-   87. The bioactive agent according to item 69, wherein the further    monosaccharide units are mannose and glucose.-   88. The bioactive agent according to item 69, wherein the further    monosaccharide units are arabinose and xylose.-   89. The bioactive agent according to item 69, wherein the further    monosaccharide units are arabinose and glucose.-   90. The bioactive agent according to item 69, wherein the further    monosaccharide units are xylose and glucose.-   91. The bioactive agent according to item 69, wherein the further    monosaccharide units are glucuronic acid, galactose and mannose.-   92. The bioactive agent according to item 69, wherein the further    monosaccharide units are glucuronic acid, galactose and arabinose.-   93. The bioactive agent according to item 69, wherein the further    monosaccharide units are glucuronic acid, galactose and xylose.-   94. The bioactive agent according to item 69, wherein the further    monosaccharide units are glucuronic acid, galactose and glucose.-   95. The bioactive agent according to item 69, wherein the further    monosaccharide units are glucuronic acid, mannose and arabinose.-   96. The bioactive agent according to item 69, wherein the further    monosaccharide units are glucuronic acid mannose and xylose.-   97. The bioactive agent according to item 69, wherein the further    monosaccharide units are glucuronic acid mannose and glucose.-   98. The bioactive agent according to item 69, wherein the further    monosaccharide units are glucuronic acid, arabinose and xylose.-   99. The bioactive agent according to item 69, wherein the further    monosaccharide units are glucuronic acid, arabinose and glucose.-   100. The bioactive agent according to item 69, wherein the further    monosaccharide units are glucuronic acid, xylose and glucose.-   101. The bioactive agent according to item 69, wherein the further    monosaccharide units are galactose, mannose and arabinose.-   102. The bioactive agent according to item 69, wherein the further    monosaccharide units are galactose, mannose and xylose.-   103. The bioactive agent according to item 69, wherein the further    monosaccharide units are galactose, mannose and glucose.-   104. The bioactive agent according to item 69, wherein the further    monosaccharide units are galactose, arabinose and xylose.-   105. The bioactive agent according to item 69, wherein the further    monosaccharide units are galactose, arabinose and glucose.-   106. The bioactive agent according to item 69, wherein the further    monosaccharide units are galactose, xylose and glucose.-   107. The bioactive agent according to item 69, wherein the further    monosaccharide units are mannose, arabinose and xylose.-   108. The bioactive agent according to item 69, wherein the further    monosaccharide units are mannose, arabinose and glucose.-   109. The bioactive agent according to item 69, wherein the further    monosaccharide units are mannose, xylose and glucose.-   110. The bioactive agent according to item 69, wherein the further    monosaccharide units are arabinose, xylose and glucose.-   111. The bioactive agent according to item 69, wherein the further    monosaccharide units are glucuronic acid, galactose, mannose and    arabinose.-   112. The bioactive agent according to item 69, wherein the further    monosaccharide units are glucuronic acid, galactose, mannose and    xylose.-   113. The bioactive agent according to item 69, wherein the further    monosaccharide units are glucuronic acid, galactose, mannose and    glucose.-   114. The bioactive agent according to item 69, wherein the further    monosaccharide units are glucuronic acid, galactose, arabinose and    xylose.-   115. The bioactive agent according to item 69, wherein the further    monosaccharide units are glucuronic acid, galactose, arabinose and    glucose.-   116. The bioactive agent according to item 69, wherein the further    monosaccharide units are glucuronic acid, galactose, xylose and    glucose.-   117. The bioactive agent according to item 69, wherein the further    monosaccharide units are glucuronic acid, mannose, arabinose and    xylose.-   118. The bioactive agent according to item 69, wherein the further    monosaccharide units are glucuronic acid, mannose, arabinose and    glucose.-   119. The bioactive agent according to item 69, wherein the further    monosaccharide units are glucuronic acid, mannose, xylose and    glucose.-   120. The bioactive agent according to item 69, wherein the further    monosaccharide units are glucuronic acid, arabinose, xylose and    glucose.-   121. The bioactive agent according to item 69, wherein the further    monosaccharide units are galactose, mannose, arabinose and xylose.-   122. The bioactive agent according to item 69, wherein the further    monosaccharide units are galactose, mannose, arabinose and glucose.-   123. The bioactive agent according to item 69, wherein the further    monosaccharide units are galactose, mannose, xylose and glucose.-   124. The bioactive agent according to item 69, wherein the further    monosaccharide units are galactose, arabinose, xylose and glucose.-   125. The bioactive agent according to item 69, wherein the further    monosaccharide units are mannose, arabinose, xylose and glucose.-   126. The bioactive agent according to item 69, wherein the further    monosaccharide units are glucuronic acid, galactose, mannose,    arabinose and xylose.-   127. The bioactive agent according to item 69, wherein the further    monosaccharide units are glucuronic acid, galactose, mannose,    arabinose and glucose.-   128. The bioactive agent according to item 69, wherein the further    monosaccharide units are glucuronic acid, galactose, mannose, xylose    and glucose.-   129. The bioactive agent according to item 69, wherein the further    monosaccharide units are glucuronic acid, galactose, arabinose    xylose and glucose.-   130. The bioactive agent according to item 69, wherein the further    monosaccharide units are glucuronic acid, mannose, arabinose xylose    and glucose.-   131. The bioactive agent according to item 69, wherein the further    monosaccharide units are galactose, mannose, arabinose xylose and    glucose.-   132. The bioactive agent according to item 2, wherein the    polysaccharide comprises a repetitive backbone macromomer comprising    from 2 to 6, such as 2, 3, 4, 5 or 6 different monosaccharide units    and having from 1 to 3 monosaccharide units selected from glucose,    mannose and galactose.-   133. The bioactive agent according to item 2, wherein the    polysaccharide comprises an average of from 1 to 1000 monosaccharide    units in the backbone between each branching point, such as from 2    to 1000 monosaccharide units, for example from 3 to 1000    monosaccharide units, such as from 4 to 1000 monosaccharide units,    for example from 5 to 1000 monosaccharide units, such as from 6 to    1000 monosaccharide units, for example from 7 to 1000 monosaccharide    units, such as from 8 to 1000 monosaccharide units, for example from    9 to 1000 monosaccharide units, such as from 10 to 1000    monosaccharide units, for example from 11 to 1000 monosaccharide    units, such as from 12 to 1000 monosaccharide units, for example    from 13 to 1000 monosaccharide units, such as from 14 to 1000    monosaccharide units, for example from 15 to 1000 monosaccharide    units, such as from 20 to 1000 monosaccharide units, for example    from 25 to 1000 monosaccharide units, such as from 30 to 1000    monosaccharide units, for example from 40 to 1000 monosaccharide    units, such as from 50 to 1000 monosaccharide units, for example    from 60 to 1000 monosaccharide units, such as from 70 to 1000    monosaccharide units, for example from 80 to 1000 monosaccharide    units, such as from 90 to 1000 monosaccharide units, for example    from 100 to 1000 monosaccharide units, such as from 2 to 500    monosaccharide units, for example from 3 to 500 monosaccharide    units, such as from 4 to 500 monosaccharide units, for example from    5 to 500 monosaccharide units, such as from 6 to 500 monosaccharide    units, for example from 7 to 500 monosaccharide units, such as from    8 to 500 monosaccharide units, for example from 9 to 500    monosaccharide units, such as from 10 to 500 monosaccharide units,    for example from 11 to 500 monosaccharide units, such as from 12 to    500 monosaccharide units, for example from 13 to 500 monosaccharide    units, such as from 14 to 500 monosaccharide units, for example from    15 to 500 monosaccharide units, such as from 20 to 500    monosaccharide units, for example from 25 to 500 monosaccharide    units, such as from 30 to 500 monosaccharide units, for example from    40 to 500 monosaccharide units, such as from 50 to 500    monosaccharide units, for example from 60 to 500 monosaccharide    units, such as from 70 to 500 monosaccharide units, for example from    80 to 500 monosaccharide units, such as from 90 to 500    monosaccharide units, for example from 100 to 500 monosaccharide    units, such as from 2 to 250 monosaccharide units, for example from    3 to 250 monosaccharide units, such as from 4 to 250 monosaccharide    units, for example from 5 to 250 monosaccharide units, such as from    6 to 250 monosaccharide units, for example from 7 to 250    monosaccharide units, such as from 8 to 250 monosaccharide units,    for example from 9 to 250 monosaccharide units, such as from 10 to    250 monosaccharide units, for example from 11 to 250 monosaccharide    units, such as from 12 to 250 monosaccharide units, for example from    13 to 250 monosaccharide units, such as from 14 to 250    monosaccharide units, for example from 15 to 250 monosaccharide    units, such as from 20 to 250 monosaccharide units, for example from    25 to 250 monosaccharide units, such as from 30 to 250    monosaccharide units, for example from 40 to 250 monosaccharide    units, such as from 50 to 250 monosaccharide units, for example from    60 to 250 monosaccharide units, such as from 70 to 250    monosaccharide units, for example from 80 to 250 monosaccharide    units, such as from 90 to 250 monosaccharide units, for example from    100 to 250 monosaccharide units, such as from 2 to 100    monosaccharide units, for example from 3 to 100 monosaccharide    units, such as from 4 to 100 monosaccharide units, for example from    5 to 100 monosaccharide units, such as from 6 to 100 monosaccharide    units, for example from 7 to 100 monosaccharide units, such as from    8 to 100 monosaccharide units, for example from 9 to 100    monosaccharide units, such as from 10 to 100 monosaccharide units,    for example from 11 to 100 monosaccharide units, such as from 12 to    100 monosaccharide units, for example from 13 to 100 monosaccharide    units, such as from 14 to 100 monosaccharide units, for example from    15 to 100 monosaccharide units, such as from 20 to 100    monosaccharide units, for example from 25 to 100 monosaccharide    units, such as from 30 to 100 monosaccharide units, for example from    40 to 100 monosaccharide units, such as from 50 to 100    monosaccharide units, for example from 60 to 100 monosaccharide    units, such as from 70 to 100 monosaccharide units, for example from    80 to 100 monosaccharide units, such as from 90 to 100    monosaccharide units, such as from 2 to 50 monosaccharide units, for    example from 3 to 50 monosaccharide units, such as from 4 to 50    monosaccharide units, for example from 5 to 50 monosaccharide units,    such as from 6 to 50 monosaccharide units, for example from 7 to 50    monosaccharide units, such as from 8 to 50 monosaccharide units, for    example from 9 to 50 monosaccharide units, such as from 10 to 50    monosaccharide units, for example from 11 to 50 monosaccharide    units, such as from 12 to 50 monosaccharide units, for example from    13 to 50 monosaccharide units, such as from 14 to 50 monosaccharide    units, for example from 15 to 50 monosaccharide units, such as from    20 to 50 monosaccharide units, for example from 25 to 50    monosaccharide units, such as from 30 to 50 monosaccharide units,    for example from 40 to 50 monosaccharide units, such as from 2 to 25    monosaccharide units, for example from 3 to 25 monosaccharide units,    such as from 4 to 25 monosaccharide units, for example from 5 to 25    monosaccharide units, such as from 6 to 25 monosaccharide units, for    example from 7 to 25 monosaccharide units, such as from 8 to 25    monosaccharide units, for example from 9 to 25 monosaccharide units,    such as from 10 to 25 monosaccharide units, for example from 11 to    25 monosaccharide units, such as from 12 to 25 monosaccharide units,    for example from 13 to 25 monosaccharide units, such as from 14 to    25 monosaccharide units, for example from 15 to 25 monosaccharide    units, such as from 20 to 25 monosaccharide units, such as from 2 to    20 monosaccharide units, for example from 3 to 20 monosaccharide    units, such as from 4 to 20 monosaccharide units, for example from 5    to 20 monosaccharide units, such as from 6 to 20 monosaccharide    units, for example from 7 to 20 monosaccharide units, such as from 8    to 20 monosaccharide units, for example from 9 to 20 monosaccharide    units, such as from 10 to 20 monosaccharide units, for example from    11 to 20 monosaccharide units, such as from 12 to 20 monosaccharide    units, for example from 13 to 20 monosaccharide units, such as from    14 to 20 monosaccharide units, for example from 15 to 20    monosaccharide units, such as from 2 to 18 monosaccharide units, for    example from 3 to 18 monosaccharide units, such as from 4 to 18    monosaccharide units, for example from 5 to 18 monosaccharide units,    such as from 6 to 18 monosaccharide units, for example from 7 to 18    monosaccharide units, such as from 8 to 18 monosaccharide units, for    example from 9 to 18 monosaccharide units, such as from 10 to 18    monosaccharide units, for example from 11 to 18 monosaccharide    units, such as from 12 to 18 monosaccharide units, for example from    13 to 18 monosaccharide units, such as from 14 to 18 monosaccharide    units, for example from 15 to 18 monosaccharide units, such as from    2 to 16 monosaccharide units, for example from 3 to 16    monosaccharide units, such as from 4 to 16 monosaccharide units, for    example from 5 to 16 monosaccharide units, such as from 6 to 16    monosaccharide units, for example from 7 to 16 monosaccharide units,    such as from 8 to 16 monosaccharide units, for example from 9 to 16    monosaccharide units, such as from 10 to 16 monosaccharide units,    for example from 11 to 16 monosaccharide units, such as from 12 to    16 monosaccharide units, for example from 13 to 16 monosaccharide    units, such as from 14 to 16 monosaccharide units, for example from    15 to 16 monosaccharide units, such as from 2 to 14 monosaccharide    units, for example from 3 to 14 monosaccharide units, such as from 4    to 14 monosaccharide units, for example from 5 to 14 monosaccharide    units, such as from 6 to 14 monosaccharide units, for example from 7    to 14 monosaccharide units, such as from 8 to 14 monosaccharide    units, for example from 9 to 14 monosaccharide units, such as from    10 to 14 monosaccharide units, for example from 11 to 14    monosaccharide units, such as from 12 to 14 monosaccharide units,    for example from 13 to 14 monosaccharide units, such as from 2 to 12    monosaccharide units, for example from 3 to 12 monosaccharide units,    such as from 4 to 12 monosaccharide units, for example from 5 to 12    monosaccharide units, such as from 6 to 12 monosaccharide units, for    example from 7 to 12 monosaccharide units, such as from 8 to 12    monosaccharide units, for example from 9 to 12 monosaccharide units,    such as from 10 to 12 monosaccharide units, for example from 11 to    12 monosaccharide units, such as from 2 to 10 monosaccharide units,    for example from 3 to 10 monosaccharide units, such as from 4 to 10    monosaccharide units, for example from 5 to 10 monosaccharide units,    such as from 6 to 10 monosaccharide units, for example from 7 to 10    monosaccharide units, such as from 8 to 10 monosaccharide units, for    example from 9 to 10 monosaccharide units, such as from 2 to 8    monosaccharide units, for example from 3 to 8 monosaccharide units,    such as from 4 to 8 monosaccharide units, for example from 5 to 8    monosaccharide units, such as from 6 to 8 monosaccharide units, for    example from 7 to 8 monosaccharide units in the backbone between    each branching point.-   134. The bioactive agent according to item 2, wherein the    polysaccharide has a molecular weight in the range of from 5,000    g/mol to about 1,000,000 g/mol, such as a molecular weight in the    range of from 5,000 g/mol to about 900,000 g/mol, for example a    molecular weight in the range of from 5,000 g/mol to about 800.000    g/mol, such as a molecular weight in the range of from 5,000 g/mol    to about 900,000 g/mol, for example a molecular weight in the range    of from 5,000 g/mol to about 800.000 g/mol, such as a molecular    weight in the range of from 5,000 g/mol to about 750,000 g/mol, for    example a molecular weight in the range of from 5,000 g/mol to about    700.000 g/mol, such as a molecular weight in the range of from 5,000    g/mol to about 1270,000 g/mol, for example a molecular weight in the    range of from 5,000 g/mol to about 600.000 g/mol, such as a    molecular weight in the range of from 5,000 g/mol to about 550,000    g/mol, for example a molecular weight in the range of from 5,000    g/mol to about 500.000 g/mol, such as a molecular weight in the    range of from 5,000 g/mol to about 450,000 g/mol, for example a    molecular weight in the range of from 5,000 g/mol to about 400.000    g/mol, such as a molecular weight in the range of from 5,000 g/mol    to about 350,000 g/mol, for example a molecular weight in the range    of from 5,000 g/mol to about 300.000 g/mol, such as a molecular    weight in the range of from 5,000 g/mol to about 250,000 g/mol, for    example a molecular weight in the range of from 5,000 g/mol to about    200.000 g/mol, such as a molecular weight in the range of from 5,000    g/mol to about 100,000 g/mol, for example a molecular weight in the    range of from 5,000 g/mol to about 80.000 g/mol, such as a molecular    weight in the range of from 5,000 g/mol to about 60,000 g/mol, for    example a molecular weight in the range of from 5,000 g/mol to about    50.000 g/mol, such as a molecular weight in the range of from 5,000    g/mol to about 40,000 g/mol, for example a molecular weight in the    range of from 5,000 g/mol to about 35.000 g/mol, such as a molecular    weight in the range of from 5,000 g/mol to about 30,000 g/mol, for    example a molecular weight in the range of from 5,000 g/mol to about    25.000 g/mol, such as a molecular weight in the range of from 5,000    g/mol to about 20,000 g/mol, for example a molecular weight in the    range of from 5,000 g/mol to about 15.000 g/mol, such as a molecular    weight in the range of from 5,000 g/mol to about 10,000 g/mol, for    example a molecular weight in the range of from 10,000 g/mol to    about 1,000,000 g/mol, such as a molecular weight in the range of    from 10,000 g/mol to about 900,000 g/mol, for example a molecular    weight in the range of from 10,000 g/mol to about 800.000 g/mol,    such as a molecular weight in the range of from 10,000 g/mol to    about 900,000 g/mol, for example a molecular weight in the range of    from 10,000 g/mol to about 800.000 g/mol, such as a molecular weight    in the range of from 10,000 g/mol to about 750,000 g/mol, for    example a molecular weight in the range of from 10,000 g/mol to    about 700.000 g/mol, such as a molecular weight in the range of from    10,000 g/mol to about 1270,000 g/mol, for example a molecular weight    in the range of from 10,000 g/mol to about 600.000 g/mol, such as a    molecular weight in the range of from 10,000 g/mol to about 550,000    g/mol, for example a molecular weight in the range of from 10,000    g/mol to about 500.000 g/mol, such as a molecular weight in the    range of from 10,000 g/mol to about 450,000 g/mol, for example a    molecular weight in the range of from 10,000 g/mol to about 400.000    g/mol, such as a molecular weight in the range of from 10,000 g/mol    to about 350,000 g/mol, for example a molecular weight in the range    of from 10,000 g/mol to about 300.000 g/mol, such as a molecular    weight in the range of from 10,000 g/mol to about 250,000 g/mol, for    example a molecular weight in the range of from 10,000 g/mol to    about 200.000 g/mol, such as a molecular weight in the range of from    10,000 g/mol to about 100,000 g/mol, for example a molecular weight    in the range of from 10,000 g/mol to about 80.000 g/mol, such as a    molecular weight in the range of from 10,000 g/mol to about 60,000    g/mol, for example a molecular weight in the range of from 10,000    g/mol to about 50.000 g/mol, such as a molecular weight in the range    of from 10,000 g/mol to about 40,000 g/mol, for example a molecular    weight in the range of from 10,000 g/mol to about 35.000 g/mol, such    as a molecular weight in the range of from 10,000 g/mol to about    30,000 g/mol, for example a molecular weight in the range of from    10,000 g/mol to about 25.000 g/mol, such as a molecular weight in    the range of from 10,000 g/mol to about 20,000 g/mol, for example a    molecular weight in the range of from 10,000 g/mol to about 15.000    g/mol, such as a molecular weight in the range of from 15,000 g/mol    to about 1,000,000 g/mol, such as a molecular weight in the range of    from 15,000 g/mol to about 900,000 g/mol, for example a molecular    weight in the range of from 15,000 g/mol to about 800.000 g/mol,    such as a molecular weight in the range of from 15,000 g/mol to    about 900,000 g/mol, for example a molecular weight in the range of    from 15,000 g/mol to about 800.000 g/mol, such as a molecular weight    in the range of from 15,000 g/mol to about 750,000 g/mol, for    example a molecular weight in the range of from 15,000 g/mol to    about 700.000 g/mol, such as a molecular weight in the range of from    15,000 g/mol to about 1270,000 g/mol, for example a molecular weight    in the range of from 15,000 g/mol to about 600.000 g/mol, such as a    molecular weight in the range of from 15,000 g/mol to about 550,000    g/mol, for example a molecular weight in the range of from 15,000    g/mol to about 500.000 g/mol, such as a molecular weight in the    range of from 15,000 g/mol to about 450,000 g/mol, for example a    molecular weight in the range of from 15,000 g/mol to about 400.000    g/mol, such as a molecular weight in the range of from 15,000 g/mol    to about 350,000 g/mol, for example a molecular weight in the range    of from 15,000 g/mol to about 300.000 g/mol, such as a molecular    weight in the range of from 15,000 g/mol to about 250,000 g/mol, for    example a molecular weight in the range of from 15,000 g/mol to    about 200.000 g/mol, such as a molecular weight in the range of from    15,000 g/mol to about 100,000 g/mol, for example a molecular weight    in the range of from 15,000 g/mol to about 80.000 g/mol, such as a    molecular weight in the range of from 15,000 g/mol to about 60,000    g/mol, for example a molecular weight in the range of from 15,000    g/mol to about 50.000 g/mol, such as a molecular weight in the range    of from 15,000 g/mol to about 40,000 g/mol, for example a molecular    weight in the range of from 15,000 g/mol to about 35.000 g/mol, such    as a molecular weight in the range of from 15,000 g/mol to about    30,000 g/mol, for example a molecular weight in the range of from    15,000 g/mol to about 25.000 g/mol, such as a molecular weight in    the range of from 15,000 g/mol to about 20,000 g/mol, for example a    molecular weight in the range of from 20,000 g/mol to about    1,000,000 g/mol, such as a molecular weight in the range of from    20,000 g/mol to about 900,000 g/mol, for example a molecular weight    in the range of from 20,000 g/mol to about 800.000 g/mol, such as a    molecular weight in the range of from 20,000 g/mol to about 900,000    g/mol, for example a molecular weight in the range of from 20,000    g/mol to about 800.000 g/mol, such as a molecular weight in the    range of from 20,000 g/mol to about 750,000 g/mol, for example a    molecular weight in the range of from 20,000 g/mol to about 700.000    g/mol, such as a molecular weight in the range of from 20,000 g/mol    to about 1270,000 g/mol, for example a molecular weight in the range    of from 20,000 g/mol to about 600.000 g/mol, such as a molecular    weight in the range of from 20,000 g/mol to about 550,000 g/mol, for    example a molecular weight in the range of from 20,000 g/mol to    about 500.000 g/mol, such as a molecular weight in the range of from    20,000 g/mol to about 450,000 g/mol, for example a molecular weight    in the range of from 20,000 g/mol to about 400.000 g/mol, such as a    molecular weight in the range of from 20,000 g/mol to about 350,000    g/mol, for example a molecular weight in the range of from 20,000    g/mol to about 300.000 g/mol, such as a molecular weight in the    range of from 20,000 g/mol to about 250,000 g/mol, for example a    molecular weight in the range of from 20,000 g/mol to about 200.000    g/mol, such as a molecular weight in the range of from 20,000 g/mol    to about 100,000 g/mol, for example a molecular weight in the range    of from 20,000 g/mol to about 80.000 g/mol, such as a molecular    weight in the range of from 20,000 g/mol to about 60,000 g/mol, for    example a molecular weight in the range of from 20,000 g/mol to    about 50.000 g/mol, such as a molecular weight in the range of from    20,000 g/mol to about 40,000 g/mol, for example a molecular weight    in the range of from 20,000 g/mol to about 35.000 g/mol, such as a    molecular weight in the range of from 20,000 g/mol to about 30,000    g/mol, for example a molecular weight in the range of from 20,000    g/mol to about 25.000 g/mol, such as a molecular weight in the range    of from 25,000 g/mol to about 1,000,000 g/mol, such as a molecular    weight in the range of from 25,000 g/mol to about 900,000 g/mol, for    example a molecular weight in the range of from 25,000 g/mol to    about 800.000 g/mol, such as a molecular weight in the range of from    25,000 g/mol to about 900,000 g/mol, for example a molecular weight    in the range of from 25,000 g/mol to about 800.000 g/mol, such as a    molecular weight in the range of from 25,000 g/mol to about 750,000    g/mol, for example a molecular weight in the range of from 25,000    g/mol to about 700.000 g/mol, such as a molecular weight in the    range of from 25,000 g/mol to about 1270,000 g/mol, for example a    molecular weight in the range of from 25,000 g/mol to about 600.000    g/mol, such as a molecular weight in the range of from 25,000 g/mol    to about 550,000 g/mol, for example a molecular weight in the range    of from 25,000 g/mol to about 500.000 g/mol, such as a molecular    weight in the range of from 25,000 g/mol to about 450,000 g/mol, for    example a molecular weight in the range of from 25,000 g/mol to    about 400.000 g/mol, such as a molecular weight in the range of from    25,000 g/mol to about 350,000 g/mol, for example a molecular weight    in the range of from 25,000 g/mol to about 300.000 g/mol, such as a    molecular weight in the range of from 25,000 g/mol to about 250,000    g/mol, for example a molecular weight in the range of from 25,000    g/mol to about 200.000 g/mol, such as a molecular weight in the    range of from 25,000 g/mol to about 100,000 g/mol, for example a    molecular weight in the range of from 25,000 g/mol to about 80.000    g/mol, such as a molecular weight in the range of from 25,000 g/mol    to about 60,000 g/mol, for example a molecular weight in the range    of from 25,000 g/mol to about 50.000 g/mol, such as a molecular    weight in the range of from 25,000 g/mol to about 40,000 g/mol, for    example a molecular weight in the range of from 25,000 g/mol to    about 35.000 g/mol, such as a molecular weight in the range of from    25,000 g/mol to about 30,000 g/mol, for example a molecular weight    in the range of from 30,000 g/mol to about 1,000,000 g/mol, such as    a molecular weight in the range of from 30,000 g/mol to about    900,000 g/mol, for example a molecular weight in the range of from    30,000 g/mol to about 800.000 g/mol, such as a molecular weight in    the range of from 30,000 g/mol to about 900,000 g/mol, for example a    molecular weight in the range of from 30,000 g/mol to about 800.000    g/mol, such as a molecular weight in the range of from 30,000 g/mol    to about 750,000 g/mol, for example a molecular weight in the range    of from 30,000 g/mol to about 700.000 g/mol, such as a molecular    weight in the range of from 30,000 g/mol to about 1270,000 g/mol,    for example a molecular weight in the range of from 30,000 g/mol to    about 600.000 g/mol, such as a molecular weight in the range of from    30,000 g/mol to about 550,000 g/mol, for example a molecular weight    in the range of from 30,000 g/mol to about 500.000 g/mol, such as a    molecular weight in the range of from 30,000 g/mol to about 450,000    g/mol, for example a molecular weight in the range of from 30,000    g/mol to about 400.000 g/mol, such as a molecular weight in the    range of from 30,000 g/mol to about 350,000 g/mol, for example a    molecular weight in the range of from 30,000 g/mol to about 300.000    g/mol, such as a molecular weight in the range of from 30,000 g/mol    to about 250,000 g/mol, for example a molecular weight in the range    of from 30,000 g/mol to about 200.000 g/mol, such as a molecular    weight in the range of from 30,000 g/mol to about 100,000 g/mol, for    example a molecular weight in the range of from 30,000 g/mol to    about 80.000 g/mol, such as a molecular weight in the range of from    30,000 g/mol to about 60,000 g/mol, for example a molecular weight    in the range of from 30,000 g/mol to about 50.000 g/mol, such as a    molecular weight in the range of from 30,000 g/mol to about 40,000    g/mol, for example a molecular weight in the range of from 30,000    g/mol to about 35.000 g/mol, such as a molecular weight in the range    of from 40,000 g/mol to about 1,000,000 g/mol, such as a molecular    weight in the range of from 40,000 g/mol to about 900,000 g/mol, for    example a molecular weight in the range of from 40,000 g/mol to    about 800.000 g/mol, such as a molecular weight in the range of from    40,000 g/mol to about 900,000 g/mol, for example a molecular weight    in the range of from 40,000 g/mol to about 800.000 g/mol, such as a    molecular weight in the range of from 40,000 g/mol to about 750,000    g/mol, for example a molecular weight in the range of from 40,000    g/mol to about 700.000 g/mol, such as a molecular weight in the    range of from 40,000 g/mol to about 1270,000 g/mol, for example a    molecular weight in the range of from 40,000 g/mol to about 600.000    g/mol, such as a molecular weight in the range of from 40,000 g/mol    to about 550,000 g/mol, for example a molecular weight in the range    of from 40,000 g/mol to about 500.000 g/mol, such as a molecular    weight in the range of from 40,000 g/mol to about 450,000 g/mol, for    example a molecular weight in the range of from 40,000 g/mol to    about 400.000 g/mol, such as a molecular weight in the range of from    40,000 g/mol to about 350,000 g/mol, for example a molecular weight    in the range of from 40,000 g/mol to about 300.000 g/mol, such as a    molecular weight in the range of from 40,000 g/mol to about 250,000    g/mol, for example a molecular weight in the range of from 40,000    g/mol to about 200.000 g/mol, such as a molecular weight in the    range of from 40,000 g/mol to about 100,000 g/mol, for example a    molecular weight in the range of from 40,000 g/mol to about 80.000    g/mol, such as a molecular weight in the range of from 40,000 g/mol    to about 60,000 g/mol, for example a molecular weight in the range    of from 40,000 g/mol to about 50.000 g/mol, such as a molecular    weight in the range of from 50,000 g/mol to about 1,000,000 g/mol,    such as a molecular weight in the range of from 50,000 g/mol to    about 900,000 g/mol, for example a molecular weight in the range of    from 50,000 g/mol to about 800.000 g/mol, such as a molecular weight    in the range of from 50,000 g/mol to about 900,000 g/mol, for    example a molecular weight in the range of from 50,000 g/mol to    about 800.000 g/mol, such as a molecular weight in the range of from    50,000 g/mol to about 750,000 g/mol, for example a molecular weight    in the range of from 50,000 g/mol to about 700.000 g/mol, such as a    molecular weight in the range of from 50,000 g/mol to about 1270,000    g/mol, for example a molecular weight in the range of from 50,000    g/mol to about 600.000 g/mol, such as a molecular weight in the    range of from 50,000 g/mol to about 550,000 g/mol, for example a    molecular weight in the range of from 50,000 g/mol to about 500.000    g/mol, such as a molecular weight in the range of from 50,000 g/mol    to about 450,000 g/mol, for example a molecular weight in the range    of from 50,000 g/mol to about 400.000 g/mol, such as a molecular    weight in the range of from 50,000 g/mol to about 350,000 g/mol, for    example a molecular weight in the range of from 50,000 g/mol to    about 300.000 g/mol, such as a molecular weight in the range of from    50,000 g/mol to about 250,000 g/mol, for example a molecular weight    in the range of from 50,000 g/mol to about 200.000 g/mol, such as a    molecular weight in the range of from 50,000 g/mol to about 100,000    g/mol, for example a molecular weight in the range of from 50,000    g/mol to about 80.000 g/mol, such as a molecular weight in the range    of from 50,000 g/mol to about 60,000 g/mol, for example a molecular    weight in the range of from 75,000 g/mol to about 1,000,000 g/mol,    such as a molecular weight in the range of from 75,000 g/mol to    about 900,000 g/mol, for example a molecular weight in the range of    from 75,000 g/mol to about 800.000 g/mol, such as a molecular weight    in the range of from 75,000 g/mol to about 900,000 g/mol, for    example a molecular weight in the range of from 75,000 g/mol to    about 800.000 g/mol, such as a molecular weight in the range of from    75,000 g/mol to about 750,000 g/mol, for example a molecular weight    in the range of from 75,000 g/mol to about 700.000 g/mol, such as a    molecular weight in the range of from 75,000 g/mol to about 1270,000    g/mol, for example a molecular weight in the range of from 75,000    g/mol to about 600.000 g/mol, such as a molecular weight in the    range of from 75,000 g/mol to about 550,000 g/mol, for example a    molecular weight in the range of from 75,000 g/mol to about 500.000    g/mol, such as a molecular weight in the range of from 75,000 g/mol    to about 450,000 g/mol, for example a molecular weight in the range    of from 75,000 g/mol to about 400.000 g/mol, such as a molecular    weight in the range of from 75,000 g/mol to about 350,000 g/mol, for    example a molecular weight in the range of from 75,000 g/mol to    about 300.000 g/mol, such as a molecular weight in the range of from    75,000 g/mol to about 250,000 g/mol, for example a molecular weight    in the range of from 75,000 g/mol to about 200.000 g/mol, such as a    molecular weight in the range of from 75,000 g/mol to about 100,000    g/mol, for example a molecular weight in the range of from 75,000    g/mol to about 80.000 g/mol, a molecular weight in the range of from    100,000 g/mol to about 1,000,000 g/mol, such as a molecular weight    in the range of from 100,000 g/mol to about 900,000 g/mol, for    example a molecular weight in the range of from 100,000 g/mol to    about 800.000 g/mol, such as a molecular weight in the range of from    100,000 g/mol to about 900,000 g/mol, for example a molecular weight    in the range of from 100,000 g/mol to about 800.000 g/mol, such as a    molecular weight in the range of from 100,000 g/mol to about 750,000    g/mol, for example a molecular weight in the range of from 100,000    g/mol to about 700.000 g/mol, such as a molecular weight in the    range of from 100,000 g/mol to about 1270,000 g/mol, for example a    molecular weight in the range of from 100,000 g/mol to about 600.000    g/mol, such as a molecular weight in the range of from 100,000 g/mol    to about 550,000 g/mol, for example a molecular weight in the range    of from 100,000 g/mol to about 500.000 g/mol, such as a molecular    weight in the range of from 100,000 g/mol to about 450,000 g/mol,    for example a molecular weight in the range of from 100,000 g/mol to    about 400.000 g/mol, such as a molecular weight in the range of from    100,000 g/mol to about 350,000 g/mol, for example a molecular weight    in the range of from 100,000 g/mol to about 300.000 g/mol, such as a    molecular weight in the range of from 100,000 g/mol to about 250,000    g/mol, for example a molecular weight in the range of from 100,000    g/mol to about 200.000 g/mol, such as a molecular weight in the    range of from 200,000 g/mol to about 300,000 g/mol, for example a    molecular weight in the range of from 300,000 g/mol to about 400.000    g/mol, such as a molecular weight in the range of from 400,000 g/mol    to about 500,000 g/mol, for example a molecular weight in the range    of from 500,000 g/mol to about 600.000 g/mol, such as a molecular    weight in the range of from 700,000 g/mol to about 800,000 g/mol,    for example a molecular weight in the range of from 800,000 g/mol to    about 900.000 g/mol, such as a molecular weight in the range of from    900,000 g/mol to about 1,000,000 g/mol.-   135. The bioactive agent according to item 2, wherein the    polysaccharide comprises a structural component selected from the    group of components consisting of-   (1-3)-alpha-D-glucan;-   (1-3)-alpha-D-glucan with (1-6)-beta branching;-   (1-3)-alpha-D-glucan with (1-6)-alpha branching;-   (1-3)-alpha-D-glucan with (1-4)-beta branching;-   (1-3)-alpha-D-glucan with (1-4)-alpha branching;-   (1-3)-beta-D-glucan;-   (1-3)-beta-D-glucan with (1-6)-beta branching;-   (1-3)-beta-D-glucan with (1-6)-alpha branching;-   (1-3)-beta-D-glucan with (1-4)-beta branching;-   (1-3)-beta-D-glucan with (1-4)-alpha branching;-   (1-4)-alpha-D-glucan;-   (1-4)-alpha-D-glucan with (1-6)-beta branching;-   (1-4)-alpha-D-glucan with (1-6)-alpha branching;-   (1-4)-alpha-D-glucan with (1-4)-beta branching;-   (1-4)-alpha-D-glucan with (1-4)-alpha branching;-   (1-4)-beta-D-glucan;-   (1-4)-beta-D-glucan with (1-6)-beta branching;-   (1-4)-beta-D-glucan with (1-6)-alpha branching;-   (1-4)-beta-D-glucan with (1-4)-beta branching;-   (1-4)-beta-D-glucan with (1-4)-alpha branching;-   (1-6)-beta-D-glucan;-   (1-6)-beta-D-glucan with (1-6)-beta branching;-   (1-6)-beta-D-glucan with (1-6)-alpha branching;-   (1-6)-beta-D-glucan with (1-4)-beta branching;-   (1-6)-beta-D-glucan with (1-4)-alpha branching;-   (1-6)-alpha-D-glucan;-   (1-6)-alpha-D-glucan with (1-6)-beta branching;-   (1-6)-alpha-D-glucan with (1-6)-alpha branching;-   (1-6)-alpha-D-glucan with (1-4)-beta branching;-   (1-6)-alpha-D-glucan with (1-4)-alpha branching;-   136. The bioactive agent according to item 2, wherein the    polysaccharide comprises a structural component comprising    (1-3)-alpha-D-glucan.-   137. The bioactive agent according to item 2, wherein the    polysaccharide comprises a structural component comprising    (1-3)-alpha-D-glucan with (1-6)-beta branching.-   138. The bioactive agent according to item 2, wherein the    polysaccharide comprises a structural component comprising    (1-3)-alpha-D-glucan with (1-6)-alpha branching.-   139. The bioactive agent according to item 2, wherein the    polysaccharide comprises a structural component comprising    (1-3)-alpha-D-glucan with (1-4)-beta branching.-   140. The bioactive agent according to item 2, wherein the    polysaccharide comprises a structural component comprising    (1-3)-alpha-D-glucan with (1-4)-alpha branching.-   141. The bioactive agent according to item 2, wherein the    polysaccharide comprises a structural component comprising    (1-3)-beta-D-glucan.-   142. The bioactive agent according to item 2, wherein the    polysaccharide comprises a structural component comprising    (1-3)-beta-D-glucan with (1-6)-beta branching.-   143. The bioactive agent according to item 2, wherein the    polysaccharide comprises a structural component comprising    (1-3)-beta-D-glucan with (1-6)-alpha branching.-   144. The bioactive agent according to item 2, wherein the    polysaccharide comprises a structural component comprising    (1-3)-beta-D-glucan with (1-4)-beta branching.-   145. The bioactive agent according to item 2, wherein the    polysaccharide comprises a structural component comprising    (1-3)-beta-D-glucan with (1-4)-alpha branching.-   146. The bioactive agent according to item 2, wherein the    polysaccharide comprises a structural component comprising    (1-4)-alpha-D-glucan.-   147. The bioactive agent according to item 2, wherein the    polysaccharide comprises a structural component comprising    (1-4)-alpha-D-glucan with (1-6)-beta branching.-   148. The bioactive agent according to item 2, wherein the    polysaccharide comprises a structural component comprising    (1-4)-alpha-D-glucan with (1-6)-alpha branching.-   149. The bioactive agent according to item 2, wherein the    polysaccharide comprises a structural component comprising    (1-4)-alpha-D-glucan with (1-4)-beta branching.-   150. The bioactive agent according to item 2, wherein the    polysaccharide comprises a structural component comprising    (1-4)-alpha-D-glucan with (1-4)-alpha branching.-   151. The bioactive agent according to item 2, wherein the    polysaccharide comprises a structural component comprising    (1-4)-beta-D-glucan.-   152. The bioactive agent according to item 2, wherein the    polysaccharide comprises a structural component comprising    (1-4)-beta-D-glucan with (1-6)-beta branching.-   153. The bioactive agent according to item 2, wherein the    polysaccharide comprises a structural component comprising    (1-4)-beta-D-glucan with (1-6)-alpha branching.-   154. The bioactive agent according to item 2, wherein the    polysaccharide comprises a structural component comprising    (1-4)-beta-D-glucan with (1-4)-beta branching.-   155. The bioactive agent according to item 2, wherein the    polysaccharide comprises a structural component comprising    (1-4)-beta-D-glucan with (1-4)-alpha branching.-   156. The bioactive agent according to item 2, wherein the    polysaccharide comprises a structural component comprising    (1-6)-beta-D-glucan.-   157. The bioactive agent according to item 2, wherein the    polysaccharide comprises a structural component comprising    (1-6)-beta-D-glucan with (1-6)-beta branching.-   158. The bioactive agent according to item 2, wherein the    polysaccharide comprises a structural component comprising    (1-6)-beta-D-glucan with (1-6)-alpha branching.-   159. The bioactive agent according to item 2, wherein the    polysaccharide comprises a structural component comprising    (1-6)-beta-D-glucan with (1-4)-beta branching.-   160. The bioactive agent according to item 2, wherein the    polysaccharide comprises a structural component comprising    (1-6)-beta-D-glucan with (1-4)-alpha branching.-   161. The bioactive agent according to item 2, wherein the    polysaccharide comprises a structural component comprising    (1-6)-alpha-D-glucan.-   162. The bioactive agent according to item 2, wherein the    polysaccharide comprises a structural component comprising    (1-6)-alpha-D-glucan with (1-6)-beta branching.-   163. The bioactive agent according to item 2, wherein the    polysaccharide comprises a structural component comprising    (1-6)-alpha-D-glucan with (1-6)-alpha branching.-   164. The bioactive agent according to item 2, wherein the    polysaccharide comprises a structural component comprising    (1-6)-alpha-D-glucan with (1-4)-beta branching.-   165. The bioactive agent according to item 2, wherein the    polysaccharide comprises a structural component comprising    (1-6)-alpha-D-glucan with (1-4)-alpha branching.-   166. The bioactive agent according to item 2, wherein the    polysaccharide backbone comprises a plurality of monosaccharide    units linked by a chemical bond selected from the group consisting    of (1-6)-beta bonds, (1-4)-beta bonds, (1-3)-beta bonds, (1-2)-beta    bonds, (1-1)-beta bonds, 1-beta-1-alpha bonds, 1-alpha-1-alpha    bonds, 1-alpha-1-beta bonds, (1-2)-alpha bonds, (1-3)-alpha bonds,    (1-4)-alpha bonds and (1-6)-alpha bonds.-   167. The bioactive agent according to item 2, wherein the    polysaccharide backbone comprises a plurality of monosaccharide    units linked by (1-6)-beta bonds.-   168. The bioactive agent according to item 2, wherein the    polysaccharide backbone comprises a plurality of monosaccharide    units linked by (1-4)-beta bonds.-   169. The bioactive agent according to item 2, wherein the    polysaccharide backbone comprises a plurality of monosaccharide    units linked by (1-3)-beta bonds.-   170. The bioactive agent according to item 2, wherein the    polysaccharide backbone comprises a plurality of monosaccharide    units linked by (1-2)-beta bonds.-   171. The bioactive agent according to item 2, wherein the    polysaccharide backbone comprises a plurality of monosaccharide    units linked by (1-1)-beta bonds.-   172. The bioactive agent according to item 2, wherein the    polysaccharide backbone comprises a plurality of monosaccharide    units linked by 1-beta-1-alpha bonds.-   173. The bioactive agent according to item 2, wherein the    polysaccharide backbone comprises a plurality of monosaccharide    units linked by 1-alpha-1-alpha bonds.-   174. The bioactive agent according to item 2, wherein the    polysaccharide backbone comprises a plurality of monosaccharide    units linked by 1-alpha-1-beta bonds.-   175. The bioactive agent according to item 2, wherein the    polysaccharide backbone comprises a plurality of monosaccharide    units linked by (1-2)-alpha bonds.-   176. The bioactive agent according to item 2, wherein the    polysaccharide backbone comprises a plurality of monosaccharide    units linked by (1-3)-alpha bonds.-   177. The bioactive agent according to item 2, wherein the    polysaccharide backbone comprises a plurality of monosaccharide    units linked by (1-4)-alpha bonds.-   178. The bioactive agent according to item 2, wherein the    polysaccharide backbone comprises a plurality of monosaccharide    units linked by (1-6)-alpha bonds.-   179. The bioactive agent according to any of items 166 to 178,    wherein the polysaccharide further comprises side chains comprising    a plurality of monosaccharides selected from the group consisting of    (1-6)-beta bonds, (1-4)-beta bonds, (1-3)-beta bonds, (1-2)-beta    bonds, (1-1)-beta bonds, 1-beta-1-alpha bonds, 1-alpha-1-alpha    bonds, 1-alpha-1-beta bonds, (1-2)-alpha bonds, (1-3)-alpha bonds,    (1-4)-alpha bonds and (1-6)-alpha bonds.-   180. The bioactive agent according to any of items 166 to 178,    wherein the polysaccharide side chains comprise a plurality of    monosaccharide units linked by (1-6)-beta bonds.-   181. The bioactive agent according to any of items 166 to 178,    wherein the polysaccharide side chains comprise a plurality of    monosaccharide units linked by (1-4)-beta bonds.-   182. The bioactive agent according to any of items 166 to 178,    wherein the polysaccharide side chains comprise a plurality of    monosaccharide units linked by (1-3)-beta bonds.-   183. The bioactive agent according to any of items 166 to 178,    wherein the polysaccharide side chains comprise a plurality of    monosaccharide units linked by (1-2)-beta bonds.-   184. The bioactive agent according to any of items 166 to 178,    wherein the polysaccharide side chains comprise a plurality of    monosaccharide units linked by (1-1)-beta bonds.-   185. The bioactive agent according to any of items 166 to 178,    wherein the polysaccharide side chains comprise a plurality of    monosaccharide units linked by 1-beta-1-alpha bonds.-   186. The bioactive agent according to any of items 166 to 178,    wherein the polysaccharide side chains comprise a plurality of    monosaccharide units linked by 1-alpha-1-alpha bonds.-   187. The bioactive agent according to any of items 166 to 178,    wherein the polysaccharide side chains comprise a plurality of    monosaccharide units linked by 1-alpha-1-beta bonds.-   188. The bioactive agent according to any of items 166 to 178,    wherein the polysaccharide side chains comprise a plurality of    monosaccharide units linked by (1-2)-alpha bonds.-   189. The bioactive agent according to any of items 166 to 178,    wherein the polysaccharide side chains comprise a plurality of    monosaccharide units linked by (1-3)-alpha bonds.-   190. The bioactive agent according to any of items 166 to 178,    wherein the polysaccharide side chains comprise a plurality of    monosaccharide units linked by (1-4)-alpha bonds.-   191. The bioactive agent according to any of items 166 to 178,    wherein the polysaccharide side chains comprise a plurality of    monosaccharide units linked by (1-6)-alpha bonds.-   192. The bioactive agent according to any of items 2 to 191, wherein    the polysaccharide is a heteropolymer comprising two or more    different monosaccharides in the main chain, such as 3 different    monosaccharides in the main chain, for example 4 different    monosaccharides in the main chain, such as 5 different    monosaccharides in the main chain, for example 6 different    monosaccharides in the main chain.-   193. The bioactive agent according to item 192, wherein the    polysaccharide further comprises two or more different    monosaccharides in the side chains, such as 3 different    monosaccharides in the side chains, for example 4 different    monosaccharides in the side chains, such as 5 different    monosaccharides in the side chains, for example 6 different    monosaccharides in the side chains.-   194. The bioactive agent according to any of items 7, 38 and 69,    wherein the ratio R=a/b between a) the number of glucose    monosaccharides and b) the number of further monosaccharides is    about 0,0001, for example about 0,0005, such as about 0,001, for    example about 0,005, such as about 0,01, for example about 0,05,    such as about 0,1, for example about 0,2, such as about 0,3, for    example about 0,4, such as about 0,5, for example about 0,6, such as    about 0,7, for example about 0,8, such as about 0,9, for example    about 1; such as from 1:10000 to 1, such as from 2:10000 to 1; for    example from 4:10000 to 1; such as from 10:10000 to 1; for example    from 20:10000 to 1; such as from 40:10000 to 1; for example from    80:10000 to 1; such as from 100:10000 to 1; for example from    100:10000 to 1; such as from 200:10000 to 1; for example from    250:10000 to 1; such as from 400:10000 to 1; for example from    500:10000 to 1; such as from 1000:10000 to 1; for example from    2000:10000 to 1; such as from 2500:10000 to 1; for example from    3000:10000 to 1; such as from 4000:10000 to 1; for example from    5000:10000 to 1; such as from 6000:10000 to 1; for example from    7000:10000 to 1; such as from 7500:10000 to 1; for example from    8000:10000 to 1; such as from 9000:10000 to 1; for example from    9500:10000 to 1, such as from 1:10000 to 5:10000; for example from    5:10000 to 20:10000, such as from 20:10000 to 100:10000; for example    from 100:10000 to 500:10000; such as from 500:10000 to 1000:10000;    for example from 1000:10000 to 2000:10000; such as from 2000:10000    to 3000:10000; for example from 3000:10000 to 4000:10000; such as    from 4000:10000 to 5000:10000; for example from 5000:10000 to    6000:10000; such as from 6000:10000 to 7000:10000; for example from    7000:10000 to 8000:10000; such as from 8000:10000 to 9000:10000.-   195. The bioactive agent according to any of items 7, 38 and 69,    wherein the ratio R=b/a between a) the number of glucose    monosaccharides and b) the number of further monosaccharides is    about 0,0001, for example about 0,0005, such as about 0,001, for    example about 0,005, such as about 0,01, for example about 0,05,    such as about 0,1, for example about 0,2, such as about 0,3, for    example about 0,4, such as about 0,5, for example about 0,6, such as    about 0,7, for example about 0,8, such as about 0,9, for example    about 1; for example from 1:10000 to 1, such as from 2:10000 to 1;    for example from 4:10000 to 1; such as from 10:10000 to 1; for    example from 20:10000 to 1; such as from 40:10000 to 1; for example    from 80:10000 to 1; such as from 100:10000 to 1; for example from    100:10000 to 1; such as from 200:10000 to 1; for example from    250:10000 to 1; such as from 400:10000 to 1; for example from    500:10000 to 1; such as from 1000:10000 to 1; for example from    2000:10000 to 1; such as from 2500:10000 to 1; for example from    3000:10000 to 1; such as from 4000:10000 to 1; for example from    5000:10000 to 1; such as from 6000:10000 to 1; for example from    7000:10000 to 1; such as from 7500:10000 to 1; for example from    8000:10000 to 1; such as from 9000:10000 to 1; for example from    9500:10000 to 1; such as from 1:10000 to 5:10000; for example from    5:10000 to 20:10000, such as from 20:10000 to 100:10000; for example    from 100:10000 to 500:10000; such as from 500:10000 to 1000:10000;    for example from 1000:10000 to 2000:10000; such as from 2000:10000    to 3000:10000; for example from 3000:10000 to 4000:10000; such as    from 4000:10000 to 5000:10000; for example from 5000:10000 to    6000:10000; such as from 6000:10000 to 7000:10000; for example from    7000:10000 to 8000:10000; such as from 8000:10000 to 9000:10000.-   196. The bioactive agent according to any of items 7, 38 and 69,    wherein the ratio R=a/b between a) the number of glucose    monosaccharides and b) the number of glucuronic acid monosaccharides    is about 0,0001, for example about 0,0005, such as about 0,001, for    example about 0,005, such as about 0,01, for example about 0,05,    such as about 0,1, for example about 0,2, such as about 0,3, for    example about 0,4, such as about 0,5, for example about 0,6, such as    about 0,7, for example about 0,8, such as about 0,9, for example    about 1; for example from 1:10000 to 1, such as from 2:10000 to 1;    for example from 4:10000 to 1; such as from 10:10000 to 1; for    example from 20:10000 to 1; such as from 40:10000 to 1; for example    from 80:10000 to 1; such as from 100:10000 to 1; for example from    100:10000 to 1; such as from 200:10000 to 1; for example from    250:10000 to 1; such as from 400:10000 to 1; for example from    500:10000 to 1; such as from 1000:10000 to 1; for example from    2000:10000 to 1; such as from 2500:10000 to 1; for example from    3000:10000 to 1; such as from 4000:10000 to 1; for example from    5000:10000 to 1; such as from 6000:10000 to 1; for example from    7000:10000 to 1; such as from 7500:10000 to 1; for example from    8000:10000 to 1; such as from 9000:10000 to 1; for example from    9500:10000 to 1; such as from 1:10000 to 5:10000; for example from    5:10000 to 20:10000, such as from 20:10000 to 100:10000; for example    from 100:10000 to 500:10000; such as from 500:10000 to 1000:10000;    for example from 1000:10000 to 2000:10000; such as from 2000:10000    to 3000:10000; for example from 3000:10000 to 4000:10000; such as    from 4000:10000 to 5000:10000; for example from 5000:10000 to    6000:10000; such as from 6000:10000 to 7000:10000; for example from    7000:10000 to 8000:10000; such as from 8000:10000 to 9000:10000.-   197. The bioactive agent according to any of items 7, 38 and 69,    wherein the ratio R=b/a between a) the number of glucose    monosaccharides and b) the number of glucuronic acid monosaccharides    is about 0,0001, for example about 0,0005, such as about 0,001, for    example about 0,005, such as about 0,01, for example about 0,05,    such as about 0,1, for example about 0,2, such as about 0,3, for    example about 0,4, such as about 0,5, for example about 0,6, such as    about 0,7, for example about 0,8, such as about 0,9, for example    about 1; for example from 1:10000 to 1, such as from 2:10000 to 1;    for example from 4:10000 to 1; such as from 10:10000 to 1; for    example from 20:10000 to 1; such as from 40:10000 to 1; for example    from 80:10000 to 1; such as from 100:10000 to 1; for example from    100:10000 to 1; such as from 200:10000 to 1; for example from    250:10000 to 1; such as from 400:10000 to 1; for example from    500:10000 to 1; such as from 1000:10000 to 1; for example from    2000:10000 to 1; such as from 2500:10000 to 1; for example from    3000:10000 to 1; such as from 4000:10000 to 1; for example from    5000:10000 to 1; such as from 6000:10000 to 1; for example from    7000:10000 to 1; such as from 7500:10000 to 1; for example from    8000:10000 to 1; such as from 9000:10000 to 1; for example from    9500:10000 to 1; such as from 1:10000 to 5:10000; for example from    5:10000 to 20:10000, such as from 20:10000 to 100:10000; for example    from 100:10000 to 500:10000; such as from 500:10000 to 1000:10000;    for example from 1000:10000 to 2000:10000; such as from 2000:10000    to 3000:10000; for example from 3000:10000 to 4000:10000; such as    from 4000:10000 to 5000:10000; for example from 5000:10000 to    6000:10000; such as from 6000:10000 to 7000:10000; for example from    7000:10000 to 8000:10000; such as from 8000:10000 to 9000:10000.-   198. The bioactive agent according to any of items 7, 38 and 69,    wherein the ratio R=a/b between a) the number of glucose    monosaccharides and b) the number of galactose monosaccharides is    about 0,0001, for example about 0,0005, such as about 0,001, for    example about 0,005, such as about 0,01, for example about 0,05,    such as about 0,1, for example about 0,2, such as about 0,3, for    example about 0,4, such as about 0,5, for example about 0,6, such as    about 0,7, for example about 0,8, such as about 0,9, for example    about 1; for example from 1:10000 to 1, such as from 2:10000 to 1;    for example from 4:10000 to 1; such as from 10:10000 to 1; for    example from 20:10000 to 1; such as from 40:10000 to 1; for example    from 80:10000 to 1; such as from 100:10000 to 1; for example from    100:10000 to 1; such as from 200:10000 to 1; for example from    250:10000 to 1; such as from 400:10000 to 1; for example from    500:10000 to 1; such as from 1000:10000 to 1; for example from    2000:10000 to 1; such as from 2500:10000 to 1; for example from    3000:10000 to 1; such as from 4000:10000 to 1; for example from    5000:10000 to 1; such as from 6000:10000 to 1; for example from    7000:10000 to 1; such as from 7500:10000 to 1; for example from    8000:10000 to 1; such as from 9000:10000 to 1; for example from    9500:10000 to 1; such as from 1:10000 to 5:10000; for example from    5:10000 to 20:10000, such as from 20:10000 to 100:10000; for example    from 100:10000 to 500:10000; such as from 500:10000 to 1000:10000;    for example from 1000:10000 to 2000:10000; such as from 2000:10000    to 3000:10000; for example from 3000:10000 to 4000:10000; such as    from 4000:10000 to 5000:10000; for example from 5000:10000 to    6000:10000; such as from 6000:10000 to 7000:10000; for example from    7000:10000 to 8000:10000; such as from 8000:10000 to 9000:10000.-   199. The bioactive agent according to any of items 7, 38 and 69,    wherein the ratio R=b/a between a) the number of glucose    monosaccharides and b) the number of galactose monosaccharides is    about 0,0001, for example about 0,0005, such as about 0,001, for    example about 0,005, such as about 0,01, for example about 0,05,    such as about 0,1, for example about 0,2, such as about 0,3, for    example about 0,4, such as about 0,5, for example about 0,6, such as    about 0,7, for example about 0,8, such as about 0,9, for example    about 1; for example from 1:10000 to 1, such as from 2:10000 to 1;    for example from 4:10000 to 1; such as from 10:10000 to 1; for    example from 20:10000 to 1; such as from 40:10000 to 1; for example    from 80:10000 to 1; such as from 100:10000 to 1; for example from    100:10000 to 1; such as from 200:10000 to 1; for example from    250:10000 to 1; such as from 400:10000 to 1; for example from    500:10000 to 1; such as from 1000:10000 to 1; for example from    2000:10000 to 1; such as from 2500:10000 to 1; for example from    3000:10000 to 1; such as from 4000:10000 to 1; for example from    5000:10000 to 1; such as from 6000:10000 to 1; for example from    7000:10000 to 1; such as from 7500:10000 to 1; for example from    8000:10000 to 1; such as from 9000:10000 to 1; for example from    9500:10000 to 1; such as from 1:10000 to 5:10000; for example from    5:10000 to 20:10000, such as from 20:10000 to 100:10000; for example    from 100:10000 to 500:10000; such as from 500:10000 to 1000:10000;    for example from 1000:10000 to 2000:10000; such as from 2000:10000    to 3000:10000; for example from 3000:10000 to 4000:10000; such as    from 4000:10000 to 5000:10000; for example from 5000:10000 to    6000:10000; such as from 6000:10000 to 7000:10000; for example from    7000:10000 to 8000:10000; such as from 8000:10000 to 9000:10000.-   200. The bioactive agent according to any of items 7, 38 and 69,    wherein the ratio R=a/b between a) the number of glucose    monosaccharides and b) the number of mannose monosaccharides is    about 0,0001, for example about 0,0005, such as about 0,001, for    example about 0,005, such as about 0,01, for example about 0,05,    such as about 0,1, for example about 0,2, such as about 0,3, for    example about 0,4, such as about 0,5, for example about 0,6, such as    about 0,7, for example about 0,8, such as about 0,9, for example    about 1; for example from 1:10000 to 1, such as from 2:10000 to 1;    for example from 4:10000 to 1; such as from 10:10000 to 1; for    example from 20:10000 to 1; such as from 40:10000 to 1; for example    from 80:10000 to 1; such as from 100:10000 to 1; for example from    100:10000 to 1; such as from 200:10000 to 1; for example from    250:10000 to 1; such as from 400:10000 to 1; for example from    500:10000 to 1; such as from 1000:10000 to 1; for example from    2000:10000 to 1; such as from 2500:10000 to 1; for example from    3000:10000 to 1; such as from 4000:10000 to 1; for example from    5000:10000 to 1; such as from 6000:10000 to 1; for example from    7000:10000 to 1; such as from 7500:10000 to 1; for example from    8000:10000 to 1; such as from 9000:10000 to 1; for example from    9500:10000 to 1; such as from 1:10000 to 5:10000; for example from    5:10000 to 20:10000, such as from 20:10000 to 100:10000; for example    from 100:10000 to 500:10000; such as from 500:10000 to 1000:10000;    for example from 1000:10000 to 2000:10000; such as from 2000:10000    to 3000:10000; for example from 3000:10000 to 4000:10000; such as    from 4000:10000 to 5000:10000; for example from 5000:10000 to    6000:10000; such as from 6000:10000 to 7000:10000; for example from    7000:10000 to 8000:10000; such as from 8000:10000 to 9000:10000.-   201. The bioactive agent according to any of items 7, 38 and 69,    wherein the ratio R=b/a between a) the number of glucose    monosaccharides and b) the number of mannose monosaccharides is    about 0,0001, for example about 0,0005, such as about 0,001, for    example about 0,005, such as about 0,01, for example about 0,05,    such as about 0,1, for example about 0,2, such as about 0,3, for    example about 0,4, such as about 0,5, for example about 0,6, such as    about 0,7, for example about 0,8, such as about 0,9, for example    about 1; for example from 1:10000 to 1, such as from 2:10000 to 1;    for example from 4:10000 to 1; such as from 10:10000 to 1; for    example from 20:10000 to 1; such as from 40:10000 to 1; for example    from 80:10000 to 1; such as from 100:10000 to 1; for example from    100:10000 to 1; such as from 200:10000 to 1; for example from    250:10000 to 1; such as from 400:10000 to 1; for example from    500:10000 to 1; such as from 1000:10000 to 1; for example from    2000:10000 to 1; such as from 2500:10000 to 1; for example from    3000:10000 to 1; such as from 4000:10000 to 1; for example from    5000:10000 to 1; such as from 6000:10000 to 1; for example from    7000:10000 to 1; such as from 7500:10000 to 1; for example from    8000:10000 to 1; such as from 9000:10000 to 1; for example from    9500:10000 to 1; such as from 1:10000 to 5:10000; for example from    5:10000 to 20:10000, such as from 20:10000 to 100:10000; for example    from 100:10000 to 500:10000; such as from 500:10000 to 1000:10000;    for example from 1000:10000 to 2000:10000; such as from 2000:10000    to 3000:10000; for example from 3000:10000 to 4000:10000; such as    from 4000:10000 to 5000:10000; for example from 5000:10000 to    6000:10000; such as from 6000:10000 to 7000:10000; for example from    7000:10000 to 8000:10000; such as from 8000:10000 to 9000:10000.-   202. The bioactive agent according to any of items 7, 38 and 69,    wherein the ratio R=a/b between a) the number of glucose    monosaccharides and b) the number of arabinose monosaccharides is    about 0,0001, for example about 0,0005, such as about 0,001, for    example about 0,005, such as about 0,01, for example about 0,05,    such as about 0,1, for example about 0,2, such as about 0,3, for    example about 0,4, such as about 0,5, for example about 0,6, such as    about 0,7, for example about 0,8, such as about 0,9, for example    about 1; for example from 1:10000 to 1, such as from 2:10000 to 1;    for example from 4:10000 to 1; such as from 10:10000 to 1; for    example from 20:10000 to 1; such as from 40:10000 to 1; for example    from 80:10000 to 1; such as from 100:10000 to 1; for example from    100:10000 to 1; such as from 200:10000 to 1; for example from    250:10000 to 1; such as from 400:10000 to 1; for example from    500:10000 to 1; such as from 1000:10000 to 1; for example from    2000:10000 to 1; such as from 2500:10000 to 1; for example from    3000:10000 to 1; such as from 4000:10000 to 1; for example from    5000:10000 to 1; such as from 6000:10000 to 1; for example from    7000:10000 to 1; such as from 7500:10000 to 1; for example from    8000:10000 to 1; such as from 9000:10000 to 1; for example from    9500:10000 to 1; such as from 1:10000 to 5:10000; for example from    5:10000 to 20:10000, such as from 20:10000 to 100:10000; for example    from 100:10000 to 500:10000; such as from 500:10000 to 1000:10000;    for example from 1000:10000 to 2000:10000; such as from 2000:10000    to 3000:10000; for example from 3000:10000 to 4000:10000; such as    from 4000:10000 to 5000:10000; for example from 5000:10000 to    6000:10000; such as from 6000:10000 to 7000:10000; for example from    7000:10000 to 8000:10000; such as from 8000:10000 to 9000:10000.-   203. The bioactive agent according to any of items 7, 38 and 69,    wherein the ratio R=b/a between a) the number of glucose    monosaccharides and b) the number of arabinose monosaccharides is    about 0,0001, for example about 0,0005, such as about 0,001, for    example about 0,005, such as about 0,01, for example about 0,05,    such as about 0,1, for example about 0,2, such as about 0,3, for    example about 0,4, such as about 0,5, for example about 0,6, such as    about 0,7, for example about 0,8, such as about 0,9, for example    about 1; for example from 1:10000 to 1, such as from 2:10000 to 1;    for example from 4:10000 to 1; such as from 10:10000 to 1; for    example from 20:10000 to 1; such as from 40:10000 to 1; for example    from 80:10000 to 1; such as from 100:10000 to 1; for example from    100:10000 to 1; such as from 200:10000 to 1; for example from    250:10000 to 1; such as from 400:10000 to 1; for example from    500:10000 to 1; such as from 1000:10000 to 1; for example from    2000:10000 to 1; such as from 2500:10000 to 1; for example from    3000:10000 to 1; such as from 4000:10000 to 1; for example from    5000:10000 to 1; such as from 6000:10000 to 1; for example from    7000:10000 to 1; such as from 7500:10000 to 1; for example from    8000:10000 to 1; such as from 9000:10000 to 1; for example from    9500:10000 to 1; such as from 1:10000 to 5:10000; for example from    5:10000 to 20:10000, such as from 20:10000 to 100:10000; for example    from 100:10000 to 500:10000; such as from 500:10000 to 1000:10000;    for example from 1000:10000 to 2000:10000; such as from 2000:10000    to 3000:10000; for example from 3000:10000 to 4000:10000; such as    from 4000:10000 to 5000:10000; for example from 5000:10000 to    6000:10000; such as from 6000:10000 to 7000:10000; for example from    7000:10000 to 8000:10000; such as from 8000:10000 to 9000:10000.-   204. The bioactive agent according to any of items 7, 38 and 69,    wherein the ratio R=a/b between a) the number of glucose    monosaccharides and b) the number of xylose monosaccharides is about    0,0001, for example about 0,0005, such as about 0,001, for example    about 0,005, such as about 0,01, for example about 0,05, such as    about 0,1, for example about 0,2, such as about 0,3, for example    about 0,4, such as about 0,5, for example about 0,6, such as about    0,7, for example about 0,8, such as about 0,9, for example about 1;    for example from 1:10000 to 1, such as from 2:10000 to 1; for    example from 4:10000 to 1; such as from 10:10000 to 1; for example    from 20:10000 to 1; such as from 40:10000 to 1; for example from    80:10000 to 1; such as from 100:10000 to 1; for example from    100:10000 to 1; such as from 200:10000 to 1; for example from    250:10000 to 1; such as from 400:10000 to 1; for example from    500:10000 to 1; such as from 1000:10000 to 1; for example from    2000:10000 to 1; such as from 2500:10000 to 1; for example from    3000:10000 to 1; such as from 4000:10000 to 1; for example from    5000:10000 to 1; such as from 6000:10000 to 1; for example from    7000:10000 to 1; such as from 7500:10000 to 1; for example from    8000:10000 to 1; such as from 9000:10000 to 1; for example from    9500:10000 to 1; such as from 1:10000 to 5:10000; for example from    5:10000 to 20:10000, such as from 20:10000 to 100:10000; for example    from 100:10000 to 500:10000; such as from 500:10000 to 1000:10000;    for example from 1000:10000 to 2000:10000; such as from 2000:10000    to 3000:10000; for example from 3000:10000 to 4000:10000; such as    from 4000:10000 to 5000:10000; for example from 5000:10000 to    6000:10000; such as from 6000:10000 to 7000:10000; for example from    7000:10000 to 8000:10000; such as from 8000:10000 to 9000:10000.-   205. The bioactive agent according to any of items 7, 38 and 69,    wherein the ratio R=b/a between a) the number of glucose    monosaccharides and b) the number of xylose monosaccharides is about    0,0001, for example about 0,0005, such as about 0,001, for example    about 0,005, such as about 0,01, for example about 0,05, such as    about 0,1, for example about 0,2, such as about 0,3, for example    about 0,4, such as about 0,5, for example about 0,6, such as about    0,7, for example about 0,8, such as about 0,9, for example about 1;    for example from 1:10000 to 1, such as from 2:10000 to 1; for    example from 4:10000 to 1; such as from 10:10000 to 1; for example    from 20:10000 to 1; such as from 40:10000 to 1; for example from    80:10000 to 1; such as from 100:10000 to 1; for example from    100:10000 to 1; such as from 200:10000 to 1; for example from    250:10000 to 1; such as from 400:10000 to 1; for example from    500:10000 to 1; such as from 1000:10000 to 1; for example from    2000:10000 to 1; such as from 2500:10000 to 1; for example from    3000:10000 to 1; such as from 4000:10000 to 1; for example from    5000:10000 to 1; such as from 6000:10000 to 1; for example from    7000:10000 to 1; such as from 7500:10000 to 1; for example from    8000:10000 to 1; such as from 9000:10000 to 1; for example from    9500:10000 to 1; such as from 1:10000 to 5:10000; for example from    5:10000 to 20:10000, such as from 20:10000 to 100:10000; for example    from 100:10000 to 500:10000; such as from 500:10000 to 1000:10000;    for example from 1000:10000 to 2000:10000; such as from 2000:10000    to 3000:10000; for example from 3000:10000 to 4000:10000; such as    from 4000:10000 to 5000:10000; for example from 5000:10000 to    6000:10000; such as from 6000:10000 to 7000:10000; for example from    7000:10000 to 8000:10000; such as from 8000:10000 to 9000:10000.-   206. The bioactive agent according to item 2, wherein the    polysaccharide comprises a structural component in the back bone    comprising beta-1,2-linked D-mannopyranosyl residues and a    structural component in the side chains comprising    beta-D-glucopyranosyl-3-O-beta-D-glucopyranosyl residues.-   207. The bioactive agent according to item 2, wherein the    polysaccharide is a complex comprising a (1,4)-alpha-D-glucan and a    (1,6)-beta glucan.-   208. The bioactive agent according to item 2, wherein the    polysaccharide is a complex comprising a (1,4)-alpha-D-glucan and a    (1,6)-alpha glucan.-   209. The bioactive agent according to any of the above items 1 to    208, wherein said bioactive agent is produced by liquid cultivation    of a Basidiomycete cell selected from the group consisting of cells    belonging to the subclasses of Agaricomycetidae,    Exobasidiomycetidae, Tremellomycetidae and Ustilaginomycetidae.-   210. The bioactive agent according to item 209, wherein the    Basidiomycete cell is selected form the subclass of    Agaricomycetidae.-   211. The bioactive agent according to item 209, wherein the    Basidiomycete cell is selected form the subclass of    Exobasidiomycetidae.-   212. The bioactive agent according to item 209, wherein the    Basidiomycete cell is selected form the subclass of    Tremellomyceditae.-   213. The bioactive agent according to item 209, wherein the    Basidiomycete cell is selected form the subclass of    Ustilaginomycetidae.-   214. The bioactive agent according to item 1 to 208, wherein said    bioactive agent is produced by liquid cultivation of a Basidiomycete    cell selected from the group consisting of cells belonging to the    orders of Agaricales, Boletales, Cantheralles, Ceratobasidiales,    Dacrymycetales, Hymenochaetales, Phallales, Polyporales, Poriales,    Russulales, Thelphorales, Auriculariales, Christianseniales,    Cystofilobasidiales, Filobasidiales, Tremellaleles, Tulasenellales    and Urocystales.-   215. The bioactive agent according to item 214, wherein the    Basidiomycete cell is selected from the order of Agaricales.-   216. The bioactive agent according to item 215, wherein said    Basidiomycete cell belongs to a family selected from the group    consisting of Agaricaceae, Bolbitiaceae, Broomeiaceae, Clavariaceae,    Coprinaceae, Cortinariaceae, Entolomataceae, Fistulinaceae,    Gigaspermaceae, Hemigasteraceae, Hydnangiaceae, Lycoperdaceae,    Marasmiaceae, Mesophelliaceae, Mycenastraceae, Niaceae,    Nidulariaceae, Phelloriniaceae, Pleurotaceae, Pluteaceae,    Pterulaceae, Schizophyllaceae, Stromatocyphaceae, Strophariaceae,    Tricholomataceae, Tulostomataceae, Typhulaceae and Xerulaceae.-   217. The bioactive agent according to item 216, wherein    Basidiomycete cell is selected from the family of Agaricaceae.-   218. The bioactive agent according to item 216, wherein    Basidiomycete cell is selected from the family of Bolbitiaceae.-   219. The bioactive agent according to item 216, wherein    Basidiomycete cell is selected from the family of Broomeiaceae.-   220. The bioactive agent according to item 216, wherein    Basidiomycete cell is selected from the family of Clavariaceae.-   221. The bioactive agent according to item 216, wherein    Basidiomycete cell is selected from the family of Coprinaceae.-   222. The bioactive agent according to item 216, wherein    Basidiomycete cell is selected from the family of Cortinariaceae.-   223. The bioactive agent according to item 216, wherein    Basidiomycete cell is selected from the family of Entolomataceae.-   224. The bioactive agent according to item 216, wherein    Basidiomycete cell is selected from the family of Fistulinaceae.-   225. The bioactive agent according to item 216, wherein    Basidiomycete cell is selected from the family of Gigaspermaceae.-   226. The bioactive agent according to item 216, wherein    Basidiomycete cell is selected from the family of Hemigasteraceae.-   227. The bioactive agent according to item 216, wherein    Basidiomycete cell is selected from the family of Hydnangiaceae.-   228. The bioactive agent according to item 216, wherein    Basidiomycete cell is selected from the family of Lycoperdaceae.-   229. The bioactive agent according to item 216, wherein    Basidiomycete cell is selected from the family of Marasmiaceae.-   230. The bioactive agent according to item 216, wherein    Basidiomycete cell is selected from the family of Mesophelliaceae.-   231. The bioactive agent according to item 216, wherein    Basidiomycete cell is selected from the family of Mycenastraceae.-   232. The bioactive agent according to item 216, wherein    Basidiomycete cell is selected from the family of Niaceae.-   233. The bioactive agent according to item 216, wherein    Basidiomycete cell is selected from the family of Nidulariaceae.-   234. The bioactive agent according to item 216, wherein    Basidiomycete cell is selected from the family of Phelloriniaceae.-   235. The bioactive agent according to item 216, wherein    Basidiomycete cell is selected from the family of Pleurotaceae.-   236. The bioactive agent according to item 216, wherein    Basidiomycete cell is selected from the family of Pluteaceae.-   237. The bioactive agent according to item 216, wherein    Basidiomycete cell is selected from the family of Pterulaceae.-   238. The bioactive agent according to item 216, wherein    Basidiomycete cell is selected from the family of Schizophyllaceae.-   239. The bioactive agent according to item 216, wherein    Basidiomycete cell is selected from the family of Stromatocyphaceae.-   240. The bioactive agent according to item 216, wherein    Basidiomycete cell is selected from the family of Strophariaceae.-   241. The bioactive agent according to item 216, wherein    Basidiomycete cell is selected from the family of Tricholomataceae.-   242. The bioactive agent according to item 216, wherein    Basidiomycete cell is selected from the family of Tulostomataceae.-   243. The bioactive agent according to item 216, wherein    Basidiomycete cell is selected from the family of Typhulaceae.-   244. The bioactive agent according to item 216, wherein    Basidiomycete cell is selected from the family of Xerulaceae.-   245. The bioactive agent according to item 214, wherein the    Basidiomycete cell is selected from the order of Polyporales.-   246. The bioactive agent according to item 245, wherein said    Basidiomycete cell belongs to a family selected from the group    consisting of Albatrellaceae, Atheliaceae, Boreostereaceae,    Corticiaceae, Cyphellaceae, Cystostereaceae, Epitheliaceae,    Fomitopsidaceae, Ganodermataceae, Gloeophyllaceae, Grammotheleaceae,    Hapalopilaceae, Hyphodermataceae, Meripilaceae, Meruliaceae,    Phanerochaetaceae, Podoscyphaceae, Polyporaceae, Sistotremataceae,    Sparassidaceae, Steccherinaceae, Tubulicrinaceae and Xenasmataceae.-   247. The bioactive agent according to item 246, wherein    Basidiomycete cell is selected from the family of Albatrellaceae.-   248. The bioactive agent according to item 246, wherein    Basidiomycete cell is selected from the family of Atheliaceae.-   249. The bioactive agent according to item 246, wherein    Basidiomycete cell is selected from the family of Boreostereaceae.-   250. The bioactive agent according to item 246, wherein    Basidiomycete cell is selected from the family of Corticiaceae.-   251. The bioactive agent according to item 246, wherein    Basidiomycete cell is selected from the family of Cyphellaceae.-   252. The bioactive agent according to item 246, wherein    Basidiomycete cell is selected from the family of Cystostereaceae.-   253. The bioactive agent according to item 246, wherein    Basidiomycete cell is selected from the family of Epitheliaceae.-   254. The bioactive agent according to item 246, wherein    Basidiomycete cell is selected from the family of Fomitopsidaceae.-   255. The bioactive agent according to item 246, wherein    Basidiomycete cell is selected from the family of Ganodermataceae.-   256. The bioactive agent according to item 246, wherein    Basidiomycete cell is selected from the family of Gloeophyllaceae.-   257. The bioactive agent according to item 246, wherein    Basidiomycete cell is selected from the family of Grammotheleaceae.-   258. The bioactive agent according to item 246, wherein    Basidiomycete cell is selected from the family of Hapalopilaceae.-   259. The bioactive agent according to item 246, wherein    Basidiomycete cell is selected from the family of Hyphodermataceae.-   260. The bioactive agent according to item 246, wherein    Basidiomycete cell is selected from the family of Meripilaceae.-   261. The bioactive agent according to item 246, wherein    Basidiomycete cell is selected from the family of Meruliaceae.-   262. The bioactive agent according to item 246, wherein    Basidiomycete cell is selected from the family of Phanerochaetaceae.-   263. The bioactive agent according to item 246, wherein    Basidiomycete cell is selected from the family of Podoscyphaceae.-   264. The bioactive agent according to item 246, wherein    Basidiomycete cell is selected from the family of Polyporaceae.-   265. The bioactive agent according to item 246, wherein    Basidiomycete cell is selected from the family of Sistotremataceae.-   266. The bioactive agent according to item 246, wherein    Basidiomycete cell is selected from the family of Sparassidaceae.-   267. The bioactive agent according to item 246, wherein    Basidiomycete cell is selected from the family of Steccherinaceae.-   268. The bioactive agent according to item 246, wherein    Basidiomycete cell is selected from the family of Tubulicrinaceae.-   269. The bioactive agent according to item 246, wherein    Basidiomycete cell is selected from the family of Xenasmataceae.-   270. The bioactive agent according to item 214, wherein the    Basidiomycete cell is selected from the order of Boletales.-   271. The bioactive agent according to item 270, wherein said    Basidiomycete cell belongs to a family selected from the group    consisting of Boletaceae, Boletinellaceae, Coniophoraceae,    Diplocystaceae, Gasterellaceae, Gastrosporiaceae, Gomphidiaceae,    Gyroporaceae, Hygrophoropsidaceae, Hymenogasteraceae,    Leucogastraceae, Melanogastraceae, Octavianiaceae, Octavianinaceae,    Paxillaceae, Protogastraceae, Rhizopogonaceae, Sclerodermataceae and    Suillaceae.-   272. The bioactive agent according to item 271, wherein    Basidiomycete cell is selected from the family of Boletaceae.-   273. The bioactive agent according to item 271, wherein    Basidiomycete cell is selected from the family of Boletinellaceae.-   274. The bioactive agent according to item 271, wherein    Basidiomycete cell is selected from the family of Coniophoraceae.-   275. The bioactive agent according to item 271, wherein    Basidiomycete cell is selected from the family of Diplocystaceae.-   276. The bioactive agent according to item 271, wherein    Basidiomycete cell is selected from the family of Gasterellaceae.-   277. The bioactive agent according to item 271, wherein    Basidiomycete cell is selected from the family of Gastrosporiaceae.-   278. The bioactive agent according to item 271, wherein    Basidiomycete cell is selected from the family of Gomphidiaceae.-   279. The bioactive agent according to item 271, wherein    Basidiomycete cell is selected from the family of Gyroporaceae.-   280. The bioactive agent according to item 271, wherein    Basidiomycete cell is selected from the family of    Hygrophoropsidaceae.-   281. The bioactive agent according to item 271, wherein    Basidiomycete cell is selected from the family of Hymenogasteraceae.-   282. The bioactive agent according to item 271, wherein    Basidiomycete cell is selected from the family of Leucogastraceae.-   283. The bioactive agent according to item 271, wherein    Basidiomycete cell is selected from the family of Melanogastraceae.-   284. The bioactive agent according to item 271, wherein    Basidiomycete cell is selected from the family of Octavianiaceae.-   285. The bioactive agent according to item 271, wherein    Basidiomycete cell is selected from the family of Octavianinaceae.-   286. The bioactive agent according to item 271, wherein    Basidiomycete cell is selected from the family of Paxillaceae.-   287. The bioactive agent according to item 271, wherein    Basidiomycete cell is selected from the family of Protogastraceae.-   288. The bioactive agent according to item 271, wherein    Basidiomycete cell is selected from the family of Rhizopogonaceae.-   289. The bioactive agent according to item 271, wherein    Basidiomycete cell is selected from the family of Sclerodermataceae.-   290. The bioactive agent according to item 271, wherein    Basidiomycete cell is selected from the family of Suillaceae.-   291. The bioactive agent according to item 214, wherein the    Basidiomycete cell is selected from the order of Cantheralles.-   292. The bioactive agent according to item 291, wherein said    Basidiomycete cell belongs to a family selected from the group    consisting of Aphelariaceae, Botryobasidiaceae, Cantharellaceae,    Clavulinaceae, and Hydnaceae.-   293. The bioactive agent according to item 271, wherein    Basidiomycete cell is selected from the family of Aphelariaceae.-   294. The bioactive agent according to item 271, wherein    Basidiomycete cell is selected from the family of Botryobasidiaceae.-   295. The bioactive agent according to item 271, wherein    Basidiomycete cell is selected from the family of Cantharellaceae.-   296. The bioactive agent according to item 271, wherein    Basidiomycete cell is selected from the family of Clavulinaceae.-   297. The bioactive agent according to item 271, wherein    Basidiomycete cell is selected from the family of Hydnaceae.-   298. The bioactive agent according to item 214, wherein the    Basidiomycete cell is selected from the order of Ceratobasidiales.-   299. The bioactive agent according to item 298, wherein said    Basidiomycete cell belongs to a family selected from the group    consisting of Ceratobasidiaceae and Oliveoniaceae.-   300. The bioactive agent according to item 299, wherein    Basidiomycete cell is selected from the family of Ceratobasidiaceae.-   301. The bioactive agent according to item 299, wherein    Basidiomycete cell is selected from the family of Oliveoniaceae.-   302. The bioactive agent according to item 214, wherein the    Basidiomycete cell is selected from the order of Dacrymycetales.-   303. The bioactive agent according to item 302, wherein said    Basidiomycete cell belongs to a family selected from the group    consisting of Cerinomycetaceae and Dacrymycetaceae.-   304. The bioactive agent according to item 303, wherein    Basidiomycete cell is selected from the family of Cerinomycetaceae.-   305. The bioactive agent according to item 303, wherein    Basidiomycete cell is selected from the family of Dacrymycetaceae.-   306. The bioactive agent according to item 214, wherein the    Basidiomycete cell is selected from the order of Hymenochaetales.-   307. The bioactive agent according to item 306, wherein said    Basidiomycete cell belongs to a family selected from the group    consisting of Asterostromataceae, Hymenochaetaceae and    Schizoporaceae.-   308. The bioactive agent according to item 307, wherein    Basidiomycete cell is selected from the family of    Asterostromataceae.-   309. The bioactive agent according to item 307, wherein    Basidiomycete cell is selected from the family of Hymenochaetaceae.-   310. The bioactive agent according to item 307, wherein    Basidiomycete cell is selected from the family of Schizoporaceae.-   311. The bioactive agent according to item 214, wherein the    Basidiomycete cell is selected from the order of Phallales.-   312. The bioactive agent according to item 311, wherein said    Basidiomycete cell belongs to a family selected from the group    consisting of Geastraceae, Gomphaceae, Hysterangiaceae, Phallaceae    and Ramariaceae.-   313. The bioactive agent according to item 312, wherein    Basidiomycete cell is selected from the family of Geastraceae.-   314. The bioactive agent according to item 312, wherein    Basidiomycete cell is selected from the family of Gomphaceae.-   315. The bioactive agent according to item 312, wherein    Basidiomycete cell is selected from the family of Hysterangiaceae.-   316. The bioactive agent according to item 312, wherein    Basidiomycete cell is selected from the family of Phallaceae.-   317. The bioactive agent according to item 312, wherein    Basidiomycete cell is selected from the family of Ramariaceae.-   318. The bioactive agent according to item 214, wherein the    Basidiomycete cell is selected from the order of Poriales.-   319. The bioactive agent according to item 318, wherein said    Basidiomycete cell belongs to a family of Polyporaceae.-   320. The bioactive agent according to item 214, wherein the    Basidiomycete cell is selected from the order of Russulales.-   321. The bioactive agent according to item 320, wherein said    Basidiomycete cell belongs to a family selected from the group    consisting of Auriscalpiaceae, Bondarzewiaceae, Echinodontiaceae,    Hericiaceae, Hybogasteraceae, Lachnocladiaceae, Peniophoraceae,    Phanerochaetaceae, Russulaceae, Stephanosporaceae and Stereaceae.-   322. The bioactive agent according to item 321, wherein    Basidiomycete cell is selected from the family of Auriscalpiaceae.-   323. The bioactive agent according to item 321, wherein    Basidiomycete cell is selected from the family of Bondarzewiaceae.-   324. The bioactive agent according to item 321, wherein    Basidiomycete cell is selected from the family of Echinodontiaceae.-   325. The bioactive agent according to item 321, wherein    Basidiomycete cell is selected from the family of Hericiaceae.-   326. The bioactive agent according to item 321, wherein    Basidiomycete cell is selected from the family of Hybogasteraceae.-   327. The bioactive agent according to item 321, wherein    Basidiomycete cell is selected from the family of Lachnocladiaceae.-   328. The bioactive agent according to item 321, wherein    Basidiomycete cell is selected from the family of Peniophoraceae.-   329. The bioactive agent according to item 321, wherein    Basidiomycete cell is selected from the family of Phanerochaetaceae.-   330. The bioactive agent according to item 321, wherein    Basidiomycete cell is selected from the family of Russulaceae.-   331. The bioactive agent according to item 321, wherein    Basidiomycete cell is selected from the family of Stephanosporaceae.-   332. The bioactive agent according to item 321, wherein    Basidiomycete cell is selected from the family of Stereaceae.-   333. The bioactive agent according to item 214, wherein the    Basidiomycete cell is selected from the order of Thelophorales.-   334. The bioactive agent according to item 333, wherein said    Basidiomycete cell belongs to a family selected from the group    consisting of Bankeraceae and Thelephoraceae.-   335. The bioactive agent according to item 334, wherein    Basidiomycete cell is selected from the family of Bankeraceae.-   336. The bioactive agent according to item 334, wherein    Basidiomycete cell is selected from the family of Thelephoraceae.-   337. The bioactive agent according to item 214, wherein the    Basidiomycete cell is selected from the order of Auriculariales.-   338. The bioactive agent according to item 337, wherein    Basidiomycete cell is selected from the family of Auriculariaceae.-   339. The bioactive agent according to item 214, wherein the    Basidiomycete cell is selected from the order of Christianseniales.-   340. The bioactive agent according to item 339, wherein    Basidiomycete cell is selected from the family of    Christianseniaceae.-   341. The bioactive agent according to item 214, wherein the    Basidiomycete cell is selected from the order of    Cystofilobasidiales.-   342. The bioactive agent according to item 341, wherein    Basidiomycete cell is selected from the family of    Cystofilobasidiaceae.-   343. The bioactive agent according to item 214, wherein the    Basidiomycete cell is selected from the order of Filobasidiales.-   344. The bioactive agent according to item 343, wherein    Basidiomycete cell is selected from the family of Filobasidiaceae.-   345. The bioactive agent according to item 214, wherein the    Basidiomycete cell is selected from the order of Tremellales.-   346. The bioactive agent according to item 345, wherein said    Basidiomycete cell belongs to a family selected from the group    consisting of Aporpiaceae, Cuniculitremaceae, Exidiaceae,    Hyaloriaceae, Phragmoxenidiaceae, Rhynchogastremataceae,    Sirobasidiaceae, Syzygosporaceae, Tetragoniomycetaceae, Tremellaceae    and Tremellodendropsidaceae.-   347. The bioactive agent according to item 346, wherein    Basidiomycete cell is selected from the family of Aporpiaceae.-   348. The bioactive agent according to item 346, wherein    Basidiomycete cell is selected from the family of Cuniculitremaceae.-   349. The bioactive agent according to item 346, wherein    Basidiomycete cell is selected from the family of Exidiaceae.-   350. The bioactive agent according to item 346, wherein    Basidiomycete cell is selected from the family of Hyaloriaceae.-   351. The bioactive agent according to item 346, wherein    Basidiomycete cell is selected from the family of    Phragmoxenidiaceae.-   352. The bioactive agent according to item 346, wherein    Basidiomycete cell is selected from the family of    Rhynchogastremataceae.-   353. The bioactive agent according to item 346, wherein    Basidiomycete cell is selected from the family of Sirobasidiaceae.-   354. The bioactive agent according to item 346, wherein    Basidiomycete cell is selected from the family of Syzygosporaceae.-   355. The bioactive agent according to item 346, wherein    Basidiomycete cell is selected from the family of    Tetragoniomycetaceae.-   356. The bioactive agent according to item 346, wherein    Basidiomycete cell is selected from the family of Tremellaceae.-   357. The bioactive agent according to item 346, wherein    Basidiomycete cell is selected from the family of    Tremellodendropsidaceae.-   358. The bioactive agent according to item 214, wherein the    Basidiomycete cell is selected from the order of Tulasenellales.-   359. The bioactive agent according to item 358, wherein    Basidiomycete cell is selected from the family of Tulasnellaceae.-   360. The bioactive agent according to item 214, wherein the    Basidiomycete cell is selected from the order of Urocystales.-   361. The bioactive agent according to item 360, wherein    Basidiomycete cell is selected from the family of Urocystaceae.-   362. The bioactive agent according to item 217, wherein said    Basidiomycete cell belongs to a genus selected from the group    consisting of Agaricus, Amanita, Amylolepiota, Araneosa, Artymenium,    Attamyces, Barcheria, Cauloglossum, Chainoderma, Chamaemyces,    Chitonia, Chitoniella, Chitonis, Chlorolepiota, Chlorophyllum,    Chlorosperma, Chlorospora, Clarkeinda, Clavogaster, Coccobotrys,    Crucispora, Cystoagaricus, Cystolepiota, Drosella, Endolepiotula,    Fungus, Fusispora, Gasterellopsis, Glaucospora, Gymnogaster,    Gyrophragmium, Heinemannomyces, Herculea, Hiatulopsis, Holocotylon,    Horakia, Hymenagaricus, Hypogaea, Hypophyllum, Lepidotus,    Lepiotella, Lepiotula, Leucoagaricus, Leucobolbitius, Leucocoprinus,    Longia, Longula, Macrolepiota, Mastocephalus, Melanophyllum,    Metraria, Metrodia, Micropsalliota, Montagnea, Montagnites, Morobia,    Myces, Neosecotium, Notholepiota, Panaeolopsis, Phaeopholiota,    Phlebonema, Phyllogaster, Podaxis, Polyplocium, Pseudoauricularia,    Pulverolepiota, Rickella, Rugosospora, Schinzinia, Schulzeria,    Schweinitzia, Secotium, Sericeomyces, Singerina, Smithiogaster,    Smithiomyces, Stellifera, Termiticola, Verrucospora, Volvigerum,    Volvolepiota and Xanthagaricus.-   363. The bioactive agent according to item 362, wherein    Basidiomycete cell is selected from the genus of Agaricus.-   364. The bioactive agent according to item 362, wherein    Basidiomycete cell is selected from the genus of Amanita.-   365. The bioactive agent according to item 362, wherein    Basidiomycete cell is selected from the genus of Amylolepiota.-   366. The bioactive agent according to item 362, wherein    Basidiomycete cell is selected from the genus of Araneosa.-   367. The bioactive agent according to item 362, wherein    Basidiomycete cell is selected from the genus of Artymenium.-   368. The bioactive agent according to item 362, wherein    Basidiomycete cell is selected from the genus of Attamyces.-   369. The bioactive agent according to item 362, wherein    Basidiomycete cell is selected from the genus of Barcheria.-   370. The bioactive agent according to item 362, wherein    Basidiomycete cell is selected from the genus of Cauloglossum.-   371. The bioactive agent according to item 362, wherein    Basidiomycete cell is selected from the genus of Chainoderma.-   372. The bioactive agent according to item 362, wherein    Basidiomycete cell is selected from the genus of Chamaemyces.-   373. The bioactive agent according to item 362, wherein    Basidiomycete cell is selected from the genus of Chitonia.-   374. The bioactive agent according to item 362, wherein    Basidiomycete cell is selected from the genus of Chitoniella.-   375. The bioactive agent according to item 362, wherein    Basidiomycete cell is selected from the genus of Chitonis.-   376. The bioactive agent according to item 362, wherein    Basidiomycete cell is selected from the genus of Chlorolepiota.-   377. The bioactive agent according to item 362, wherein    Basidiomycete cell is selected from the genus of Chlorophyllum.-   378. The bioactive agent according to item 362, wherein    Basidiomycete cell is selected from the genus of Chlorosperma.-   379. The bioactive agent according to item 362, wherein    Basidiomycete cell is selected from the genus of Chlorospora.-   380. The bioactive agent according to item 362, wherein    Basidiomycete cell is selected from the genus of Clarkeinda.-   381. The bioactive agent according to item 362, wherein    Basidiomycete cell is selected from the genus of Clavogaster.-   382. The bioactive agent according to item 362, wherein    Basidiomycete cell is selected from the genus of Coccobotrys.-   383. The bioactive agent according to item 362, wherein    Basidiomycete cell is selected from the genus of Crucispora.-   384. The bioactive agent according to item 362, wherein    Basidiomycete cell is selected from the genus of Cystoagaricus.-   385. The bioactive agent according to item 362, wherein    Basidiomycete cell is selected from the genus of Cystolepiota.-   386. The bioactive agent according to item 362, wherein    Basidiomycete cell is selected from the genus of Drosella.-   387. The bioactive agent according to item 362, wherein    Basidiomycete cell is selected from the genus of Endolepiotula.-   388. The bioactive agent according to item 362, wherein    Basidiomycete cell is selected from the genus of Fungus.-   389. The bioactive agent according to item 362, wherein    Basidiomycete cell is selected from the genus of Fusispora.-   390. The bioactive agent according to item 362, wherein    Basidiomycete cell is selected from the genus of Gasterellopsis.-   391. The bioactive agent according to item 362, wherein    Basidiomycete cell is selected from the genus of Glaucospora.-   392. The bioactive agent according to item 362, wherein    Basidiomycete cell is selected from the genus of Gymnogaster.-   393. The bioactive agent according to item 362, wherein    Basidiomycete cell is selected from the genus of Gyrophragmium.-   394. The bioactive agent according to item 362, wherein    Basidiomycete cell is selected from the genus of Heinemannomyces.-   395. The bioactive agent according to item 362, wherein    Basidiomycete cell is selected from the genus of Herculea.-   396. The bioactive agent according to item 362, wherein    Basidiomycete cell is selected from the genus of Hiatulopsis.-   397. The bioactive agent according to item 362, wherein    Basidiomycete cell is selected from the genus of Holocotylon.-   398. The bioactive agent according to item 362, wherein    Basidiomycete cell is selected from the genus of Horakia.-   399. The bioactive agent according to item 362, wherein    Basidiomycete cell is selected from the genus of Hymenagaricus.-   400. The bioactive agent according to item 362, wherein    Basidiomycete cell is selected from the genus of Hypogaea.-   401. The bioactive agent according to item 362, wherein    Basidiomycete cell is selected from the genus of Hypophyllum.-   402. The bioactive agent according to item 362, wherein    Basidiomycete cell is selected from the genus of Lepidotus.-   403. The bioactive agent according to item 362, wherein    Basidiomycete cell is selected from the genus of Lepiotella.-   404. The bioactive agent according to item 362, wherein    Basidiomycete cell is selected from the genus of Lepiotula.-   405. The bioactive agent according to item 362, wherein    Basidiomycete cell is selected from the genus of Leucoagaricus.-   406. The bioactive agent according to item 362, wherein    Basidiomycete cell is selected from the genus of Leucobolbitius.-   407. The bioactive agent according to item 362, wherein    Basidiomycete cell is selected from the genus of Leucocoprinus.-   408. The bioactive agent according to item 362, wherein    Basidiomycete cell is selected from the genus of Longia.-   409. The bioactive agent according to item 362, wherein    Basidiomycete cell is selected from the genus of Longula.-   410. The bioactive agent according to item 362, wherein    Basidiomycete cell is selected from the genus of Macrolepiota.-   411. The bioactive agent according to item 362, wherein    Basidiomycete cell is selected from the genus of Mastocephalus.-   412. The bioactive agent according to item 362, wherein    Basidiomycete cell is selected from the genus of Melanophyllum.-   413. The bioactive agent according to item 362, wherein    Basidiomycete cell is selected from the genus of Metraria.-   414. The bioactive agent according to item 362, wherein    Basidiomycete cell is selected from the genus of Metrodia.-   415. The bioactive agent according to item 362, wherein    Basidiomycete cell is selected from the genus of Micropsalliota.-   416. The bioactive agent according to item 362, wherein    Basidiomycete cell is selected from the genus of Montagnea.-   417. The bioactive agent according to item 362, wherein    Basidiomycete cell is selected from the genus of Montagnites.-   418. The bioactive agent according to item 362, wherein    Basidiomycete cell is selected from the genus of Morobia.-   419. The bioactive agent according to item 362, wherein    Basidiomycete cell is selected from the genus of Myces.-   420. The bioactive agent according to item 362, wherein    Basidiomycete cell is selected from the genus of Neosecotium.-   421. The bioactive agent according to item 362, wherein    Basidiomycete cell is selected from the genus of Notholepiota.-   422. The bioactive agent according to item 362, wherein    Basidiomycete cell is selected from the genus of Panaeolopsis.-   423. The bioactive agent according to item 362, wherein    Basidiomycete cell is selected from the genus of Phaeopholiota.-   424. The bioactive agent according to item 362, wherein    Basidiomycete cell is selected from the genus of Phlebonema.-   425. The bioactive agent according to item 362, wherein    Basidiomycete cell is selected from the genus of Phyllogaster.-   426. The bioactive agent according to item 362, wherein    Basidiomycete cell is selected from the genus of Podaxis.-   427. The bioactive agent according to item 362, wherein    Basidiomycete cell is selected from the genus of Polyplocium.-   428. The bioactive agent according to item 362, wherein    Basidiomycete cell is selected from the genus of Pseudoauricularia.-   429. The bioactive agent according to item 362, wherein    Basidiomycete cell is selected from the genus of Pulverolepiota.-   430. The bioactive agent according to item 362, wherein    Basidiomycete cell is selected from the genus of Rickella.-   431. The bioactive agent according to item 362, wherein    Basidiomycete cell is selected from the genus of Rugosospora.-   432. The bioactive agent according to item 362, wherein    Basidiomycete cell is selected from the genus of Schinzinia.-   433. The bioactive agent according to item 362, wherein    Basidiomycete cell is selected from the genus of Schulzeria.-   434. The bioactive agent according to item 362, wherein    Basidiomycete cell is selected from the genus of Schweinitzia.-   435. The bioactive agent according to item 362, wherein    Basidiomycete cell is selected from the genus of Secotium. 436. The    bioactive agent according to item 362, wherein Basidiomycete cell is    selected from the genus of Sericeomyces.-   437. The bioactive agent according to item 362, wherein    Basidiomycete cell is selected from the genus of Singerina.-   438. The bioactive agent according to item 362, wherein    Basidiomycete cell is selected from the genus of Smithiogaster.-   439. The bioactive agent according to item 362, wherein    Basidiomycete cell is selected from the genus of Smithiomyces.-   440. The bioactive agent according to item 362, wherein    Basidiomycete cell is selected from the genus of Stellifera.-   441. The bioactive agent according to item 362, wherein    Basidiomycete cell is selected from the genus of Termiticola.-   442. The bioactive agent according to item 362, wherein    Basidiomycete cell is selected from the genus of Verrucospora.-   443. The bioactive agent according to item 362, wherein    Basidiomycete cell is selected from the genus of Volvigerum.-   444. The bioactive agent according to item 362, wherein    Basidiomycete cell is selected from the genus of Volvolepiota.-   445. The bioactive agent according to item 362, wherein    Basidiomycete cell is selected from the genus of Xanthagaricus.-   446. The bioactive agent according to item 218, wherein said    Basidiomycete cell belongs to a genus selected from the group    consisting of Acetabularia, Agrocybe, Agrogaster, Alnicola,    Anellaria, Bolbitius, Bulla, Campanularius, Chalymmota, Conocybe,    Copelandia, Coprinarius, Cyclocybe, Cyclopus, Cyphellopus,    Cyttarophyllopsis, Cyttarophyllum, Galerella, Galeropsis,    Gastrocybe, Gymnoglossum, Hebeloma, Hebelomatis, Hylophila,    Myxocybe, Naucoria, Panaeolina, Panaeolus, Pholiotella, Pholiotina,    Picromyces, Pluteolus, Psammomyces, Pseudoconocybe, Pseudodeconica,    Ptychella, Raddetes, Roumeguerites, Sarcoloma, Setchelliogaster,    Togaria, Tubariella, Tubariopsis, Tympanella and Wielandomyces.-   447. The bioactive agent according to item 446, wherein    Basidiomycete cell is selected from the genus of Acetabularia.-   448. The bioactive agent according to item 446, wherein    Basidiomycete cell is selected from the genus of Agrocybe.-   449. The bioactive agent according to item 446, wherein    Basidiomycete cell is selected from the genus of Agrogaster.-   450. The bioactive agent according to item 446, wherein    Basidiomycete cell is selected from the genus of Alnicola.-   451. The bioactive agent according to item 446, wherein    Basidiomycete cell is selected from the genus of Anellaria.-   452. The bioactive agent according to item 446, wherein    Basidiomycete cell is selected from the genus of Bolbitius.-   453. The bioactive agent according to item 446, wherein    Basidiomycete cell is selected from the genus of Bulla.-   454. The bioactive agent according to item 446, wherein    Basidiomycete cell is selected from the genus of Campanularius.-   455. The bioactive agent according to item 446, wherein    Basidiomycete cell is selected from the genus of Chalymmota.-   456. The bioactive agent according to item 446, wherein    Basidiomycete cell is selected from the genus of Conocybe.-   457. The bioactive agent according to item 446, wherein    Basidiomycete cell is selected from the genus of Copelandia.-   458. The bioactive agent according to item 446, wherein    Basidiomycete cell is selected from the genus of Coprinarius.-   459. The bioactive agent according to item 446, wherein    Basidiomycete cell is selected from the genus of Cyclocybe.-   460. The bioactive agent according to item 446, wherein    Basidiomycete cell is selected from the genus of Cyclopus.-   461. The bioactive agent according to item 446, wherein    Basidiomycete cell is selected from the genus of Cyphellopus.-   462. The bioactive agent according to item 446, wherein    Basidiomycete cell is selected from the genus of Cyttarophyllopsis.-   463. The bioactive agent according to item 446, wherein    Basidiomycete cell is selected from the genus of Cyttarophyllum.-   464. The bioactive agent according to item 446, wherein    Basidiomycete cell is selected from the genus of Galerella.-   465. The bioactive agent according to item 446, wherein    Basidiomycete cell is selected from the genus of Galeropsis.-   466. The bioactive agent according to item 446, wherein    Basidiomycete cell is selected from the genus of Gastrocybe.-   467. The bioactive agent according to item 446, wherein    Basidiomycete cell is selected from the genus of Gymnoglossum.-   468. The bioactive agent according to item 446, wherein    Basidiomycete cell is selected from the genus of Hebeloma.-   469. The bioactive agent according to item 446, wherein    Basidiomycete cell is selected from the genus of Hebelomatis.-   470. The bioactive agent according to item 446, wherein    Basidiomycete cell is selected from the genus of Hylophila.-   471. The bioactive agent according to item 446, wherein    Basidiomycete cell is selected from the genus of Myxocybe.-   472. The bioactive agent according to item 446, wherein    Basidiomycete cell is selected from the genus of Naucoria.-   473. The bioactive agent according to item 446, wherein    Basidiomycete cell is selected from the genus of Panaeolina.-   474. The bioactive agent according to item 446, wherein    Basidiomycete cell is selected from the genus of Panaeolus.-   475. The bioactive agent according to item 446, wherein    Basidiomycete cell is selected from the genus of Pholiotella.-   476. The bioactive agent according to item 446, wherein    Basidiomycete cell is selected from the genus of Pholiotina.-   477. The bioactive agent according to item 446, wherein    Basidiomycete cell is selected from the genus of Picromyces.-   478. The bioactive agent according to item 446, wherein    Basidiomycete cell is selected from the genus of Pluteolus.-   479. The bioactive agent according to item 446, wherein    Basidiomycete cell is selected from the genus of Psammomyces.-   480. The bioactive agent according to item 446, wherein    Basidiomycete cell is selected from the genus of Pseudoconocybe.-   481. The bioactive agent according to item 446, wherein    Basidiomycete cell is selected from the genus of Pseudodeconica.-   482. The bioactive agent according to item 446, wherein    Basidiomycete cell is selected from the genus of Ptychella.-   483. The bioactive agent according to item 446, wherein    Basidiomycete cell is selected from the genus of Raddetes.-   484. The bioactive agent according to item 446, wherein    Basidiomycete cell is selected from the genus of Roumeguerites.-   485. The bioactive agent according to item 446, wherein    Basidiomycete cell is selected from the genus of Sarcoloma.-   486. The bioactive agent according to item 446, wherein    Basidiomycete cell is selected from the genus of Setchelliogaster.-   487. The bioactive agent according to item 446, wherein    Basidiomycete cell is selected from the genus of Togaria.-   488. The bioactive agent according to item 446, wherein    Basidiomycete cell is selected from the genus of Tubarieila.-   489. The bioactive agent according to item 446, wherein    Basidiomycete cell is selected from the genus of Tubariopsis.-   490. The bioactive agent according to item 446, wherein    Basidiomycete cell is selected from the genus of Tympanella. 491.    The bioactive agent according to item 446, wherein Basidiomycete    cell is selected from the genus of Wielandomyces.-   492. The bioactive agent according to item 219, wherein    Basidiomycete cell is selected from the genus of Broomeia.-   493. The bioactive agent according to item 220, wherein said    Basidiomycete cell belongs to a genus selected from the group    consisting of Capitoclavaria, Clavaria, Clavulinopsis, Cornicularia,    Donkella, Holocoryne, Macrotyphula, Manina, Multiclavula,    Podostrombium, Ramaria, Ramariopsis, Scytinopogon, Setigeroclavula    and Stichoclavaria.-   494. The bioactive agent according to item 493, wherein    Basidiomycete cell is selected from the genus of Capitoclavaria.-   495. The bioactive agent according to item 493, wherein    Basidiomycete cell is selected from the genus of Clavaria.-   496. The bioactive agent according to item 493, wherein    Basidiomycete cell is selected from the genus of Clavulinopsis.-   497. The bioactive agent according to item 493, wherein    Basidiomycete cell is selected from the genus of Cornicularia.-   498. The bioactive agent according to item 493, wherein    Basidiomycete cell is selected from the genus of Donkella.-   499. The bioactive agent according to item 493, wherein    Basidiomycete cell is selected from the genus of Holocoryne.-   500. The bioactive agent according to item 493, wherein    Basidiomycete cell is selected from the genus of Macrotyphula.-   501. The bioactive agent according to item 493, wherein    Basidiomycete cell is selected from the genus of Manina.-   502. The bioactive agent according to item 493, wherein    Basidiomycete cell is selected from the genus of Multiclavula.-   503. The bioactive agent according to item 493, wherein    Basidiomycete cell is selected from the genus of Podostrombium.-   504. The bioactive agent according to item 493, wherein    Basidiomycete cell is selected from the genus of Ramaria.-   505. The bioactive agent according to item 493, wherein    Basidiomycete cell is selected from the genus of Ramariopsis.-   506. The bioactive agent according to item 493, wherein    Basidiomycete cell is selected from the genus of Scytinopogon.-   507. The bioactive agent according to item 493, wherein    Basidiomycete cell is selected from the genus of Setigeroclavula.-   508. The bioactive agent according to item 493, wherein    Basidiomycete cell is selected from the genus of Stichoclavaria.-   509. The bioactive agent according to item 221, wherein said    Basidiomycete cell belongs to a genus selected from the group    consisting of Annularius, Astylospora, Coprinellus, Coprinopsis,    Coprinus, Coprinusella, Cortiniopsis, Drosophila, Ephemerocybe,    Gasteroagaricoides, Glyptospora, Gymnochilus, Homophron,    Hypholomopsis, Lacrymaria, Lentispora, Macrometrula, Onchopus,    Palaeocybe, Pannucia, Parasola, Pluteopsis, Psalliotina,    Psammocoparius, Psathyra, Psathyrella, Pselliophora, Pseudocoprinus,    Psilocybe, Rhacophyllus, Xerocoprinus and Zerovaemyces.-   510. The bioactive agent according to item 509, wherein    Basidiomycete cell is selected from the genus of Annularius.-   511. The bioactive agent according to item 509, wherein    Basidiomycete cell is selected from the genus of Astylospora.-   512. The bioactive agent according to item 509, wherein    Basidiomycete cell is selected from the genus of Coprinellus.-   513. The bioactive agent according to item 509, wherein    Basidiomycete cell is selected from the genus of Coprinopsis.-   514. The bioactive agent according to item 509, wherein    Basidiomycete cell is selected from the genus of Coprinus.-   515. The bioactive agent according to item 509, wherein    Basidiomycete cell is selected from the genus of Coprinusella.-   516. The bioactive agent according to item 509, wherein    Basidiomycete cell is selected from the genus of Cortiniopsis.-   517. The bioactive agent according to item 509, wherein    Basidiomycete cell is selected from the genus of Drosophila.-   518. The bioactive agent according to item 509, wherein    Basidiomycete cell is selected from the genus of Ephemerocybe.-   519. The bioactive agent according to item 509, wherein    Basidiomycete cell is selected from the genus of Gasteroagaricoides.-   520. The bioactive agent according to item 509, wherein    Basidiomycete cell is selected from the genus of Glyptospora.-   521. The bioactive agent according to item 509, wherein    Basidiomycete cell is selected from the genus of Gymnochilus.-   522. The bioactive agent according to item 509, wherein    Basidiomycete cell is selected from the genus of Homophron.-   523. The bioactive agent according to item 509, wherein    Basidiomycete cell is selected from the genus of Hypholomopsis.-   524. The bioactive agent according to item 509, wherein    Basidiomycete cell is selected from the genus of Lacrymaria.-   525. The bioactive agent according to item 509, wherein    Basidiomycete cell is selected from the genus of Lentispora.-   526. The bioactive agent according to item 509, wherein    Basidiomycete cell is selected from the genus of Macrometrula.-   527. The bioactive agent according to item 509, wherein    Basidiomycete cell is selected from the genus of Onchopus.-   528. The bioactive agent according to item 509, wherein    Basidiomycete cell is selected from the genus of Palaeocybe.-   529. The bioactive agent according to item 509, wherein    Basidiomycete cell is selected from the genus of Pannucia.-   530. The bioactive agent according to item 509, wherein    Basidiomycete cell is selected from the genus of Parasola.-   531. The bioactive agent according to item 509, wherein    Basidiomycete cell is selected from the genus of Pluteopsis.-   532. The bioactive agent according to item 509, wherein    Basidiomycete cell is selected from the genus of Psalliotina.-   533. The bioactive agent according to item 509, wherein    Basidiomycete cell is selected from the genus of Psammocoparius.-   534. The bioactive agent according to item 509, wherein    Basidiomycete cell is selected from the genus of Psathyra.-   535. The bioactive agent according to item 509, wherein    Basidiomycete cell is selected from the genus of Psathyrella.-   536. The bioactive agent according to item 509, wherein    Basidiomycete cell is selected from the genus of Pselliophora.-   537. The bioactive agent according to item 509, wherein    Basidiomycete cell is selected from the genus of Pseudocoprinus.-   538. The bioactive agent according to item 509, wherein    Basidiomycete cell is selected from the genus of Psilocybe.-   539. The bioactive agent according to item 509, wherein    Basidiomycete cell is selected from the genus of Rhacophyllus.-   540. The bioactive agent according to item 509, wherein    Basidiomycete cell is selected from the genus of Xerocoprinus.-   541. The bioactive agent according to item 509, wherein    Basidiomycete cell is selected from the genus of Zerovaemyces.-   542. The bioactive agent according to item 222, wherein said    Basidiomycete cell belongs to a genus selected from the group    consisting of Agmocybe, Anamika, Aroramyces, Astrosporina,    Bulbopodium, Calathinus, Cereicium, Chromocyphella, Clypeus,    Cortinarius, Crepidotus, Cribbea, Cuphocybe, Cyanicium, Cymbella,    Cyphellathelia, Cystocybe, Dermocybe, Descolea, Dochmiopus,    Epicorticium, Episphaeria, Flammulaster, Flocculina, Fulvidula,    Galera, Galerina, Galerula, Gomphos, Gymnopilus, Hebelomina,    Horakomyces, Hydrocybe, Hydrocybium, Hydrotelamonia, Hygramaricium,    Hygromyxacium, Inocibium, Inocybe, Inocybella, Inoloma, Kjeldsenia,    Leucocortinarius, Leucopus, Locellina, Mackintoshia, Marasmiopsis,    Melanomphalia, Meliderma, Mycolevis, Myxacium, Myxopholis,    Nanstelocephala, Octojuga, Pellidiscus, Phaeocarpus, Phaeocollybia,    Phaeocyphella, Phaeogalera, Phaeoglabrotricha, Phaeomarasmius,    Phaeosolenia, Phialocybe, Phlegmacium, Pholidotopsis, Pleurotellus,    Pseudodescolea, Pseudogymnopilus, Pyrrhoglossum, Quercella, Ram    icola, Rapacea, Raphanozon, Rozites, Sericeocybe, Simocybe,    Sphaerotrachys, Squamaphlegma, Stagnicola, Stephanopus, Telamonia,    Thaxterogaster, Tremellastrum, Tremellopsis, Tubaria, Velomycena and    Weinzettlia.-   543. The bioactive agent according to item 542, wherein    Basidiomycete cell is selected from the genus of Agmocybe.-   544. The bioactive agent according to item 542, wherein    Basidiomycete cell is selected from the genus of Anamika.-   545. The bioactive agent according to item 542, wherein    Basidiomycete cell is selected from the genus of Aroramyces.-   546. The bioactive agent according to item 542, wherein    Basidiomycete cell is selected from the genus of Astrosporina.-   547. The bioactive agent according to item 542, wherein    Basidiomycete cell is selected from the genus of Bulbopodium.-   548. The bioactive agent according to item 542, wherein    Basidiomycete cell is selected from the genus of Calathinus.-   549. The bioactive agent according to item 542, wherein    Basidiomycete cell is selected from the genus of Cereicium.-   550. The bioactive agent according to item 542, wherein    Basidiomycete cell is selected from the genus of Chromocyphella.-   551. The bioactive agent according to item 542, wherein    Basidiomycete cell is selected from the genus of Clypeus.-   552. The bioactive agent according to item 542, wherein    Basidiomycete cell is selected from the genus of Cortinarius.-   553. The bioactive agent according to item 542, wherein    Basidiomycete cell is selected from the genus of Crepidotus.-   554. The bioactive agent according to item 542, wherein    Basidiomycete cell is selected from the genus of Cribbea.-   555. The bioactive agent according to item 542, wherein    Basidiomycete cell is selected from the genus of Cuphocybe.-   556. The bioactive agent according to item 542, wherein    Basidiomycete cell is selected from the genus of Cyanicium.-   557. The bioactive agent according to item 542, wherein    Basidiomycete cell is selected from the genus of Cymbella.-   558. The bioactive agent according to item 542, wherein    Basidiomycete cell is selected from the genus of Cyphellathelia.-   559. The bioactive agent according to item 542, wherein    Basidiomycete cell is selected from the genus of Cystocybe.-   560. The bioactive agent according to item 542, wherein    Basidiomycete cell is selected from the genus of Dermocybe.-   561. The bioactive agent according to item 542, wherein    Basidiomycete cell is selected from the genus of Descolea.-   562. The bioactive agent according to item 542, wherein    Basidiomycete cell is selected from the genus of Dochmiopus.-   563. The bioactive agent according to item 542, wherein    Basidiomycete cell is selected from the genus of Epicorticium.-   564. The bioactive agent according to item 542, wherein    Basidiomycete cell is selected from the genus of Episphaeria.-   565. The bioactive agent according to item 542, wherein    Basidiomycete cell is selected from the genus of Flammulaster.-   566. The bioactive agent according to item 542, wherein    Basidiomycete cell is selected from the genus of Flocculina.-   567. The bioactive agent according to item 542, wherein    Basidiomycete cell is selected from the genus of Fulvidula.-   568. The bioactive agent according to item 542, wherein    Basidiomycete cell is selected from the genus of Galera.-   569. The bioactive agent according to item 542, wherein    Basidiomycete cell is selected from the genus of Galerina.-   570. The bioactive agent according to item 542, wherein    Basidiomycete cell is selected from the genus of Galerula.-   571. The bioactive agent according to item 542, wherein    Basidiomycete cell is selected from the genus of Gomphos.-   572. The bioactive agent according to item 542, wherein    Basidiomycete cell is selected from the genus of Gymnopilus.-   573. The bioactive agent according to item 542, wherein    Basidiomycete cell is selected from the genus of Hebelomina.-   574. The bioactive agent according to item 542, wherein    Basidiomycete cell is selected from the genus of Horakomyces.-   575. The bioactive agent according to item 542, wherein    Basidiomycete cell is selected from the genus of Hydrocybe.-   576. The bioactive agent according to item 542, wherein    Basidiomycete cell is selected from the genus of Hydrocybium.-   577. The bioactive agent according to item 542, wherein    Basidiomycete cell is selected from the genus of Hydrotelamonia.-   578. The bioactive agent according to item 542, wherein    Basidiomycete cell is selected from the genus of Hygramaricium.-   579. The bioactive agent according to item 542, wherein    Basidiomycete cell is selected from the genus of Hygromyxacium.-   580. The bioactive agent according to item 542, wherein    Basidiomycete cell is selected from the genus of Inocibium.-   581. The bioactive agent according to item 542, wherein    Basidiomycete cell is selected from the genus of Inocybe.-   582. The bioactive agent according to item 542, wherein    Basidiomycete cell is selected from the genus of Inocybella.-   583. The bioactive agent according to item 542, wherein    Basidiomycete cell is selected from the genus of Inoloma.-   584. The bioactive agent according to item 542, wherein    Basidiomycete cell is selected from the genus of Kjeldsenia.-   585. The bioactive agent according to item 542, wherein    Basidiomycete cell is selected from the genus of Leucocortinarius.-   586. The bioactive agent according to item 542, wherein    Basidiomycete cell is selected from the genus of Leucopus.-   587. The bioactive agent according to item 542, wherein    Basidiomycete cell is selected from the genus of Locellina.-   588. The bioactive agent according to item 542, wherein    Basidiomycete cell is selected from the genus of Mackintoshia.-   589. The bioactive agent according to item 542, wherein    Basidiomycete cell is selected from the genus of Marasmiopsis.-   590. The bioactive agent according to item 542, wherein    Basidiomycete cell is selected from the genus of Melanomphalia.-   591. The bioactive agent according to item 542, wherein    Basidiomycete cell is selected from the genus of Meliderma.-   592. The bioactive agent according to item 542, wherein    Basidiomycete cell is selected from the genus of Mycolevis.-   593. The bioactive agent according to item 542, wherein    Basidiomycete cell is selected from the genus of Myxacium.-   594. The bioactive agent according to item 542, wherein    Basidiomycete cell is selected from the genus of Myxopholis.-   595. The bioactive agent according to item 542, wherein    Basidiomycete cell is selected from the genus of Nanstelocephala.-   596. The bioactive agent according to item 542, wherein    Basidiomycete cell is selected from the genus of Octojuga.-   597. The bioactive agent according to item 542, wherein    Basidiomycete cell is selected from the genus of Pellidiscus.-   598. The bioactive agent according to item 542, wherein    Basidiomycete cell is selected from the genus of Phaeocarpus.-   599. The bioactive agent according to item 542, wherein    Basidiomycete cell is selected from the genus of Phaeocollybia.-   600. The bioactive agent according to item 542, wherein    Basidiomycete cell is selected from the genus of Phaeocyphella.-   601. The bioactive agent according to item 542, wherein    Basidiomycete cell is selected from the genus of Phaeogalera.-   602. The bioactive agent according to item 542, wherein    Basidiomycete cell is selected from the genus of Phaeoglabrotricha.-   603. The bioactive agent according to item 542, wherein    Basidiomycete cell is selected from the genus of Phaeomarasmius.-   604. The bioactive agent according to item 542, wherein    Basidiomycete cell is selected from the genus of Phaeosolenia.-   605. The bioactive agent according to item 542, wherein    Basidiomycete cell is selected from the genus of Phialocybe.-   606. The bioactive agent according to item 542, wherein    Basidiomycete cell is selected from the genus of Phlegmacium.-   607. The bioactive agent according to item 542, wherein    Basidiomycete cell is selected from the genus of Pholidotopsis.-   608. The bioactive agent according to item 542, wherein    Basidiomycete cell is selected from the genus of Pleurotellus.-   609. The bioactive agent according to item 542, wherein    Basidiomycete cell is selected from the genus of Pseudodescolea.-   610. The bioactive agent according to item 542, wherein    Basidiomycete cell is selected from the genus of Pseudogymnopilus.-   611. The bioactive agent according to item 542, wherein    Basidiomycete cell is selected from the genus of Pyrrhoglossum.-   612. The bioactive agent according to item 542, wherein    Basidiomycete cell is selected from the genus of Quercella.-   613. The bioactive agent according to item 542, wherein    Basidiomycete cell is selected from the genus of Ramicola.-   614. The bioactive agent according to item 542, wherein    Basidiomycete cell is selected from the genus of Rapacea.-   615. The bioactive agent according to item 542, wherein    Basidiomycete cell is selected from the genus of Raphanozon.-   616. The bioactive agent according to item 542, wherein    Basidiomycete cell is selected from the genus of Rozites.-   617. The bioactive agent according to item 542, wherein    Basidiomycete cell is selected from the genus of Sericeocybe.-   618. The bioactive agent according to item 542, wherein    Basidiomycete cell is selected from the genus of Simocybe.-   619. The bioactive agent according to item 542, wherein    Basidiomycete cell is selected from the genus of Sphaerotrachys.-   620. The bioactive agent according to item 542, wherein    Basidiomycete cell is selected from the genus of Squamaphlegma.-   621. The bioactive agent according to item 542, wherein    Basidiomycete cell is selected from the genus of Stagnicola.-   622. The bioactive agent according to item 542, wherein    Basidiomycete cell is selected from the genus of Stephanopus.-   623. The bioactive agent according to item 542, wherein    Basidiomycete cell is selected from the genus of Telamonia.-   624. The bioactive agent according to item 542, wherein    Basidiomycete cell is selected from the genus of Thaxterogaster.-   625. The bioactive agent according to item 542, wherein    Basidiomycete cell is selected from the genus of Tremellastrum.-   626. The bioactive agent according to item 542, wherein    Basidiomycete cell is selected from the genus of Tremellopsis.-   627. The bioactive agent according to item 542, wherein    Basidiomycete cell is selected from the genus of Tubaria.-   628. The bioactive agent according to item 542, wherein    Basidiomycete cell is selected from the genus of Velomycena.-   629. The bioactive agent according to item 542, wherein    Basidiomycete cell is selected from the genus of Weinzettlia.-   630. The bioactive agent according to item 223, wherein said    Basidiomycete cell belongs to a genus selected from the group    consisting of Alboleptonia, Arenicola, Calliderma, Claudopus,    Clitopiloidea, Clitopilopsis, Clitopilus, Eccilia, Entoloma,    Fibropilus, Hexajuga, Hirneola, Inocephalus, Inopilus, Lanolea,    Latzinaea, Leptonia, Leptoniella, Nigropogon, Nolanea, Omphaliopsis,    Orcella, Paraeccilia, Paraleptonia, Paxillopsis, Pouzarella,    Pouzaromyces, Rhodocybe, Rhodocybella, Rhodogaster, Rhodophana,    Rhodophyllus, Richoniella and Trichopilus.-   631. The bioactive agent according to item 630, wherein    Basidiomycete cell is selected from the genus of Alboleptonia.-   632. The bioactive agent according to item 630, wherein    Basidiomycete cell is selected from the genus of Arenicola.-   633. The bioactive agent according to item 630, wherein    Basidiomycete cell is selected from the genus of Calliderma.-   634. The bioactive agent according to item 630, wherein    Basidiomycete cell is selected from the genus of Claudopus.-   635. The bioactive agent according to item 630, wherein    Basidiomycete cell is selected from the genus of Clitopiloidea.-   636. The bioactive agent according to item 630, wherein    Basidiomycete cell is selected from the genus of Clitopilopsis.-   637. The bioactive agent according to item 630, wherein    Basidiomycete cell is selected from the genus of Clitopilus.-   638. The bioactive agent according to item 630, wherein    Basidiomycete cell is selected from the genus of Eccilia.-   639. The bioactive agent according to item 630, wherein    Basidiomycete cell is selected from the genus of Entoloma.-   640. The bioactive agent according to item 630, wherein    Basidiomycete cell is selected from the genus of Fibropilus.-   641. The bioactive agent according to item 630, wherein    Basidiomycete cell is selected from the genus of Hexajuga.-   642. The bioactive agent according to item 630, wherein    Basidiomycete cell is selected from the genus of Hirneola.-   643. The bioactive agent according to item 630, wherein    Basidiomycete cell is selected from the genus of Inocephalus.-   644. The bioactive agent according to item 630, wherein    Basidiomycete cell is selected from the genus of Inopilus.-   645. The bioactive agent according to item 630, wherein    Basidiomycete cell is selected from the genus of Lanolea.-   646. The bioactive agent according to item 630, wherein    Basidiomycete cell is selected from the genus of Latzinaea.-   647. The bioactive agent according to item 630, wherein    Basidiomycete cell is selected from the genus of Leptonia.-   648. The bioactive agent according to item 630, wherein    Basidiomycete cell is selected from the genus of Leptoniella.-   649. The bioactive agent according to item 630, wherein    Basidiomycete cell is selected from the genus of Nigropogon.-   650. The bioactive agent according to item 630, wherein    Basidiomycete cell is selected from the genus of Nolanea.-   651. The bioactive agent according to item 630, wherein    Basidiomycete cell is selected from the genus of Omphaliopsis.-   652. The bioactive agent according to item 630, wherein    Basidiomycete cell is selected from the genus of Orcella.-   653. The bioactive agent according to item 630, wherein    Basidiomycete cell is selected from the genus of Paraeccilia.-   654. The bioactive agent according to item 630, wherein    Basidiomycete cell is selected from the genus of Paraleptonia.-   655. The bioactive agent according to item 630, wherein    Basidiomycete cell is selected from the genus of Paxillopsis.-   656. The bioactive agent according to item 630, wherein    Basidiomycete cell is selected from the genus of Pouzarella.-   657. The bioactive agent according to item 630, wherein    Basidiomycete cell is selected from the genus of Pouzaromyces.-   658. The bioactive agent according to item 630, wherein    Basidiomycete cell is selected from the genus of Rhodocybe.-   659. The bioactive agent according to item 630, wherein    Basidiomycete cell is selected from the genus of Rhodocybella.-   660. The bioactive agent according to item 630, wherein    Basidiomycete cell is selected from the genus of Rhodogaster.-   661. The bioactive agent according to item 630, wherein    Basidiomycete cell is selected from the genus of Rhodophana.-   662. The bioactive agent according to item 630, wherein    Basidiomycete cell is selected from the genus of Rhodophyllus.-   663. The bioactive agent according to item 630, wherein    Basidiomycete cell is selected from the genus of Richoniella.-   664. The bioactive agent according to item 630, wherein    Basidiomycete cell is selected from the genus of Trichopilus.-   665. The bioactive agent according to item 224, wherein said    Basidiomycete cell belongs to a genus selected from the group    consisting of Agarico-carnis, Buglossus, Confistulina, Fistulina,    Hypodrys and Pseudofistulina.-   666. The bioactive agent according to item 665, wherein    Basidiomycete cell is selected from the genus of Agarico-carnis.-   667. The bioactive agent according to item 665, wherein    Basidiomycete cell is selected from the genus of Buglossus.-   668. The bioactive agent according to item 665, wherein    Basidiomycete cell is selected from the genus of Confistulina.-   669. The bioactive agent according to item 665, wherein    Basidiomycete cell is selected from the genus of Fistulina.-   670. The bioactive agent according to item 665, wherein    Basidiomycete cell is selected from the genus of Hypodrys.-   671. The bioactive agent according to item 665, wherein    Basidiomycete cell is selected from the genus of Pseudofistulina.-   672. The bioactive agent according to item 225, wherein    Basidiomycete cell is selected from the genus of Gigasperma.-   673. The bioactive agent according to item 226, wherein    Basidiomycete cell is selected from the genus of Hemigaster.-   674. The bioactive agent according to item 227, wherein said    Basidiomycete cell belongs to a genus selected from the group    consisting of Hydnangium, Laccaria, Maccagnia, Podohydnangium and    Russuliopsis.-   675. The bioactive agent according to item 674, wherein    Basidiomycete cell is selected from the genus of Hydnangium.-   676. The bioactive agent according to item 674, wherein    Basidiomycete cell is selected from the genus of Laccaria.-   677. The bioactive agent according to item 674, wherein    Basidiomycete cell is selected from the genus of Maccagnia.-   678. The bioactive agent according to item 674, wherein    Basidiomycete cell is selected from the genus of Podohydnangium.-   679. The bioactive agent according to item 674, wherein    Basidiomycete cell is selected from the genus of Russuliopsis.-   680. The bioactive agent according to item 228, wherein said    Basidiomycete cell belongs to a genus selected from the group    consisting of Abstoma, Acutocapillitium, Arachnion, Arachniopsis,    Bovista, Bovistaria, Bovistella, Bovistina, Calbovista, Calvatia,    Calvatiella, Calvatiopsis, Capillaria, Catastoma, Cerophora,    Disciseda, Enteromyxa, Eriosphaera, Gastropila, Globaria,    Glyptoderma, Handkea, Hippoperdon, Hypoblema, Japonogaster,    Langermannia, Lanopila, Lasiosphaera, Lycogalopsis, Lycoperdon,    Lycoperdopsis, Morganella, Omalycus, Piemycus, Piesmycus, Pila,    Priapus, Pseudolycoperdon, Sackea, Scoleciocarpus, Sufa, Utraria and    Vascellum.-   681. The bioactive agent according to item 680, wherein    Basidiomycete cell is selected from the genus of Abstoma.-   682. The bioactive agent according to item 680, wherein    Basidiomycete cell is selected from the genus of Acutocapillitium.-   683. The bioactive agent according to item 680, wherein    Basidiomycete cell is selected from the genus of Arachnion.-   684. The bioactive agent according to item 680, wherein    Basidiomycete cell is selected from the genus of Arachniopsis.-   685. The bioactive agent according to item 680, wherein    Basidiomycete cell is selected from the genus of Bovista.-   686. The bioactive agent according to item 680, wherein    Basidiomycete cell is selected from the genus of Bovistaria.-   687. The bioactive agent according to item 680, wherein    Basidiomycete cell is selected from the genus of Bovistella.-   688. The bioactive agent according to item 680, wherein    Basidiomycete cell is selected from the genus of Bovistina.-   689. The bioactive agent according to item 680, wherein    Basidiomycete cell is selected from the genus of Calbovista.-   690. The bioactive agent according to item 680, wherein    Basidiomycete cell is selected from the genus of Calvatia,-   691. The bioactive agent according to item 680, wherein    Basidiomycete cell is selected from the genus of Calvatiella.-   692. The bioactive agent according to item 680, wherein    Basidiomycete cell is selected from the genus of Calvatiopsis.-   693. The bioactive agent according to item 680, wherein    Basidiomycete cell is selected from the genus of Capillaria.-   694. The bioactive agent according to item 680, wherein    Basidiomycete cell is selected from the genus of Catastoma.-   695. The bioactive agent according to item 680, wherein    Basidiomycete cell is selected from the genus of Cerophora.-   696. The bioactive agent according to item 680, wherein    Basidiomycete cell is selected from the genus of Disciseda.-   697. The bioactive agent according to item 680, wherein    Basidiomycete cell is selected from the genus of Enteromyxa.-   698. The bioactive agent according to item 680, wherein    Basidiomycete cell is selected from the genus of Eriosphaera.-   699. The bioactive agent according to item 680, wherein    Basidiomycete cell is selected from the genus of Gastropila.-   700. The bioactive agent according to item 680, wherein    Basidiomycete cell is selected from the genus of Globaria.-   701. The bioactive agent according to item 680, wherein    Basidiomycete cell is selected from the genus of Glyptoderma.-   702. The bioactive agent according to item 680, wherein    Basidiomycete cell is selected from the genus of Handkea.-   703. The bioactive agent according to item 680, wherein    Basidiomycete cell is selected from the genus of Hippoperdon.-   704. The bioactive agent according to item 680, wherein    Basidiomycete cell is selected from the genus of Hypoblema.-   705. The bioactive agent according to item 680, wherein    Basidiomycete cell is selected from the genus of Japonogaster.-   706. The bioactive agent according to item 680, wherein    Basidiomycete cell is selected from the genus of Langermannia.-   707. The bioactive agent according to item 680, wherein    Basidiomycete cell is selected from the genus of Lanopila.-   708. The bioactive agent according to item 680, wherein    Basidiomycete cell is selected from the genus of Lasiosphaera.-   709. The bioactive agent according to item 680, wherein    Basidiomycete cell is selected from the genus of Lycogalopsis.-   710. The bioactive agent according to item 680, wherein    Basidiomycete cell is selected from the genus of Lycoperdon.-   711. The bioactive agent according to item 680, wherein    Basidiomycete cell is selected from the genus of Lycoperdopsis.-   712. The bioactive agent according to item 680, wherein    Basidiomycete cell is selected from the genus of Morganella.-   713. The bioactive agent according to item 680, wherein    Basidiomycete cell is selected from the genus of Omalycus.-   714. The bioactive agent according to item 680, wherein    Basidiomycete cell is selected from the genus of Piemycus.-   715. The bioactive agent according to item 680, wherein    Basidiomycete cell is selected from the genus of Piesmycus.-   716. The bioactive agent according to item 680, wherein    Basidiomycete cell is selected from the genus of Pila.-   717. The bioactive agent according to item 680, wherein    Basidiomycete cell is selected from the genus of Priapus.-   718. The bioactive agent according to item 680, wherein    Basidiomycete cell is selected from the genus of Pseudolycoperdon.-   719. The bioactive agent according to item 680, wherein    Basidiomycete cell is selected from the genus of Sackea.-   720. The bioactive agent according to item 680, wherein    Basidiomycete cell is selected from the genus of Scoleciocarpus.-   721. The bioactive agent according to item 680, wherein    Basidiomycete cell is selected from the genus of Sufa.-   722. The bioactive agent according to item 680, wherein    Basidiomycete cell is selected from the genus of Utraria.-   723. The bioactive agent according to item 680, wherein    Basidiomycete cell is selected from the genus of Vascellum.-   724. The bioactive agent according to item 229, wherein said    Basidiomycete cell belongs to a genus selected from the group    consisting of Amyloflagellula, Anastrophella, Androsaceus,    Anthracophyllum, Aphotistus, Aphyllotus, Armillaria, Armillariella,    Baeospora, Baumanniella, Calathella, Campanella, Cephaloscypha,    Chaetocalathus, Chamaeceras, Collybidium, Collybiopsis, Coprinopsis,    Cymatella, Cymatellopsis, Cyphellopsis, Cyptotrama, Dactylosporina,    Deigloria, Discocyphella, Eoagaricus, Epicnaphus, Favolaschia,    Fissolimbus, Flagelloscypha, Flammulina, Galeromycena, Gerronema,    Glabrocyphella, Gloiocephala, Heliomyces, Hispidocalyptella,    Hologloea, Hormomitaria, Hymenoconidium, Hymenogloea,    Hymenomarasmius, Lachnella, Laschia, Lecanocybe, Lentinula,    Libellus, Macrocystidia, Macrocystis, Manuripia, Marasmiellus,    Marasmius, Merismodes, Micromphale, Monodelphus, Mucidula,    Mycetinis, Mycomedusa, Myxocollybia, Nochascypha, Omphalotus,    Oudemansia, Oudemansiella, Phaeocyphellopsis, Phaeodepas,    Phaeolimacium, Physalacria, Plagiotus, Polymarasmius, Polymyces,    Poroauricula, Porolaschia, Protomarasmius, Pseudodasyscypha,    Pseudotyphula, Pterospora, Rhizomorpha, Rhodocollybia, Scorteus,    Setulipes, Shitaker, Skepperiella, Stipitocyphella, Strobilurus,    Stromatocyphella, Sympodia, Tephrophana, Tetrapyrgos, Vanromburghia,    Xerula and Xerulina.-   725. The bioactive agent according to item 724, wherein    Basidiomycete cell is selected from the genus of Amyloflagellula.-   726. The bioactive agent according to item 724, wherein    Basidiomycete cell is selected from the genus of Anastrophella.-   727. The bioactive agent according to item 724, wherein    Basidiomycete cell is selected from the genus of Androsaceus.-   728. The bioactive agent according to item 724, wherein    Basidiomycete cell is selected from the genus of Anthracophyllum.-   729. The bioactive agent according to item 724, wherein    Basidiomycete cell is selected from the genus of Aphotistus.-   730. The bioactive agent according to item 724, wherein    Basidiomycete cell is selected from the genus of Aphyllotus.-   731. The bioactive agent according to item 724, wherein    Basidiomycete cell is selected from the genus of Armillaria.-   732. The bioactive agent according to item 724, wherein    Basidiomycete cell is selected from the genus of Armillariella.-   733. The bioactive agent according to item 724, wherein    Basidiomycete cell is selected from the genus of Baeospora.-   734. The bioactive agent according to item 724, wherein    Basidiomycete cell is selected from the genus of Baumanniella.-   735. The bioactive agent according to item 724, wherein    Basidiomycete cell is selected from the genus of Calathella.-   736. The bioactive agent according to item 724, wherein    Basidiomycete cell is selected from the genus of Campanella.-   737. The bioactive agent according to item 724, wherein    Basidiomycete cell is selected from the genus of Cephaloscypha.-   738. The bioactive agent according to item 724, wherein    Basidiomycete cell is selected from the genus of Chaetocalathus.-   739. The bioactive agent according to item 724, wherein    Basidiomycete cell is selected from the genus of Chamaeceras.-   740. The bioactive agent according to item 724, wherein    Basidiomycete cell is selected from the genus of Collybidium.-   741. The bioactive agent according to item 724, wherein    Basidiomycete cell is selected from the genus of Collybiopsis.-   742. The bioactive agent according to item 724, wherein    Basidiomycete cell is selected from the genus of Coprinopsis.-   743. The bioactive agent according to item 724, wherein    Basidiomycete cell is selected from the genus of Cymatella.-   744. The bioactive agent according to item 724, wherein    Basidiomycete cell is selected from the genus of Cymatellopsis.-   745. The bioactive agent according to item 724, wherein    Basidiomycete cell is selected from the genus of Cyphellopsis.-   746. The bioactive agent according to item 724, wherein    Basidiomycete cell is selected from the genus of Cyptotrama.-   747. The bioactive agent according to item 724, wherein    Basidiomycete cell is selected from the genus of Dactylosporina.-   748. The bioactive agent according to item 724, wherein    Basidiomycete cell is selected from the genus of Deigloria.-   749. The bioactive agent according to item 724, wherein    Basidiomycete cell is selected from the genus of Discocyphella.-   750. The bioactive agent according to item 724, wherein    Basidiomycete cell is selected from the genus of Eoagaricus.-   751. The bioactive agent according to item 724, wherein    Basidiomycete cell is selected from the genus of Epicnaphus.-   752. The bioactive agent according to item 724, wherein    Basidiomycete cell is selected from the genus of Favolaschia.-   753. The bioactive agent according to item 724, wherein    Basidiomycete cell is selected from the genus of Fissolimbus.-   754. The bioactive agent according to item 724, wherein    Basidiomycete cell is selected from the genus of Flagelloscypha.-   755. The bioactive agent according to item 724, wherein    Basidiomycete cell is selected from the genus of Flammulina.-   756. The bioactive agent according to item 724, wherein    Basidiomycete cell is selected from the genus of Galeromycena.-   757. The bioactive agent according to item 724, wherein    Basidiomycete cell is selected from the genus of Gerronema.-   758. The bioactive agent according to item 724, wherein    Basidiomycete cell is selected from the genus of Glabrocyphella.-   759. The bioactive agent according to item 724, wherein    Basidiomycete cell is selected from the genus of Gloiocephala.-   760. The bioactive agent according to item 724, wherein    Basidiomycete cell is selected from the genus of Heliomyces.-   761. The bioactive agent according to item 724, wherein    Basidiomycete cell is selected from the genus of Hispidocalyptella.-   762. The bioactive agent according to item 724, wherein    Basidiomycete cell is selected from the genus of Hologloea.-   763. The bioactive agent according to item 724, wherein    Basidiomycete cell is selected from the genus of Hormomitaria.-   764. The bioactive agent according to item 724, wherein    Basidiomycete cell is selected from the genus of Hymenoconidium.-   765. The bioactive agent according to item 724, wherein    Basidiomycete cell is selected from the genus of Hymenogloea.-   766. The bioactive agent according to item 724, wherein    Basidiomycete cell is selected from the genus of Hymenomarasmius.-   767. The bioactive agent according to item 724, wherein    Basidiomycete cell is selected from the genus of Lachnella.-   768. The bioactive agent according to item 724, wherein    Basidiomycete cell is selected from the genus of Laschia.-   769. The bioactive agent according to item 724, wherein    Basidiomycete cell is selected from the genus of Lecanocybe.-   770. The bioactive agent according to item 724, wherein    Basidiomycete cell is selected from the genus of Lentinula.-   771. The bioactive agent according to item 724, wherein    Basidiomycete cell is selected from the genus of Libellus.-   772. The bioactive agent according to item 724, wherein    Basidiomycete cell is selected from the genus of Macrocystidia.-   773. The bioactive agent according to item 724, wherein    Basidiomycete cell is selected from the genus of Macrocystis.-   774. The bioactive agent according to item 724, wherein    Basidiomycete cell is selected from the genus of Manuripia.-   775. The bioactive agent according to item 724, wherein    Basidiomycete cell is selected from the genus of Marasmiellus.-   776. The bioactive agent according to item 724, wherein    Basidiomycete cell is selected from the genus of Marasmius.-   777. The bioactive agent according to item 724, wherein    Basidiomycete cell is selected from the genus of Merismodes.-   778. The bioactive agent according to item 724, wherein    Basidiomycete cell is selected from the genus of Micromphale.-   779. The bioactive agent according to item 724, wherein    Basidiomycete cell is selected from the genus of Monodelphus.-   780. The bioactive agent according to item 724, wherein    Basidiomycete cell is selected from the genus of Mucidula.-   781. The bioactive agent according to item 724, wherein    Basidiomycete cell is selected from the genus of Mycetinis.-   782. The bioactive agent according to item 724, wherein    Basidiomycete cell is selected from the genus of Mycomedusa.-   783. The bioactive agent according to item 724, wherein    Basidiomycete cell is selected from the genus of Myxocollybia.-   784. The bioactive agent according to item 724, wherein    Basidiomycete cell is selected from the genus of Nochascypha.-   785. The bioactive agent according to item 724, wherein    Basidiomycete cell is selected from the genus of Omphalotus.-   786. The bioactive agent according to item 724, wherein    Basidiomycete cell is selected from the genus of Oudemansia.-   787. The bioactive agent according to item 724, wherein    Basidiomycete cell is selected from the genus of Oudemansiella.-   788. The bioactive agent according to item 724, wherein    Basidiomycete cell is selected from the genus of Phaeocyphellopsis.-   789. The bioactive agent according to item 724, wherein    Basidiomycete cell is selected from the genus of Phaeodepas.-   790. The bioactive agent according to item 724, wherein    Basidiomycete cell is selected from the genus of Phaeolimacium.-   791. The bioactive agent according to item 724, wherein    Basidiomycete cell is selected from the genus of Physalacria.-   792. The bioactive agent according to item 724, wherein    Basidiomycete cell is selected from the genus of Plagiotus.-   793. The bioactive agent according to item 724, wherein    Basidiomycete cell is selected from the genus of Polymarasmius.-   794. The bioactive agent according to item 724, wherein    Basidiomycete cell is selected from the genus of Polymyces.-   795. The bioactive agent according to item 724, wherein    Basidiomycete cell is selected from the genus of Poroauricula.-   796. The bioactive agent according to item 724, wherein    Basidiomycete cell is selected from the genus of Porolaschia.-   797. The bioactive agent according to item 724, wherein    Basidiomycete cell is selected from the genus of Protomarasmius.-   798. The bioactive agent according to item 724, wherein    Basidiomycete cell is selected from the genus of Pseudodasyscypha.-   799. The bioactive agent according to item 724, wherein    Basidiomycete cell is selected from the genus of Pseudotyphula.-   800. The bioactive agent according to item 724, wherein    Basidiomycete cell is selected from the genus of Pterospora.-   801. The bioactive agent according to item 724, wherein    Basidiomycete cell is selected from the genus of Rhizomorpha.-   802. The bioactive agent according to item 724, wherein    Basidiomycete cell is selected from the genus of Rhodocollybia.-   803. The bioactive agent according to item 724, wherein    Basidiomycete cell is selected from the genus of Scorteus.-   804. The bioactive agent according to item 724, wherein    Basidiomycete cell is selected from the genus of Setulipes.-   805. The bioactive agent according to item 724, wherein    Basidiomycete cell is selected from the genus of Shitaker.-   806. The bioactive agent according to item 724, wherein    Basidiomycete cell is selected from the genus of Skepperiella.-   807. The bioactive agent according to item 724, wherein    Basidiomycete cell is selected from the genus of Stipitocyphella.-   808. The bioactive agent according to item 724, wherein    Basidiomycete cell is selected from the genus of Strobilurus.-   809. The bioactive agent according to item 724, wherein    Basidiomycete cell is selected from the genus of Stromatocyphella.-   810. The bioactive agent according to item 724, wherein    Basidiomycete cell is selected from the genus of Sympodia.-   811. The bioactive agent according to item 724, wherein    Basidiomycete cell is selected from the genus of Tephrophana.-   812. The bioactive agent according to item 724, wherein    Basidiomycete cell is selected from the genus of Tetrapyrgos.-   813. The bioactive agent according to item 724, wherein    Basidiomycete cell is selected from the genus of Vanromburghia.-   814. The bioactive agent according to item 724, wherein    Basidiomycete cell is selected from the genus of Xerula.-   815. The bioactive agent according to item 724, wherein    Basidiomycete cell is selected from the genus of Xerulina.-   816. The bioactive agent according to item 230, wherein said    Basidiomycete cell belongs to a genus selected from the group    consisting of Andebbia, Castoreum, Gummiglobus, Gummivena, Inoderma,    Malajczukia, Mesophellia, Nothocastoreum and Potoromyces.-   817. The bioactive agent according to item 816, wherein    Basidiomycete cell is selected from the genus of Andebbia.-   818. The bioactive agent according to item 816, wherein    Basidiomycete cell is selected from the genus of Castoreum.-   819. The bioactive agent according to item 816, wherein    Basidiomycete cell is selected from the genus of Gummiglobus.-   820. The bioactive agent according to item 816, wherein    Basidiomycete cell is selected from the genus of Gummivena.-   821. The bioactive agent according to item 816, wherein    Basidiomycete cell is selected from the genus of Inoderma.-   822. The bioactive agent according to item 816, wherein    Basidiomycete cell is selected from the genus of Malajczukia.-   823. The bioactive agent according to item 816, wherein    Basidiomycete cell is selected from the genus of Mesophellia.-   824. The bioactive agent according to item 816, wherein    Basidiomycete cell is selected from the genus of Nothocastoreum.-   825. The bioactive agent according to item 816, wherein    Basidiomycete cell is selected from the genus of Potoromyces.-   826. The bioactive agent according to item 231, wherein said    Basidiomycete cell belongs to a genus selected from the group    consisting of Endonevrum, Mycenastrum and Pachyderma.-   827. The bioactive agent according to item 826, wherein    Basidiomycete cell is selected from the genus of Endonevrum.-   828. The bioactive agent according to item 826, wherein    Basidiomycete cell is selected from the genus of Mycenastrum.-   829. The bioactive agent according to item 826, wherein    Basidiomycete cell is selected from the genus of Pachyderma.-   830. The bioactive agent according to item 232, wherein    Basidiomycete cell is selected from the genus of Nia.-   831. The bioactive agent according to item 233, wherein said    Basidiomycete cell belongs to a genus selected from the group    consisting of Crucibulum, Cyathia, Cyathodes, Cyathus, Granularia,    Mycocalia, Nidula, Nidularia and Peziza.-   832. The bioactive agent according to item 831, wherein    Basidiomycete cell is selected from the genus of Crucibulum.-   833. The bioactive agent according to item 831, wherein    Basidiomycete cell is selected from the genus of Cyathia.-   834. The bioactive agent according to item 831, wherein    Basidiomycete cell is selected from the genus of Cyathodes.-   835. The bioactive agent according to item 831, wherein    Basidiomycete cell is selected from the genus of Cyathus.-   836. The bioactive agent according to item 831, wherein    Basidiomycete cell is selected from the genus of Granularia.-   837. The bioactive agent according to item 831, wherein    Basidiomycete cell is selected from the genus of Mycocalia.-   838. The bioactive agent according to item 831, wherein    Basidiomycete cell is selected from the genus of Nidula.-   839. The bioactive agent according to item 831, wherein    Basidiomycete cell is selected from the genus of Nidularia.-   840. The bioactive agent according to item 831, wherein    Basidiomycete cell is selected from the genus of Peziza.-   841. The bioactive agent according to item 234, wherein said    Basidiomycete cell belongs to a genus selected from the group    consisting of Areolaria, Battarreopsis, Cyphellomyces,    Dictyocephalos, Phellorinia, Whetstonia and Xylopodium.-   842. The bioactive agent according to item 841, wherein    Basidiomycete cell is selected from the genus of Areolaria.-   843. The bioactive agent according to item 841, wherein    Basidiomycete cell is selected from the genus of Battarreopsis.-   844. The bioactive agent according to item 841, wherein    Basidiomycete cell is selected from the genus of Cyphellomyces.-   845. The bioactive agent according to item 841, wherein    Basidiomycete cell is selected from the genus of Dictyocephalos.-   846. The bioactive agent according to item 841, wherein    Basidiomycete cell is selected from the genus of Phellorinia.-   847. The bioactive agent according to item 841, wherein    Basidiomycete cell is selected from the genus of Whetstonia.-   848. The bioactive agent according to item 841, wherein    Basidiomycete cell is selected from the genus of Xylopodium.-   849. The bioactive agent according to item 235, wherein said    Basidiomycete cell belongs to a genus selected from the group    consisting of Acanthocystis, Agaricochaete, Crepidopus,    Cyclopleurotus, Gelona, Geopetalum, Hohenbuehelia, Lentodiopsis,    Pleurotus, Pterophyllus and Scleroma.-   850. The bioactive agent according to item 849, wherein    Basidiomycete cell is selected from the genus of Acanthocystis.-   851. The bioactive agent according to item 849, wherein    Basidiomycete cell is selected from the genus of Agaricochaete.-   852. The bioactive agent according to item 849, wherein    Basidiomycete cell is selected from the genus of Crepidopus.-   853. The bioactive agent according to item 849, wherein    Basidiomycete cell is selected from the genus of Cyclopleurotus.-   854. The bioactive agent according to item 849, wherein    Basidiomycete cell is selected from the genus of Gelona.-   855. The bioactive agent according to item 849, wherein    Basidiomycete cell is selected from the genus of Geopetalum.-   856. The bioactive agent according to item 849, wherein    Basidiomycete cell is selected from the genus of Hohenbuehelia.-   857. The bioactive agent according to item 849, wherein    Basidiomycete cell is selected from the genus of Lentodiopsis.-   858. The bioactive agent according to item 849, wherein    Basidiomycete cell is selected from the genus of Pleurotus.-   859. The bioactive agent according to item 849, wherein    Basidiomycete cell is selected from the genus of Pterophyllus.-   860. The bioactive agent according to item 849, wherein    Basidiomycete cell is selected from the genus of Scleroma.-   861. The bioactive agent according to item 236, wherein said    Basidiomycete cell belongs to a genus selected from the group    consisting of Agaricus, Amanita, Amanitaria, Amanitella, Amanitina,    Amanitopsis, Amarrendia, Amidella, Amplariella, Annularia, Ariella,    Aspidella, Boletium, Chamaeota, Gilbertia, Hyporrhodius, Lepidella,    Leucomyces, Limacella, Myxoderma, Pluteus, Pseudofarinaceus,    Rhodosporus, Termitosphaera, Torrendia, Vaginaria, Vaginarius,    Vaginata, Venenarius, Volva, Volvaria, Volvariella, Volvariopsis,    Volvarius, Volvella, Volvoamanita and Volvoboletus.-   862. The bioactive agent according to item 861, wherein    Basidiomycete cell is selected from the genus of Agaricus.-   863. The bioactive agent according to item 861, wherein    Basidiomycete cell is selected from the genus of Amanita.-   864. The bioactive agent according to item 861, wherein    Basidiomycete cell is selected from the genus of Amanitaria.-   865. The bioactive agent according to item 861, wherein    Basidiomycete cell is selected from the genus of Amanitella.-   866. The bioactive agent according to item 861, wherein    Basidiomycete cell is selected from the genus of Amanitina.-   867. The bioactive agent according to item 861, wherein    Basidiomycete cell is selected from the genus of Amanitopsis.-   868. The bioactive agent according to item 861, wherein    Basidiomycete cell is selected from the genus of Amarrendia.-   869. The bioactive agent according to item 861, wherein    Basidiomycete cell is selected from the genus of Amidella.-   870. The bioactive agent according to item 861, wherein    Basidiomycete cell is selected from the genus of Amplariella.-   871. The bioactive agent according to item 861, wherein    Basidiomycete cell is selected from the genus of Annularia.-   872. The bioactive agent according to item 861, wherein    Basidiomycete cell is selected from the genus of Ariella.-   873. The bioactive agent according to item 861, wherein    Basidiomycete cell is selected from the genus of Aspidella.-   874. The bioactive agent according to item 861, wherein    Basidiomycete cell is selected from the genus of Boletium.-   875. The bioactive agent according to item 861, wherein    Basidiomycete cell is selected from the genus of Chamaeota.-   876. The bioactive agent according to item 861, wherein    Basidiomycete cell is selected from the genus of Gilbertia.-   877. The bioactive agent according to item 861, wherein    Basidiomycete cell is selected from the genus of Hyporrhodius.-   878. The bioactive agent according to item 861, wherein    Basidiomycete cell is selected from the genus of Lepidella.-   879. The bioactive agent according to item 861, wherein    Basidiomycete cell is selected from the genus of Leucomyces.-   880. The bioactive agent according to item 861, wherein    Basidiomycete cell is selected from the genus of Limacella.-   881. The bioactive agent according to item 861, wherein    Basidiomycete cell is selected from the genus of Myxoderma.-   882. The bioactive agent according to item 861, wherein    Basidiomycete cell is selected from the genus of Pluteus.-   883. The bioactive agent according to item 861, wherein    Basidiomycete cell is selected from the genus of Pseudofarinaceus.-   884. The bioactive agent according to item 861, wherein    Basidiomycete cell is selected from the genus of Rhodosporus.-   885. The bioactive agent according to item 861, wherein    Basidiomycete cell is selected from the genus of Termitosphaera.-   886. The bioactive agent according to item 861, wherein    Basidiomycete cell is selected from the genus of Torrendia.-   887. The bioactive agent according to item 861, wherein    Basidiomycete cell is selected from the genus of Vaginaria.-   888. The bioactive agent according to item 861, wherein    Basidiomycete cell is selected from the genus of Vaginarius.-   889. The bioactive agent according to item 861, wherein    Basidiomycete cell is selected from the genus of Vaginata.-   890. The bioactive agent according to item 861, wherein    Basidiomycete cell is selected from the genus of Venenarius.-   891. The bioactive agent according to item 861, wherein    Basidiomycete cell is selected from the genus of Volva.-   892. The bioactive agent according to item 861, wherein    Basidiomycete cell is selected from the genus of Volvaria.-   893. The bioactive agent according to item 861, wherein    Basidiomycete cell is selected from the genus of Volvariella.-   894. The bioactive agent according to item 861, wherein    Basidiomycete cell is selected from the genus of Volvariopsis.-   895. The bioactive agent according to item 861, wherein    Basidiomycete cell is selected from the genus of Volvarius.-   896. The bioactive agent according to item 861, wherein    Basidiomycete cell is selected from the genus of Volvella.-   897. The bioactive agent according to item 861, wherein    Basidiomycete cell is selected from the genus of Volvoamanita.-   898. The bioactive agent according to item 861, wherein    Basidiomycete cell is selected from the genus of Volvoboletus.-   899. The bioactive agent according to item 237, wherein said    Basidiomycete cell belongs to a genus selected from the group    consisting of Actiniceps, Allantula, Ceratella, Deflexula,    Dimorphocystis, Parapterulicium, Penicillaria, Phaeopterula, Pterula    and Pterulicium.-   900. The bioactive agent according to item 899, wherein    Basidiomycete cell is selected from the genus of Actiniceps.-   901. The bioactive agent according to item 899, wherein    Basidiomycete cell is selected from the genus of Allantula.-   902. The bioactive agent according to item 899, wherein    Basidiomycete cell is selected from the genus of Ceratella.-   903. The bioactive agent according to item 899, wherein    Basidiomycete cell is selected from the genus of Deflexula.-   904. The bioactive agent according to item 899, wherein    Basidiomycete cell is selected from the genus of Dimorphocystis.-   905. The bioactive agent according to item 899, wherein    Basidiomycete cell is selected from the genus of Parapterulicium.-   906. The bioactive agent according to item 899, wherein    Basidiomycete cell is selected from the genus of Penicillaria.-   907. The bioactive agent according to item 899, wherein    Basidiomycete cell is selected from the genus of Phaeopterula.-   908. The bioactive agent according to item 899, wherein    Basidiomycete cell is selected from the genus of Pterula.-   909. The bioactive agent according to item 899, wherein    Basidiomycete cell is selected from the genus of Pterulicium.-   910. The bioactive agent according to item 238, wherein said    Basidiomycete cell belongs to a genus selected from the group    consisting of Apus, Auriculariopsis, Cytidiella, Ditiola,    Flabellaria, Henningsomyces, Hyponevris, Petrona,    Phaeoschizophyllum, Porotheleum, Rectipilus, Rhipidium,    Scaphophoeum, Schizonia, Schizophyllum and Solenia.-   911. The bioactive agent according to item 910, wherein    Basidiomycete cell is selected from the genus of Apus.-   912. The bioactive agent according to item 910, wherein    Basidiomycete cell is selected from the genus of Auriculariopsis.-   913. The bioactive agent according to item 910, wherein    Basidiomycete cell is selected from the genus of Cytidiella.-   914. The bioactive agent according to item 910, wherein    Basidiomycete cell is selected from the genus of Ditiola.-   915. The bioactive agent according to item 910, wherein    Basidiomycete cell is selected from the genus of Flabellaria.-   916. The bioactive agent according to item 910, wherein    Basidiomycete cell is selected from the genus of Henningsomyces.-   917. The bioactive agent according to item 910, wherein    Basidiomycete cell is selected from the genus of Hyponevris.-   918. The bioactive agent according to item 910, wherein    Basidiomycete cell is selected from the genus of Petrona.-   919. The bioactive agent according to item 910, wherein    Basidiomycete cell is selected from the genus of Phaeoschizophyllum.-   920. The bioactive agent according to item 910, wherein    Basidiomycete cell is selected from the genus of Porotheleum.-   921. The bioactive agent according to item 910, wherein    Basidiomycete cell is selected from the genus of Rectipilus.-   922. The bioactive agent according to item 910, wherein    Basidiomycete cell is selected from the genus of Rhipidium.-   923. The bioactive agent according to item 910, wherein    Basidiomycete cell is selected from the genus of Scaphophoeum.-   924. The bioactive agent according to item 910, wherein    Basidiomycete cell is selected from the genus of Schizonia.-   925. The bioactive agent according to item 910, wherein    Basidiomycete cell is selected from the genus of Schizophyllum.-   926. The bioactive agent according to item 910, wherein    Basidiomycete cell is selected from the genus of Solenia.-   927. The bioactive agent according to item 239, wherein    Basidiomycete cell is selected from the genus of Stromatoscypha.-   928. The bioactive agent according to item 240, wherein said    Basidiomycete cell belongs to a genus selected from the group    consisting of Cytophyllopsis, Deconica, Delitescor, Derminus,    Dryophila, Flammopsis, Flammula, Galeropsina, Geophila, Gymnocybe,    Hemipholiota, Hypholoma, Hypodendrum, Kuehneromyces, Le-Ratia,    Leratiomyces, Melanotus, Mythicomyces, Nematoloma, Nemecomyces,    Nivatogastrium, Pachylepyrium, Phaeonematoloma, Pholiota,    Pleuroflammula, Psilocybe, Ryssospora, Stropharia, Stropholoma,    Visculus and Weraroa.-   929. The bioactive agent according to item 928, wherein    Basidiomycete cell is selected from the genus of Cytophyllopsis.-   930. The bioactive agent according to item 928, wherein    Basidiomycete cell is selected from the genus of Deconica.-   931. The bioactive agent according to item 928, wherein    Basidiomycete cell is selected from the genus of Delitescor.-   932. The bioactive agent according to item 928, wherein    Basidiomycete cell is selected from the genus of Derminus.-   933. The bioactive agent according to item 928, wherein    Basidiomycete cell is selected from the genus of Dryophila.-   934. The bioactive agent according to item 928, wherein    Basidiomycete cell is selected from the genus of Flammopsis.-   935. The bioactive agent according to item 928, wherein    Basidiomycete cell is selected from the genus of Flammula.-   936. The bioactive agent according to item 928, wherein    Basidiomycete cell is selected from the genus of Galeropsina.-   937. The bioactive agent according to item 928, wherein    Basidiomycete cell is selected from the genus of Geophila.-   938. The bioactive agent according to item 928, wherein    Basidiomycete cell is selected from the genus of Gymnocybe.-   939. The bioactive agent according to item 928, wherein    Basidiomycete cell is selected from the genus of Hemipholiota.-   940. The bioactive agent according to item 928, wherein    Basidiomycete cell is selected from the genus of Hypholoma.-   941. The bioactive agent according to item 928, wherein    Basidiomycete cell is selected from the genus of Hypodendrum.-   942. The bioactive agent according to item 928, wherein    Basidiomycete cell is selected from the genus of Kuehneromyces.-   943. The bioactive agent according to item 928, wherein    Basidiomycete cell is selected from the genus of Le-Ratia.-   944. The bioactive agent according to item 928, wherein    Basidiomycete cell is selected from the genus of Leratiomyces.-   945. The bioactive agent according to item 928, wherein    Basidiomycete cell is selected from the genus of Melanotus.-   946. The bioactive agent according to item 928, wherein    Basidiomycete cell is selected from the genus of Mythicomyces.-   947. The bioactive agent according to item 928, wherein    Basidiomycete cell is selected from the genus of Nematoloma.-   948. The bioactive agent according to item 928, wherein    Basidiomycete cell is selected from the genus of Nemecomyces.-   949. The bioactive agent according to item 928, wherein    Basidiomycete cell is selected from the genus of Nivatogastrium.-   950. The bioactive agent according to item 928, wherein    Basidiomycete cell is selected from the genus of Pachylepyrium.-   951. The bioactive agent according to item 928, wherein    Basidiomycete cell is selected from the genus of Phaeonematoloma.-   952. The bioactive agent according to item 928, wherein    Basidiomycete cell is selected from the genus of Pholiota.-   953. The bioactive agent according to item 928, wherein    Basidiomycete cell is selected from the genus of Pleuroflammula.-   954. The bioactive agent according to item 928, wherein    Basidiomycete cell is selected from the genus of Psilocybe.-   955. The bioactive agent according to item 928, wherein    Basidiomycete cell is selected from the genus of Ryssospora.-   956. The bioactive agent according to item 928, wherein    Basidiomycete cell is selected from the genus of Stropharia.-   957. The bioactive agent according to item 928, wherein    Basidiomycete cell is selected from the genus of Stropholoma.-   958. The bioactive agent according to item 928, wherein    Basidiomycete cell is selected from the genus of Visculus.-   959. The bioactive agent according to item 928, wherein    Basidiomycete cell is selected from the genus of Weraroa.-   960. The bioactive agent according to item 241, wherein said    Basidiomycete cell belongs to a genus selected from the group    consisting of Aeruginospora, Amparoina, Ampulloclitocybe, Arrhenia,    Arthrosporella, Asproinocybe, Aspropaxillus, Asterophora,    Asterotrichum, Asterotus, Austroclitocybe, Austroomphaliaster,    Bactroboletus, Basidopus, Bertrandia, Bertrandiella, Biannularia,    Boehmia, Botrydina, Caesposus, Callistodermatium, Callistosporium,    Calocybe, Calyptella, Camarophyllopsis, Camarophyllus,    Campanophyllum, Cantharellopsis, Cantharellula, Cantharocybe,    Catathelasma, Catatrama, Caulorhiza, Cellypha, Cheimonophyllum,    Chromosera, Chrysobostrychodes, Chrysomphalina, Clavicybe,    Clavomphalia, Clitocybe, Clitocybula, Collopus, Collybia,    Conchomyces, Coolia, Coriscium, Corniola, Corrugaria, Cortinellus,    Crinipellis, Cuphophyllus, Cynema, Cyphellocalathus, Cystoderma,    Cystodermella, Decapitatus, Delicatula, Dendrocollybia,    Dennisiomyces, Dermoloma, Dictyolus, Dictyopanus, Dictyoploca,    Dissoderma, Echinosporella, Eomycenella, Fayodia, Filoboletus,    Flabellimycena, Floccularia, Galactopus, Gamundia, Geotus,    Gerhardtia, Gliophorus, Glutinaster, Godfrinia, Gymnopus,    Gyroflexus, Gyrophila, Haasiella, Heimiomyces, Helotium, Hemimycena,    Heterosporula, Hiatula, Hodophilus, Humidicutis, Hydrophorus,    Hydropus, Hygroaster, Hygrocybe, Hygrophorus, Hygrotrama,    Hypsizygus, Infundibulicybe, Insiticia, Jacobia, Lactocollybia,    Lampteromyces, Leiopoda, Lepista, Leptoglossum, Leptomyces,    Leptotus, Leucoinocybe, Leucopaxillus, Leucopholiota,    Lichenomphalia, Limacinus, Limacium, Linopodium, Lulesia,    Lyophyllopsis, Lyophyllum, Macrocybe, Maireina, Mastoleucomyces,    Megacollybia, Megatricholoma, Melaleuca, Melanoleuca,    Metulocyphella, Microcollybia, Microcollybia, Mniopetalum,    Moniliophthora, Monomyces, Mycena, Mycenella, Mycenoporella,    Mycenopsis, Mycenula, Mycoalvimia, Myxomphalia, Nematoctonus,    Neoclitocybe, Neohygrocybe, Neohygrophorus, Neonothopanus,    Nothoclavulina, Nothopanus, Nyctalis, Omphalia, Omphalia,    Omphaliaster, Omphalina, Omphalius, Omphalopsis, Ossicaulis,    Palaeocephala, Panellus, Paralepista, Peglerochaete, Peg leromyces,    Perona, Phaeolepiota, Phaeomycena, Phaeotellus, Phalomia,    Phlebomarasmius, Phlebomycena, Phlebophora, Phyllotopsis,    Phyllotremella, Phyllotus, Physocystidium, Phytoconis, Pleuralia,    Pleurocollybia, Pleurocybella, Pleuromycenula, Pleurotopsis,    Podabrella, Poromycena, Porpoloma, Prunulus, Psammospora,    Pseudoarmillariella, Pseudobaeospora, Pseudoclitocybe,    Pseudohiatula, Pseudohygrocybe, Pseudohygrophorus, Pseudolyophyllum,    Pseudomycena, Pseudoomphalina, Rajapa, Resinomycena, Resupinatus,    Retocybe, Rhodocyphella, Rhodopaxillus, Rhodotus, Rickenella,    Rimbachia, Ripartitella, Ripartites, Roridomyces, Rubeolarius,    Rugosomyces, Sarcomyxa, Sclerostilbum, Scytinotopsis, Scytinotus,    Semiomphalina, Singerella, Singerocybe, Sinotermitomyces,    Sphaerocephalus, Squamanita, Stachyomphalina, Stanglomyces,    Stereopodium, Stigmatolemma, Tectella, Tephrocybe, Termitomyces,    Tilachlidiopsis, Tilotus, Tomentifolium, Tricholoma, Tricholomella,    Tricholomopsis, Tricholosporum, Trigonipes, Trogia, Ugola, Urceolus,    Urospora, Urosporellina, Valentinia, Xeromphalina and Zephirea.-   961. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Aeruginospora.-   962. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Amparoina.-   963. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Ampulloclitocybe.-   964. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Ampulloclitocybe.-   965. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Arrhenia.-   966. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Arthrosporella.-   967. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Asproinocybe.-   968. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Aspropaxillus.-   969. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Asterophora.-   970. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Asterotrichum.-   971. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Asterotus.-   972. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Austroclitocybe.-   973. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Austroomphaliaster.-   974. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Bactroboletus.-   975. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Basidopus.-   976. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Bertrandia.-   977. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Bertrandiella.-   978. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus Biannularia.-   979. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Boehmia.-   980. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Botrydina.-   981. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Caesposus.-   982. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Callistodermatium.-   983. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Callistosporium.-   984. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Calocybe.-   985. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Calyptella.-   986. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Camarophyllopsis.-   987. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Camarophyllus.-   988. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Campanophyllum.-   989. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Cantharellopsis.-   990. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Cantharellula.-   991. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Cantharocybe.-   992. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Catathelasma.-   993. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Catatrama.-   994. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Caulorhiza.-   995. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Cellypha.-   996. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Cheimonophyllum.-   997. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Chromosera.-   998. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Chrysobostrychodes.-   999. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Chrysomphalina.-   1000. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Clavicybe.-   1001. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Clavomphalia.-   1002. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Clitocybe.-   1003. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Clitocybula.-   1004. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Collopus.-   1005. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Collybia.-   1006. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Conchomyces.-   1007. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Coolia.-   1008. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Coriscium.-   1009. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Corniola.-   1010. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Corrugaria.-   1011. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Cortinellus.-   1012. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Crinipellis.-   1013. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Cuphophyllus.-   1014. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Cynema.-   1015. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Cyphellocalathus.-   1016. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Cystoderma.-   1017. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Cystodermella.-   1018. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Decapitatus.-   1019. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Delicatula.-   1020. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Dendrocollybia.-   1021. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Dennisiomyces.-   1022. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Dermoloma.-   1023. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Dictyolus.-   1024. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Dictyopanus.-   1025. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Dictyoploca.-   1026. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Dissoderma.-   1027. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Echinosporella.-   1028. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Eomycenella.-   1029. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Fayodia.-   1030. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Filoboletus.-   1031. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Flabellimycena.-   1032. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Floccularia.-   1033. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Galactopus.-   1034. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Gamundia.-   1035. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Geotus.-   1036. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Gerhardtia.-   1037. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Gliophorus.-   1038. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Glutinaster.-   1039. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Godfrinia.-   1040. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Gymnopus.-   1041. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Gyroflexus.-   1042. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Gyrophila.-   1043. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Haasiella.-   1044. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Heinniomyces.-   1045. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Helotium.-   1046. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Hemimycena.-   1047. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Heterosporula.-   1048. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Hiatula.-   1049. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Hodophilus.-   1050. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Humidicutis.-   1051. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Hydrophorus.-   1052. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Hydropus.-   1053. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Hygroaster.-   1054. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Hygrocybe.-   1055. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Hygrophorus.-   1056. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Hygrotrama.-   1057. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Hypsizygus.-   1058. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Infundibulicybe.-   1059. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Insiticia.-   1060. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Jacobia.-   1061. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Lactocollybia.-   1062. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Lampteromyces.-   1063. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Leiopoda.-   1064. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Lepista.-   1065. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Leptoglossum.-   1066. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Leptotus.-   1067. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Leucoinocybe.-   1068. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Leucopaxillus.-   1069. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Leucopholiota.-   1070. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Lichenomphalia.-   1071. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Limacinus.-   1072. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Limacium.-   1073. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Linopodium.-   1074. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Lulesia.-   1075. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Lyophyllopsis.-   1076. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Lyophyllum.-   1077. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Macrocybe.-   1078. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Maireina.-   1079. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Mastoleucomyces.-   1080. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Megacollybia.-   1081. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Megatricholoma.-   1082. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Melaleuca.-   1083. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Melanoleuca.-   1084. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Metulocyphella.-   1085. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Microcollybia.-   1086. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Mniopetalum.-   1087. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Moniliophthora.-   1088. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Monomyces.-   1089. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Mycena.-   1090. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Mycenella.-   1091. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Mycenoporella.-   1092. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Mycenopsis.-   1093. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Mycenula.-   1094. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Mycoalvimia.-   1095. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Myxomphalia.-   1096. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Nematoctonus.-   1097. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Neoclitocybe.-   1098. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Neohygrocybe.-   1099. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Neohygrophorus.-   1100. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Neonothopanus.-   1101. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Nothoclavulina.-   1102. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Nothopanus.-   1103. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Nyctalis.-   1104. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Omphalia.-   1105. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Omphaliaster.-   1106. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Omphalina.-   1107. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Omphalius.-   1108. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Omphalopsis.-   1109. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Ossicaulis.-   1110. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Palaeocephala.-   1111. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Panellus.-   1112. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Paralepista.-   1113. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Peglerochaete.-   1114. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Pegleromyces.-   1115. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Perona.-   1116. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Phaeolepiota.-   1117. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Phaeomycena.-   1118. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Phaeotellus.-   1119. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Phalomia.-   1120. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Phlebomarasmius.-   1121. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Phlebomycena.-   1122. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Phlebophora.-   1123. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Phyllotopsis.-   1124. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Phyllotremella.-   1125. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Phyllotus.-   1126. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Physocystidium.-   1127. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Phytoconis.-   1128. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Pleurella.-   1129. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Pleurocollybia.-   1130. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Pleurocybella.-   1131. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Pleuromycenula.-   1132. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Pleurotopsis.-   1133. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Podabrella.-   1134. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Poromycena.-   1135. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Porpoloma.-   1136. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Prunulus.-   1137. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Psammospora.-   1138. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of    Pseudoarmillariella.-   1139. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Pseudobaeospora.-   1140. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Pseudoclitocybe.-   1141. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Pseudohiatula.-   1142. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Pseudohygrocybe.-   1143. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Pseudohygrophorus.-   1144. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Pseudolyophyllum.-   1145. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Pseudomycena.-   1146. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Pseudoomphalina.-   1147. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Rajapa.-   1148. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Resinomycena.-   1149. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Resupinatus.-   1150. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Retocybe.-   1151. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Rhodocyphella.-   1152. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Rhodopaxillus.-   1153. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Rhodotus.-   1154. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Rickenella.-   1155. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Rimbachia.-   1156. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Ripartitella.-   1157. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Ripartites.-   1158. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Roridomyces.-   1159. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Rubeolarius.-   1160. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Rugosomyces.-   1161. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Sarcomyxa.-   1162. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Sclerostilbum.-   1163. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Scytinotopsis.-   1164. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Scytinotus.-   1165. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Semiomphalina.-   1166. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Singerella.-   1167. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Singerocybe.-   1168. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Sinotermitomyces.-   1169. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Sphaerocephalus.-   1170. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Squamanita.-   1171. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Stachyomphalina.-   1172. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Stanglomyces.-   1173. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Stereopodium.-   1174. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Stigmatolemma.-   1175. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Tectella.-   1176. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Tephrocybe.-   1177. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Termitomyces.-   1178. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Tilachlidiopsis.-   1179. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Tilotus.-   1180. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Tomentifolium.-   1181. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Tricholoma.-   1182. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Tricholomella.-   1183. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Tricholomopsis.-   1184. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Tricholosporum.-   1185. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Trigonipes.-   1186. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Trogia.-   1187. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Ugola.-   1188. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Urceolus.-   1189. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Urospora.-   1190. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Urosporellina.-   1191. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Valentinia.-   1192. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Xeromphalina.-   1193. The bioactive agent according to item 960, wherein    Basidiomycete cell is selected from the genus of Zephirea.-   1194. The bioactive agent according to item 242, wherein said    Basidiomycete cell belongs to a genus selected from the group    consisting of Battarraeastrum, Battarrea, Battarreoides,    Chlamydopus, Dendromyces, Queletia, Schizostoma, Sphaericeps,    Tulasnodea and Tulostoma.-   1195. The bioactive agent according to item 1195, wherein    Basidiomycete cell is selected from the genus of Battarraeastrum.-   1196. The bioactive agent according to item 1195, wherein    Basidiomycete cell is selected from the genus of Battarrea.-   1197. The bioactive agent according to item 1195, wherein    Basidiomycete cell is selected from the genus of Battarreoides.-   1198. The bioactive agent according to item 1195, wherein    Basidiomycete cell is selected from the genus of Chlamydopus.-   1199. The bioactive agent according to item 1195, wherein    Basidiomycete cell is selected from the genus of Dendromyces.-   1200. The bioactive agent according to item 1195, wherein    Basidiomycete cell is selected from the genus of Queletia.-   1201. The bioactive agent according to item 1195, wherein    Basidiomycete cell is selected from the genus of Schizostoma.-   1202. The bioactive agent according to item 1195, wherein    Basidiomycete cell is selected from the genus of Sphaericeps.-   1203. The bioactive agent according to item 1195, wherein    Basidiomycete cell is selected from the genus of Tulasnodea.-   1204. The bioactive agent according to item 1195, wherein    Basidiomycete cell is selected from the genus of Tulostoma.-   1205. The bioactive agent according to item 243, wherein said    Basidiomycete cell belongs to a genus selected from the group    consisting of Apiosporium, Astoma, Bromicolla, Cnazonaria,    Coccopleum, Dacryopsella, Gliocoryne, Lutypha, Phacorhiza,    Pistillaria, Pistillina, Scleromitra, Sclerotiomyces, Sclerotium,    Sphaerula, Typhula and Xylochoeras.-   1206. The bioactive agent according to item 1205, wherein    Basidiomycete cell is selected from the genus of Apiosporium.-   1207. The bioactive agent according to item 1205, wherein    Basidiomycete cell is selected from the genus of Astoma.-   1208. The bioactive agent according to item 1205, wherein    Basidiomycete cell is selected from the genus of Bromicolla.-   1209. The bioactive agent according to item 1205, wherein    Basidiomycete cell is selected from the genus of Cnazonaria.-   1210. The bioactive agent according to item 1205, wherein    Basidiomycete cell is selected from the genus of Coccopleum.-   1211. The bioactive agent according to item 1205, wherein    Basidiomycete cell is selected from the genus of Dacryopsella.-   1212. The bioactive agent according to item 1205, wherein    Basidiomycete cell is selected from the genus of Gliocoryne.-   1213. The bioactive agent according to item 1205, wherein    Basidiomycete cell is selected from the genus of Lutypha.-   1214. The bioactive agent according to item 1205, wherein    Basidiomycete cell is selected from the genus of Phacorhiza.-   1215. The bioactive agent according to item 1205, wherein    Basidiomycete cell is selected from the genus of Pistillaria.-   1216. The bioactive agent according to item 1205, wherein    Basidiomycete cell is selected from the genus of Pistillina.-   1217. The bioactive agent according to item 1205, wherein    Basidiomycete cell is selected from the genus of Scleromitra.-   1218. The bioactive agent according to item 1205, wherein    Basidiomycete cell is selected from the genus of Sclerotiomyces.-   1219. The bioactive agent according to item 1205, wherein    Basidiomycete cell is selected from the genus of Sclerotium.-   1220. The bioactive agent according to item 1205, wherein    Basidiomycete cell is selected from the genus of Sphaerula.-   1221. The bioactive agent according to item 1205, wherein    Basidiomycete cell is selected from the genus of Typhula.-   1222. The bioactive agent according to item 1205, wherein    Basidiomycete cell is selected from the genus of Xylochoeras.-   1223. The bioactive agent according to item 244, wherein    Basidiomycete cell is selected from the genus of Rhizomarasmius.-   1224. The bioactive agent according to item 247, wherein said    Basidiomycete cell belongs to a genus selected from the group    consisting of Albatrellopsis, Albatrellus, Jahnoporus, Ovinus,    Polyporoletus and Scutiger.-   1225. The bioactive agent according to item 1225, wherein    Basidiomycete cell is selected from the genus of Albatrellopsis.-   1226. The bioactive agent according to item 1225, wherein    Basidiomycete cell is selected from the genus of Albatrellus.-   1227. The bioactive agent according to item 1225, wherein    Basidiomycete cell is selected from the genus of Jahnoporus.-   1228. The bioactive agent according to item 1225, wherein    Basidiomycete cell is selected from the genus of Ovinus.-   1229. The bioactive agent according to item 1225, wherein    Basidiomycete cell is selected from the genus of Polyporoletus.-   1230. The bioactive agent according to item 1225, wherein    Basidiomycete cell is selected from the genus of Scutiger.-   1231. The bioactive agent according to item 248, wherein said    Basidiomycete cell belongs to a genus selected from the group    consisting of Amphinema, Amyloathelia, Amylocorticium, Athelia,    Athelicium, Athelidium, Athelopsis, Butlerelfia, Byssocorticium,    Byssocristella, Byssoporia, Caerulicium, Cora, Coraemyces, Corella,    Cristinia, Dacryobasidium, Dichonema, Dictyonema, Dictyonematomyces,    Digitatispora, Diplonema, Fibulomyces, Fibulorhizoctonia,    Gyrolophium, Hypochnella, Hypochniciellum, Irpicodon, Laudatea,    Leptosporomyces, Lobulicium, Luellia, Melzericium, Mycostigma,    Piloderma, Plicatura, Plicaturopsis, Rhipidonema,    Rhipidonematomyces, Rhizonema, Taeniospora, Tomentellopsis,    Tylosperma, Tylospora and Wainiocora.-   1232. The bioactive agent according to item 1231, wherein    Basidiomycete cell is selected from the genus of Amphinema.-   1233. The bioactive agent according to item 1231, wherein    Basidiomycete cell is selected from the genus of Amyloathelia.-   1234. The bioactive agent according to item 1231, wherein    Basidiomycete cell is selected from the genus of Amylocorticium.-   1235. The bioactive agent according to item 1231, wherein    Basidiomycete cell is selected from the genus of Athelia.-   1236. The bioactive agent according to item 1231, wherein    Basidiomycete cell is selected from the genus of Athelicium.-   1237. The bioactive agent according to item 1231, wherein    Basidiomycete cell is selected from the genus of Athelidium.-   1238. The bioactive agent according to item 1231, wherein    Basidiomycete cell is selected from the genus of Athelopsis.-   1239. The bioactive agent according to item 1231, wherein    Basidiomycete cell is selected from the genus of Butlerelfia.-   1240. The bioactive agent according to item 1231, wherein    Basidiomycete cell is selected from the genus of Byssocorticium.-   1241. The bioactive agent according to item 1231, wherein    Basidiomycete cell is selected from the genus of Byssocristella.-   1242. The bioactive agent according to item 1231, wherein    Basidiomycete cell is selected from the genus of Byssoporia.-   1243. The bioactive agent according to item 1231, wherein    Basidiomycete cell is selected from the genus of Caerulicium.-   1244. The bioactive agent according to item 1231, wherein    Basidiomycete cell is selected from the genus of Cora.-   1245. The bioactive agent according to item 1231, wherein    Basidiomycete cell is selected from the genus of Coraemyces.-   1246. The bioactive agent according to item 1231, wherein    Basidiomycete cell is selected from the genus of Corella.-   1247. The bioactive agent according to item 1231, wherein    Basidiomycete cell is selected from the genus of Cristinia.-   1248. The bioactive agent according to item 1231, wherein    Basidiomycete cell is selected from the genus of Dacryobasidium.-   1249. The bioactive agent according to item 1231, wherein    Basidiomycete cell is selected from the genus of Dichonema.-   1250. The bioactive agent according to item 1231, wherein    Basidiomycete cell is selected from the genus of Dictyonema.-   1251. The bioactive agent according to item 1231, wherein    Basidiomycete cell is selected from the genus of Dictyonematomyces.-   1252. The bioactive agent according to item 1231, wherein    Basidiomycete cell is selected from the genus of Digitatispora.-   1253. The bioactive agent according to item 1231, wherein    Basidiomycete cell is selected from the genus of Diplonema.-   1254. The bioactive agent according to item 1231, wherein    Basidiomycete cell is selected from the genus of Fibulomyces.-   1255. The bioactive agent according to item 1231, wherein    Basidiomycete cell is selected from the genus of Fibulorhizoctonia.-   1256. The bioactive agent according to item 1231, wherein    Basidiomycete cell is selected from the genus of Gyrolophium.-   1257. The bioactive agent according to item 1231, wherein    Basidiomycete cell is selected from the genus of Hypochnella.-   1258. The bioactive agent according to item 1231, wherein    Basidiomycete cell is selected from the genus of Hypochniciellum.-   1259. The bioactive agent according to item 1231, wherein    Basidiomycete cell is selected from the genus of Irpicodon.-   1260. The bioactive agent according to item 1231, wherein    Basidiomycete cell is selected from the genus of Laudatea.-   1261. The bioactive agent according to item 1231, wherein    Basidiomycete cell is selected from the genus of Amphinema,    Amyloathelia, Amylocorticium, Athelia, Leptosporomyces.-   1262. The bioactive agent according to item 1231, wherein    Basidiomycete cell is selected from the genus of Lobulicium.-   1263. The bioactive agent according to item 1231, wherein    Basidiomycete cell is selected from the genus of Luellia.-   1264. The bioactive agent according to item 1231, wherein    Basidiomycete cell is selected from the genus of Melzericium.-   1265. The bioactive agent according to item 1231, wherein    Basidiomycete cell is selected from the genus of Mycostigma.-   1266. The bioactive agent according to item 1231, wherein    Basidiomycete cell is selected from the genus of Piloderma.-   1267. The bioactive agent according to item 1231, wherein    Basidiomycete cell is selected from the genus of Plicatura.-   1268. The bioactive agent according to item 1231, wherein    Basidiomycete cell is selected from the genus of Plicaturopsis.-   1269. The bioactive agent according to item 1231, wherein    Basidiomycete cell is selected from the genus of Rhipidonema.-   1270. The bioactive agent according to item 1231, wherein    Basidiomycete cell is selected from the genus of Rhipidonematomyces.-   1271. The bioactive agent according to item 1231, wherein    Basidiomycete cell is selected from the genus of Rhizonema.-   1272. The bioactive agent according to item 1231, wherein    Basidiomycete cell is selected from the genus of Taeniospora.-   1273. The bioactive agent according to item 1231, wherein    Basidiomycete cell is selected from the genus of Tomentellopsis.-   1274. The bioactive agent according to item 1231, wherein    Basidiomycete cell is selected from the genus of Tylosperma.-   1275. The bioactive agent according to item 1231, wherein    Basidiomycete cell is selected from the genus of Tylospora.-   1276. The bioactive agent according to item 1231, wherein    Basidiomycete cell is selected from the genus of Wainiocora.-   1277. The bioactive agent according to item 249, wherein said    Basidiomycete cell belongs to a genus selected from the group    consisting Boreostereum, Chaetocarpus, Chaetodermella,    Columnocystis, Grandinioides, Hirneola, Mycobonia, Mycothele and    Veluticeps.-   1278. The bioactive agent according to item 1277, wherein    Basidiomycete cell is selected from the genus of Boreostereum.-   1279. The bioactive agent according to item 1277, wherein    Basidiomycete cell is selected from the genus of Chaetocarpus.-   1280. The bioactive agent according to item 1277, wherein    Basidiomycete cell is selected from the genus of Chaetodermella.-   1281. The bioactive agent according to item 1277, wherein    Basidiomycete cell is selected from the genus of Columnocystis.-   1282. The bioactive agent according to item 1277, wherein    Basidiomycete cell is selected from the genus of Grandinioides.-   1283. The bioactive agent according to item 1277, wherein    Basidiomycete cell is selected from the genus of Hirneola.-   1284. The bioactive agent according to item 1277, wherein    Basidiomycete cell is selected from the genus of Mycobonia.-   1285. The bioactive agent according to item 1277, wherein    Basidiomycete cell is selected from the genus Mycothele.-   1286. The bioactive agent according to item 1277, wherein    Basidiomycete cell is selected from the genus of Veluticeps.-   1287. The bioactive agent according to item 250, wherein said    Basidiomycete cell belongs to a genus selected from the group    consisting Acantholichen, Aleurocorticium, Allosphaerium, Ambivina,    Amylobasidium, Auricula, Bryochysium, Corticirama, Corticium,    Cyanobasidium, Cytidia, Dendrocorticium, Dendrodontia,    Dendrophysellum, Dendrothele, Dextrinodontia, Hemmesomyces,    Laeticorticium, Laetisaria, Leptocorticium, Licrostroma,    Limonomyces, Lindtneria, Lomatia, Lomatina, Lyomyces, Matula,    Melzerodontia, Merulicium, Moniliopsis, Mutatoderma, Mycinema,    Mycolindtneria, Necator, Nothocorticium, Papyrodiscus, Phaeophlebia,    Pulcherricium, Punctularia, Rhizoctonia, Ripexicium, Thanatophytum    and Vuilleminia.-   1288. The bioactive agent according to item 1287, wherein    Basidiomycete cell is selected from the genus of Acantholichen.-   1289. The bioactive agent according to item 1287, wherein    Basidiomycete cell is selected from the genus of Aleurocorticium.-   1290. The bioactive agent according to item 1287, wherein    Basidiomycete cell is selected from the genus of Allosphaerium.-   1291. The bioactive agent according to item 1287, wherein    Basidiomycete-   1292. The bioactive agent according to item 1287, wherein    Basidiomycete cell is selected from the genus of Amylobasidium.-   1293. The bioactive agent according to item 1287, wherein    Basidiomycete cell is selected from the genus of Auricula.-   1294. The bioactive agent according to item 1287, wherein    Basidiomycete cell is selected from the genus of Bryochysium.-   1295. The bioactive agent according to item 1287, wherein    Basidiomycete cell is selected from the genus of Corticirama.-   1296. The bioactive agent according to item 1287, wherein    Basidiomycete cell is selected from the genus of Corticium.-   1297. The bioactive agent according to item 1287, wherein    Basidiomycete cell is selected from the genus of Cyanobasidium.-   1298. The bioactive agent according to item 1287, wherein    Basidiomycete cell is selected from the genus of Cytidia.-   1299. The bioactive agent according to item 1287, wherein    Basidiomycete cell is selected from the genus of Dendrocorticium.-   1300. The bioactive agent according to item 1287, wherein    Basidiomycete cell is selected from the genus of Dendrodontia.-   1301. The bioactive agent according to item 1287, wherein    Basidiomycete cell is selected from the genus of Dendrophysellum.-   1302. The bioactive agent according to item 1287, wherein    Basidiomycete cell is selected from the genus of Dendrothele.-   1303. The bioactive agent according to item 1287, wherein    Basidiomycete cell is selected from the genus of Dextrinodontia.-   1304. The bioactive agent according to item 1287, wherein    Basidiomycete cell is selected from the genus of Hemmesomyces.-   1305. The bioactive agent according to item 1287, wherein    Basidiomycete cell is selected from the genus of Laeticorticium.-   1306. The bioactive agent according to item 1287, wherein    Basidiomycete cell is selected from the genus of Laetisaria.-   1307. The bioactive agent according to item 1287, wherein    Basidiomycete cell is selected from the genus of Leptocorticium.-   1308. The bioactive agent according to item 1287, wherein    Basidiomycete cell is selected from the genus of Licrostroma.-   1309. The bioactive agent according to item 1287, wherein    Basidiomycete cell is selected from the genus of Limonomyces.-   1310. The bioactive agent according to item 1287, wherein    Basidiomycete cell is selected from the genus of Lindtneria.-   1311. The bioactive agent according to item 1287, wherein    Basidiomycete cell is selected from the genus of Lomatia.-   1312. The bioactive agent according to item 1287, wherein    Basidiomycete cell is selected from the genus of Lomatina.-   1313. The bioactive agent according to item 1287, wherein    Basidiomycete cell is selected from the genus of Lyomyces.-   1314. The bioactive agent according to item 1287, wherein    Basidiomycete cell is selected from the genus of Matula.-   1315. The bioactive agent according to item 1287, wherein    Basidiomycete cell is selected from the genus of Melzerodontia.-   1316. The bioactive agent according to item 1287, wherein    Basidiomycete cell is selected from the genus of Merulicium.-   1317. The bioactive agent according to item 1287, wherein    Basidiomycete cell is selected from the genus of Moniliopsis.-   1318. The bioactive agent according to item 1287, wherein    Basidiomycete cell is selected from the genus of Mutatoderma.-   1319. The bioactive agent according to item 1287, wherein    Basidiomycete cell is selected from the genus of Mycinema.-   1320. The bioactive agent according to item 1287, wherein    Basidiomycete cell is selected from the genus of Mycolindtneria.-   1321. The bioactive agent according to item 1287, wherein    Basidiomycete cell is selected from the genus of Necator.-   1322. The bioactive agent according to item 1287, wherein    Basidiomycete cell is selected from the genus of Nothocorticium.-   1323. The bioactive agent according to item 1287, wherein    Basidiomycete cell is selected from the genus of Papyrodiscus.-   1324. The bioactive agent according to item 1287, wherein    Basidiomycete cell is selected from the genus of Phaeophlebia.-   1325. The bioactive agent according to item 1287, wherein    Basidiomycete cell is selected from the genus of Pulcherricium.-   1326. The bioactive agent according to item 1287, wherein    Basidiomycete cell is selected from the genus of Punctularia.-   1327. The bioactive agent according to item 1287, wherein    Basidiomycete cell is selected from the genus of Rhizoctonia.-   1328. The bioactive agent according to item 1287, wherein    Basidiomycete cell is selected from the genus of Ripexicium.-   1329. The bioactive agent according to item 1287, wherein    Basidiomycete cell is selected from the genus of Thanatophytum.-   1330. The bioactive agent according to item 1287, wherein    Basidiomycete cell is selected from the genus of Vuilleminia.-   1331. The bioactive agent according to item 251, wherein said    Basidiomycete cell belongs to a genus selected from the group    consisting of Adustomyces, Asterocyphella, Catilla, Cyphella,    Dendrocyphella, Flavophlebia, Globulicium, Gloeocorticium,    Halocyphina, Hyphoradulum, Incrustocalyptella, Limnoperdon,    Oxydontia, Phaeoporotheleum, Pseudolagarobasidium, Radulodon,    Radulomyces, Rhodoarrhenia, Sarcodontia, Seticyphella,    Sphaerobasidioscypha, Thujacorticium, Wiesnerina, and Woldmaria.-   1332. The bioactive agent according to item 1331, wherein    Basidiomycete cell is selected from the genus of Adustomyces.-   1333. The bioactive agent according to item 1331, wherein    Basidiomycete cell is selected from the genus of Asterocyphella.-   1334. The bioactive agent according to item 1331, wherein    Basidiomycete cell is selected from the genus of Catilla.-   1335. The bioactive agent according to item 1331, wherein    Basidiomycete cell is selected from the genus of Cyphella.-   1336. The bioactive agent according to item 1331, wherein    Basidiomycete cell is selected from the genus of Dendrocyphella.-   1337. The bioactive agent according to item 1331, wherein    Basidiomycete cell is selected from the genus of Flavophlebia.-   1338. The bioactive agent according to item 1331, wherein    Basidiomycete cell is selected from the genus of Globulicium.-   1339. The bioactive agent according to item 1331, wherein    Basidiomycete cell is selected from the genus of Gloeocorticium.-   1340. The bioactive agent according to item 1331, wherein    Basidiomycete cell is selected from the genus of Halocyphina.-   1341. The bioactive agent according to item 1331, wherein    Basidiomycete cell is selected from the genus of Hyphoradulum.-   1342. The bioactive agent according to item 1331, wherein    Basidiomycete cell is selected from the genus of Incrustocalyptella.-   1343. The bioactive agent according to item 1331, wherein    Basidiomycete cell is selected from the genus of Limnoperdon.-   1344. The bioactive agent according to item 1331, wherein    Basidiomycete cell is selected from the genus of Oxydontia.-   1345. The bioactive agent according to item 1331, wherein    Basidiomycete cell is selected from the genus of Phaeoporotheleum.-   1346. The bioactive agent according to item 1331, wherein    Basidiomycete cell is selected from the genus of    Pseudolagarobasidium.-   1347. The bioactive agent according to item 1331, wherein    Basidiomycete cell is selected from the genus of Radulodon.-   1348. The bioactive agent according to item 1331, wherein    Basidiomycete cell is selected from the genus of Radulomyces.-   1349. The bioactive agent according to item 1331, wherein    Basidiomycete cell is selected from the genus of Rhodoarrhenia.-   1350. The bioactive agent according to item 1331, wherein    Basidiomycete cell is selected from the genus of Sarcodontia.-   1351. The bioactive agent according to item 1331, wherein    Basidiomycete cell is selected from the genus of Seticyphella.-   1352. The bioactive agent according to item 1331, wherein    Basidiomycete cell is selected from the genus of    Sphaerobasidioscypha.-   1353. The bioactive agent according to item 1331, wherein    Basidiomycete cell is selected from the genus of Thujacorticium.-   1354. The bioactive agent according to item 1331, wherein    Basidiomycete cell is selected from the genus of Wiesnerina.-   1355. The bioactive agent according to item 1331, wherein    Basidiomycete cell is selected from the genus of Woldmaria.-   1356. The bioactive agent according to item 252, wherein said    Basidiomycete cell belongs to a genus selected from the group    consisting of Cericium, Crustomyces, Cystidiodontia, Cystostereum,    Dentocorticium, Parvobasidium, Physodontia and Pteridomyces.-   1357. The bioactive agent according to item 1356, wherein    Basidiomycete cell is selected from the genus of Cericium.-   1358. The bioactive agent according to item 1356, wherein    Basidiomycete cell is selected from the genus of Crustomyces.-   1359. The bioactive agent according to item 1356, wherein    Basidiomycete cell is selected from the genus of Cystidiodontia.-   1360. The bioactive agent according to item 1356, wherein    Basidiomycete cell is selected from the genus of Cystostereum.-   1361. The bioactive agent according to item 1356, wherein    Basidiomycete cell is selected from the genus of Dentocorticium.-   1362. The bioactive agent according to item 1356, wherein    Basidiomycete cell is selected from the genus of Parvobasidium.-   1363. The bioactive agent according to item 1356, wherein    Basidiomycete cell is selected from the genus of Physodontia.-   1364. The bioactive agent according to item 1356, wherein    Basidiomycete cell is selected from the genus of Pteridomyces.-   1365. The bioactive agent according to item 253, wherein said    Basidiomycete cell belongs to a genus selected from the group    consisting of Epithele, Epithelopsis and Skeletohydnum.-   1366. The bioactive agent according to item 1365, wherein    Basidiomycete cell is selected from the genus of Epithele.-   1367. The bioactive agent according to item 1365, wherein    Basidiomycete cell is selected from the genus of Epithelopsis.-   1368. The bioactive agent according to item 1365, wherein    Basidiomycete cell is selected from the genus of Skeletohydnum.-   1369. The bioactive agent according to item 254, wherein said    Basidiomycete cell belongs to a genus selected from the group    consisting of Agaricon, Agarico-pulpa, Agarico-suber, Agaricum,    Agaricus, Amylocystis, Anomoporia, Auriporia, Buglossoporus,    Daedalea, Donkioporia, Fomitopsis, Gilbertsonia, Hemidiscia,    Laricifomes, Osteina, Parmastomyces, Phaeodaedalea, Pilatoporus,    Piptoporus, Placoderma, Podoporia, Postia, Rhodofomes, Spelaeomyces,    Spongiporus, Strangulidium, Striglia, Ungularia, Wolfiporia and    Xylostroma.-   1370. The bioactive agent according to item 1369, wherein    Basidiomycete cell is selected from the genus of Agaricon.-   1371. The bioactive agent according to item 1369, wherein    Basidiomycete cell is selected from the genus of Agarico-pulpa.-   1372. The bioactive agent according to item 1369, wherein    Basidiomycete cell is selected from the genus of Agarico-suber.-   1373. The bioactive agent according to item 1369, wherein    Basidiomycete cell is selected from the genus of Agaricum.-   1374. The bioactive agent according to item 1369, wherein    Basidiomycete cell is selected from the genus of Agaricus.-   1375. The bioactive agent according to item 1369, wherein    Basidiomycete cell is selected from the genus of Amylocystis.-   1376. The bioactive agent according to item 1369, wherein    Basidiomycete cell is selected from the genus of Anomoporia.-   1377. The bioactive agent according to item 1369, wherein    Basidiomycete cell is selected from the genus of Auriporia.-   1378. The bioactive agent according to item 1369, wherein    Basidiomycete cell is selected from the genus of Buglossoporus.-   1379. The bioactive agent according to item 1369, wherein    Basidiomycete cell is selected from the genus of Daedalea.-   1380. The bioactive agent according to item 1369, wherein    Basidiomycete cell is selected from the genus of Donkioporia.-   1381. The bioactive agent according to item 1369, wherein    Basidiomycete cell is selected from the genus of Fomitopsis.-   1382. The bioactive agent according to item 1369, wherein    Basidiomycete cell is selected from the genus of Gilbertsonia.-   1383. The bioactive agent according to item 1369, wherein    Basidiomycete cell is selected from the genus of Hemidiscia.-   1384. The bioactive agent according to item 1369, wherein    Basidiomycete cell is selected from the genus of Laricifomes.-   1385. The bioactive agent according to item 1369, wherein    Basidiomycete cell is selected from the genus of Osteina.-   1386. The bioactive agent according to item 1369, wherein    Basidiomycete cell is selected from the genus of Parmastomyces.-   1387. The bioactive agent according to item 1369, wherein    Basidiomycete cell is selected from the genus of Phaeodaedalea.-   1388. The bioactive agent according to item 1369, wherein    Basidiomycete cell is selected from the genus of Pilatoporus.-   1389. The bioactive agent according to item 1369, wherein    Basidiomycete cell is selected from the genus of Piptoporus.-   1390. The bioactive agent according to item 1369, wherein    Basidiomycete cell is selected from the genus of Placoderma.-   1391. The bioactive agent according to item 1369, wherein    Basidiomycete cell is selected from the genus of Podoporia.-   1392. The bioactive agent according to item 1369, wherein    Basidiomycete cell is selected from the genus of Postia.-   1393. The bioactive agent according to item 1369, wherein    Basidiomycete cell is selected from the genus of Rhodofomes.-   1394. The bioactive agent according to item 1369, wherein    Basidiomycete cell is selected from the genus of Spelaeomyces.-   1395. The bioactive agent according to item 1369, wherein    Basidiomycete cell is selected from the genus of Spongiporus.-   1396. The bioactive agent according to item 1369, wherein    Basidiomycete cell is selected from the genus of Strangulidium.-   1397. The bioactive agent according to item 1369, wherein    Basidiomycete cell is selected from the genus of Striglia.-   1398. The bioactive agent according to item 1369, wherein    Basidiomycete cell is selected from the genus of Ungularia.-   1399. The bioactive agent according to item 1369, wherein    Basidiomycete cell is selected from the genus of Wolfiporia.-   1400. The bioactive agent according to item 1369, wherein    Basidiomycete cell is selected from the genus of Xylostroma.-   1401. The bioactive agent according to item 255, wherein said    Basidiomycete cell belongs to a genus selected from the group    consisting of Amauroderma, Dendrophagus, Elfvingia, Friesia,    Ganoderma, Haddowia, Humphreya, Lazulinospora, Magoderna,    Thermophymatospora, Tomophagus, Trachyderma and Whitfordia.-   1402. The bioactive agent according to item 1401, wherein    Basidiomycete cell is selected from the genus of Amauroderma.-   1403. The bioactive agent according to item 1401, wherein    Basidiomycete cell is selected from the genus of Dendrophagus.-   1404. The bioactive agent according to item 1401, wherein    Basidiomycete cell is selected from the genus of Elfvingia.-   1405. The bioactive agent according to item 1401, wherein    Basidiomycete cell is selected from the genus of Friesia.-   1406. The bioactive agent according to item 1401, wherein    Basidiomycete cell is selected from the genus of Ganoderma.-   1407. The bioactive agent according to item 1401, wherein    Basidiomycete cell is selected from the genus of Haddowia.-   1408. The bioactive agent according to item 1401, wherein    Basidiomycete cell is selected from the genus of Humphreya.-   1409. The bioactive agent according to item 1401, wherein    Basidiomycete cell is selected from the genus of Lazulinospora.-   1410. The bioactive agent according to item 1401, wherein    Basidiomycete cell is selected from the genus of Magoderna.-   1411. The bioactive agent according to item 1401, wherein    Basidiomycete cell is selected from the genus of Thermophymatospora.-   1412. The bioactive agent according to item 1401, wherein    Basidiomycete cell is selected from the genus of Tomophagus.-   1413. The bioactive agent according to item 1401, wherein    Basidiomycete cell is selected from the genus of Trachyderma.-   1414. The bioactive agent according to item 1401, wherein    Basidiomycete cell is selected from the genus of Whitfordia.-   1415. The bioactive agent according to item 256, wherein said    Basidiomycete cell belongs to a genus selected from the group    consisting of Anisomyces, Ceratophora, Gloeophyllum, Griseoporia,    Lenzitina, Phaeocoriolellus, Reisneria, Serda and Sesia.-   1416. The bioactive agent according to item 1415, wherein    Basidiomycete cell is selected from the genus of Anisomyces.-   1417. The bioactive agent according to item 1415, wherein    Basidiomycete cell is selected from the genus of Ceratophora.-   1418. The bioactive agent according to item 1415, wherein    Basidiomycete cell is selected from the genus of Gloeophyllum.-   1419. The bioactive agent according to item 1415, wherein    Basidiomycete cell is selected from the genus of Griseoporia.-   1420. The bioactive agent according to item 1415, wherein    Basidiomycete cell is selected from the genus of Lenzitina.-   1421. The bioactive agent according to item 1415, wherein    Basidiomycete cell is selected from the genus of Phaeocoriolellus.-   1422. The bioactive agent according to item 1415, wherein    Basidiomycete cell is selected from the genus of Reisneria.-   1423. The bioactive agent according to item 1415, wherein    Basidiomycete cell is selected from the genus of Serda.-   1424. The bioactive agent according to item 1415, wherein    Basidiomycete cell is selected from the genus of Sesia.-   1425. The bioactive agent according to item 257, wherein said    Basidiomycete cell belongs to a genus selected from the group    consisting of Grammothele, Hymenogramme, Porogramme, Theleporus and    Tinctoporia.-   1426. The bioactive agent according to item 1425, wherein    Basidiomycete cell is selected from the genus of Grammothele.-   1427. The bioactive agent according to item 1425, wherein    Basidiomycete cell is selected from the genus of Hymenogramme.-   1428. The bioactive agent according to item 1425, wherein    Basidiomycete cell is selected from the genus of Porogramme.-   1429. The bioactive agent according to item 1425, wherein    Basidiomycete cell is selected from the genus of Theleporus.-   1430. The bioactive agent according to item 1425, wherein    Basidiomycete cell is selected from the genus of Tinctoporia.-   1431. The bioactive agent according to item 258, wherein said    Basidiomycete cell belongs to a genus selected from the group    consisting of Aurantiporus, Bjerkandera, Ceraporus, Ceriporia,    Ceriporiopsis, Climacocystis, Gelatoporia, Hapalopilus, Irpiciporus,    Ischnoderma, Leptoporus, Myriadoporus, Porpomyces, Pouzaroporia,    Sarcoporia, Somion and Spongipellis.-   1432. The bioactive agent according to item 1431, wherein    Basidiomycete cell is selected from the genus of Aurantiporus.-   1433. The bioactive agent according to item 1431, wherein    Basidiomycete cell is selected from the genus of Bjerkandera.-   1434. The bioactive agent according to item 1431, wherein    Basidiomycete cell is selected from the genus of Ceraporus.-   1435. The bioactive agent according to item 1431, wherein    Basidiomycete cell is selected from the genus of Ceriporia.-   1436. The bioactive agent according to item 1431, wherein    Basidiomycete cell is selected from the genus Ceriporiopsis.-   1437. The bioactive agent according to item 1431, wherein    Basidiomycete cell is selected from the genus of Climacocystis.-   1438. The bioactive agent according to item 1431, wherein    Basidiomycete cell is selected from the genus of Gelatoporia.-   1439. The bioactive agent according to item 1431, wherein    Basidiomycete cell is selected from the genus of Hapalopilus.-   1440. The bioactive agent according to item 1431, wherein    Basidiomycete cell is selected from the genus of Irpiciporus.-   1441. The bioactive agent according to item 1431, wherein    Basidiomycete cell is selected from the genus of Ischnoderma.-   1442. The bioactive agent according to item 1431, wherein    Basidiomycete cell is selected from the genus of Leptoporus.-   1443. The bioactive agent according to item 1431, wherein    Basidiomycete cell is selected from the genus of Myriadoporus.-   1444. The bioactive agent according to item 1431, wherein    Basidiomycete cell is selected from the genus of Porpomyces.-   1445. The bioactive agent according to item 1431, wherein    Basidiomycete cell is selected from the genus of Pouzaroporia.-   1446. The bioactive agent according to item 1431, wherein    Basidiomycete cell is selected from the genus of Sarcoporia.-   1447. The bioactive agent according to item 1431, wherein    Basidiomycete cell is selected from the genus of Somion.-   1448. The bioactive agent according to item 1431, wherein    Basidiomycete cell is selected from the genus of Spongipellis.-   1449. The bioactive agent according to item 259, wherein said    Basidiomycete cell belongs to a genus selected from the group    consisting of Aegerita, Aegeritina, Aegeritopsis, Amaurohydnum,    Amauromyces, Atheloderma, Brevicellicium, Bulbillomyces,    Cerocorticium, Chrysoderma, Conohypha, Coronicium, Crocysporium,    Cyanodontia, Dermosporium, Elaphocephala, Galzinia,    Gloeohypochnicium, Hydnellum, Hyphoderma, Hyphodontiastra,    Hyphodontiella, Hypochnicium, Intextomyces, Kneiffia, Kneiffiella,    Lyomyces, Metulodontia, Neokneiffia, Nodotia, Odontiopsis, Pirex,    Pycnodon, Subulicium, Subulicystidium, Uncobasidium and Xylodon.-   1450. The bioactive agent according to item 1449, wherein    Basidiomycete cell is selected from the genus of Aegerita.-   1451. The bioactive agent according to item 1449, wherein    Basidiomycete cell is selected from the genus of Aegeritina.-   1452. The bioactive agent according to item 1449, wherein    Basidiomycete cell is selected from the genus of Aegeritopsis.-   1453. The bioactive agent according to item 1449, wherein    Basidiomycete cell is selected from the genus of Amaurohydnum.-   1454. The bioactive agent according to item 1449, wherein    Basidiomycete cell is selected from the genus of Amauromyces.-   1455. The bioactive agent according to item 1449, wherein    Basidiomycete cell is selected from the genus of Atheloderma.-   1456. The bioactive agent according to item 1449, wherein    Basidiomycete cell is selected from the genus of Brevicellicium.-   1457. The bioactive agent according to item 1449, wherein    Basidiomycete cell is selected from the genus of Bulbillomyces.-   1458. The bioactive agent according to item 1449, wherein    Basidiomycete cell is selected from the genus of Cerocorticium.-   1459. The bioactive agent according to item 1449, wherein    Basidiomycete cell is selected from the genus of Chrysoderma.-   1460. The bioactive agent according to item 1449, wherein    Basidiomycete cell is selected from the genus of Conohypha.-   1461. The bioactive agent according to item 1449, wherein    Basidiomycete cell is selected from the genus of Coronicium.-   1462. The bioactive agent according to item 1449, wherein    Basidiomycete cell is selected from the genus of Crocysporium.-   1463. The bioactive agent according to item 1449, wherein    Basidiomycete cell is selected from the genus of Cyanodontia.-   1464. The bioactive agent according to item 1449, wherein    Basidiomycete cell is selected from the genus of Dermosporium.-   1465. The bioactive agent according to item 1449, wherein    Basidiomycete cell is selected from the genus of Elaphocephala.-   1466. The bioactive agent according to item 1449, wherein    Basidiomycete cell is selected from the genus of Galzinia.-   1467. The bioactive agent according to item 1449, wherein    Basidiomycete cell is selected from the genus of Gloeohypochnicium.-   1468. The bioactive agent according to item 1449, wherein    Basidiomycete cell is selected from the genus of Hydnellum.-   1469. The bioactive agent according to item 1449, wherein    Basidiomycete cell is selected from the genus of Hyphoderma.-   1470. The bioactive agent according to item 1449, wherein    Basidiomycete cell is selected from the genus of Hyphodontiastra.-   1471. The bioactive agent according to item 1449, wherein    Basidiomycete cell is selected from the genus of Hyphodontiella.-   1472. The bioactive agent according to item 1449, wherein    Basidiomycete cell is selected from the genus of Hypochnicium.-   1473. The bioactive agent according to item 1449, wherein    Basidiomycete cell is selected from the genus of Intextomyces.-   1474. The bioactive agent according to item 1449, wherein    Basidiomycete cell is selected from the genus of Kneiffia.-   1475. The bioactive agent according to item 1449, wherein    Basidiomycete cell is selected from the genus of Kneiffiella.-   1476. The bioactive agent according to item 1449, wherein    Basidiomycete cell is selected from the genus of Lyomyces.-   1477. The bioactive agent according to item 1449, wherein    Basidiomycete cell is selected from the genus of Metulodontia.-   1478. The bioactive agent according to item 1449, wherein    Basidiomycete cell is selected from the genus of Neokneiffia.-   1479. The bioactive agent according to item 1449, wherein    Basidiomycete cell is selected from the genus of Nodotia.-   1480. The bioactive agent according to item 1449, wherein    Basidiomycete cell is selected from the genus of Odontiopsis.-   1481. The bioactive agent according to item 1449, wherein    Basidiomycete cell is selected from the genus of Pirex.-   1482. The bioactive agent according to item 1449, wherein    Basidiomycete cell is selected from the genus of Pycnodon.-   1483. The bioactive agent according to item 1449, wherein    Basidiomycete cell is selected from the genus of Subulicium.-   1484. The bioactive agent according to item 1449, wherein    Basidiomycete cell is selected from the genus of Subulicystidium.-   1485. The bioactive agent according to item 1449, wherein    Basidiomycete cell is selected from the genus of Uncobasidium.-   1486. The bioactive agent according to item 1449, wherein    Basidiomycete cell is selected from the genus of Xylodon.-   1487. The bioactive agent according to item 260, wherein said    Basidiomycete cell belongs to a genus selected from the group    consisting of Abortiporus, Antrodia, Bornetina, Cartilosoma,    Cautinia, Cladodendron, Cladomeris, Coriolellus, Diacanthodes,    Flabellopilus, Grifola, Henningsia, Heteroporus, Hydnopolyporus,    Irpicium, Leucofomes, Loweomyces, Meripilus, Merisma, Physisporinus,    Polypilus and Rigidoporus.-   1488. The bioactive agent according to item 1487, wherein    Basidiomycete cell is selected from the genus of Abortiporus.-   1489. The bioactive agent according to item 1487, wherein    Basidiomycete cell is selected from the genus of Antrodia.-   1490. The bioactive agent according to item 1487, wherein    Basidiomycete cell is selected from the genus of Bornetina.-   1491. The bioactive agent according to item 1487, wherein    Basidiomycete cell is selected from the genus of Cartilosoma.-   1492. The bioactive agent according to item 1487, wherein    Basidiomycete cell is selected from the genus of Cautinia.-   1493. The bioactive agent according to item 1487, wherein    Basidiomycete cell is selected from the genus of Cladodendron.-   1494. The bioactive agent according to item 1487, wherein    Basidiomycete cell is selected from the genus of Cladomeris.-   1495. The bioactive agent according to item 1487, wherein    Basidiomycete cell is selected from the genus of Coriolellus.-   1496. The bioactive agent according to item 1487, wherein    Basidiomycete cell is selected from the genus of Diacanthodes.-   1497. The bioactive agent according to item 1487, wherein    Basidiomycete cell is selected from the genus of Flabellopilus.-   1498. The bioactive agent according to item 1487, wherein    Basidiomycete cell is selected from the genus of Grifola.-   1499. The bioactive agent according to item 1487, wherein    Basidiomycete cell is selected from the genus of Henningsia.-   1500. The bioactive agent according to item 1487, wherein    Basidiomycete cell is selected from the genus of Heteroporus.-   1501. The bioactive agent according to item 1487, wherein    Basidiomycete cell is selected from the genus of Hydnopolyporus.-   1502. The bioactive agent according to item 1487, wherein    Basidiomycete cell is selected from the genus of Irpicium.-   1503. The bioactive agent according to item 1487, wherein    Basidiomycete cell is selected from the genus of Leucofomes.-   1504. The bioactive agent according to item 1487, wherein    Basidiomycete cell is selected from the genus of Loweomyces.-   1505. The bioactive agent according to item 1487, wherein    Basidiomycete cell is selected from the genus of Meripilus.-   1506. The bioactive agent according to item 1487, wherein    Basidiomycete cell is selected from the genus of Merisma.-   1507. The bioactive agent according to item 1487, wherein    Basidiomycete cell is selected from the genus of Physisporinus.-   1508. The bioactive agent according to item 1487, wherein    Basidiomycete cell is selected from the genus of Polypilus.-   1509. The bioactive agent according to item 1487, wherein    Basidiomycete cell is selected from the genus of Rigidoporus.-   1510. The bioactive agent according to item 261, wherein said    Basidiomycete cell belongs to a genus selected from the group    consisting of Ada, Byssomerulius, Caloporia, Caloporus,    Castanoporus, Ceraceohydnum, Ceraceomerulius, Chondrostereum,    Climacodon, Columnodontia, Crustoderma, Cylindrobasidium,    Dacryobolus, Donkia, Gloeocystidium, Gloeoporus, Gloeostereum,    Himantia, Jacksonomyces, Meruliopsis, Merulius, Mycoacia,    Mycoaciella, Phlebia, Resinicium, Ricnophora, Scopuloides,    Skvortzovia and Trabecularia.-   1511. The bioactive agent according to item 1510, wherein    Basidiomycete cell is selected from the genus of Acia.-   1512. The bioactive agent according to item 1510, wherein    Basidiomycete cell is selected from the genus of Byssomerulius.-   1513. The bioactive agent according to item 1510, wherein    Basidiomycete cell is selected from the genus of Caloporia.-   1514. The bioactive agent according to item 1510, wherein    Basidiomycete cell is selected from the genus of Caloporus.-   1515. The bioactive agent according to item 1510, wherein    Basidiomycete cell is selected from the genus of Castanoporus.-   1516. The bioactive agent according to item 1510, wherein    Basidiomycete cell is selected from the genus of Ceraceohydnum.-   1517. The bioactive agent according to item 1510, wherein    Basidiomycete cell is selected from the genus of Ceraceomerulius.-   1518. The bioactive agent according to item 1510, wherein    Basidiomycete cell is selected from the genus of Chondrostereum.-   1519. The bioactive agent according to item 1510, wherein    Basidiomycete cell is selected from the genus of Climacodon.-   1520. The bioactive agent according to item 1510, wherein    Basidiomycete cell is selected from the genus of Columnodontia.-   1521. The bioactive agent according to item 1510, wherein    Basidiomycete cell is selected from the genus of Crustoderma.-   1522. The bioactive agent according to item 1510, wherein    Basidiomycete cell is selected from the genus of Cylindrobasidium.-   1523. The bioactive agent according to item 1510, wherein    Basidiomycete cell is selected from the genus of Dacryobolus.-   1524. The bioactive agent according to item 1510, wherein    Basidiomycete cell is selected from the genus of Donkia.-   1525. The bioactive agent according to item 1510, wherein    Basidiomycete cell is selected from the genus of Gloeocystidium.-   1526. The bioactive agent according to item 1510, wherein    Basidiomycete cell is selected from the genus of Gloeoporus.-   1527. The bioactive agent according to item 1510, wherein    Basidiomycete cell is selected from the genus of Gloeostereum.-   1528. The bioactive agent according to item 1510, wherein    Basidiomycete cell is selected from the genus of Himantia.-   1529. The bioactive agent according to item 1510, wherein    Basidiomycete cell is selected from the genus of Jacksonomyces.-   1530. The bioactive agent according to item 1510, wherein    Basidiomycete cell is selected from the genus of Meruliopsis.-   1531. The bioactive agent according to item 1510, wherein    Basidiomycete cell is selected from the genus of Merulius.-   1532. The bioactive agent according to item 1510, wherein    Basidiomycete cell is selected from the genus of Mycoacia.-   1533. The bioactive agent according to item 1510, wherein    Basidiomycete cell is selected from the genus of Mycoaciella.-   1534. The bioactive agent according to item 1510, wherein    Basidiomycete cell is selected from the genus of Phlebia.-   1535. The bioactive agent according to item 1510, wherein    Basidiomycete cell is selected from the genus of Resinicium.-   1536. The bioactive agent according to item 1510, wherein    Basidiomycete cell is selected from the genus of Ricnophora.-   1537. The bioactive agent according to item 1510, wherein    Basidiomycete cell is selected from the genus of Scopuloides.-   1538. The bioactive agent according to item 1510, wherein    Basidiomycete cell is selected from the genus of Skvortzovia.-   1539. The bioactive agent according to item 1510, wherein    Basidiomycete cell is selected from the genus of Trabecularia.-   1540. The bioactive agent according to item 262, wherein said    Basidiomycete cell belongs to a genus selected from the group    consisting of Australicium, Botryodontia, Candelabrochaete,    Ceraceomyces, Corticium, Efibula, Erythricium, Grandiniella,    Gyrophanopsis, Hjortstamia, Hydnophlebia, Hyphodermella,    Hyphodermopsis, Licentia, Lloydella, Lopharia, Membranicium,    Odonticium, Phanerochaete, Phlebiopsis, Porostereum, Terana,    Thwaitesiella and Xerocarpus.-   1541. The bioactive agent according to item 1540, wherein    Basidiomycete cell is selected from the genus of Australicium.-   1542. The bioactive agent according to item 1540, wherein    Basidiomycete cell is selected from the genus of Botryodontia.-   1543. The bioactive agent according to item 1540, wherein    Basidiomycete cell is selected from the genus of Candelabrochaete.-   1544. The bioactive agent according to item 1540, wherein    Basidiomycete cell is selected from the genus of Ceraceomyces.-   1545. The bioactive agent according to item 1540, wherein    Basidiomycete cell is selected from the genus of Corticium.-   1546. The bioactive agent according to item 1540, wherein    Basidiomycete cell is selected from the genus of Efibula.-   1547. The bioactive agent according to item 1540, wherein    Basidiomycete cell is selected from the genus of Erythricium.-   1548. The bioactive agent according to item 1540, wherein    Basidiomycete cell is selected from the genus of Grandiniella.-   1549. The bioactive agent according to item 1540, wherein    Basidiomycete cell is selected from the genus of Gyrophanopsis.-   1550. The bioactive agent according to item 1540, wherein    Basidiomycete cell is selected from the genus of Hjortstamia.-   1551. The bioactive agent according to item 1540, wherein    Basidiomycete cell is selected from the genus of Hydnophlebia.-   1552. The bioactive agent according to item 1540, wherein    Basidiomycete cell is selected from the genus of Hyphodermella.-   1553. The bioactive agent according to item 1540, wherein    Basidiomycete cell is selected from the genus of Hyphodermopsis.-   1554. The bioactive agent according to item 1540, wherein    Basidiomycete cell is selected from the genus of Licentia.-   1555. The bioactive agent according to item 1540, wherein    Basidiomycete cell is selected from the genus of Lloydella.-   1556. The bioactive agent according to item 1540, wherein    Basidiomycete cell is selected from the genus of Lopharia.-   1557. The bioactive agent according to item 1540, wherein    Basidiomycete cell is selected from the genus of Membranicium.-   1558. The bioactive agent according to item 1540, wherein    Basidiomycete cell is selected from the genus of Odonticium.-   1559. The bioactive agent according to item 1540, wherein    Basidiomycete cell is selected from the genus of Phanerochaete.-   1560. The bioactive agent according to item 1540, wherein    Basidiomycete cell is selected from the genus of Phlebiopsis.-   1561. The bioactive agent according to item 1540, wherein    Basidiomycete cell is selected from the genus of Porostereum.-   1562. The bioactive agent according to item 1540, wherein    Basidiomycete cell is selected from the genus of Terana.-   1563. The bioactive agent according to item 1540, wherein    Basidiomycete cell is selected from the genus of Thwaitesiella.-   1564. The bioactive agent according to item 1540, wherein    Basidiomycete cell is selected from the genus of Xerocarpus.-   1565. The bioactive agent according to item 263, wherein said    Basidiomycete cell belongs to a genus selected from the group    consisting of Actinostroma, Aquascypha, Beccaria, Beccariella,    Bresadolina, Caripia, Cladoderris, Coralloderma, Cotylidia,    Craterella, Cymatoderma, Cyphellostereum, Granulobasidium,    Inflatostereum, Podoscypha, Pseudolasiobolus, Stereogloeocystidium,    Stereophyllum and Stereopsis.-   1566. The bioactive agent according to item 1565, wherein    Basidiomycete cell is selected from the genus of Actinostroma.-   1567. The bioactive agent according to item 1565, wherein    Basidiomycete cell is selected from the genus of Aquascypha.-   1568. The bioactive agent according to item 1565, wherein    Basidiomycete cell is selected from the genus of Beccaria.-   1569. The bioactive agent according to item 1565, wherein    Basidiomycete cell is selected from the genus of Beccariella.-   1570. The bioactive agent according to item 1565, wherein    Basidiomycete cell is selected from the genus of Bresadolina.-   1571. The bioactive agent according to item 1565, wherein    Basidiomycete cell is selected from the genus of Caripia.-   1572. The bioactive agent according to item 1565, wherein    Basidiomycete cell is selected from the genus of Cladoderris.-   1573. The bioactive agent according to item 1565, wherein    Basidiomycete cell is selected from the genus of Coralloderma.-   1574. The bioactive agent according to item 1565, wherein    Basidiomycete cell is selected from the genus of Cotylidia.-   1575. The bioactive agent according to item 1565, wherein    Basidiomycete cell is selected from the genus of Craterella.-   1576. The bioactive agent according to item 1565, wherein    Basidiomycete cell is selected from the genus of Cymatoderma.-   1577. The bioactive agent according to item 1565, wherein    Basidiomycete cell is selected from the genus of Cyphellostereum.-   1578. The bioactive agent according to item 1565, wherein    Basidiomycete cell is selected from the genus of Granulobasidium.-   1579. The bioactive agent according to item 1565, wherein    Basidiomycete cell is selected from the genus of Inflatostereum.-   1580. The bioactive agent according to item 1565, wherein    Basidiomycete cell is selected from the genus Podoscypha.-   1581. The bioactive agent according to item 1565, wherein    Basidiomycete cell is selected from the genus of Pseudolasiobolus.-   1582. The bioactive agent according to item 1565, wherein    Basidiomycete cell is selected from the genus of    Stereogloeocystidium.-   1583. The bioactive agent according to item 1565, wherein    Basidiomycete cell is selected from the genus of Stereophyllum.-   1584. The bioactive agent according to item 1565, wherein    Basidiomycete cell is selected from the genus of Stereopsis.-   1585. The bioactive agent according to item 264, wherein said    Basidiomycete cell belongs to a genus selected from the group    consisting of Abundisporus, Agarico-igniarium, Agaricum, Amyloporia,    Amyloporiella, Antromycopsis, Apoxona, Artolenzites, Asterochaete,    Atroporus, Aurantiporellus, Australoporus, Austrolentinus,    Bresadolia, Bridgeoporus, Bulliardia, Burgoa, Caloporus, Cellularia,    Ceriomyces, Cerioporus, Cerrena, Choriphyllum, Cladoporus,    Coriolopsis, Coriolus, Cryptomphalina, Cryptoporus, Cubamyces,    Cyanosporus, Cystidiophorus, Cystostiptoporus, Daedaleopsis,    Datronia, Dendrochaete, Dendropolyporus, Dextrinosporium,    Dichomitus, Digitellus, Earliella, Echinochaete, Elfvingiella,    Enslinia, Fabisporus, Faerberia, Favolus, Fibroporia, Flabellophora,    Fomes, Fomitella, Funalia, Fuscocerrena, Gemmularia, Geopetalum,    Globifomes, Grammothelopsis, Hansenia, Haploporus, Heliocybe,    Hexagonia, Hirschioporus, Hornodermoporus, Incrustoporia,    Laccocephalum, Laetifomes, Laetiporus, Lasiochlaena, Lentinopanus,    Lentinus, Lentodiellum, Lentodium, Lentus, Lenzites, Leptopora,    Leptoporellus, Leptotrimitus, Leucolenzites, Leucoporus, Lignosus,    Lithopolyporales, Loweporus, Macrohyporia, Macroporia,    Megasporoporia, Melanoporella, Melanoporia, Melanopus, Merulioporia,    Microporellus, Microporus, Mollicarpus, Mycelithe, Navisporus,    Neolentinus, Neolentiporus, Nigrofomes, Nigroporus, Oligoporus,    Osmoporus, Pachykytospora, Pachyma, Panus, Paramyces, Perenniporia,    Perenniporiella, Persooniana, Petaloides, Phaeolus, Phaeotrametes,    Pherima, Phorima, Phyllodontia, Physisporus, Piloporia, Placodes,    Pleuropus, Pocillaria, Podofomes, Pogonomyces, Polyporellus,    Polyporus, Polyporus, Polyporus, Poria, Porodisculus, Porodiscus,    Poronidulus, Poroptyche, Pseudofavolus, Pseudophaeolus,    Pseudopiptoporus, Pseudotrametes, Ptychogaster, Pycnoporellus,    Pycnoporus, Pyrofomes, Riopa, Romellia, Royoporus, Rubroporus,    Ryvardenia, Scenidium, Scierodepsis, Sistotrema, Skeletocutis,    Sparsitubus, Spongiosus, Stiptophyllum, Tinctoporellus,    Tomentoporus, Trametella, Trametes, Trichaptum, Truncospora,    Tuberaster, Tyromyces, Ungulina, Vanderbylia, Velolentinus,    Xerotinus, Xerotus, Xylometron and Xylopilus.-   1586. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Abundisporus.-   1587. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Agarico-igniarium.-   1588. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Agaricum.-   1589. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Amyloporia.-   1590. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Amyloporiella.-   1591. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Antromycopsis.-   1592. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Apoxona.-   1593. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Artolenzites.-   1594. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Asterochaete.-   1595. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Atroporus.-   1596. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Aurantiporellus.-   1597. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Australoporus.-   1598. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Austrolentinus.-   1599. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Bresadolia.-   1600. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Bridgeoporus.-   1601. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Bulliardia.-   1602. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Burgoa.-   1603. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Caloporus.-   1604. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Cellularia.-   1605. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Ceriomyces.-   1606. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Cerioporus.-   1607. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Cerrena.-   1608. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Choriphyllum.-   1609. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Cladoporus.-   1610. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Coriolopsis.-   1611. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Coriolus.-   1612. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Cryptomphalina.-   1613. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Cryptoporus.-   1614. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Cubamyces.-   1615. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Cyanosporus.-   1616. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Cystidiophorus.-   1617. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Cystostiptoporus.-   1618. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Daedaleopsis.-   1619. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Datronia.-   1620. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Dendrochaete.-   1621. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Dendropolyporus.-   1622. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Dextrinosporium.-   1623. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Dichomitus.-   1624. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Digitellus.-   1625. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Earliella.-   1626. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus Echinochaete.-   1627. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus Elfvingiella.-   1628. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Enslinia.-   1629. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Fabisporus.-   1630. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Faerberia.-   1631. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Favolus.-   1632. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Fibroporia.-   1633. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus Flabellophora.-   1634. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Fomes.-   1635. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Fomitella.-   1636. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Funalia.-   1637. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Fuscocerrena.-   1638. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Gemmularia.-   1639. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Geopetalum.-   1640. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus Globifomes.-   1641. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Grammothelopsis.-   1642. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Hansenia.-   1643. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Haploporus.-   1644. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Heliocybe.-   1645. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus Hexagonia.-   1646. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Hirschioporus.-   1647. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Hornodermoporus.-   1648. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Incrustoporia.-   1649. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Laccocephalum.-   1650. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Laetifomes.-   1651. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Laetiporus.-   1652. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Lasiochlaena.-   1653. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus Lentinopanus.-   1654. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus Lentinus.-   1655. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Lentodiellum.-   1656. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Lentodium.-   1657. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Lentus.-   1658. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Lenzites.-   1659. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Leptopora.-   1660. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Leptoporellus.-   1661. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Leptotrimitus.-   1662. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Leucolenzites.-   1663. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Leucoporus.-   1664. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus Lignosus.-   1665. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Lithopolyporales.-   1666. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Loweporus.-   1667. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Macrohyporia.-   1668. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Macroporia.-   1669. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Megasporoporia.-   1670. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Melanoporella.-   1671. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Melanoporia.-   1672. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Melanopus.-   1673. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Merulioporia.-   1674. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Meruliporia.-   1675. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Microporellus.-   1676. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Microporus.-   1677. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Mollicarpus.-   1678. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Mycelithe.-   1679. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Navisporus.-   1680. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Neolentinus.-   1681. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Neolentiporus.-   1682. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Nigrofomes.-   1683. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Nigroporus.-   1684. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus Oligoporus.-   1685. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Osmoporus.-   1686. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Pachykytospora.-   1687. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Pachyma.-   1688. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Panus.-   1689. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Paramyces.-   1690. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Perenniporia.-   1691. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Perenniporiella.-   1692. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Persooniana.-   1693. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Petaloides.-   1694. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Phaeolus.-   1695. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Phaeotrametes.-   1696. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Pherima.-   1697. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Phorima.-   1698. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Phyllodontia.-   1699. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Physisporus.-   1700. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Piloporia.-   1701. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Piloporia.-   1702. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Placodes.-   1703. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Pleuropus.-   1704. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Pocillaria.-   1705. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Podofomes.-   1706. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus Pogonomyces.-   1707. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Polyporellus.-   1708. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Polyporus.-   1709. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Poria.-   1710. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus Porodisculus.-   1711. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Porodiscus.-   1712. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Poronidulus.-   1713. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Poroptyche.-   1714. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Pseudofavolus.-   1715. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Pseudophaeolus.-   1716. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Pseudopiptoporus.-   1717. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus Pseudotrametes.-   1718. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Ptychogaster.-   1719. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Pycnoporellus.-   1720. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Pycnoporus.-   1721. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Pyrofomes.-   1722. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus Riopa.-   1723. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Romellia.-   1724. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Royoporus.-   1725. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Rubroporus.-   1726. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Ryvardenia.-   1727. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Scenidium.-   1728. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Sclerodepsis.-   1729. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Sistotrema.-   1730. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Skeletocutis.-   1731. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Sparsitubus.-   1732. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Spongiosus.-   1733. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Stiptophyllum.-   1734. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Tinctoporellus.-   1735. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus Tomentoporus.-   1736. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Trametella.-   1737. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Trametes.-   1738. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Trichaptum.-   1739. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Truncospora.-   1740. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Tuberaster.-   1741. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Tyromyces.-   1742. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Ungulina.-   1743. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Vanderbylia.-   1744. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Velolentinus.-   1745. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Xerotinus.-   1746. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Xerotus.-   1747. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Xylometron.-   1748. The bioactive agent according to item 1585, wherein    Basidiomycete cell is selected from the genus of Xylopilus.-   1749. The bioactive agent according to item 265, wherein said    Basidiomycete cell belongs to a genus selected from the group    consisting of Cristelloporia, Echinotrema, Fibriciellum,    Fibuloporia, Galziniella, Heptasporium, Hydnotrema, Ingoldiella,    Minimedusa, Osteomorpha, Paullicorticium, Repetobasidiellum,    Repetobasidium, Sistotrema, Sistotremastrum, Sistotremella,    Sphaerobasidium, Tomentella, Trechispora and Urnobasidium.-   1750. The bioactive agent according to item 1749, wherein    Basidiomycete cell is selected from the genus of Cristelloporia.-   1751. The bioactive agent according to item 1749, wherein    Basidiomycete cell is selected from the genus of Echinotrema.-   1752. The bioactive agent according to item 1749, wherein    Basidiomycete cell is selected from the genus of Fibriciellum.-   1753. The bioactive agent according to item 1749, wherein    Basidiomycete cell is selected from the genus of Fibuloporia.-   1754. The bioactive agent according to item 1749, wherein    Basidiomycete cell is selected from the genus of Galziniella.-   1755. The bioactive agent according to item 1749, wherein    Basidiomycete cell is selected from the genus of Heptasporium.-   1756. The bioactive agent according to item 1749, wherein    Basidiomycete cell is selected from the genus of Hydnotrema.-   1757. The bioactive agent according to item 1749, wherein    Basidiomycete cell is selected from the genus Ingoldiella.-   1758. The bioactive agent according to item 1749, wherein    Basidiomycete cell is selected from the genus of Minimedusa.-   1759. The bioactive agent according to item 1749, wherein    Basidiomycete cell is selected from the genus of Osteomorpha.-   1760. The bioactive agent according to item 1749, wherein    Basidiomycete cell is selected from the genus of Paullicorticium.-   1761. The bioactive agent according to item 1749, wherein    Basidiomycete cell is selected from the genus of Repetobasidiellum.-   1762. The bioactive agent according to item 1749, wherein    Basidiomycete cell is selected from the genus of Repetobasidium.-   1763. The bioactive agent according to item 1749, wherein    Basidiomycete cell is selected from the genus of Sistotrema.-   1764. The bioactive agent according to item 1749, wherein    Basidiomycete cell is selected from the genus of Sistotremastrum.-   1765. The bioactive agent according to item 1749, wherein    Basidiomycete cell is selected from the genus of Sistotremella.-   1766. The bioactive agent according to item 1749, wherein    Basidiomycete cell is selected from the genus of Sphaerobasidium.-   1767. The bioactive agent according to item 1749, wherein    Basidiomycete cell is selected from the genus of Tomentella.-   1768. The bioactive agent according to item 1749, wherein    Basidiomycete cell is selected from the genus of Trechispora.-   1769. The bioactive agent according to item 1749, wherein    Basidiomycete cell is selected from the genus of Urnobasidium.-   1770. The bioactive agent according to item 266, wherein said    Basidiomycete cell belongs to a genus selected from the group    consisting of Bondarcevomyces, Masseeola, Sparassiella and    Sparassis.-   1771. The bioactive agent according to item 1770, wherein    Basidiomycete cell is selected from the genus of Bondarcevomyces.-   1772. The bioactive agent according to item 1770, wherein    Basidiomycete cell is selected from the genus of Masseeola.-   1773. The bioactive agent according to item 1770, wherein    Basidiomycete cell is selected from the genus of Sparassiella.-   1774. The bioactive agent according to item 1770, wherein    Basidiomycete cell is selected from the genus of Sparassis.-   1775. The bioactive agent according to item 267, wherein said    Basidiomycete cell belongs to a genus selected from the group    consisting of Amethicium, Antrodiella, Aschersonia, Australohydnum,    Baeostratoporus, Chaetoporus, Cinereomyces, Diplomitoporus,    Etheirodon, Fibricium, Flaviporus, Flavodon, Irpex, Junghuhnia,    Lamelloporus, Laschia, Leptodon, Metuloidea, Mycoleptodon,    Mycoleptodonoides, Mycorrhaphium, Odontia, Odontina, Spathulina,    Steccherinum and Stegiacantha.-   1776. The bioactive agent according to item 1775, wherein    Basidiomycete cell is selected from the genus of Amethicium.-   1777. The bioactive agent according to item 1775, wherein    Basidiomycete cell is selected from the genus of Antrodiella.-   1778. The bioactive agent according to item 1775, wherein    Basidiomycete cell is selected from the genus of Aschersonia.-   1779. The bioactive agent according to item 1775, wherein    Basidiomycete cell is selected from the genus of Australohydnum.-   1780. The bioactive agent according to item 1775, wherein    Basidiomycete cell is selected from the genus of Baeostratoporus.-   1781. The bioactive agent according to item 1775, wherein    Basidiomycete cell is selected from the genus of Chaetoporus.-   1782. The bioactive agent according to item 1775, wherein    Basidiomycete cell is selected from the genus of Cinereomyces.-   1783. The bioactive agent according to item 1775, wherein    Basidiomycete cell is selected from the genus of Diplomitoporus.-   1784. The bioactive agent according to item 1775, wherein    Basidiomycete cell is selected from the genus of Etheirodon.-   1785. The bioactive agent according to item 1775, wherein    Basidiomycete cell is selected from the genus of Fibricium.-   1786. The bioactive agent according to item 1775, wherein    Basidiomycete cell is selected from the genus of Flaviporus.-   1787. The bioactive agent according to item 1775, wherein    Basidiomycete cell is selected from the genus of Flavodon.-   1788. The bioactive agent according to item 1775, wherein    Basidiomycete cell is selected from the genus of Irpex.-   1789. The bioactive agent according to item 1775, wherein    Basidiomycete cell is selected from the genus of Junghuhnia.-   1790. The bioactive agent according to item 1775, wherein    Basidiomycete cell is selected from the genus of Lamelloporus.-   1791. The bioactive agent according to item 1775, wherein    Basidiomycete cell is selected from the genus of Laschia.-   1792. The bioactive agent according to item 1775, wherein    Basidiomycete cell is selected from the genus of Leptodon.-   1793. The bioactive agent according to item 1775, wherein    Basidiomycete cell is selected from the genus of Metuloidea.-   1794. The bioactive agent according to item 1775, wherein    Basidiomycete cell is selected from the genus of Mycoleptodon. 1795.    The bioactive agent according to item 1775, wherein Basidiomycete    cell is selected from the genus of Mycoleptodonoides.-   1796. The bioactive agent according to item 1775, wherein    Basidiomycete cell is selected from the genus of Mycorrhaphium.-   1797. The bioactive agent according to item 1775, wherein    Basidiomycete cell is selected from the genus of Odontia.-   1798. The bioactive agent according to item 1775, wherein    Basidiomycete cell is selected from the genus of Odontina.-   1799. The bioactive agent according to item 1775, wherein    Basidiomycete cell is selected from the genus of Spathulina.-   1800. The bioactive agent according to item 1775, wherein    Basidiomycete cell is selected from the genus Steccherinum.-   1801. The bioactive agent according to item 1775, wherein    Basidiomycete cell is selected from the genus of Stegiacantha.-   1802. The bioactive agent according to item 268, wherein said    Basidiomycete cell belongs to a genus selected from the group    consisting of Granulocystis, Leifia, Litschauerella, Tubulicium,    Tubulicrinis and Tubulixenasma.-   1803. The bioactive agent according to item 1802, wherein    Basidiomycete cell is selected from the genus of Granulocystis.-   1804. The bioactive agent according to item 1802, wherein    Basidiomycete cell is selected from the genus of Leifia.-   1805. The bioactive agent according to item 1802, wherein    Basidiomycete cell is selected from the genus of Litschauerella.-   1806. The bioactive agent according to item 1802, wherein    Basidiomycete cell is selected from the genus of Tubulicium.-   1807. The bioactive agent according to item 1802, wherein    Basidiomycete cell is selected from the genus of Tubulicrinis.-   1808. The bioactive agent according to item 1802, wherein    Basidiomycete cell is selected from the genus of Tubulixenasma.-   1809. The bioactive agent according to item 268, wherein said    Basidiomycete cell belongs to a genus selected from the group    consisting of Aphanobasidium, Clitopilina, Cunninghammyces,    Lepidomyces, Phlebiella, Xenasma, Xenasmatella and Xenosperma.-   1810. The bioactive agent according to item 1809, wherein    Basidiomycete cell is selected from the genus of Aphanobasidium.-   1811. The bioactive agent according to item 1809, wherein    Basidiomycete cell is selected from the genus of Clitopilina.-   1812. The bioactive agent according to item 1809, wherein    Basidiomycete cell is selected from the genus of Cunninghammyces.-   1813. The bioactive agent according to item 1809, wherein    Basidiomycete cell is selected from the genus of Lepidomyces.-   1814. The bioactive agent according to item 1809, wherein    Basidiomycete cell is selected from the genus of Phlebiella.-   1815. The bioactive agent according to item 1809, wherein    Basidiomycete cell is selected from the genus of Xenasma.-   1816. The bioactive agent according to item 1809, wherein    Basidiomycete cell is selected from the genus of Xenasmatella.-   1817. The bioactive agent according to item 1809, wherein    Basidiomycete cell is selected from the genus of Xenosperma.-   1818. The bioactive agent according to item 363, wherein said    Basidiomycete cell belongs to a species selected from the group    consisting of Agaricus arorae, Agaricus arvensis, Agaricus augustus,    Agaricus benesi, Agaricus bernardii, Agaricus bitorquis, Agaricus    californicus, Agaricus campestris, Agaricus comptulus, Agaricus    cupreo-brunneus, Agaricus diminutivus, Agaricus fusco-fibrillosus,    Agaricus fuscovelatus, Agaricus hondensis, Agaricus lilaceps,    Agaricus micromegathus, Agaricus praeclaresquamosus, Agaricus    pattersonae, Agaricus perobscurus, Agaricus semotus, Agaricus    silvicola, Agaricus subrutilescens and Agaricus xanthodermus.-   1819. The bioactive agent according to item 1819, wherein    Basidiomycete cell is Agaricus arorae.-   1820. The bioactive agent according to item 1819, wherein    Basidiomycete cell is Agaricus arvensis.-   1821. The bioactive agent according to item 1819, wherein    Basidiomycete cell is Agaricus augustus.-   1822. The bioactive agent according to item 1819, wherein    Basidiomycete cell is Agaricus benesi.-   1823. The bioactive agent according to item 1819, wherein    Basidiomycete cell is Agaricus bernardii.-   1824. The bioactive agent according to item 1819, wherein    Basidiomycete cell is Agaricus bitorquis.-   1825. The bioactive agent according to item 1819, wherein    Basidiomycete cell is Agaricus californicus.-   1826. The bioactive agent according to item 1819, wherein    Basidiomycete cell is Agaricus campestris.-   1827. The bioactive agent according to item 1819, wherein    Basidiomycete cell is Agaricus comptulus.-   1828. The bioactive agent according to item 1819, wherein    Basidiomycete cell is Agaricus cupreo-brunneus.-   1829. The bioactive agent according to item 1819, wherein    Basidiomycete cell is Agaricus diminutivus.-   1830. The bioactive agent according to item 1819, wherein    Basidiomycete cell is Agaricus fusco-fibrillosus.-   1831. The bioactive agent according to item 1819, wherein    Basidiomycete cell is Agaricus fuscovelatus.-   1832. The bioactive agent according to item 1819, wherein    Basidiomycete cell is Agaricus hondensis.-   1833. The bioactive agent according to item 1819, wherein    Basidiomycete cell is Agaricus lilaceps.-   1834. The bioactive agent according to item 1819, wherein    Basidiomycete cell is Agaricus micromegathus.-   1835. The bioactive agent according to item 1819, wherein    Basidiomycete cell is Agaricus praeclaresquamosus.-   1836. The bioactive agent according to item 1819, wherein    Basidiomycete cell is Agaricus pattersonae.-   1837. The bioactive agent according to item 1819, wherein    Basidiomycete cell is Agaricus perobscurus.-   1838. The bioactive agent according to item 1819, wherein    Basidiomycete cell is Agaricus semotus.-   1839. The bioactive agent according to item 1819, wherein    Basidiomycete cell is Agaricus silvicola.-   1840. The bioactive agent according to item 1819, wherein    Basidiomycete cell is Agaricus subrutilescens.-   1841. The bioactive agent according to item 1819, wherein    Basidiomycete cell is Agaricus xanthodermus.-   1842. The bioactive agent according to item 925, wherein said    Basidiomycete cell belongs to a species selected from the group    consisting of Schizophyllum album, Schizophyllum alneum,    Schizophyllum alneum, Schizophyllum amplum, Schizophyllum    brasiliense, Schizophyllum brevilamellatum, Schizophyllum commune,    Schizophyllum egelingianum, Schizophyllum exiguum, Schizophyllum    fasciatum, Schizophyllum flabellare, Schizophyllum leprieurii,    Schizophyllum lobatum, Schizophyllum mexicanum, Schizophyllum    multifidum, Schizophyllum murrayi, Schizophyllum mya, Schizophyllum    palmatum, Schizophyllum radiatum, Schizophyllum umbrinum and    Schizophyllum variabile.-   1843. The bioactive agent according to item 1842, wherein    Basidiomycete cell is Schizophyllum album.-   1844. The bioactive agent according to item 1842, wherein    Basidiomycete cell is Schizophyllum alneum.-   1845. The bioactive agent according to item 1842, wherein    Basidiomycete cell is Schizophyllum alneum.-   1846. The bioactive agent according to item 1842, wherein    Basidiomycete cell is Schizophyllum amplum.-   1847. The bioactive agent according to item 1842, wherein    Basidiomycete cell is Schizophyllum brasiliense.-   1848. The bioactive agent according to item 1842, wherein    Basidiomycete cell is Schizophyllum brevilamellatum.-   1849. The bioactive agent according to item 1842, wherein    Basidiomycete cell is Schizophyllum commune.-   1850. The bioactive agent according to item 1842, wherein    Basidiomycete cell is Schizophyllum egelingianum.-   1851. The bioactive agent according to item 1842, wherein    Basidiomycete cell is Schizophyllum exiguum.-   1852. The bioactive agent according to item 1842, wherein    Basidiomycete cell is Schizophyllum fasciatum.-   1853. The bioactive agent according to item 1842, wherein    Basidiomycete cell is Schizophyllum flabellare.-   1854. The bioactive agent according to item 1842, wherein    Basidiomycete cell is Schizophyllum leprieurii.-   1855. The bioactive agent according to item 1842, wherein    Basidiomycete cell is Schizophyllum lobatum.-   1856. The bioactive agent according to item 1842, wherein    Basidiomycete cell is Schizophyllum mexicanum.-   1857. The bioactive agent according to item 1842, wherein    Basidiomycete cell is Schizophyllum multifidum.-   1858. The bioactive agent according to item 1842, wherein    Basidiomycete cell is Schizophyllum murrayi. 1859. The bioactive    agent according to item 1842, wherein Basidiomycete cell is    Schizophyllum mya.-   1860. The bioactive agent according to item 1842, wherein    Basidiomycete cell is Schizophyllum palmatum.-   1861. The bioactive agent according to item 1842, wherein    Basidiomycete cell is Schizophyllum radiatum.-   1862. The bioactive agent according to item 1842, wherein    Basidiomycete cell is Schizophyllum umbrinum.-   1863. The bioactive agent according to item 1842, wherein    Basidiomycete cell is Schizophyllum variabile.-   1864. The bioactive agent according to item 1406, wherein said    Basidiomycete cell belongs to a species selected from the group    consisting of Ganoderma adspersum, Ganoderma africanum, Ganoderma    applanatum, Ganoderma arcuatum, Ganoderma areolatum, Ganoderma    bakeri, Ganoderma balabacense, Ganoderma cacainum, Ganoderma    calcigenum, Ganoderma calidophilum, Ganoderma camphoratum, Ganoderma    cantharelloideum, Ganoderma capense, Ganoderma carnosum, Ganoderma    cehengense, Ganoderma cervinum, Ganoderma chaffangeonii, Ganoderma    chalceum, Ganoderma chaperi, Ganoderma chenhaiense, Ganoderma    chilense, Ganoderma chiungchungense, Ganoderma chonoides, Ganoderma    cochlear, Ganoderma coffeatum, Ganoderma colossus, Ganoderma    comorense, Ganoderma comphoratum, Ganoderma concinnum, Ganoderma    conicus, Ganoderma corrugatum, Ganoderma costatus, Ganoderma    crebrostriatum, Ganoderma cupreolaccatum, Ganoderma cupreum,    Ganoderma cupulatiprocerum, Ganoderma curranii, Ganoderma curtisii,    Ganoderma dahlii, Ganoderma daiqingshanense, Ganoderma dejongii,    Ganoderma densizonatum, Ganoderma diaoluoshanense, Ganoderma donkii,    Ganoderma dorsale, Ganoderma dubio-cochlear, Ganoderma dussii,    Ganoderma elmeri, Ganoderma elmerianum, Ganoderma eminii, Ganoderma    endochrum, Ganoderma europaeum, Ganoderma exile, Ganoderma    expallens, Ganoderma fasciatum, Ganoderma fasciculatum, Ganoderma    fassii, Ganoderma fassioides, Ganoderma fici, Ganoderma    flabelliforme, Ganoderma flaviporum, Ganoderma flexipes, Ganoderma    formosanum, Ganoderma formosissimum, Ganoderma fornicatum, Ganoderma    frondosum, Ganoderma fulvellum, Ganoderma fuscum, Ganoderma    galegense, Ganoderma gelsicola, Ganoderma ghesquierei, Ganoderma    gibbosum, Ganoderma gilletii, Ganoderma guadelupense, Ganoderma    guinanense, Ganoderma guizhouense, Ganoderma hainanense, Ganoderma    henningsii, Ganoderma hildebrandii, Ganoderma hinnuleum, Ganoderma    hoehnelianum, Ganoderma hollidayi, Ganoderma hoploides, Ganoderma    hypoxanthum, Ganoderma impolitum, Ganoderma incrassatum, Ganoderma    incrustatum, Ganoderma infulgens, Ganoderma infundibuliforme,    Ganoderma insulare, Ganoderma intermedium, Ganoderma japonicum,    Ganoderma jianfenglingense, Ganoderma koningsbergii, Ganoderma    kosteri, Ganoderma kunmingense, Ganoderma laccatum, Ganoderma    lamaoense, Ganoderma leptopum, Ganoderma leucocreas, Ganoderma    leucophaeum, Ganoderma leytense, Ganoderma lignosum, Ganoderma    limushanense, Ganoderma lingua, Ganoderma linhartii, Ganoderma    lionnetii, Ganoderma lipsiense, Ganoderma loydii, Ganoderma    lobatoideum, Ganoderma lobatum, Ganoderma longipes, Ganoderma    longistipatum, Ganoderma longistipitatum, Ganoderma lorenzianum,    Ganoderma lucidum, Ganoderma lusambilaense, Ganoderma luteicinctum,    Ganoderma luteomarginatum, Ganoderma luteum, Ganoderma macer,    Ganoderma magniporum, Ganoderma maitlandii, Ganoderma malayanum,    Ganoderma malosporum, Ganoderma mangiferae, Ganoderma manoutchehrii,    Ganoderma mastoporum, Ganoderma mediosinense, Ganoderma megaloma,    Ganoderma megalosporum, Ganoderma meijangense, Ganoderma    melanophaeum, Ganoderma meredithiae, Ganoderma microsporum,    Ganoderma miniatocinctum, Ganoderma mirabile, Ganoderma    mirivelutinum, Ganoderma mongolicum, Ganoderma multicornum,    Ganoderma multipileum, Ganoderma multiplicatum, Ganoderma    namutambalaense, Ganoderma neglectus, Ganoderma neojaponicum,    Ganoderma neurosporum, Ganoderma nevadense, Ganoderma nigrolucidum,    Ganoderma nitens, Ganoderma nitidum, Ganoderma noukahivense,    Ganoderma nutans, Ganoderma obockense, Ganoderma obokensis,    Ganoderma ochrolaccatum, Ganoderma oerstedii, Ganoderma omphalodes,    Ganoderma opacum, Ganoderma orbiforme, Ganoderma oregonense,    Ganoderma oroflavum, Ganoderma oroleucum, Ganoderma ostracodes,    Ganoderma ostreatum, Ganoderma papillatum, Ganoderma parviungulatum,    Ganoderma parvulum, Ganoderma pernanum, Ganoderma personatum,    Ganoderma perturbatum, Ganoderma petchii, Ganoderma pfeifferi,    Ganoderma philippli, Ganoderma platense, Ganoderma plicatum,    Ganoderma polychromum, Ganoderma polymorphum, Ganoderma praelongum    Murrill, Ganoderma praetervisum, Ganoderma preussii, Ganoderma    pseudoboletus, Ganoderma pseudoferreum, Ganoderma puberulum,    Ganoderma puglisii, Ganoderma pulchella, Ganoderma pullatum,    Ganoderma pulverulentum, Ganoderma pygmoideum, Ganoderma    ramosissimum, Ganoderma ravenelii, Ganoderma renidens, Ganoderma    renii, Ganoderma resinaceum, Ganoderma reticulatosporum, Ganoderma    rhacodes, Ganoderma rivulosum, Ganoderma rothwellii, Ganoderma    rotundatum, Ganoderma rubeolum, Ganoderma rude, Ganoderma rufoalbum,    Ganoderma rufobadium, Ganoderma rugosissimus, Ganoderma rugosum,    Ganoderma sanmingense, Ganoderma sarasinii, Ganoderma schomburgkii,    Ganoderma sculpturatum, Ganoderma septatum, Ganoderma sequoiae,    Ganoderma sessile, Ganoderma sessiliforme, Ganoderma shandongense,    Ganoderma shangsiens, Ganoderma sichuanense, Ganoderma sikorae,    Ganoderma silveirae, Ganoderma simaoense, Ganoderma simulans,    Ganoderma sinense, Ganoderma soniense, Ganoderma soyeri, Ganoderma    sprucei, Ganoderma staneri, Ganoderma steyaertanum, Ganoderma    stipitatum, Ganoderma stratoideum, Ganoderma subamboinense,    Ganoderma subfornicatum, Ganoderma subfulvum, Ganoderma    subincrustatum, Ganoderma sublucidum, Ganoderma subperforatum,    Ganoderma subrenatum, Ganoderma subresinosum, Ganoderma subrugosus,    Ganoderma substipitata, Ganoderma subtornatum, Ganoderma    subtuberculosum, Ganoderma subumbraculum, Ganoderma sulcatum,    Ganoderma tenue, Ganoderma testaceum, Ganoderma theaecolum,    Ganoderma tibetanum, Ganoderma tornatum, Ganoderma torosum,    Ganoderma torrendii, Ganoderma trengganuense, Ganoderma triangulum,    Ganoderma triviale, Ganoderma tropicum, Ganoderma trulla, Ganoderma    trulliforme, Ganoderma tsugae, Ganoderma tsunodae, Ganoderma    tuberculosum, Ganoderma tumidum, Ganoderma umbraculum, Ganoderma    umbrinum, Ganoderma ungulatum, Ganoderma valesiacum, Ganoderma    vanheurnii, Ganoderma vanmeelii, Ganoderma variabile, Ganoderma    weberianum, Ganoderma williamsianum, Ganoderma wuhuense, Ganoderma    wynaadense, Ganoderma xanthocreas, Ganoderma xingyiense, Ganoderma    xylodes, Ganoderma xylonoides, Ganoderma zhenningense and Ganoderma    zonatum.-   1865. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma adspersum.-   1866. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma africanum.-   1867. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma applanatum.-   1868. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma arcuatum.-   1869. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma areolatum.-   1870. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma bakeri.-   1871. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma balabacense.-   1872. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma cacainum.-   1873. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma cacainum.-   1874. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma calcigenum.-   1875. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma calidophilum.-   1876. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma camphoratum.-   1877. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma cantharelloideum.-   1878. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma capense.-   1879. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma carnosum.-   1880. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma cehengense.-   1881. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma cervinum.-   1882. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma chaffangeonii.-   1883. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma chalceum.-   1884. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma chaperi.-   1885. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma chenhaiense.-   1886. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma chilense.-   1887. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma chiungchungense.-   1888. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma chonoides.-   1889. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma cochlear.-   1890. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma coffeatum.-   1891. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma colossus.-   1892. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma comorense.-   1893. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma comphoratum.-   1894. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma concinnum.-   1895. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma conicus.-   1896. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma corrugatum.-   1897. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma costatus.-   1898. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma crebrostriatum.-   1899. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma cupreolaccatum.-   1900. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma curranii.-   1901. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma curtisii.-   1902. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma dahlii.-   1903. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma daiqingshanense.-   1904. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma dejongii.-   1905. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma densizonatum.-   1906. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma diaoluoshanense.-   1907. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma donkii.-   1908. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma dorsale.-   1909. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma dubio-cochlear.-   1910. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma dussii.-   1911. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma elmeri.-   1912. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma elmerianum.-   1913. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma eminii.-   1914. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma endochrum.-   1915. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma europaeum.-   1916. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma exile.-   1917. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma expallens.-   1918. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma fasciatum.-   1919. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma fassii.-   1920. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma fassioides.-   1921. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma fici.-   1922. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma flabelliforme.-   1923. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma flaviporum.-   1924. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma flexipes.-   1925. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma formosanum.-   1926. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma formosissimum.-   1927. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma fornicatum.-   1928. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma frondosum.-   1929. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma fulvellum.-   1930. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma fuscum.-   1931. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma galegense.-   1932. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma gelsicola.-   1933. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma ghesquierei.-   1934. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma gibbosum.-   1935. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma gilletii.-   1936. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma guadelupense.-   1937. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma guinanense.-   1938. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma guizhouense.-   1939. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma hainanense.-   1940. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma henningsii.-   1941. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma hildebrandii.-   1942. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma hinnuleum.-   1943. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma hoehnelianum.-   1944. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma hollidayi.-   1945. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma hoploides.-   1946. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma hypoxanthum.-   1947. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma impolitum.-   1948. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma incrassatum.-   1949. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma incrustatum.-   1950. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma infulgens.-   1951. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma infundibuliforme.-   1952. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma insulare.-   1953. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma intermedium.-   1954. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma japonicum.-   1955. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma jianfenglingense.-   1956. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma koningsbergii.-   1957. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma kosteri.-   1958. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma kunmingense.-   1959. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma laccatum.-   1960. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma lamaoense.-   1961. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma leptopum.-   1962. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma leucocreas.-   1963. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma leucophaeum.-   1964. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma leytense.-   1965. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma lignosum.-   1966. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma limushanense.-   1967. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma lingua.-   1968. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma linhartii.-   1969. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma lionnetii.-   1970. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma lipsiense.-   1971. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma lloydii.-   1972. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma lobatoideum.-   1973. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma lobatum.-   1974. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma longipes.-   1975. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma longistipatum.-   1976. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma lorenzianum.-   1977. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma lucidum.-   1978. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma lusambilaense.-   1979. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma luteicinctum.-   1980. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma luteomarginatum.-   1981. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma luteum.-   1982. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma macer.-   1983. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma magniporum.-   1984. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma maitlandii.-   1985. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma malayanum.-   1986. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma malosporum.-   1987. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma mangiferae.-   1988. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma manoutchehrii.-   1989. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma mastoporum.-   1990. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma mediosinense.-   1991. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma megaloma.-   1992. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma megalosporum.-   1993. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma meijangense.-   1994. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma melanophaeum.-   1995. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma meredithiae.-   1996. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma microsporum.-   1997. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma miniatocinctum.-   1998. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma mirabile.-   1999. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma mirivelutinum.-   2000. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma mongolicum.-   2001. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma multicornum.-   2002. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma multipileum.-   2003. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma multiplicatum.-   2004. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma namutambalaense.-   2005. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma neglectus.-   2006. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma neojaponicum.-   2007. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma neurosporum.-   2008. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma nevadense.-   2009. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma nigrolucidum.-   2010. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma nitens.-   2011. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma nitidum.-   2012. The bioactive agent according to item 1864, wherein    Basidiomycete cell Ganoderma noukahivense.-   2013. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma nutans.-   2014. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma obockense.-   2015. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma obokensis.-   2016. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma ochrolaccatum.-   2017. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma oerstedii.-   2018. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma omphalodes.-   2019. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma opacum.-   2020. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma orbiforme.-   2021. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma oregonense.-   2022. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma oroflavum.-   2023. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma oroleucum.-   2024. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma ostracodes.-   2025. The bioactive agent according to item 1864, wherein    Basidiomycete cell is ostreatum.-   2026. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma papillatum.-   2027. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma parviungulatum.-   2028. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma parvulum.-   2029. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma pernanum.-   2030. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma personatum.-   2031. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma perturbatum.-   2032. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma petchii.-   2033. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma pfeifferi.-   2034. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma philippii.-   2035. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma platense.-   2036. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma plicatum.-   2037. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma polychromum.-   2038. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma polymorphum.-   2039. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma praelongum.-   2040. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma praetervisum.-   2041. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma preussii.-   2042. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma pseudoboletus.-   2043. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma pseudoferreum.-   2044. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma puberulum.-   2045. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma puglisii.-   2046. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma puichella.-   2047. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma pullatum.-   2048. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma pulverulentum.-   2049. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma pygmoideum.-   2050. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma ramosissimum.-   2051. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma ravenelii.-   2052. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma renidens.-   2053. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma renii.-   2054. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma resinaceum.-   2055. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma reticulatosporum.-   2056. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma rhacode.-   2057. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma rivulosum.-   2058. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma rothwellii.-   2059. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma rotundatum.-   2060. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma rubeolum.-   2061. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma rude.-   2062. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma rufoalbum.-   2063. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma rufobadium.-   2064. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma rugosissimus.-   2065. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma rugosum.-   2066. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma sanmingense.-   2067. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma sarasinii.-   2068. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma schomburgkii.-   2069. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma sculpturatum.-   2070. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma septatum.-   2071. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma sequoiae.-   2072. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma sessile.-   2073. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma sessiliforme.-   2074. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma shandongense.-   2075. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma shangsiens.-   2076. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma sichuanense.-   2077. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma sikorae.-   2078. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma silveirae.-   2079. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma simaoense.-   2080. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma simulans.-   2081. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma sinense.-   2082. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma soniense.-   2083. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma soyeri.-   2084. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma sprucei.-   2085. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma staneri.-   2086. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma steyaertanum.-   2087. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma stipitatum.-   2088. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma stratoideum.-   2089. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma subamboinense.-   2090. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma subfornicatum.-   2091. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma subfulvum.-   2092. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma subincrustatum.-   2093. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma sublucidum.-   2094. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma subperForatum.-   2095. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma subrenatum.-   2096. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma subresinosum.-   2097. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma subrugosus.-   2098. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma substipitata.-   2099. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma subtornatum.-   2100. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma subtuberculosum.-   2101. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma subumbraculum.-   2102. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma sulcatum.-   2103. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma tenue.-   2104. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma testaceum.-   2105. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma theaecolum.-   2106. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma tibetanum.-   2107. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma tornatum.-   2108. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma torosum.-   2109. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma torrendii.-   2110. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma trengganuense.-   2111. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma triangulum.-   2112. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma triviale.-   2113. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma tropicum.-   2114. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma trulla.-   2115. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma trulliforme.-   2116. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma tsugae.-   2117. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma tsunodae.-   2118. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma tuberculosum.-   2119. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma tumidum.-   2120. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma umbraculum.-   2121. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma umbrinum.-   2122. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma ungulatum.-   2123. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma valesiacum.-   2124. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma vanheurnii.-   2125. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma vanmeelii.-   2126. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma variabile.-   2127. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma weberianum.-   2128. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma williamsianum.-   2129. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma wuhuense.-   2130. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma wynaadense.-   2131. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma xanthocreas.-   2132. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma xingyiense.-   2133. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma xylodes.-   2134. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma xylonoides.-   2135. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma zhenningense.-   2136. The bioactive agent according to item 1864, wherein    Basidiomycete cell is Ganoderma zonatum.-   2137. The bioactive agent according to item 1498, wherein said    Basidiomycete cell belongs to a species selected from the group    consisting of Grifola acanthoides, Grifola albicans, Grifola    armeniaca, Grifola badia, Grifola colensoi, Grifola eos, Grifola    fractipes, Grifola frondosa, Grifola gargal, Grifola gigantea,    Grifola intybacea, Grifola lentifrondosa, Grifola obducta, Grifola    platypora, Grifola rosularis, Grifola sordulenta, Grifola sulphurea,    Grifola sumstinei and Grifola tuckahoe.-   2138. The bioactive agent according to item 2137, wherein    Basidiomycete cell is Grifola acanthoides.-   2139. The bioactive agent according to item 2137, wherein    Basidiomycete cell is Grifola albicans.-   2140. The bioactive agent according to item 2137, wherein    Basidiomycete cell is Grifola armeniaca.-   2141. The bioactive agent according to item 2137, wherein    Basidiomycete cell is Grifola badia.-   2142. The bioactive agent according to item 2137, wherein    Basidiomycete cell is Grifola colensoi.-   2143. The bioactive agent according to item 2137, wherein    Basidiomycete cell is Grifola eos.-   2144. The bioactive agent according to item 2137, wherein    Basidiomycete cell is Grifola fractipes.-   2145. The bioactive agent according to item 2137, wherein    Basidiomycete cell is Grifola frondosa.-   2146. The bioactive agent according to item 2137, wherein    Basidiomycete cell is Grifola gargal.-   2147. The bioactive agent according to item 2137, wherein    Basidiomycete cell is Grifola gigantea.-   2148. The bioactive agent according to item 2137, wherein    Basidiomycete cell is Grifola intybacea.-   2149. The bioactive agent according to item 2137, wherein    Basidiomycete cell is Grifola lentifrondosa.-   2150. The bioactive agent according to item 2137, wherein    Basidiomycete cell is Grifola obducta.-   2151. The bioactive agent according to item 2137, wherein    Basidiomycete cell is Grifola platypora.-   2152. The bioactive agent according to item 2137, wherein    Basidiomycete cell is Grifola rosularis.-   2153. The bioactive agent according to item 2137, wherein    Basidiomycete cell is Grifola sordulenta.-   2154. The bioactive agent according to item 2137, wherein    Basidiomycete cell is Grifola sulphurea.-   2155. The bioactive agent according to item 2137, wherein    Basidiomycete cell is Grifola sumstinei.-   2156. The bioactive agent according to item 2137, wherein    Basidiomycete cell is Grifola tuckahoe.-   2157. The bioactive agent according to item 1654, wherein said    Basidiomycete cell belongs to a species selected from the group    consisting of Lentinus albovelutinus, Lentinus anthocephalus,    Lentinus badius, Lentinus castoreus, Lentinus chrysopeplus, Lentinus    cochleatus, Lentinus concinnus, Lentinus delicatus, Lentinus edodes,    Lentinus fasciatus, Lentinus hyracinus, Lentinus lepideus sensu,    Lentinus lepideus, Lentinus novaezelandiae, Lentinus pulvinulus,    Lentinus punctaticeps, Lentinus punctaticeps, Lentinus pygmaeus,    Lentinus sajor-caju, Lentinus squarrulosus, Lentinus strigosus,    Lentinus suffrutescens, Lentinus tuber-regium and Lentinus    zelandicus.-   2158. The bioactive agent according to item 2157, wherein    Basidiomycete cell is Lentinus albovelutinus.-   2159. The bioactive agent according to item 2157, wherein    Basidiomycete cell is Lentinus albovelutinus.-   2160. The bioactive agent according to item 2157, wherein    Basidiomycete cell is Lentinus anthocephalus.-   2161. The bioactive agent according to item 2157, wherein    Basidiomycete cell is Lentinus badius.-   2162. The bioactive agent according to item 2157, wherein    Basidiomycete cell is Lentinus castoreus.-   2163. The bioactive agent according to item 2157, wherein    Basidiomycete cell is Lentinus chrysopeplus.-   2164. The bioactive agent according to item 2157, wherein    Basidiomycete cell is Lentinus cochleatus.-   2165. The bioactive agent according to item 2157, wherein    Basidiomycete cell is Lentinus concinnus.-   2166. The bioactive agent according to item 2157, wherein    Basidiomycete cell is Lentinus delicatus.-   2167. The bioactive agent according to item 2157, wherein    Basidiomycete cell is Lentinus edodes.-   2168. The bioactive agent according to item 2157, wherein    Basidiomycete cell is Lentinus fasciatus.-   2169. The bioactive agent according to item 2157, wherein    Basidiomycete cell is Lentinus hyracinus.-   2170. The bioactive agent according to item 2157, wherein    Basidiomycete cell is Lentinus lepideus sensu.-   2171. The bioactive agent according to item 2157, wherein    Basidiomycete cell is Lentinus lepideus.-   2172. The bioactive agent according to item 2157, wherein    Basidiomycete cell is Lentinus novaezelandiae.-   2173. The bioactive agent according to item 2157, wherein    Basidiomycete cell is Lentinus pulvinulus.-   2174. The bioactive agent according to item 2157, wherein    Basidiomycete cell is Lentinus punctaticeps.-   2175. The bioactive agent according to item 2157, wherein    Basidiomycete cell is Lentinus pygmaeus.-   2176. The bioactive agent according to item 2157, wherein    Basidiomycete cell is Lentinus sajor-caju.-   2177. The bioactive agent according to item 2157, wherein    Basidiomycete cell is Lentinus squarrulosus.-   2178. The bioactive agent according to item 2157, wherein    Basidiomycete cell is Lentinus strigosus.-   2179. The bioactive agent according to item 2157, wherein    Basidiomycete cell is Lentinus suffrutescens.-   2180. The bioactive agent according to item 2157, wherein    Basidiomycete cell is Lentinus tuber-regium.-   2181. The bioactive agent according to item 2157, wherein    Basidiomycete cell is Lentinus zelandicus.-   2182. The bioactive agent according to item 1737, wherein said    Basidiomycete cell belongs to a species selected from the group    consisting of Trametes cervina, Trametes cingulata, Trametes    cotonea, Trametes gibbosa, Trametes hirsuta, Trametes incerta,    Trametes lactine, Trametes maxima, Trametes meyenii, Trametes    morganii, Trametes ochracea, Trametes pubescens, Trametes    robiniophila, Trametes suaveolens, Trametes subsinuosa, Trametes    tegularis, Trametes tenuis, Trametes trabea, Trametes umbrina,    Trametes unicolor, Trametes versicolor, Trametes villosa and    Trametes zonata.-   2183. The bioactive agent according to item 2182, wherein    Basidiomycete cell is Trametes cervina.-   2184. The bioactive agent according to item 2182, wherein    Basidiomycete cell is Trametes cingulata.-   2185. The bioactive agent according to item 2182, wherein    Basidiomycete cell is Trametes cotonea.-   2186. The bioactive agent according to item 2182, wherein    Basidiomycete cell is Trametes gibbosa.-   2187. The bioactive agent according to item 2182, wherein    Basidiomycete cell is Trametes hirsuta.-   2188. The bioactive agent according to item 2182, wherein    Basidiomycete cell is Trametes incerta.-   2189. The bioactive agent according to item 2182, wherein    Basidiomycete cell is Trametes lactine.-   2190. The bioactive agent according to item 2182, wherein    Basidiomycete cell is Trametes maxima.-   2191. The bioactive agent according to item 2182, wherein    Basidiomycete cell is Trametes meyenii.-   2192. The bioactive agent according to item 2182, wherein    Basidiomycete cell is Trametes morganii.-   2193. The bioactive agent according to item 2182, wherein    Basidiomycete cell is Trametes ochracea.-   2194. The bioactive agent according to item 2182, wherein    Basidiomycete cell is Trametes pubescens.-   2195. The bioactive agent according to item 2182, wherein    Basidiomycete cell is Trametes robiniophila.-   2196. The bioactive agent according to item 2182, wherein    Basidiomycete cell is Trametes suaveolens.-   2197. The bioactive agent according to item 2182, wherein    Basidiomycete cell is Trametes subsinuosa.-   2198. The bioactive agent according to item 2182, wherein    Basidiomycete cell is Trametes tegularis.-   2199. The bioactive agent according to item 2182, wherein    Basidiomycete cell is Trametes tenuis.-   2200. The bioactive agent according to item 2182, wherein    Basidiomycete cell is Trametes trabea.-   2201. The bioactive agent according to item 2182, wherein    Basidiomycete cell is Trametes umbrina.-   2202. The bioactive agent according to item 2182, wherein    Basidiomycete cell is Trametes unicolor.-   2203. The bioactive agent according to item 2182, wherein    Basidiomycete cell is Trametes versicolor.-   2204. The bioactive agent according to item 2182, wherein    Basidiomycete cell is Trametes villosa.-   2205. The bioactive agent according to item 2182, wherein    Basidiomycete cell is Trametes zonata.-   2206. A composition comprising the bioactive agent according to any    of the items above and a physiologically acceptable carrier.-   2207. A pharmaceutical composition comprising the bioactive agent    according to any of the items above and a pharmaceutically    acceptable carrier.-   2208. Use of the pharmaceutical composition according to item 2207    in the manufacture of a medicament.

In one embodiment, the bioactive agent is an Agaricus bioactive agent. Abioactive agent from any of the below Agaricus species may be used inthe present invention, such as any bioactive agents from the groupconsisting of: Agaricus arorae, Agaricus arvensis, Agaricus augustus,Agaricus benesi, Agaricus bernardii, Agaricus bisporus, Agaricusbitorquis, Agaricus blazei Murill yh (has reclassified as Agaricusbrasiliensis), Agaricus californicus, Agaricus campestris, Agaricuscomptulus, Agaricus cupreo-brunneus, Agaricus diminutives, Agaricusfusco-fibrillosus, Agaricus fuscovelatus, Agaricus hondensis, Agaricuslilaceps, Agaricus micromegathus, Agaricus praeclaresquamosus, Agaricuspattersonae, Agaricus perobscurus, Agaricus semotus, Agaricus silvicola,Agaricus subrutilescens, Agaricus xanthodermus.

It is preferred that the Agaricus bioactive agent is from any of thefollowing: A. blazei, A. blazei Murill, A. bisporus, A. hortensis, A.campestris.

In a particularly preferred embodiment of the present invention, theAgaricus bioactive agent is from A. blazei, preferably A. blazei Murill.

In another preferred embodiment of the present invention, the Agaricusbioactive agent is from A. bisporus. In another preferred embodiment ofthe present invention, the Agaricus bioactive agent is from A.hortensis. In another preferred embodiment of the present invention, theAgaricus bioactive agent is from A. campestris

Accordingly, in a preferred embodiment of the present invention thecompositions disclosed herein have been produced by an Agaricus fungus.Preferably, the compositions have been purified from the extracellularenvironment of an Agaricus fungus. Even more preferably the fungus,preferably a fungal mycelium, has been cultivated in a liquid growthmedium and said composition has been purified from said liquid growthmedium.

It is thus preferred that the composition of the invention has beenproduced by a method comprising the steps of

-   -   i) cultivating an Agaricus fungus, such as an Agaricus fungal        mycelium, in a liquid growth medium, and    -   ii) isolating the composition from said liquid growth medium

By fungal mycelium is intended any fungal biomass, which can be grown ina submerged culture. The fungal biomass may be in the form of singlehyphae, spores, aggregates of mycelium, and partly differentiatedmycelium.

The liquid growth medium may be any of the liquid growth media describedherein below.

The Agaricus bioactive agent comprised in the kit of parts according tothe present invention may be in solid or liquid form.

In one preferred embodiment, the Agaricus bioactive agent is selectedfrom the group consisting of:

-   -   agents comprising or consisting of an oligosaccharide,    -   agents comprising or consisting of a polysaccharide,    -   agents comprising or consisting of an optionally glycosylated        peptide,    -   agents comprising or consisting of an optionally glycosylated        polypeptide,    -   agents comprising or consisting of an oligonucleotide,    -   agents comprising or consisting of a polynucleotide,    -   agents comprising or consisting of a lipid,    -   agents comprising or consisting of a fatty acid,    -   agents comprising or consisting of a fatty acid ester and    -   agents comprising or consisting of secondary metabolites.

Thus, in one preferred embodiment of the present invention, the Agaricusbioactive agent is selected from the group consisting of: an agentselected from an oligosaccharide, a polysaccharide and an optionallyglycosylated polypeptide.

In another preferred embodiment of the present invention, the Agaricusbioactive agent is a polysaccharide.

In another preferred embodiment of the present invention, the Agaricusbioactive agent is an oligosaccharide.

In another preferred embodiment of the present invention, the Agaricusbioactive agent is an optionally glycosylated polypeptide.

In another preferred embodiment of the present invention, the Agaricusbioactive agent is a homopolymer

In another preferred embodiment of the present invention, the Agaricusbioactive agent is a heteropolymer

Further Characterisation of the Agaricus Bioactive Species:

In one preferred embodiment of the present invention, the Agaricusbioactive agent comprises or consists of an optionally glycosylatedpeptide.

In another preferred embodiment of the present invention, the Agaricusbioactive agent comprises or consists of a polypeptide

In another preferred embodiment of the present invention, the Agaricusbioactive agent comprises or consists of an oligonucleotide

In another preferred embodiment of the present invention, the Agaricusbioactive agent comprises or consists of a polynucleotide.

In another preferred embodiment of the present invention, the Agaricusbioactive agent comprises or consists of a lipid.

In another preferred embodiment of the present invention, the Agaricusbioactive agent comprises or consists of a fatty acid.

In another preferred embodiment of the present invention, the Agaricusbioactive agent comprises or consists of fatty acid esters.

In another preferred embodiment of the present invention, the Agaricusbioactive agent comprises or consists of secondary metabolite(s), suchas steroids, shikimic acids, alkaloids and benzodiazepins.

In one embodiment, the Agaricus bioactive agent is a polysaccharide,such as a polysaccharide having a molar ratio ofgalactose:mannose:glucose of 1:10 to 20:30 to 50, such as 1:12 to 18:35to 45; for example 1:14 to 16:38 to 42, such as 1:about 15:about 40, forexample 1:15:40.

Accordingly, the Agaricus bioactive agent may in one embodiment compriseone or more polypeptides and/or a mixture of polysaccharides, whereinthe majority of the polysaccharides of the composition has a molecularweight of at least 10,000 Da and wherein said one or more polypeptidesand/or said mixture of polysaccharides comprises the monosaccharidesgalactose, mannose and glucose in the ratio (galactose:mannose:glucose)of 1:0 to 25:1 to 50, such as 1:10 to 20:30 to 50, such as 1:12 to 18:35to 45; for example 1:14 to 16:38 to 42, such as 1: about 15:about 40,for example 1:15:40.

In another one embodiment, the Agaricus bioactive agent according to thepresent invention has a molar ratio of galactose:mannose:glucose of1:0.5 to 5:6 to 12, such as 1:1 to 4:7 to 11; for example 1:1.5 to3.5:7.5 to 10, such as 1:2.0 to 3.0:7.5 to 9.5, for example 1:2.2 to2.8:8.0 to 9.0, such as 1:about 2.5:8.0 to 9.0, for example 1:2.5:8.0 to9.0, such as 1:2.5:8.6.

Accordingly, the Agaricus bioactive agent according to the presentinvention can comprise one or more polypeptides and/or a mixture ofpolysaccharides, wherein the majority of the polysaccharides of thecomposition has a molecular weight of at least 10,000 Da and whereinsaid one or more polysaccharides and/or said mixture of polysaccharidescomprises the monosaccharides galactose, mannose and glucose in theratio (galactose:mannose:glucose) of 1:0 to 25:1 to 50, for example1:0.5 to 5:6 to 12, such as 1:1 to 4:7 to 11; for example 1:1.5 to3.5:7.5 to 10, such as 1:2.0 to 3.0:7.5 to 9.5, for example 1:2.2 to2.8:8.0 to 9.0, such as 1:about 2.5:8.0 to 9.0, for example 1:2.5:8.0 to9.0, such as 1:2.5:8.6.

Particularly Preferred Embodiments of the Agaricus Bioactive Agent

Particularly preferred embodiments of the Agaricus bioactive agent foruse in the present invention are described below:

(1) In one preferred embodiment of the present invention, the Agaricusbioactive agent comprises or consists of the (1-4)-alpha D glucan and/or(1-6)-beta-D-glucan described by Fujimiya et al., (“Selective Tumoricialeffect of soluble proteoglucan extracted from the basidiomycete,Agaricus blazei Murill, mediated via natural killer cell activation andapoptosis, Cancer Immunol Immunother (1998) 46: 147-159)(2) In another preferred embodiment of the present invention, theAgaricus bioactive agent comprises or consists of the solublebeta-(1-6)-glucans described by Fujimiya et al., (“Peroral effect ontumour progression of soluble beta-(1,6)-glucans prepared by acidtreatment from Agaricus blazei. Murr (Agaricaceae, Higherbasidiomycetes). International Journal of Medicinal Mushrooms 2, 43-49).(3) In another preferred embodiment of the present invention, theAgaricus bioactive agent comprises or consists of any of the followingcompounds described by Smith et al., (“Medicinal mushrooms: theirtherapeutic properties and current medical usage with special emphasison cancer treatments.”, downloadable fromhttp://sci.cancerresearchuk.orq/labs/med_mush/med_mush.html): FI₁-a-beta(beta-glucan from the fruiting body), FIII2-beta (beta glucan-proteinfrom the fruiting body), FA-1a-beta (hetero-beta glucan from thefruiting body), FA-2b-beta (RNA from the fruiting body), FV-1 (insolublebeta-glucan from the fruiting body), ATOM (glucomannan-protein, isolatedfrom submerged cultured mycelial biomass), AB-FP (mannan protein,isolated from the liquid cultured broth), Beta (1-6)-D-glucan.(4) In another preferred embodiment of the present invention, theAgaricus bioactive agent comprises or consists of the beta-(1-6)-D:-glucan described by Kobayashi et al., (“Suppressing effects of dailyoral supplementation of beta-glucan extracted from Agaricus blazeiMurill on spontaneous and peritoneal disseminated metastasis in mousemodel”, J Cancer Res Clin Oncol. 2005 May 10)(5) In another preferred embodiment of the present invention, theAgaricus bioactive agent comprises or consists of the HM3-G (molecularmass 380 kDa), mainly (1-4)-alpha D glucan with (1-6)-beta branching,described by Fujimiya et al., (“Selective Tumoricial effect of solubleproteoglucan extracted from the basidiomycete, Agaricus blazei Murill,mediated via natural killer cell activation and apoptosis, CancerImmunol Immunother (1998) 46: 147-159).(6) In another preferred embodiment of the present invention, theAgaricus bioactive agent comprises or consists of Glucomannan with amain chain of beta-1,2-linked D-mannopyranosyl residues andbeta-D-glucopyranosyl-3-O-beta-D-glucopyranosyl residues as a side chaindescribed by Mizuno et al. (“Anti-tumor polysaccharide from the myceliumof liquid-cultured Agaricus blazei mill“, Biochem Mol Biol Int. 1999April; 47(4):707-14)(7) In another preferred embodiment of the present invention, theAgaricus bioactive agent comprises or consists of the polysaccharidefraction prepared using cold or hot NaOH extraction described by Ohno etal., (Antitumor beta glucan from the cultured fruit body of Agaricusblazei. Biol Pharm Bull. 2001 July; 24(7):820-8).(8) In another preferred embodiment of the present invention, theAgaricus bioactive agent comprises or consists of the Glucomannan with amain chain of beta-1,2-linked D-mannopyranosyl residues andbeta-D-glucopyranosyl-3-O-beta-D-glucopyranosyl residues as a side chaindescribed by Mizuno et al. (“Anti-tumor polysaccharide from the myceliumof liquid-cultured Agaricus blazei mill”, Biochem Mol Biol Int. 1999April; 47(4):707-14)(9) In another preferred embodiment of the present invention, theAgaricus bioactive agent comprises or consists of thealpha-1,4-glucan-beta-1,6-glucan complex with an average molecularweight of 20 kDa described by Fujimiya et al., (Tumor-specific cytocidaland immunopotentiating effects of relatively low molecular weightproducts derived from the basidiomycete, Agaricus blazei Murill.Anticancer Res. 1999 January-February; 19(1A):113-8)(10) In another preferred embodiment of the present invention, theAgaricus bioactive agent comprises or consists of the complex ofalpha-1,6- and alpha-1,4-glucan described by Mizuno et al.,(Polysaccharides from Agaricus blazei stimulate lymphocyte T-cellsubsets in mice. Biosci Biotechnol Biochem. 1998 March; 62(3):434-7)(11) In another preferred embodiment of the present invention, theAgaricus bioactive agent comprises or consists of the ergosteroldescribed by Takaku et al., (Isolation of an antitumor compound fromAgaricus blazei Murill and its mechanism of action. J Nutr. 2001 May;131(5):1409-13)(12) In another preferred embodiment of the present invention, theAgaricus bioactive agent comprises or consists of ATOM(glucomannan-protein, isolated from submerged cultured mycelial biomass)described by Ito et al., “Antitumour effects of a newpolysaccharide-protein complex (ATOM) prepared from Agaricusblazei(Iwade strain 101) “Himematsutake” and its mechanisms intumor-bearing mice”, Anticancer research 17:277-284 (1997)

(13) In another preferred embodiment of the present invention, theAgaricus bioactive agent comprises or consists of the FIII-2-b((1-6)-beta-D-glucan complex) described by Kawagishi et al. (“Formolysisof a potent antitumor (1-6)-beta-D-glucan-protein complex from Agaricusblazei fruiting bodies and antitumor activity of the resulting products.Carbohydr polymers 12:393-403, 1990)

(14) In another preferred embodiment of the present invention, theAgaricus bioactive agent comprises or consists of theIsoflavone-beta-D-glucan, produced by culturing Agaricus blazei myceliain isoflavone-containing liquid medium described in US2005069989.(15) In another preferred embodiment of the present invention, theAgaricus bioactive agent comprises or consists of the Glucomannan havinga mannose chain of −1, −2 bonds as its primary chain described in JP11080206.(16) In another preferred embodiment of the present invention, theAgaricus bioactive agent comprises or consists of the polysaccharidedescribed by Fan et al., “Production of polysaccharide byculinary-medicinal mushroom Agaricus brasiliensis S Wasser et al. LPB 03(Agaricomycetideae) in submerged fermentation and its antitumor effect”,International Journal of Medicinal Mushrooms 2003), 5(1), 17-23.(17) In another preferred embodiment of the present invention, theAgaricus bioactive agent comprises or consists of the Linoleic acid;and/or 13-hydroxy cis-9, trans-11-octadecadienoic acid (13ZE-LOH)described in “Fruit body of a basidiomycete Agaricus-Blazei”, YakugakuZasshi-Journal of the Pharmaceutical Society of Japan 1994(18) In another preferred embodiment of the present invention, theAgaricus bioactive agent comprises or consists of the Ab-FP described byLiu et al., (“Fractionation of extracellular polysaccharide fromAgaricus blazei murill and its antitumor activity”, Shipin Yu FajiaoGongye (2001), 27(11), 27-29;)(19) In another preferred embodiment of the present invention, theAgaricus bioactive agent comprises or consists of the Glucan-proteincomplex described by Gonzaga et al., (“Isolation and characterisation ofpolysaccharides from Agaricus blazei Murill”, Carbohydrate polymers2005, Vol. 60, Iss 1, p 43-49)(20) In another preferred embodiment of the present invention, theAgaricus bioactive agent comprises or consists of the Ap-MP(water-soluble mycelia polysaccharide) described by Liu et al., “Studyon antitumor activity of Agaricus blazei”.(21) In another preferred embodiment of the present invention, theAgaricus bioactive agent comprises or consists of the 1SY16 described byLee et al. (“1SY16 isolated from Agaricus blazei Murill K as a potentmultipotential chemopreventative agent”, Cancer Epidemiology Biomarkersand Prevention 2004, Vol 13, Iss 11, p 1861S).(22) In another preferred embodiment of the present invention, theAgaricus bioactive agent comprises or consists of the Sodiumpyroglutamate described by Kimura et al. (“Isolation of ananti-angiogenic substance from Agaricus blazei Murill: Its antitumor andantimetastatic actions”, Cancer Science 2004, Vol 95, Iss 9, p758-764).(23) In another preferred embodiment of the present invention, theAgaricus bioactive agent comprises or consists of the Blazeispiranederivatives described by Hirotani et al., (“Blazeispirane andprotoblazeispirane derivatives from the cultured mycelia of the fungusAgaricus blazei”, Phytochemistry 2002, Vol. 61, Iss 5, p 589-595).(24) In another preferred embodiment of the present invention, theAgaricus bioactive agent comprises or consists of any of thebasidiolipids BI-1, BI-2, BI-3 or BI-4 as described by Jennemann et al.,“Novel glycoinositolphosphosphingolipds, basidiolipds, from Agaricus”,Eur. J. Biochem. 259, 331-338 (1999).(25) In another preferred embodiment of the present invention, theAgaricus bioactive agent is a composition comprising one or morepolypeptides and a mixture of polysaccharides, wherein the majority ofthe polysaccharides of the composition has a molecular weight of atleast 10,000 Da and wherein said mixture of polysaccharides comprisesthe monosaccharides galactose, mannose and glucose in the ratio 1:0 to25:1 to 50.

In another preferred embodiment of the present invention, the compoundmay be Beta-(1-3)-D-glucan, Beta-(1-4)-a-D-glucan orBeta—(1-6)-D-glucan.

The bioactive agent can be obtained from the extracellular medium afterhaving been subjected to at least one further method step selected froma purification step or a precipitation step, such as precipitation bymixing the extracellular medium with an alcohol. The mycelium is removedfrom the liquid growth medium prior to the isolation of the bioactiveagent. The fungal mycelium can be removed e.g. by filtration orcentrifugation.

The bioactive agent can also be precipitated by ultracentrifugation. Thebioactive agent can be size fractionated prior to precipitation orcentrifugation and the bioactive agent can be further purified by one ormore steps involving washing, desalting, size fractionation, andaffinity chromatography, such as ion-exchange chromatography. In oneembodiment, the bioactive agent is further purified by washing andion-exchange chromatography.

The precipitated immune stimulating agent can also be further purifiedby size exclusion chromatography or gel filtration.

In one embodiment, the bioactive agent isolatable from the liquid growthmedium is also produced intracellularly in said Basidiomycete sp. Thebioactive agent isolatable from the liquid growth medium can beimmunologically distinct from an intracellularly produced bioactivevariant of the agent having essentially the same activity.

The liquid growth medium can comprise one or more of malt extract, yeastextract, peptone, glucose, sucrose, salts providing phosphate, magnesiumand potassium, corn-steep liquor and vitamins, such as thiamine. In oneembodiment, the liquid growth medium comprises malt extract, yeastextract, peptone, and glucose. The liquid growth medium is agitated andsupplied with an oxygen source and the growth temperature is preferablyin the range of from 23° C. to 32° C.

Modulation of the Immune System

The compositions according to the invention may be immune modulating,preferably, the compositions are immune stimulating. The stimulation ofthe immune system can be demonstrated by e.g. increased antibodyproduction, by activation of helper T-cells, or by increased productionof interleukins such as Interleukin 1 and Interleukin 2.

Any assay known to the skilled person, which is suitable for testingwhether a composition is immune modulating may be employed to testwhether a composition of the present invention is immune modulating.Such an assay may be an in vitro or an in vivo assay.

One preferred assay is to test whether the composition is capable ofinducing IL-1 production, such as IL1-α and/or IL1-β production. Thus,in a preferred embodiment of the invention, the composition according tothe present invention is capable of inducing IL-1 production from atleast one kind of 1L-1 producing cells in an in-vitro assay. The cellsmay be any IL-1 producing cells, such as P388 mouse macrophage cells.IL-1 production may be determined using any suitable assay. In general,assays involving the use of specific IL-1 antibodies, such as specificIL1-α and/or IL1-1β antibodies, are useful. Such assays may for examplebe Western blotting, ELISA or similar assays. The assay may be performedas described in example 4.

Because it is difficult to calibrate an IL1 assay, the assay ispreferably performed using a specific composition as reference. Thus inone preferred embodiment of the present invention, the composition iscapable of inducing production of at least 1.5, preferably at least 2,such as at least 4, for example at least 6, such as at least 8, forexample at least 10, such as at least 15, for example at least 20, suchas at least 30, for example at least 40 times more IL1-α, than theamount of IL1-α induced using the commercially available Lentinan forinjection (Eureka Bio-Chemicals Pty, Little Collins Street. Melbourne3000, Australia) in a reference experiment performed in parallel. In onepreferred embodiment of the present invention, the composition iscapable of inducing production of at least 1.5, preferably at least 2,such as at least 4, for example at least 6, such as at least 8, forexample at least 10, such as at least 15, for example at least 20 timesmore IL1-11, than the amount of IL1-11 induced using Lentinan forinjection from Eureka Biochemicals Pty. in a reference experimentperformed in parallel. Preferably, the aforementioned assays areperformed as described in example 4. It is most preferred that thecomposition induced production of both IL1α and IL1β as described above.

In another embodiment of the invention, the composition is capable ofenhancing antibody production in a mammal, when administered to saidmammal. The mammal may for example be a mouse, rat, rabbit or even ahuman being. Preferably such an assay is performed by administering thecomposition to a mammal prior to and simultaneously with administrationof an antigen, optionally in the presence of an adjuvant. Preferably,the composition is administered in the range of 1 to 30 days, preferablyin the range of 1 to 10 days, more preferably in the range of 1 to 3days prior to administration of the antigen. Subsequently, antibodyproduction in the mammal may be determined. The composition ispreferably capable of inducing production of at least 1.5, morepreferably at least 2, even more preferably at least 2.5, such as atleast 3, for example at least 4, such as 6 times more antibody comparedto the amount of antibody produced without administration of thecomposition. An example of such an assay is outlined in example 6.

It is preferred that the composition is immune modulating in more thanone assay system, such as in a combination of any of the assay systemsdescribed herein above.

Manufacture of an Agaricus Bioactive Agent

Methods of manufacture of the bioactive agent for use in the presentinvention are well-known to those skilled in the art, such as disclosedin any of the following references, incorporated herein by reference:Fujimiya et al., (“Selective Tumoricial effect of soluble proteoglucanextracted from the basidiomycete, Agaricus blazei Murill, mediated vianatural killer cell activation and apoptosis, Cancer Immunol Immunother(1998) 46: 147-159); Fujimiya et al., (“Peroral effect on tumourprogression of soluble beta-(1,6)-glucans prepared by acid treatmentfrom Agaricus blazei. Murr (Agaricaceae, Higher basidiomycetes).International Journal of Medicinal Mushrooms 2, 43-49); Smith et al.,(“Medicinal mushrooms: their therapeutic properties and current medicalusage with special emphasis on cancer treatments.”, downloadable fromhttp://sci.cancerresearchuk.orq/labs/med_mush/med_mush.html); Kobayashiet al., (“Suppressing effects of daily oral supplementation ofbeta-glucan extracted from Agaricus blazei Murill on spontaneous andperitoneal disseminated metastasis in mouse model”, J Cancer Res ClinOncol. 2005 May 10); Fujimiya et al., (“Selective Tumoricial effect ofsoluble proteoglucan extracted from the basidiomycete, Agaricus blazeiMurill, mediated via natural killer cell activation and apoptosis,Cancer Immunol Immunother (1998) 46: 147-159); Mizuno et al.(“Anti-tumor polysaccharide from the mycelium of liquid-culturedAgaricus blazei mill”, Biochem Mol Biol Int. 1999 April; 47(4):707-14);Ohno et al., (Antitumor beta glucan from the cultured fruit body ofAgaricus blazei. Biol Pharm Bull. 2001 July; 24(7):820-8); Mizuno et al.(“Anti-tumor polysaccharide from the mycelium of liquid-culturedAgaricus blazei mill”, Biochem Mol Biol Int. 1999 April; 47(4):707-14);Fujimiya et al., (Tumor-specific cytocidal and immunopotentiatingeffects of relatively low molecular weight products derived from thebasidiomycete, Agaricus blazei Murill. Anticancer Res. 1999January-February; 19(1A):113-8); Mizuno et al., (Polysaccharides fromAgaricus blazei stimulate lymphocyte T-cell subsets in mice. BiosciBiotechnol Biochem. 1998 March; 62(3):434-7); Takaku et al., (Isolationof an antitumor compound from Agaricus blazei Murill and its mechanismof action. J Nutr. 2001 May; 131(5):1409-13); Ito et al., “Antitumoureffects of a new polysaccharide-protein complex (ATOM) prepared fromAgaricus blazei (Iwade strain 101) “Himematsutake” and its mechanisms intumor-bearing mice”, Anticancer research 17:277-284 (1997); Kawagishi etal. (“Formolysis of a potent antitumor (1-6)-beta-D-glucan-proteincomplex from Agaricus blazei fruiting bodies and antitumor activity ofthe resulting products. Carbohydr polymers 12:393-403, 1990);US2005069989; JP 11080206; Fan et al., “Production of polysaccharide byculinary-medicinal mushroom Agaricus brasiliensis S Wasser et al. LPB 03(Agaricomycetideae) in submerged fermentation and its antitumor effect”,International Journal of Medicinal Mushrooms 2003), 5(1), 17-23; “Fruitbody of a basidiomycete Agaricus-Blazei”, Yakugaku Zasshi-Journal of thePharmaceutical Society of Japan 1994; Liu et al., (“Fractionation ofextracellular polysaccharide from Agaricus blazei murill and itsantitumor activity”, Shipin Yu Fajiao Gongye (2001), 27(11), 27-29;);Gonzaga et al., (“Isolation and characterisation of polysaccharides fromAgaricus blazei Murill”, Carbohydrate polymers 2005, Vol. 60, Iss 1, p43-49); Liu et al., “Study on antitumor activity of Agaricus blazei”;Lee et al. (“1SY16 isolated from Agaricus blazei Murill K as a potentmultipotential chemopreventative agent”, Cancer Epidemiology Biomarkersand Prevention 2004, Vol 13, Iss 11, p 1861S); Kimura et al. (“Isolationof an anti-angiogenic substance from Agaricus blazei Murill: Itsantitumor and antimetastatic actions”, Cancer Science 2004, Vol 95, Iss9, p758-764); Hirotani et al., (“Blazeispirane and protoblazeispiranederivatives from the cultured mycelia of the fungus Agaricus blazei”,Phytochemistry 2002, Vol. 61, Iss 5, p 589-595); Jennemann et al.,“Novel glycoinositolphosphosphingolipds, basidiolipds, from Agaricus”,Eur. J. Biochem. 259, 331-338 (1999).

It is preferred that the Agaricus species is produced in a liquid mediumusing submerged fermentation techniques. The liquid growth medium may inone embodiment comprise one or more of malt extract, yeast extract,peptone, glucose, sucrose, salts providing phosphate, magnesium andpotassium, corn-steep liquor and vitamins, such as thiamine. Agaricusmay also be grown in a liquid growth medium comprising malt extract,yeast extract, peptone, and glucose.

For use in the present invention, the Agaricus may be grown in a liquidgrowth medium which is agitated and supplied with an oxygen source.

For use in the present invention, the Agaricus may be grown at atemperature in the range of from 23° C. to 32° C.

For use in the present invention, the Agaricus mycelium may be removedfrom the liquid growth medium prior to the isolation of the Agaricusbioactive agent.

For use in the present invention, the Agaricus fungal mycelium may beremoved from the initial Agaricus culture by filtration orcentrifugation.

Individual Treated Using the Compositions of the Present Invention

Any individual may be treated using the kit-of-parts according to theinvention, for example in any of the uses or methods described herein.Preferably, said individual is a mammal, such as a human being. In oneembodiment of the present invention, the individual isimmunocompromised.

In one embodiment of the present invention, said individual is elderly,such as 60-120 years old, for example 70-120 years old, such as 80-120years old, for instance 90-120 years old. In another embodiment of thepresent invention, said individual is 20-60 years old, such as 30-50years old. In another embodiment of the present invention, saidindividual is a child, such as from 0-20 years old, for example 0-15years old, such as 0-10 years old, for example 0-5 years old, such as0-1 years old, such as a newborn child less than 2 months old.

Pharmaceutical Composition

While it is possible for the compounds or salts thereof useful in thepresent invention to be administered as the raw chemical, it ispreferred to present them in the form of a pharmaceutical composition.The anti-cancer compound and Agaricus bioactive agent may beco-formulated as two separate pharmaceutical compositions.

In one particular embodiment the invention relates to the use of apharmaceutical composition comprising a mixture of at least twodifferent Agaricus bioactive compounds and/or at least one or twoanti-cancer medicaments.

The pharmaceutical composition may comprise any anti-cancer agent and/orAgaricus bioactive agent or a pharmaceutically acceptable salt thereof,and pharmaceutically acceptable carriers, vehicles and/or excipients.Said composition may further optionally comprise transport molecules.The transport molecules are primarily added in order to increase thehalf-life of the compound(s). Transport molecules act by havingincorporated into or anchored to it the compound according to theinvention.

Any suitable transport molecules known to the skilled person may beused, such as liposomes, micelles, and/or microspheres.

Conventional liposomes are typically composed of phospholipids (neutralor negatively charged) and/or cholesterol. The liposomes are vesicularstructures based on lipid bilayers surrounding aqueous compartments.They can vary in their physiochemical properties such as size, lipidcomposition, surface charge and number and fluidity of the phospholipidsbilayers. The most frequently used lipid for liposome formation are:1,2-Dilauroyl-sn-Glycero-3-Phosphocholine (DLPC),1,2-Dimyristoyl-sn-Glycero-3-Phosphocholine (DMPC),1,2-Dipalmitoyl-sn-Glycero-3-Phosphocholine (DPPC),1,2-Distearoyl-sn-Glycero-3-Phosphocholine (DSPC),1,2-Dioleoyl-sn-Glycero-3-Phosphocholine (DOPC),1,2-Dimyristoyl-sn-Glycero-3-Phosphoethanolamine (DMPE),1,2-Dipalmitoyl-sn-Glycero-3-Phosphoethanolamine (DPPE),1,2-Dioleoyl-sn-Glycero-3-Phosphoethanolamine (DOPE),1,2-Dimyristoyl-sn-Glycero-3-Phosphate (Monosodium Salt) (DMPA),1,2-Dipalmitoyl-sn-Glycero-3-Phosphate (Monosodium Salt) (DPPA),1,2-Dioleoyl-sn-Glycero-3-Phosphate (Monosodium Salt) (DOPA),1,2-Dimyristoyl-sn-Glycero-3-[Phospho-rac-(1-glycerol)] (Sodium Salt)(DMPG), 1,2-Dipalmitoyl-sn-Glycero-3-[Phospho-rac-(1-glycerol)] (SodiumSalt) (DPPG), 1,2-Dioleoyl-sn-Glycero-3-[Phospho-rac-(1-glycerol)](Sodium Salt) (DOPG), 1,2-Dimyristoyl-sn-Glycero-3-[Phospho-L-Serine](Sodium Salt) (DMPS), 1,2-Dipalmitoyl-sn-Glycero-3-[Phospho-L-Serine](Sodium Salt) (DPPS), 1,2-Dioleoyl-sn-Glycero-3-[Phospho-L-Serine](Sodium Salt) (DOPS),1,2-Dioleoyl-sn-Glycero-3-Phosphoethanolamine-N-(glutaryl) (Sodium Salt)and 1,1′,2,2′-Tetramyristoyl Cardiolipin (Ammonium Salt). Formulationscomposed of DPPC in combination with other lipid or modifiers ofliposomes are preferred e.g. in combination with cholesterol and/orphosphatidylcholine.

Long-circulating liposomes are characterized by their ability toextravasate at body sites where the permeability of the vascular wall isincreased. The most popular way to produce long circulating liposomes isto attach hydrophilic polymer polyethylene glycol (PEG) covalently tothe outer surface of the liposome. Some of the preferred lipids are:1,2-Dipalmitoyl-sn-Glycero-3-Phosphoethanolamine-N-[Methoxy(Polyethyleneglycol)-2000] (Ammonium Salt),1,2-Dipalmitoyl-sn-Glycero-3-Phosphoethanolamine-N-[Methoxy(Polyethyleneglycol)-5000] (Ammonium Salt), 1,2-Dioleoyl-3-Trimethylammonium-Propane(Chloride Salt) (DOTAP).

A variety of methods are available for preparing liposomes, as describedin, e.g., Szoka et al., Ann. Rev. Biophys. Bioeng. 9:467 (1980), U.S.Pat. Nos. 4,235,871, 4,501,728 and 4,837,028, all of which areincorporated herein by reference. One method is described in example 9.Another method produces multilamellar vesicles of heterogeneous sizes.In this method, the vesicle-forming lipids are dissolved in a suitableorganic solvent or solvent system and dried under vacuum or an inert gasto form a thin lipid film. If desired, the film may be redissolved in asuitable solvent, such as tertiary butanol, and then lyophilized to forma more homogeneous lipid mixture which is in a more easily hydratedpowder like form. This film is covered with an aqueous solution of thetargeted drug and the targeting component and allowed to hydrate,typically over a 15-60 minute period with agitation. The sizedistribution of the resulting multilamellar vesicles can be shiftedtoward smaller sizes by hydrating the lipids under more vigorousagitation conditions or by adding solubilizing detergents such asdeoxycholate. Additionally, the liposome suspension may includelipid-protective agents which protect lipids against free-radical andlipid-peroxidative damages on storage. Lipophilic free-radicalquenchers, such as alpha-tocopherol and water-soluble iron-specificchelators, such as ferrioxianine, are preferred.

Micelles are formed by surfactants (molecules that contain a hydrophobicportion and one or more ionic or otherwise strongly hydrophilic groups)in aqueous solution. As the concentration of a solid surfactantincreases, its monolayers adsorbed at the air/water or glass/waterinterfaces become so tightly packed that further occupancy requiresexcessive compression of the surfactant molecules already in the twomonolayers. Further increments in the amount of dissolved surfactantbeyond that concentration cause amounts equivalent to the new moleculesto aggregate into micelles. This process begins at a characteristicconcentration called “critical micelle concentration”.

The shape of micelles formed in dilute surfactant solutions isapproximately spherical. The polar head groups of the surfactantmolecules are arranged in an outer spherical shell whereas theirhydrocarbon chains are oriented toward the center, forming a sphericalcore for the micelle. The hydrocarbon chains are randomly coiled andentangled and the micellar interior has a nonpolar, liquid-likecharacter. In the micelles of polyoxyethylated non-ionic detergents, thepolyoxyethlene moieties are oriented outward and permeated by water.This arrangement is energetically favourable since the hydrophilic headgroups are in contact with water and the hydrocarbon moieties areremoved from the aqueous medium and partly shielded from contact withwater by the polar head groups. The hydrocarbon tails of the surfactantmolecules, located in the interior of the micelle, interact with oneanother by weak van der Waals forces.

The size of a micelle or its aggregation number is governed largely bygeometric factors. The radius of the hydrocarbon core cannot exceed thelength of the extended hydrocarbon chain of the surfactant molecule.Therefore, increasing the chain length or ascending homologous seriesincreases the aggregation number of spherical micelles. If thesurfactant concentration is increased beyond a few percent and ifelectrolytes are added (in the case of ionic surfactants) or thetemperature is raised (in the case of non-ionic surfactants), themicelles increase in size. Under these conditions, the micelles are toolarge to remain spherical and become ellipsoidal, cylindrical or finallylamellar in shape.

Common surfactants well known to one of skill in the art can be used inthe micelles of the present invention. Suitable surfactants includesodium laureate, sodium oleate, sodium lauryl sulfate, octaoxyethyleneglycol monododecyl ether, octoxynol 9 and PLURONIC F-127 (WyandotteChemicals Corp.). Preferred surfactants are nonionic polyoxyethylene andpolyoxypropylene detergents compatible with IV injection such as,TWEEN-80., PLURONIC F-68., n-octyl-.beta.-D-glucopyranoside, and thelike. In addition, phospholipids, such as those described for use in theproduction of liposomes, may also be used for micelle formation.

In another preferred embodiment, the compounds of the present inventionare formulated as described in the literature for an administrationroute selected from: buccal delivery, sublingual delivery, transdermaldelivery, inhalation and needle-free injection, such as using themethods developed by Powderjet.

For inhalation, the compounds of the present invention can be formulatedas using methods known to those skilled in the art, for example anaerosol, dry powder or solubilized such as in micro droplets, preferablyin a device intended for such delivery (such as commercially availablefrom Aradigm, Alkerme or Nektar).

Pharmaceutical compositions of the present invention may contain aphysiologically tolerable carrier together with at least one compoundaccording to the present invention, dissolved or dispersed therein as anactive ingredient.

As used herein, the terms “pharmaceutically acceptable”,“physiologically tolerable” and grammatical variations thereof, as theyrefer to compositions, carriers, diluents and reagents, are usedinterchangeably and represent that the materials are capable ofadministration to or upon a human without the production of undesirablephysiological effects such as nausea, dizziness, gastric upset and thelike.

The preparation of a pharmacological composition that contains activeingredients dissolved or dispersed therein is well understood in theart. Typically such compositions are prepared as sterile injectableseither as liquid solutions or suspensions, aqueous or non-aqueous,however, solid forms suitable for solution, or suspensions, in liquidprior to use can also be prepared. The preparation can also beemulsified.

The active ingredient can be mixed with excipients which arepharmaceutically acceptable and compatible with the active ingredientand in amounts suitable for use in the therapeutic methods describedherein. Suitable excipients are, for example, water, saline, dextrose,glycerol, ethanol or the like and combinations thereof. In addition, ifdesired, the composition can contain minor amounts of auxiliarysubstances such as wetting or emulsifying agents, pH buffering agentsand the like which enhance the effectiveness of the active ingredient.It is preferred that the formulation has a pH within the range of 3.5-8,such as in the range 4.5-7.5, such as in the range 5.5-7, such as in therange 6-7.5, most preferably around 7.3. However, as is understood byone skilled in the art, the pH range may be adjusted according to theindividual treated and the administration procedure. For example, inanother preferred embodiment of the invention the formulation has a pHwithin the range 3.5-7, such as 4-6, such as 5-6, such as 5.3-5.7, suchas 5.5.

The pharmaceutical composition of the present invention can includepharmaceutically acceptable salts of the compounds therein. These saltswill be ones which are acceptable in their application to apharmaceutical use. By that it is meant that the salt will retain thebiological activity of the parent compound and the salt will not haveuntoward or deleterious effects in its application and use in treatingdiseases.

Pharmaceutically acceptable salts are prepared in a standard manner. Ifthe parent compound is a base it is treated with an excess of an organicor inorganic acid in a suitable solvent. If the parent compound is anacid, it is treated with an inorganic or organic base in a suitablesolvent.

The compounds of the invention may be administered in the form of analkali metal or earth alkali metal salt thereof, concurrently,simultaneously, or together with a pharmaceutically acceptable carrieror diluent, especially and preferably in the form of a pharmaceuticalcomposition thereof, whether by e.g. oral, rectal, or parenteral(including subcutaneous) route, in an effective amount.

Examples of pharmaceutically acceptable acid addition salts for use inthe present inventive pharmaceutical composition include those derivedfrom mineral acids, such as hydrochloric, hydrobromic, phosphoric,metaphosphoric, nitric and sulfuric acids, and organic acids, such astartaric, acetic, citric, malic, lactic, fumaric, benzoic, glycolic,gluconic, succinic, p-toluenesulphonic acids, and arylsulphonic, forexample.

Other suitable pharmaceutically acceptable salts include the acidaddition salts (formed with the free amino groups of the polypeptide).Other examples of salts include pharmaceutically acceptable acidaddition salts, pharmaceutically acceptable metal salts, ammonium saltsand alkylated ammonium salts. Acid addition salts include salts ofinorganic acids as well as organic acids. Representative examples ofsuitable inorganic acids include hydrochloric, hydrobromic, hydriodic,phosphoric, sulpfuric and nitric acids and the like. Representativeexamples of suitable organic acids include formic, acetic,trichloroacetic, trifluoroacetic, propionic, benzoic, cinnamic, citric,fumaric, glycolic, lactic, maleic, malic, malonic, mandelic, oxalic,picric, pyruvic, salicylic, succinic, methanesulfonic, ethanesulfonic,tartaric, ascorbic, pamoic, bismethylene salicylic, ethanedisulfonic,gluconic, citraconic, aspartic, stearic, palmitic,ethylenediaminetetraacetic (EDTA), p-aminobenzoic, glutamic,benzenesulfonic and ptoluenesulfonic acids and the like. Furtherexamples of pharmaceutically acceptable inorganic or organic acidaddition salts include the pharmaceutical acceptable salts listed in J.Pharm. Sci. 1977,66,2, which is incorporated herein by reference.Examples of metal salts include lithium, sodium, potassium and magnesiumsalts and the like.

Examples of ammonium and alkylated ammonium salts include ammonium,methylammonium, dimethylammonium, trimethylammonium, ethylammonium,hydroxyethylammonium, diethylammonium, butylammonium andtetramethylammonium salts and the like.

Salts formed with the free carboxyl groups can also be derived frominorganic bases such as, for example, sodium, potassium, ammonium,calcium or ferric hydroxides, and such organic bases as isopropylamine,trimethylamine, 2-ethylamino ethanol, histidine, procaine and the like.

Also included within the scope of compounds or pharmaceutical acceptableacid addition salts thereof in the context of the present invention areany hydrates (hydrated forms) thereof.

For parenteral administration, solutions of the present compounds insterile aqueous solution, aqueous propylene glycol or sesame or peanutoil may be employed. Such aqueous solutions should be suitably bufferedif necessary, and the liquid diluent first rendered isotonic withsufficient saline or glucose. The aqueous solutions are particularlysuitable for intravenous, intramuscular, subcutaneous andintraperitoneal administration. The sterile aqueous media employed areall readily available by standard techniques known to those skilled inthe art.

Liquid compositions can also contain liquid phases in addition to and tothe exclusion of water. Exemplary of such additional liquid phases areglycerin, vegetable oils such as cottonseed oil, organic esters such asethyl oleate, and water-oil emulsions.

Suitable pharmaceutical carriers include inert solid diluents orfillers, sterile aqueous solution and various organic solvents. Examplesof solid carriers are lactose, terra alba, sucrose, cyclodextrin, talc,gelatine, agar, pectin, acacia, magnesium stearate, stearic acid orlower alkyl ethers of cellulose. Examples of liquid carriers are syrup,peanut oil, olive oil, phospholipids, fatty acids, fatty acid amines,polyoxyethylene or water. Administered by nasal aerosol or inhalationformulations may be prepared, for example, as solutions in saline,employing benzyl alcohol or other suitable preservatives, absorptionpromoters to enhance bioavailability, employing fluorocarbons, and/oremploying other solubilizing or dispersing agents.

The pharmaceutical compositions formed by combining the compounds of theinvention and the pharmaceutical acceptable carriers are then readilyadministered in a variety, of dosage forms suitable for the disclosedroutes of administration. The formulations may conveniently be presentedin unit dosage form by methods known in the art of pharmacy.

In a preferred embodiment of the invention the formulation comprises thecompound or salt(s) thereof as a lyophilisate and the formulationfurther comprises a solvent, said lyophilisate and said solvent being inseparate compartments until administration.

Administration

The components of the kit-of-parts according to the present invention donot have to be administered concurrently, however in one preferredembodiment the anti-cancer medicament is administered simultaneouslywith the administration of the Agaricus bioactive agent, such as in aco-formulation. In another preferred embodiment, the anti-cancermedicament and the bioactive agent are administered sequentially, in anyorder, such as first the Agaricus bioactive agent and then theanti-cancer medicament.

In one preferred embodiment of the present invention, the medicamentand/or agent are administered subcutaneously.

In another preferred embodiment of the present invention, the medicamentand/or agent are administered nasally.

In another preferred embodiment of the present invention, the medicamentand/or agent are administered via the pulmonary route, such as viaaerosol administration.

In another preferred embodiment of the present invention, the medicamentand/or agent are administered via parenteral administration.

In another preferred embodiment of the present invention, saidmedicament and/or agent are administered orally.

In another preferred embodiment of the present invention, saidmedicament and/or agent are administered topically.

In another preferred embodiment of the present invention, saidmedicament and/or agent are co-formulated in a composition.

The kit-of-parts according to the present invention may comprise two ormore administration types, but co-formulation or at least the sameadministration route is preferred for all the elements in thekit-of-parts.

In another aspect the Agaricus agent and/or anti-cancer medicament isadministered as a bolus, wherein the administration form may be anysuitable parenteral form.

In a preferred embodiment the Agaricus agent and/or anti-cancermedicament is administered subcutaneously in a bolus.

Pharmaceutical compositions for parenteral administration includesterile aqueous and non-aqueous injectable solutions, dispersions,suspensions or emulsions, as well as sterile powders to be reconstitutedin sterile injectable solutions or dispersions prior to use.

Other suitable administration forms include suppositories, sprays,ointments, cremes, gels, inhalants, dermal patches, implants, pills,tablets, lozenges and capsules.

The compounds of the present invention may be formulated for nasaladministration.

The solutions or suspensions are applied directly to the nasal cavity byconventional means, for example with a dropper, pipette or spray. Thecompositions may be provided in a single or multidose form. In thelatter case of a dropper or pipette this may be achieved by the patientadministering an appropriate, predetermined volume of the solution orsuspension. In the case of a spray this may be achieved for example bymeans of a metering atomizing spray pump.

The compounds of the present invention may be formulated for aerosoladministration, particularly to the respiratory tract and includingintranasal administration. The compound will generally have a smallparticle size for example of the order of 5 microns or less. Such aparticle size may be obtained by means known in the art, for example bymicronization. The active ingredient is provided in a pressurized packwith a suitable propellant such as a chlorofluorocarbon (CFC) forexample dichlorodifluoromethane, trichlorofluoromethane, ordichlorotetrafluoroethane, carbon dioxide or other suitable gas. Theaerosol may conveniently also contain a surfactant such as lecithin. Thedose of drug may be controlled by a metered valve. Alternatively theactive ingredients may be provided in a form of a dry powder, forexample a powder mix of the compound in a suitable powder base such aslactose, starch, starch derivatives such as hydroxypropylmethylcellulose and polyvinylpyrrolidine (PVP). The powder carrier will form agel in the nasal cavity. The powder composition may be presented in unitdose form for example in capsules or cartridges of e.g., gelatin orblister packs from which the powder may be administered by means of aninhaler.

Compositions administered by aerosols may be prepared, for example, assolutions in saline, employing benzyl alcohol or other suitablepreservatives, absorption promoters to enhance bioavailability,employing fluorocarbons, and/or employing other solubilizing ordispersing agents.

Compositions for Oral Administration

Those compound types capable of remaining biologically active in anindividual after oral administration (such as e.g. small molecules andshort peptides) can be formulated in a wide range of oral administrationdosage forms. The pharmaceutical compositions and dosage forms maycomprise the compounds of the invention or its pharmaceuticallyacceptable salt or a crystal form thereof as the active component. Thepharmaceutically acceptable carriers can be either solid or liquid.Solid form preparations include powders, tablets, pills, capsules,cachets, suppositories, and dispersible granules. A solid carrier can beone or more substances which may also act as diluents, flavouringagents, solubilizers, lubricants, suspending agents, binders,preservatives, wetting agents, tablet disintegrating agents, or anencapsulating material.

Preferably, the composition will be about 0.5% to 75% by weight of acompound or compounds of the invention, with the remainder consisting ofsuitable pharmaceutical excipients. For oral administration, suchexcipients include pharmaceutical grades of mannitol, lactose, starch,magnesium stearate, sodium saccharine, talcum, cellulose, glucose,gelatin, sucrose, magnesium carbonate, and the like.

In powders, the carrier is a finely divided solid which is a mixturewith the finely divided active component. In tablets, the activecomponent is mixed with the carrier having the necessary bindingcapacity in suitable proportions and compacted in the shape and sizedesired. The powders and tablets preferably containing from one to aboutseventy percent of the active compound. Suitable carriers are magnesiumcarbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin,starch, gelatin, tragacanth, methylcellulose, sodiumcarboxymethylcellulose, a low melting wax, cocoa butter, and the like.The term “preparation” is intended to include the composition of theactive compound with encapsulating material as carrier providing acapsule in which the active component, with or without carriers, issurrounded by a carrier, which is in association with it. Similarly,cachets and lozenges are included. Tablets, powders, capsules, pills,cachets, and lozenges can be as solid forms suitable for oraladministration.

Drops according to the present invention may comprise sterile ornon-sterile aqueous or oil solutions or suspensions, and may be preparedby dissolving the active ingredient in a suitable aqueous solution,optionally including a bactericidal and/or fungicidal agent and/or anyother suitable preservative, and optionally including a surface activeagent. The resulting solution may then be clarified by filtration,transferred to a suitable container which is then sealed and sterilizedby autoclaving or maintaining at 98-100° C. for half an hour.Alternatively, the solution may be sterilized by filtration andtransferred to the container aseptically. Examples of bactericidal andfungicidal agents suitable for inclusion in the drops are phenylmercuricnitrate or acetate (0.002%), benzalkonium chloride (0.01%) andchlorhexidine acetate (0.01%). Suitable solvents for the preparation ofan oily solution include glycerol, diluted alcohol and propylene glycol.

Also included are solid form preparations which are intended to beconverted, shortly before use, to liquid form preparations for oraladministration. Such liquid forms include solutions, suspensions, andemulsions. These preparations may contain, in addition to the activecomponent, colorants, flavours, stabilizers, buffers, artificial andnatural sweeteners, dispersants, thickeners, solubilizing agents, andthe like.

Other forms suitable for oral administration include liquid formpreparations including emulsions, syrups, elixirs, aqueous solutions,aqueous suspensions, toothpaste, gel dentifrice, chewing gum, or solidform preparations which are intended to be converted shortly before useto liquid form preparations. Emulsions may be prepared in solutions inaqueous propylene glycol solutions or may contain emulsifying agentssuch as lecithin, sorbitan monooleate, or acacia. Aqueous solutions canbe prepared by dissolving the active component in water and addingsuitable colorants, flavours, stabilizing and thickening agents. Aqueoussuspensions can be prepared by dispersing the finely divided activecomponent in water with viscous material, such as natural or syntheticgums, resins, methylcellulose, sodium carboxymethylcellulose, and otherwell known suspending agents. Solid form preparations include solutions,suspensions, and emulsions, and may contain, in addition to the activecomponent, colorants, flavours, stabilizers, buffers, artificial andnatural sweeteners, dispersants, thickeners, solubilizing agents, andthe like.

Compositions for Parenteral Administration

The compounds of the present invention may be formulated for parenteraladministration (e.g., by injection, for example bolus injection orcontinuous infusion) and may be presented in unit dose form in ampoules,pre-filled syringes, small volume infusion or in multi-dose containerswith an added preservative. The compositions may take such forms assuspensions, solutions, or emulsions in oily or aqueous vehicles, forexample solutions in aqueous polyethylene glycol. Examples of oily ornonaqueous carriers, diluents, solvents or vehicles include propyleneglycol, polyethylene glycol, vegetable oils (e.g., olive oil), andinjectable organic esters (e.g., ethyl oleate), and may containformulatory agents such as preserving, wetting, emulsifying orsuspending, stabilizing and/or dispersing agents. Alternatively, theactive ingredient may be in powder form, obtained by aseptic isolationof sterile solid or by lyophilisation from solution for constitutionbefore use with a suitable vehicle, e.g., sterile, pyrogen-free water.Aqueous solutions should be suitably buffered if necessary, and theliquid diluent first rendered isotonic with sufficient saline orglucose. The aqueous solutions are particularly suitable forintravenous, intramuscular, subcutaneous and intraperitonealadministration. The sterile aqueous media employed are all readilyavailable by standard techniques known to those skilled in the art.

Solutions of the compound(s) or pharmaceutically acceptable salt(s)thereof, (and for example antigenic epitopes and protease inhibitors)can be prepared in water or saline, and optionally mixed with a nontoxicsurfactant. Compositions for intravenous or intra-arterialadministration may include sterile aqueous solutions that may alsocontain buffers, liposomes, diluents and other suitable additives.

Oils useful in parenteral compositions include petroleum, animal,vegetable, or synthetic oils. Specific examples of oils useful in suchcompositions include peanut, soybean, sesame, cottonseed, corn, olive,petrolatum, and mineral. Suitable fatty acids for use in parenteralcompositions include oleic acid, stearic acid, and isostearic acid.Ethyl oleate and isopropyl myristate are examples of suitable fatty acidesters.

Suitable soaps for use in parenteral compositions include fatty alkalimetal, ammonium, and triethanolamine salts, and suitable detergentsinclude (a) cationic detergents such as, for example, dimethyl dialkylammonium halides, and alkyl pyridinium halides; (b) anionic detergentssuch as, for example, alkyl, aryl, and olefin sulfonates, alkyl, olefin,ether, and monoglyceride sulfates, and sulfosuccinates, (c) nonionicdetergents such as, for example, fatty amine oxides, fatty acidalkanolamides, and polyoxyethylenepolypropylene copolymers, (d)amphoteric detergents such as, for example,alkyl-.beta.-aminopropionates, and 2-alkyl-imidazoline quaternaryammonium salts, and (e) mixtures thereof.

The parenteral compositions typically will contain from about 0.5 toabout 25% by weight of the active ingredient in solution. Preservativesand buffers may be used. In order to minimize or eliminate irritation atthe site of injection, such compositions may contain one or morenonionic surfactants having a hydrophile-lipophile balance (HLB) of fromabout 12 to about 17. The quantity of surfactant in such compositionswill typically range from about 5 to about 15% by weight. Suitablesurfactants include polyethylene sorbitan fatty acid esters, such assorbitan monooleate and the high molecular weight adducts of ethyleneoxide with a hydrophobic base, formed by the condensation of propyleneoxide with propylene glycol. The parenteral compositions can bepresented in unit-dose or multi-dose sealed containers, such as ampulesand vials, and can be stored in a freeze-dried (lyophilized) conditionrequiring only the addition of the sterile liquid excipient, forexample, water, for injections, immediately prior to use. Extemporaneousinjection solutions and suspensions can be prepared from sterilepowders, granules, and tablets of the kind previously described.

The pharmaceutical dosage forms suitable for injection or infusion caninclude sterile aqueous solutions or dispersions comprising the activeingredient that are adapted for administration by encapsulation inliposomes. In all cases, the ultimate dosage form must be sterile, fluidand stable under the conditions of manufacture and storage.

Sterile injectable solutions are prepared by incorporating the compoundor pharmaceutically acceptable salt thereof in the required amount inthe appropriate solvent with various of the other ingredients enumeratedabove, as required, followed by filter sterilization.

Compositions for Topical Administration

The compounds of the invention can also be delivered topically. Regionsfor topical administration include the skin surface and also mucousmembrane tissues of the rectum, nose, mouth, and throat. Compositionsfor topical administration via the skin and mucous membranes should notgive rise to signs of irritation, such as swelling or redness.

The topical composition may include a pharmaceutically acceptablecarrier adapted for topical administration. Thus, the composition maytake the form of a suspension, solution, ointment, lotion, cream, foam,aerosol, spray, suppository, implant, inhalant, tablet, capsule, drypowder, syrup, balm or lozenge, for example. Methods for preparing suchcompositions are well known in the pharmaceutical industry.

The compounds of the present invention may be formulated for topicaladministration to the epidermis as ointments, creams or lotions, or as atransdermal patch. Ointments and creams may, for example, be formulatedwith an aqueous or oily base with the addition of suitable thickeningand/or gelling agents. Lotions may be formulated with an aqueous or oilybase and will in general also containing one or more emulsifying agents,stabilizing agents, dispersing agents, suspending agents, thickeningagents, or coloring agents. Compositions suitable for topicaladministration in the mouth include lozenges comprising active agents ina flavoured base, usually sucrose and acacia or tragacanth; pastillescomprising the active ingredient in an inert base such as gelatin andglycerin or sucrose and acacia; and mouthwashes comprising the activeingredient in a suitable liquid carrier.

Creams, ointments or pastes according to the present invention aresemi-solid compositions of the active ingredient for externalapplication. They may be made by mixing the active ingredient infinely-divided or powdered form, alone or in solution or suspension inan aqueous or non-aqueous fluid, with the aid of suitable machinery,with a greasy or non-greasy base. The base may comprise hydrocarbonssuch as hard, soft or liquid paraffin, glycerol, beeswax, a metallicsoap; a mucilage; an oil of natural origin such as almond, corn,arachis, castor or olive oil; wool fat or its derivatives or a fattyacid such as steric or oleic acid together with an alcohol such aspropylene glycol or a macrogel. The composition may incorporate anysuitable surface active agent such as an anionic, cationic or non-ionicsurfactant such as a sorbitan ester or a polyoxyethylene derivativethereof. Suspending agents such as natural gums, cellulose derivativesor inorganic materials such as silicaceous silicas, and otheringredients such as lanolin, may also be included.

Lotions according to the present invention include those suitable forapplication to the skin or eye. An eye lotion may comprise a sterileaqueous solution optionally containing a bactericide and may be preparedby methods similar to those for the preparation of drops. Lotions orliniments for application to the skin may also include an agent tohasten drying and to cool the skin, such as an alcohol or acetone,and/or a moisturizer such as glycerol or an oil such as castor oil orarachis oil.

The compounds described herein can be administered transdermally.Transdermal administration typically involves the delivery of apharmaceutical agent for percutaneous passage of the drug into thesystemic circulation of the patient. The skin sites include anatomicregions for transdermally administering the drug and include theforearm, abdomen, chest, back, buttock, mastoidal area, and the like.

Transdermal delivery is accomplished by exposing a source of the complexto a patient's skin for an extended period of time. Transdermal patcheshave the added advantage of providing controlled delivery of apharmaceutical agent-chemical modifier complex to the body. SeeTransdermal Drug Delivery: Developmental Issues and ResearchInitiatives, Hadgraft and Guy (eds.), Marcel Dekker, Inc., (1989);Controlled Drug Delivery: Fundamentals and Applications, Robinson andLee (eds.), Marcel Dekker Inc., (1987); and Transdermal Delivery ofDrugs, Vols. 1-3, Kydonieus and Berner (eds.), CRC Press, (1987). Suchdosage forms can be made by dissolving, dispersing, or otherwiseincorporating the pharmaceutical agent-chemical modifier complex in aproper medium, such as an elastomeric matrix material. Absorptionenhancers can also be used to increase the flux of the compound acrossthe skin. The rate of such flux can be controlled by either providing arate-controlling membrane or dispersing the compound in a polymer matrixor gel.

A variety of types of transdermal patches will find use in the methodsdescribed herein. For example, a simple adhesive patch can be preparedfrom a backing material and an acrylate adhesive. The compound(s) areformulated into the adhesive casting solution and allowed to mixthoroughly. The solution is cast directly onto the backing material andthe casting solvent is evaporated in an oven, leaving an adhesive film.The release liner can be attached to complete the system.

Alternatively, a polyurethane matrix patch can be employed to deliverthe compound(s). The layers of this patch comprise a backing, apolyurethane drug/enhancer matrix, a membrane, an adhesive, and arelease liner. The polyurethane matrix is prepared using a roomtemperature curing polyurethane prepolymer. Addition of water, alcohol,and complex to the prepolymer results in the formation of a tacky firmelastomer that can be directly cast only the backing material.

A further embodiment of this invention will utilize a hydrogel matrixpatch. Typically, the hydrogel matrix will comprise alcohol, water,drug, and several hydrophilic polymers. This hydrogel matrix can beincorporated into a transdermal patch between the backing and theadhesive layer.

The liquid reservoir patch will also find use in the methods describedherein. This patch comprises an impermeable or semipermeable, heatsealable backing material, a heat sealable membrane, an acrylate basedpressure sensitive skin adhesive, and a siliconized release liner. Thebacking is heat sealed to the membrane to form a reservoir which canthen be filled with a solution of the complex, enhancers, gelling agent,and other excipients.

Foam matrix patches are similar in design and components to the liquidreservoir system, except that the gelled compound solution isconstrained in a thin foam layer, typically a polyurethane. This foamlayer is situated between the backing and the membrane which have beenheat sealed at the periphery of the patch.

For passive delivery systems, the rate of release is typicallycontrolled by a membrane placed between the reservoir and the skin, bydiffusion from a monolithic device, or by the skin itself serving as arate-controlling barrier in the delivery system. See U.S. Pat. Nos.4,816,258; 4,927,408; 4,904,475; 4,588,580, 4,788,062; and the like. Therate of drug delivery will be dependent, in part, upon the nature of themembrane. For example, the rate of drug delivery across membranes withinthe body is generally higher than across dermal barriers. The rate atwhich the compound(s) is delivered from the device to the membrane ismost advantageously controlled by the use of rate-limiting membraneswhich are placed between the reservoir and the skin. Assuming that theskin is sufficiently permeable to the compound (i.e., absorption throughthe skin is greater than the rate of passage through the membrane), themembrane will serve to control the dosage rate experienced by thepatient.

Suitable permeable membrane materials may be selected based on thedesired degree of permeability, the nature of the complex, and themechanical considerations related to constructing the device. Exemplarypermeable membrane materials include a wide variety of natural andsynthetic polymers, such as polydimethylsiloxanes (silicone rubbers),ethylenevinylacetate copolymer (EVA), polyurethanes,polyurethane-polyether copolymers, polyethylenes, polyamides,polyvinylchlorides (PVC), polypropylenes, polycarbonates,polytetrafluoroethylenes (PTFE), cellulosic materials, e.g., cellulosetriacetate and cellulose nitrate/acetate, and hydrogels, e.g.,2-hydroxyethylmethacrylate (HEMA).

Other items may be contained in the device, such as other conventionalcomponents of therapeutic products, depending upon the desired devicecharacteristics. For example, the compositions according to thisinvention may also include one or more preservatives or bacteriostaticagents, e.g., methyl hydroxybenzoate, propyl hydroxybenzoate,chlorocresol, benzalkonium chlorides, and the like. These pharmaceuticalcompositions also can contain other active ingredients such asantimicrobial agents, particularly antibiotics, anesthetics, analgesics,and antipruritic agents.

Compositions for Administration as Suppositories

The compounds of the present invention may be formulated foradministration as suppositories. A low melting wax, such as a mixture offatty acid glycerides or cocoa butter is first melted and the activecomponent is dispersed homogeneously, for example, by stirring. Themolten homogeneous mixture is then poured into convenient sized molds,allowed to cool, and to solidify.

The active compound may be formulated into a suppository comprising, forexample, about 0.5% to about 50% of a compound of the invention,disposed in a polyethylene glycol (PEG) carrier (e.g., PEG 1000 [96%]and PEG 4000 [4%].

Dosage

Suitable dosing regimens for the various compounds and methods of thepresent invention are preferably determined taking into account factorswell known in the art including type of subject being dosed; age,weight, sex and medical condition of the subject; the route ofadministration; the renal and hepatic function of the subject; thedesired effect; and the particular compound employed.

Optimal precision in achieving concentrations of drug within the rangethat yields efficacy without toxicity requires a regimen based on thekinetics of the drug's availability to target sites. This involves aconsideration of the distribution, equilibrium, and elimination of adrug.

The compositions of the invention may be administered using any suitableadministration form; usually however, administration will be oral orparenteral. Oral administration in the form of a syrup comprising thecomposition and/or a capsule containing a syrup comprising thecomposition or in a powder form of the composition is preferred.

The dosage requirements will vary with the particular compositionemployed, the route of administration and the particular individualbeing treated. Ideally, an individual to be treated by the presentmethod will receive a pharmaceutically effective amount of the compoundin the maximum tolerated dose.

In general the daily (preferably oral) dosage regimen may be about 0.001to about 100 mg/kg, preferably in the range of 0.01 to 50 mg/kg, morepreferably in the range of 0.1 to 10, even more preferably in the rangeof 1 to 2 mg/kg of total body weight. It will also be recognised by oneskilled in the art that the optimal quantity and spacing of individualdosages of the composition will be determined by the nature and extentof the condition being treated, the form, route and site ofadministration, and the particular patient being treated, and that suchoptimums can be determined by conventional techniques. It will also beappreciated by one skilled in the art that the optimal course oftreatment, i.e., the number of doses of the composition given per dayfor a defined number of days, can be ascertained by those skilled in theart using conventional course of treatment determination tests.

It is preferred that the kit according to the present inventioncomprises dosage regime instructions with guidelines for dose and timeadministration.

Medical Methods and Use

One aspect of the present invention relates to use of any of theanti-cancer medicaments described herein and any of the Agaricusbioactive agents described herein for the manufacture of a kit of partssuitable for administration to an individual in need thereof, preferablyfor treatment or prophylaxis of a neoplastic disease, such as any of thediseases described herein.

In one preferred embodiment of the present invention, the Agaricusbioactive agent stimulates the immune system of an animal or a humanwhen administered to said animal or human in a pharmaceutically activeamount. Preferably, said agent is capable of stimulating in anindividual in need of such stimulation, the production of one or more ofantibodies, such as IgG, IgA, and IgE, T helper cells, interleukins,such as IL-1 and IL-2, interferon, such as IFN-gamma, natural killercells, and macrophages.

It is further envisaged that any of the uses and products describedherein may be used in a method for the treatment of a neoplastic diseasein an individual, said method comprising the steps of

-   -   a. providing any of the kit of parts as described herein, and    -   b. administering any of the anti-cancer medicaments and Agaricus        bioactive agents described herein to said individual.

Examples

The following examples describe illustrative embodiments of theinvention and should not be regarded as limiting for the invention.

Example 1

Protocol for cultivation of Basidiomycete cells according to the presentinvention.

The protocol is used in the further examples unless otherwise stated.

Cultivation Conditions: Temperature: 25° C.±1° C. pH: Medium pH

Water: Tap waterMedium: Glucose 30 g/l;

Mycological peptone 10 g/l;

Yeast extract 6 g/l

Malt extract 6 g/l

Plate Cultivation of Basidiomycete Cells

15 cm Petri dishes containing about 60 ml of the medium+agar at aconcentration corresponding to 15 g/l. Inoculate the plates by scrapingoff the top layer of mycelium on a Petri dish using a sterile scalpeland spread it onto the new plate. One Petri dish will yield enoughmycelium to inoculate three new plates. Cultivate the plates at 25° C.for at least three weeks prior to use. They can be kept at thistemperature for a total of 7 more weeks before they should be discarded.

Shake Flask Cultivation of Basidiomycete Cells

500 ml Ehrlenmeyer flasks containing 200 ml of medium. Scrape off thetop layer of mycelium on two plates using a sterile scalpel and place ina 300 ml Ehrlenmeyer flask containing 100 ml of medium. Homogenise theresulting mixture. Inoculate the 500 ml flasks with 50 ml of thehomogenised material per flask. Put on orbital shaker at 25° C. and 140rpm and leave for 7-10 days. If required, longer fermentation periodscan also be used, such as e.g. 15-30 days.

Fermenter (3 Litres) Cultivation of Basidiomycete Cells

Place 1.7 litres of the medium in the fermenter and sterilise at 121° C.for 20 mins. Set the fermentation conditions: 25° C., 200-300 rpm andair at 0.2-0.5 vvm. Decant as much liquid as possible from two shakeflasks and inoculate the fermenter with the remaining broth (this willnormally amount to 300-500 ml). Add a suitable antifoam agent whenrequired (normally throughout the run). Harvests after 6-8 days. Ifrequired, longer fermentation periods can also be used, such as e.g.15-30 days.

Harvesting of Basidiomycete Cells

Biomass:

Remove the biomass from the broth using a nylon cloth with pore size 45as a filter medium. Wash the biomass thoroughly with water and dry in amicrowave oven set at defrost until dry (normal sample size will requireabout 15 mins). Store in a desiccator until cool and weigh.

Fermentation Liquor:

The concentration of bioactive agent in the fermentation liquor isdetermined by precipitation with abs ethanol. Sterile, distilled wateris added if necessary to adjust the concentration to the desired level.The resulting liquid is autoclave and stored.

Medical Grade:

Pass the biomass-free fermentation liquor through a UF filter having asuitable cut-off value, such as e.g. a cut-off value of 300 kD. When70-80% of the liquid has been removed add water to the retentate to washthe solution. Repeat until the solution has lost much (at least most of)its colour and appears clean.

Example 2

Protocol for cultivation of Trametes sp.—and polysaccharides obtainedfrom such a cultivation.

Trametes versicolour

A Trametes sp. fermentation, in the cultivation medium used in Example1, takes about 7 days. The initial pH is 4.7, final pH is 3. The finalbiomass concentration is about 7 g/l and precipitated compound is about0.3 g/l, the monosaccharide composition of which is about 1:0.15:1:4(glucose:galactose:mannose). The fermentation liquid contains, afterremoval of biomass, no detectable free glucose,

Example 3

Protocol for cultivation of Schizophyllum sp.—and polysaccharidesobtained from such a cultivation.

Schizophyllum commune

This fermentation, using the same medium as in example 1, takes about 3days. pH falls from 4.7 to 3.3 and the biomass concentration at the endof the fermentation is about 8 g/l. The fermentation broth, afterremoval of biomass, contains no detectable free glucose. Theprecipitated product concentration is about 0.6 g/l. The monosaccharidecomposition is about 1:0.1:0.65.

Example 4. Bacteriostatic Effect

In this example it is demonstrated that the bioactive agent obtained bythe method as described in example 1 (precipited from the Fermentationliquor) has a bacteriostatic effect on E. coli K12.

Method:

The bacteriostatic effect of the bioactive agent was determined bymeasuring the cell-density of E. coli K12 cultures grown in Antibioticassay medium 3 with different dilutions of the bioactive agent. Aculture without the bioactive agent in the medium was used as control.

Cells were grown in a 50 ml conical flask at 34° C. for 26 h. Thedilutions of the bioactive agent in the growth medium were 1:10, 1:20and 1:40. The optical density was measured robotically every 2 h at 660nm.

Results:

Results are shown in FIG. 1. The optical density significantly decreasedin the cultures with a 1:10 and 1:20 dilution of the bioactive agent inthe stationary phase (between 15 and 26 h). The incubation with a 1:40dilution of the bioactive agent does not lead to a significant decreasein optical density in comparison with the control.

Conclusion:

The bioactive agent is shown to have a bacteriostatic effect on E. coliK12.

Example 5. Anti-Tumor Effect

In this example it is demonstrated that human and mouse cancer celllines are sensitive to treatment with bioactive agent obtained by themethod as described in example 1 (precipited from the Fermentationliquor).

Method:

The anti-tumor effect of the bioactive agent was determined by measuringthe cell-viability of different human and mouse cell lines afterexposure to different concentrations of Lentinex. The MRC-5 cell linefrom normal human fetal lung fibroblasts was used as control.

Cells were grown in a 96 well dish to a sub confluent cell layer. Themedium was removed and the cells washed with PBS. Fresh medium withoutthe bioactive agent (negative control) or containing 0,1; 0,2; 0,3 or0.4 mg/ml bioactive agent was added and cells were incubated for 24 h at37° C.

A MTT-Assay, which measures the activity of the mitochondrialsuccinate-dehydrogenase, was used to determine the cytotoxic effect ofthe bioactive agent. In living cells this enzyme converts the yellowwater-soluble3-(4,5-dimethylthiazol-2yl)-2,5-diphenyl-tetrazolium-bromide (MTT) toblue water-insoluble formazan, whereas there is no conversion in deadcells. Thus the amount of formazan directly correlates to the number ofliving cells.

10 μl MTT solution was added to each well and the plates were incubatedfor additional 2 h. 70 μl of supernatant were removed from each well and100 μl acidic isopropanol was added to extract the formazan. After 1 hthe absorption was measured at 590 nm.

Results:

Results are shown in FIG. 2. The number of viable cells wassignificantly decreased in all cancer cell lines after incubation withthe bioactive agent for 24 h. This effect increased with theconcentration of the bioactive agent in the medium. In all cancer celllines, fewer than 50% of the cells were viable after incubation with 0.4mg/ml bioactive agent for 24 h. The most severe effect of the bioactiveagent was observed in the mouse colon cancer cell line C-26, where therewere almost no viable cells after the incubation with 0.4 mg/mlbioactive agent for 24 h.

Conclusion:

The bioactive agent is shown to have a cytotoxic effect specificallydirected against cancer cells, and not normal cells.

Example 7

For a determination of immunostimulating characteristics, the followingmethod may be used: 12 weeks old Sprague Dawley rats receives 1 mg ofthe composition according to the invention in 0.5 ml 0.09 saline (i.p.)2 days before the immunisation. Control animals receives 1 mg casein.The animals are immunised with BSA (0.5 mg) in 0.25 “Freunds CompleteAdjuvant” and blood samples are obtained after 11 days for measurementof the antibody response. The specific anti-BSA antibody concentrationis determined against an absolute standard of antibody BSA by means of“sandwich” ELISA.

1. A pharmaceutical kit of parts comprising a) an anti-cancermedicament, b) a Basidiomycete bioactive agent in solid or liquid form,and, optionally c) instructions for a dosing regime.
 2. The kitaccording to claim 1, wherein the anti-cancer medicament is selectedfrom the group consisting of: Aldesleukin/Proleukin (Chiron Corp)Alemtuzumab/Campath (Millennium and ILEX Partners, LP)alitretinoin/Panretin (Ligand Pharmaceuticals) allopurinol/Zyloprim(GlaxoSmithKline) altretamine/Hexalen (US Bioscience) amifostine/Ethyol(US Bioscience) anastrozole/Arimidex (AstraZeneca) arsenictrioxide/Trisenox (Cell Therapeutic) Asparaginase/Elspar (Merck & Co,Inc) BCG Live/TICE BCG (Organon Teknika Corp) bexarotenecapsules/Targretin (Ligand Pharmaceuticals) bleomycin/Blenoxane(Bristol-Myers Squibb) busulfan/Busulfex (GlaxoSmithKline)calusterone/Methosarb (Pharmacia & Upjohn Company) capecitabine/Xeloda(Roche) carboplatin/Paraplatin (Bristol-Myers Squibb) carmustine/BCNU,BiCNU (Bristol-Myers Squibb) carmustine with Polifeprosan 20Implant/Gliadel Wafer (Guilford Pharmaceuticals Inc.) celecoxib/Celebrex(Searle) chlorambucil/Leukeran (GlaxoSmithKline) cisplatin/Platinol(Bristol-Myers Squibb) cladribine/Leustatin, 2-CdA (R. W. JohnsonPharmaceutical Research Institute) cyclophosphamide Cytoxan/Neosar(Bristol-Myers Squibb) cytarabine/Cytosar-U (Pharmacia & Upjohn Company)dacarbazine/DTIC-Dome (Bayer) dactinomycin/actinomycin D Cosmegen(Merck) Darbepoetin alfa/Aranesp (Amgen, Inc)daunorubicin/daunomycin/Daunorubicin (Bedford Labs)daunorubicin/daunomycin/Cerubidine (Wyeth Ayerst)Denileukin/diftitox/Ontak (Seragen, Inc) dexrazoxane/Zinecard (Pharmacia& Upjohn Company) docetaxel/Taxotere (Aventis Pharmaceutical)doxorubicin Adriamycin/Rubex (Pharmacia & Upjohn Company) Dromostanolonepropionate/Masterone Injection (Syntex) Elliott's B Solution (OrphanMedical, Inc) epirubicin/Ellence (Pharmacia & Upjohn Company) etoposidephosphate (Bristol-Myers Squibb) etoposide/VP-16/Vepesid (Bristol-MyersSquibb) exemestane/Aromasin (Pharmacia & Upjohn Company)Filgrastim/Neupogen (Amgen, Inc) floxuridine/FUDR (Roche)fludarabine/Fludara (Berlex Laboratories Inc.) fluorouracil/5-FU/Adrucil(ICN Puerto Rico) fulvestrant/Faslodex (IPR) gemcitabine/Gemzar (EliLilly) gemtuzumab/ozogamicin/Mylotarg (Wyeth Ayerst) goserelinacetate/Zoladex Implant (AstraZeneca Pharmaceuticals) hydroxyurea/Hydrea(Bristol-Myers Squibb) Ibritumomab Tiuxetan/Zevalin (IDECPharmaceuticals Corp) idarubicin/Idamycin (Adria Laboratories)ifosfamide/IFEX (Bristol-Myers Squibb) imatinib mesylate/Gleevec(Novartis) Interferon alfa-2a/Roferon-A (Hoffmann-La Roche Inc)Interferon alfa-2b/Intron A (Schering Corp) irinotecan/Camptosar(Pharmacia & Upjohn Company) letrozole/Femara (Novartis) leucovorinWellcovorin/Leucovorin (Immunex Corporation) levamisole/Ergamisol(Janssen Research Foundation) lomustine/CCNU/CeeBU (Bristol-MyersSquibb) meclorethamine/nitrogen mustard/Mustargen (Merck) megestrolacetate/Megace (Bristol-Myers Squibb) melphalan/L-PAM/Alkeran(GlaxoSmithKline) mercaptopurine/6-MP Purinethol (GlaxoSmithKline)mesna/Mesnex (Asta Medica) methotrexate (Lederle Laboratories)methoxsalen/Uvadex (Therakos) mitomycin C/Mutamycin (Bristol-MyersSquibb) mitomycin C/Mitozytrex (Supergen) mitotane/Lysodren(Bristol-Myers Squibb) mitoxantrone/Novantrone (Lederle Laboratories)nandrolone phenpropionate/Durabolin-50 (Organon) Nofetumomab/Verluma(Boehringer Ingelheim Pharma KG (formerly Dr. Karl Thomae GmbH))Oprelvekin/Neumega (Genetics Institute) oxaliplatin/Eloxatin (SanofiSynthelabo) paclitaxel/Taxol (Bristol-Myers Squibb) pamidronate/Aredia(Novartis) pegademase/Adagen (Pegademase Bovine) (Enzon)Pegaspargase/Oncaspar (Enzon, Inc) Pegfilgrastim/Neulasta (Amgen, Inc)pentostatin/Nipent (Parke-Davis Pharmaceutical Co.) pipobroman/Vercyte(Abbott Labs) plicamycin/mithramycin/Mithracin (Pfizer Labs) porfimersodium/Photofrin (QLT Phototherapeutics Inc.) procarbazine/Matulane(Sigma Tau Pharms) quinacrine/Atabrine (Abbott Labs) Rasburicase/Elitek(Sanofi-Synthelabo, Inc) Rituximab/Rituxan (Genentech, Inc)Sargramostim/Prokine (Immunex Corp) streptozocin/Zanosar (Pharmacia &Upjohn Company) talc/Sclerosol (Bryan) tamoxifen/Nolvadex (AstraZenecaPharmaceuticals) temozolomide/Temodar (Schering) teniposide/VM-26/Vumon(Bristol-Myers Squibb) testolactone/Teslac (Bristol-Myers Squibb)thioguanine/6-TG/Thioguanine (GlaxoSmithKline) thiotepa/Thioplex(Lederle Laboratories) topotecan/Hycamtin (GlaxoSmithKline)topotecan/Hycamtin (GlaxoSmithKline) toremifene/Fareston (Orion Corp)Tositumomab/Bexxar (Corixa Corporation) Trastuzumab/Herceptin(Genentech, Inc) tretinoin/ATRA/Vesanoid (Roche) Uracil Mustard (RobertsLabs) valrubicin/Valstar (Medeva) vinblastine/Velban (Eli Lilly)vincristine/Oncovin (Eli Lilly) vinorelbine/Navelbine (GlaxoSmithKline),and zoledronate/Zometa (Novartis)
 3. The kit according to any of claims1 and 2, wherein the anti-cancer drug is Aldesleukin/Proleukin (ChironCorp)
 4. The kit according to any of claims 1 and 2, wherein theanti-cancer drug is Alemtuzumab/Campath (Millennium and ILEX Partners,LP), such as for the treatment or prophylaxis of B-cell chroniclymphocytic leukaemia (B-CLL)
 5. The kit according to any of claims 1and 2, wherein the anti-cancer drug is alitretinoin/Panretin (LigandPharmaceuticals), such as for the treatment or prophylaxis of cutaneouslesions in sarcoma patients, such as in patients suffering fromAIDS-related Kaposi's sarcoma.
 6. The kit according to any of claims 1and 2, wherein the anti-cancer drug is allopurinol/Zyloprim(GlaxoSmithKline), such as for the treatment of patients with leukaemiaand/or lymphoma and/or one or more solid tumor malignancies who arereceiving cancer therapy which causes elevations of serum and urinaryuric acid levels.
 7. The kit according to any of claims 1 and 2, whereinthe anti-cancer drug is altretamine/Hexalen (US Bioscience), such as fortreatment or prophylaxis of ovarian cancer.
 8. The kit according to anyof claims 1 and 2, wherein the anti-cancer drug is amifostine/Ethyol (USBioscience), such as for treatment or prophylaxis of post-radiationxerostomia for e.g. head and neck cancer and/or ovarian cancer(preferably advanced) and/or non-small cell lung cancer.
 9. The kitaccording to any of claims 1 and 2, wherein the anti-cancer drug isanastrozole/Arimidex (AstraZeneca), such as for the treatment of breastcancer, for example hormone receptor positive early breast cancer,advanced breast cancer, locally advanced or metastatic breast cancer.10. The kit according to any of claims 1 and 2, wherein the anti-cancerdrug is arsenic trioxide/Trisenox (Cell Therapeutic).
 11. The kitaccording to any of claims 1 and 2, wherein the anti-cancer drug isAsparaginase/Elspar (Merck & Co, Inc), such as for the treatment ofpediatric patients.
 12. The kit according to any of claims 1 and 2,wherein the anti-cancer drug is BCG Live/TICE BCG (Organon TeknikaCorp).
 13. The kit according to any of claims 1 and 2, wherein theanti-cancer drug is bexarotene capsules/Targretin (LigandPharmaceuticals), such as for treatment of cutaneous manifestations ofcutaneous T-cell lymphoma, preferably via oral administration.
 14. Thekit according to any of claims 1 and 2, wherein the anti-cancer drug isbleomycin/Blenoxane (Bristol-Myers Squibb), such as for treatment ofmalignant pleural effusion (MPE) and prevention of recurrent pleuraleffusions.
 15. The kit according to any of claims 1 and 2, wherein theanti-cancer drug is busulfan/Busulfex (GlaxoSmithKline), such as priorto hematopoietic progenitor cell transplantation for chronic myelogenousleukemia, preferably via oral administration.
 16. The kit according toany of claims 1 and 2, wherein the anti-cancer drug iscalusterone/Methosarb (Pharmacia & Upjohn Company).
 17. The kitaccording to any of claims 1 and 2, wherein the anti-cancer drug iscapecitabine/Xeloda (Roche), such as for treatment of breast cancer,preferably metastatic breast cancer, or colorectal carcinoma, preferablymetastatic colorectal carcinoma.
 18. The kit according to any of claims1 and 2, wherein the anti-cancer drug is Carboplatin/Paraplatin(Bristol-Myers Squibb), such as for treatment of ovarian carcinoma. 19.The kit according to any of claims 1 and 2, wherein the anti-cancer drugis carmustine/BCNU, BiCNU (Bristol-Myers Squibb)
 20. The kit accordingto any of claims 1 and 2, wherein the anti-cancer drug is carmustinewith Polifeprosan 20 Implant/Gliadel Wafer (Guilford PharmaceuticalsInc.), such as to prolong survival in patients with recurrentglioblastoma multiforme who qualify for surgery.
 21. The kit accordingto any of claims 1 and 2, wherein the anti-cancer drug iscelecoxib/Celebrex (Searle), such as for treatment of familialadenomatous polyposis.
 22. The kit according to any of claims 1 and 2,wherein the anti-cancer drug is chlorambucil/Leukeran (GlaxoSmithKline),such as for treatment of chronic lymphocytic leukaemia.
 23. The kitaccording to any of claims 1 and 2, wherein the anti-cancer drug iscisplatin/Platinol (Bristol-Myers Squibb), such as for treatment ofovarian tumour preferably metastatic ovarian tumour, testicular tumour,preferably testicular tumour, transitional cell bladder cancer.
 24. Thekit according to any of claims 1 and 2, wherein the anti-cancer drug iscladribine/Leustatin, 2-CdA (R. W. Johnson Pharmaceutical ResearchInstitute), such as for treatment of active hairy cell leukaemia. 25.The kit according to any of claims 1 and 2, wherein the anti-cancer drugis cyclophosphamide Cytoxan/Neosar (Bristol-Myers Squibb)
 26. The kitaccording to any of claims 1 and 2, wherein the anti-cancer drug iscytarabine/Cytosar-U (Pharmacia & Upjohn Company)
 27. The kit accordingto any of claims 1 and 2, wherein the anti-cancer drug isdacarbazine/DTIC-Dome (Bayer).
 28. The kit according to any of claims 1and 2, wherein the anti-cancer drug is dactinomycin/actinomycin DCosmegen (Merck)
 29. The kit according to any of claims 1 and 2, whereinthe anti-cancer drug is Darbepoetin alfa/Aranesp (Amgen, Inc), such asfor treatment of anemia associated with chemotherapeutic regimes. 30.The kit according to any of claims 1 and 2, wherein the anti-cancer drugis daunorubicin/daunomycin/Daunorubicin (Bedford Labs), such as inliposomal form, for example for the treatment of HIV-related Kaposi'ssarcoma.
 31. The kit according to any of claims 1 and 2, wherein theanti-cancer drug is daunorubicin/daunomycin/Cerubidine (Wyeth Ayerst),such as for treatment of leukaemia.
 32. The kit according to any ofclaims 1 and 2, wherein the anti-cancer drug isDenileukin/diftitox/Ontak (Seragen, Inc), such as for treatment ofT-cell lymphoma, preferably of individuals whose malignant cells expressthe CDC25 component of the IL-2 receptor.
 33. The kit according to anyof claims 1 and 2, wherein the anti-cancer drug is dexrazoxane/Zinecard(Pharmacia & Upjohn Company), such as to aid in reducing the severity ofcardiomyopathy associated with doxorubicin administration in women withmetastatic breast cancer.
 34. The kit according to any of claims 1 and2, wherein the anti-cancer drug is docetaxel/Taxotere (AventisPharmaceutical), such as for treatment of breast cancer, preferablylocally advanced or metastatic breast cancer, or non-small cell lungcancer, preferably locally advanced or metastatic non-small cell lungcancer.
 35. The kit according to any of claims 1 and 2, wherein theanti-cancer drug is doxorubicin/Adriamycin Rubex (Pharmacia & UpjohnCompany), such as for treatment of AIDS-related Kaposi's sarcoma ormetastatic carcinoma of the ovary.
 36. The kit according to any ofclaims 1 and 2, wherein the anti-cancer drug is Dromostanolonepropionate/Masterone injection (SYNTEX).
 37. The kit according to any ofclaims 1 and 2, wherein the anti-cancer drug is Elliott's B Solution(Orphan Medical, Inc), such as for treatment or prophylaxis of miningealleukaemia or lymphocytic lymphoma.
 38. The kit according to any ofclaims 1 and 2, wherein the anti-cancer drug is Epirubicin/Ellence(Pharmacia & Upjohn Company), such as for treatment or prophylaxis ofbreast cancer.
 39. The kit according to any of claims 1 and 2, whereinthe anti-cancer drug is etoposide phosphate (Bristol-Myers Squibb), suchas for treatment or prophylaxis of refractory testicular tumours, orsmall cell lung cancer.
 40. The kit according to any of claims 1 and 2,wherein the anti-cancer drug is etoposide/VP-16/Vepesid (Bristol-MyersSquibb), such as for treatment or prophylaxis of refractory testiculartumours, small cell lung cancer.
 41. The kit according to any of claims1 and 2, wherein the anti-cancer drug is exemestane/Aromasin (Pharmacia& Upjohn Company), such as for treatment or prophylaxis of breastcancer, preferably for treatment of advanced breast cancer.
 42. The kitaccording to any of claims 1 and 2, wherein the anti-cancer drug isFilgrastim/Neupogen (Amgen, Inc), such as for treatment of non-myeloidmalignancies undergoing myeloablative chemotherapy followed by marrowtransplantation.
 43. The kit according to any of claims 1 and 2, whereinthe anti-cancer drug is floxuridine/FUDR (Roche)
 44. The kit accordingto any of claims 1 and 2, wherein the anti-cancer drug isfludarabine/Fludara (Berlex Laboratories Inc.), such as for treatment orprophylaxis of B-cell lymphocytic leukaemia.
 45. The kit according toany of claims 1 and 2, wherein the anti-cancer drug isfluorouracil/5-FU/Adrucil (ICN Puerto Rico), such as to prolongsurvival.
 46. The kit according to any of claims 1 and 2, wherein theanti-cancer drug is fulvestrant/Faslodex (IPR), such as for treatment orprophylaxis of breast cancer, preferably in post-menopausal women. 47.The kit according to any of claims 1 and 2, wherein the anti-cancer drugis gemcitabine/Gemzar (Eli Lilly), such as for treatment or prophylaxisof adenocarcinoma of the pancreas or non-small cell lung cancer,preferably locally advanced or metastatic adenocarcinoma of the pancreasor non-small cell lung cancer.
 48. The kit according to any of claims 1and 2, wherein the anti-cancer drug is gemtuzumab/ozogamicin/Mylotarg(Wyeth Ayerst), such as for treatment or prophylaxis of CD33 positiveacute myeloid leukaemia in patients who are preferably 60 years of ageor older.
 49. The kit according to any of claims 1 and 2, wherein theanti-cancer drug is goserelin acetate/Zoladex Implant (AstraZenecaPharmaceuticals), such as for treatment or prophylaxis of breast cancer,preferably advanced stage breast cancer.
 50. The kit according to any ofclaims 1 and 2, wherein the anti-cancer drug is hydroxyurea/Hydrea(Bristol-Myers Squibb).
 51. The kit according to any of claims 1 and 2,wherein the anti-cancer drug is Ibritumomab Tiuxetan/Zevalin (IDECPharmaceuticals Corp), such as for treatment or prophylaxis ofnon-Hodgkin's lymphoma, for example patients with Rituximab refractoryfollicular non-Hodgkin's lymphoma.
 52. The kit according to any ofclaims 1 and 2, wherein the anti-cancer drug is idarubicin/Idamycin(Adria Laboratories), such as for treatment or prophylaxis of acutemyeloid leukaemia, for example in adults.
 53. The kit according to anyof claims 1 and 2, wherein the anti-cancer drug is ifosfamide/IFEX(Bristol-Myers Squibb), such as for treatment of germ cell testicularcancer.
 54. The kit according to any of claims 1 and 2, wherein theanti-cancer drug is imatinib mesylate/Gleevec (Novartis), such as fortreatment of chronic myelogeneous leukaemia or gastrointestinal stromaltumours.
 55. The kit according to any of claims 1 and 2, wherein theanti-cancer drug is Interferon alfa-2a/Roferon-A (Hoffmann-La RocheInc), such as for treatment or prophylaxis of malignant melanoma,Non-Hodgkin's Lymphoma, condylomata acuminate, hairy cell leukaemia orAIDS-related Kaposi's sarcoma.
 56. The kit according to any of claims 1and 2, wherein the anti-cancer drug is Interferon alfa-2b/Intron A(Schering Corp).
 57. The kit according to any of claims 1 and 2, whereinthe anti-cancer drug is irinotecan/Camptosar (Pharmacia & UpjohnCompany), such as for treatment or prophylaxis of carcinoma of the colonor rectum, preferably metastatic carcinoma of the colon or rectum. 58.The kit according to any of claims 1 and 2, wherein the anti-cancer drugis letrozole/Femara (Novartis), carcinoma of the colon or rectum, suchas for treatment or prophylaxis of breast cancer, preferably inpost-menopausal women.
 59. The kit according to any of claims 1 and 2,wherein the anti-cancer drug is Leucovorin/Wellcovorin (ImmunexCorporation), such as for treatment or prophylaxis of colorectal cancer,preferably advanced colorectal cancer.
 60. The kit according to any ofclaims 1 and 2, wherein the anti-cancer drug is levamisole/Ergamisol(Janssen Research Foundation), such as for treatment or prophylaxis ofcolon cancer, preferably after surgical resection.
 61. The kit accordingto any of claims 1 and 2, wherein the anti-cancer drug islomustine/CCNU/CeeBU (Bristol-Myers Squibb).
 62. The kit according toany of claims 1 and 2, wherein the anti-cancer drug ismeclorethamine/nitrogen mustard/Mustargen (Merck)
 63. The kit accordingto any of claims 1 and 2, wherein the anti-cancer drug is megestrolacetate/Megace (Bristol-Myers Squibb)
 64. The kit according to any ofclaims 1 and 2, wherein the anti-cancer drug is melphalan/L-PAM/Alkeran(GlaxoSmithKline), such as for treatment or prophylaxis of multiplemyeloma.
 65. The kit according to any of claims 1 and 2, wherein theanti-cancer drug is mercaptopurine/6-MP Purinethol (GlaxoSmithKline) 66.The kit according to any of claims 1 and 2, wherein the anti-cancer drugis mesna/Mesnex (Asta Medica) such as for treatment or prophylaxis ofifosfamide-indeuced hemorrhagic cystitis.
 67. The kit according to anyof claims 1 and 2, wherein the anti-cancer drug is methotrexate (LederleLaboratories), such as for treatment or prophylaxis of osteosarcoma. 68.The kit according to any of claims 1 and 2, wherein the anti-cancer drugis methoxsalen/Uvadex (Therakos), such as for treatment or prophylaxisof skin manifestations of cutaneous T-cell lymphoma (CTCL).
 69. The kitaccording to any of claims 1 and 2, wherein the anti-cancer drug ismitomycin C/Mutamycin (Bristol-Myers Squibb).
 70. The kit according toany of claims 1 and 2, wherein the anti-cancer drug is mitomycinC/Mitozytrex (Supergen), such as for treatment or prophylaxis ofdisseminated adenocarcinoma of the stomach or pancreas.
 71. The kitaccording to any of claims 1 and 2, wherein the anti-cancer drug ismitotane/Lysodren (Bristol-Myers Squibb)
 72. The kit according to any ofclaims 1 and 2, wherein the anti-cancer drug is mitoxantrone/Novantrone(Lederle Laboratories), such as for treatment or prophylaxis ofprostrate cancer or acute nonlymphocytic leukaemia (ANLL) in adults. 73.The kit according to any of claims 1 and 2, wherein the anti-cancer drugis nandrolone phenpropionate/Durabolin-50 (Organon).
 74. The kitaccording to any of claims 1 and 2, wherein the anti-cancer drug isNofetumomab/Verluma (Boehringer Ingelheim Pharma KG (formerly Dr. KarlTomae GmbH).
 75. The kit according to any of claims 1 and 2, wherein theanti-cancer drug is doxorubicin/Adriamycin PFS.
 76. The kit according toany of claims 1 and 2, wherein the anti-cancer drug isOprelvekin/Neumega (Genetics Institute), preferably administered aftermyelosuppressive chemotherapy in patients with nonmyeloid malignancies77. The kit according to any of claims 1 and 2, wherein the anti-cancerdrug is oxaliplatin/Eloxatin (Sanofi Synthelabo), such as for treatmentor prophylaxis of carcinoma of the colon, preferably metastaticcarcinoma of the colon.
 78. The kit according to any of claims 1 and 2,wherein the anti-cancer drug is paclitaxel/Taxol/Paxene (Bristol-MyersSquibb), such as for treatment or prophylaxis of advanced AIDS-relatedKaposi's sarcoma, breast cancer, metastatic breast cancer, carcinoma ofthe ovary, AIDS-related Kaposi's sarcoma, metastatic carcinoma of theovary, non-small cell lung cancer or node-positive breast cancer. 79.The kit according to any of claims 1 and 2, wherein the anti-cancer drugis pamidronate/Aredia (Novartis), such as for treatment or prophylaxisof osteolytic bone metastases of breast cancer.
 80. The kit according toany of claims 1 and 2, wherein the anti-cancer drug is pegademase/Adagen(Pegademase Bovine) (Enzon).
 81. The kit according to any of claims 1and 2, wherein the anti-cancer drug is Pegaspargase/Oncaspar (Enzon,Inc).
 82. The kit according to any of claims 1 and 2, wherein theanti-cancer drug is Pegfilgrastim/Neulasta (Amgen, Inc), such as fortreatment or prophylaxis of non-myeloid malignancies.
 83. The kitaccording to any of claims 1 and 2, wherein the anti-cancer drug ispentostatin/Nipent (Parke-Davis Pharmaceutical Co.), such as fortreatment or prophylaxis of hairy cell leukaemia, for example alphainterferon refractory hairy cell leukaemia.
 84. The kit according to anyof claims 1 and 2, wherein the anti-cancer drug is pipobroman/Vercyte(Abbott Labs)
 85. The kit according to any of claims 1 and 2, whereinthe anti-cancer drug is plicamycin/mithramycin/Mithracin (Pfizer Labs)86. The kit according to any of claims 1 and 2, wherein the anti-cancerdrug is porfimer sodium/Photofrin (QLT Phototherapeutics Inc.), such asfor the treatment or prophylaxis of partially obstructing or completelyobstructing esophogeal cancer.
 87. The kit according to any of claims 1and 2, wherein the anti-cancer drug is procarbazine/Matulane (Sigma TauPharms).
 88. The kit according to any of claims 1 and 2, wherein theanti-cancer drug is quinacrine/Atabrine (Abbott Labs)
 89. The kitaccording to any of claims 1 and 2, wherein the anti-cancer drug isRasburicase/Elitek (Sanofi-Synthelabo, Inc), such as for the treatmentor prophylaxis of patients suffering from leukaemia, lymphoma or solidtumor malignancies.
 90. The kit according to any of claims 1 and 2,wherein the anti-cancer drug is Rituximab/Rituxan (Genentech, Inc) 91.The kit according to any of claims 1 and 2, wherein the anti-cancer drugis Sargramostim/Prokine (Immunex Corp)
 92. The kit according to any ofclaims 1 and 2, wherein the anti-cancer drug is streptozocin/Zanosar(Pharmacia & Upjohn Company).
 93. The kit according to any of claims 1and 2, wherein the anti-cancer drug is talc/Sclerosol (Bryan), such asfor the treatment or prophylaxis of malignant pleural effusion insymptomatic patients.
 94. The kit according to any of claims 1 and 2,wherein the anti-cancer drug is tamoxifen/Nolvadex (AstraZenecaPharmaceuticals), such as for the treatment or prophylaxis of breastcancer, for example following mastectomy and axillary dissection inpostmenopausal women, or for metastatic breast cancer, for example inmen.
 95. The kit according to any of claims 1 and 2, wherein theanti-cancer drug is temozolomide/Temodar (Schering), such as for thetreatment or prophylaxis of refractory anaplastic astrocytma.
 96. Thekit according to any of claims 1 and 2, wherein the anti-cancer drug isteniposide/VM-26/Vumon (Bristol-Myers Squibb), such as for the treatmentor prophylaxis of refractory childhood acute lymphoblastic leukaemia.97. The kit according to any of claims 1 and 2, wherein the anti-cancerdrug is testolactone/Teslac (Bristol-Myers Squibb)
 98. The kit accordingto any of claims 1 and 2, wherein the anti-cancer drug isthioguanine/6-TG/Thioguanine (GlaxoSmithKline)
 99. The kit according toany of claims 1 and 2, wherein the anti-cancer drug is thiotepa/Thioplex(Lederle Laboratories)
 100. The kit according to any of claims 1 and 2,wherein the anti-cancer drug is topotecan/Hycamtin (GlaxoSmithKline),such as for the treatment or prophylaxis of metastatic carcinoma of theovary, or small cell lung cancer.
 101. The kit according to any ofclaims 1 and 2, wherein the anti-cancer drug is toremifene/Fareston(Orion Corp), such as for the treatment or prophylaxis of advancedbreast cancer in postmenopausal women.
 102. The kit according to any ofclaims 1 and 2, wherein the anti-cancer drug is Tositumomab/Bexxar(Corixa Corporation), such as for the treatment or prophylaxis ofnon-Hodgkin's lymphoma.
 103. The kit according to any of claims 1 and 2,wherein the anti-cancer drug is Trastuzumab/Herceptin (Genentech, Inc),such as for the treatment or prophylaxis of metastatic breast cancer.104. The kit according to any of claims 1 and 2, wherein the anti-cancerdrug is tretinoin/ATRA/Vesanoid (Roche), such as for the treatment orprophylaxis of acute promyeocytic leukaemia.
 105. The kit according toany of claims 1 and 2, wherein the anti-cancer drug is Uracil Mustard(Roberts Labs)
 106. The kit according to any of claims 1 and 2, whereinthe anti-cancer drug is valrubicin/Valstar (Medeva), such as for thetreatment or prophylaxis of BCG-refractory carcinoma in situ (CIS) ofthe urinary bladder.
 107. The kit according to any of claims 1 and 2,wherein the anti-cancer drug is vinblastine/Velban (Eli Lilly)
 108. Thekit according to any of claims 1 and 2, wherein the anti-cancer drug isvincristine/Oncovin (Eli Lilly)
 109. The kit according to any of claims1 and 2, wherein the anti-cancer drug is vinorelbine/Navelbine(GlaxoSmithKline), such as for the treatment or prophylaxis of non-smallcell lung cancer, such as unresectable, advanced non-small cell lungcancer.
 110. The kit according to any of claims 1 and 2, wherein theanti-cancer drug is zoledronate/Zometa (Novartis), such as for thetreatment or prophylaxis of multiple myeloma or patients with documentedbone metastases from solid tumours.
 111. The kit according to any ofclaims 1 to 110, wherein the Basidiomycete bioactive agent is selectedfrom the group consisting of: agents comprising or consisting of anoligosaccharide, agents comprising or consisting of a polysaccharide,agents comprising or consisting of an optionally glycosylated peptide,agents comprising or consisting of an optionally glycosylatedpolypeptide, agents comprising or consisting of an oligonucleotide,agents comprising or consisting of a polynucleotide, agents comprisingor consisting of a lipid, agents comprising or consisting of a fattyacid, agents comprising or consisting of a fatty acid ester and agentscomprising or consisting of secondary metabolites.
 112. The kitaccording to any of claims 1 to 111, wherein the bioactive agent isselected from the group consisting of: an oligosaccharide, apolysaccharide and an optionally glycosylated polypeptide.
 113. The kitaccording to any of claims 1 to 111, wherein the bioactive agent is apolysaccharide.
 114. The kit according to any of claims 1 to 111,wherein the bioactive agent is an oligosaccharide.
 115. The kitaccording to any of claims 1 to 111, wherein the bioactive agent is anoptionally glycosylated polypeptide.
 116. The kit according any ofclaims 1 to 111, wherein the polysaccharide is a homopolymer.
 117. Thekit according any of claims 1 to 111, wherein the polysaccharide is aheteropolymer.
 118. The kit according any of claims 1 to 117, whereinthe Basidiomycete bioactive agent is an Agaricus bioactive agent is fromany of the following: A. blazei, A. blazei Murill, A. bisporus, A.hortensis, A. campestris.
 119. The kit according to any of claims 1 to117, wherein the Agaricus bioactive agent is from A. blazei, preferablyblazei Murill.
 120. The kit according to any of claims 1 to 117, whereinthe Agaricus bioactive agent is from A. bisporus.
 121. The kit accordingto any of claims 1 to 117, wherein the Agaricus bioactive agent is fromA. hortensis.
 122. The kit according to any of claims 1 to 117, whereinthe Agaricus bioactive agent is from A. campestris.
 123. The kitaccording to any of the preceding claims, wherein the Agaricus bioactiveagent comprises or consists of an optionally glycosylated peptide. 124.The kit according to any of claims 1 to 122, wherein the Agaricusbioactive agent comprises or consists of a polypeptide.
 125. The kitaccording to any of claims 1 to 122, wherein the Agaricus bioactiveagent comprises or consists of an oligonucleotide.
 126. The kitaccording to any of claims 1 to 122, wherein the Agaricus bioactiveagent comprises or consists of a polynucleotide.
 127. The kit accordingto any of claims 1 to 122, wherein the Agaricus bioactive agentcomprises or consists of a lipid.
 128. The kit according to any ofclaims 1 to 122, wherein the Agaricus bioactive agent comprises orconsists of a fatty acid.
 129. The kit according to any of claims 1 to122, wherein the Agaricus bioactive agent comprises or consists of fattyacid esters.
 130. The kit according to any of claims 1 to 122, whereinthe Agaricus bioactive agent comprises or consists of secondarymetabolite(s), such as steroids, shikimic acids, alkaloids andbenzodiazepins.
 131. The kit according to any of claims 1 to 122,wherein the Agaricus bioactive agent comprises or consists of at leastone steroid.
 132. The kit according to claim 119, wherein the Agaricusbioactive agent comprises or consists of the (1-4)-alpha D glucan and/or(1-6)-beta-D-glucan described by Fujimiya et al., (“Selective Tumoricialeffect of soluble proteoglucan extracted from the basidiomycete,Agaricus blazei Murill, mediated via natural killer cell activation andapoptosis, Cancer Immunol Immunother (1998) 46: 147-159)
 133. The kitaccording to claim 119, wherein the Agaricus bioactive agent comprisesor consists of the soluble beta-(1-6)-glucans described by Fujimiya etal., (“Peroral effect on tumour progression of solublebeta-(1,6)-glucans prepared by acid treatment from Agaricus blazei. Murr(Agaricaceae, Higher basidiomycetes), International Journal of MedicinalMushrooms 2, 43-49).
 134. The kit according to any of claims 1 to 117,wherein the Agaricus bioactive agent comprises or consists of any of thefollowing compounds described by Smith et al., (“Medicinal mushrooms:their therapeutic properties and current medical usage with specialemphasis on cancer treatments.”, downloadable fromhttp://sci.cancerresearchuk.org/labs/med_mush/med_mush.html): FI₁-a-beta(beta-glucan from the fruiting body), FIII2-beta (beta glucan-proteinfrom the fruiting body), FA-1a-beta (hetero-beta glucan from thefruiting body), FA-2b-beta (RNA from the fruiting body), FV-1 (insolublebeta-glucan from the fruiting body), ATOM (glucomannan-protein, isolatedfrom submerged cultured mycelial biomass), AB-FP (mannan protein,isolated from the liquid cultured broth), Beta (1-6)-D-glucan.
 135. Thekit according to claim 119, wherein the Agaricus bioactive agentcomprises or consists of the beta-(1-6)-D: -glucan described byKobayashi et al., (“Suppressing effects of daily oral supplementation ofbeta-glucan extracted from Agaricus blazei Murill on spontaneous andperitoneal disseminated metastasis in mouse model”, J Cancer Res ClinOncol. 2005 May 10).
 136. The kit according to claim 119, wherein theAgaricus bioactive agent comprises or consists of the HM3-G (molecularmass 380 kDa), mainly (1-4)-alpha D glucan with (1-6)-beta branching,described by Fujimiya et al., (“Selective Tumoricial effect of solubleproteoglucan extracted from the basidiomycete, Agaricus blazei Murill,mediated via natural killer cell activation and apoptosis, CancerImmunol Immunother (1998) 46: 147-159).
 137. The kit according to claim119, wherein the Agaricus bioactive agent comprises or consists ofGlucomannan with a main chain of beta-1,2-linked D-mannopyranosylresidues and beta-D-glucopyranosyl-3-O-beta-D-glucopyranosyl residues asa side chain described by Mizuno et al. (“Anti-tumor polysaccharide fromthe mycelium of liquid-cultured Agaricus blazei mill”, Biochem Mol BiolInt. 1999 April; 47(4):707-14).
 138. The kit according to claim 119,wherein the Agaricus bioactive agent comprises or consists of thepolysaccharide fraction prepared using cold or hot NaOH extractiondescribed by Ohno et al., (Antitumor beta glucan from the cultured fruitbody of Agaricus blazei. Biol Pharm Bull. 2001 July; 24(7):820-8). 139.The kit according to claim 119, wherein the Agaricus bioactive agentcomprises or consists of the Glucomannan with a main chain ofbeta-1,2-linked D-mannopyranosyl residues andbeta-D-glucopyranosyl-3-O-beta-D-glucopyranosyl residues as a side chaindescribed by Mizuno et al. (“Anti-tumor polysaccharide from the myceliumof liquid-cultured Agaricus blazei mill”, Biochem Mol Biol Int. 1999April; 47(4):707-14).
 140. The kit according to claim 119, wherein theAgaricus bioactive agent comprises or consists of thealpha-1,4-glucan-beta-1,6-glucan complex with an average molecularweight of 20 kDa described by Fujimiya et al., (Tumor-specific cytocidaland immunopotentiating effects of relatively low molecular weightproducts derived from the basidiomycete, Agaricus blazei Murill.Anticancer Res. 1999 January-February; 19(1A):113-8)
 141. The kitaccording to claim 119, wherein the Agaricus bioactive agent comprisesor consists of the complex of alpha-1,6- and alpha-1,4-glucan describedby Mizuno et al., (Polysaccharides from Agaricus blazei stimulatelymphocyte T-cell subsets in mice. Biosci Biotechnol Biochem. 1998March; 62(3):434-7).
 142. The kit according to claim 119, wherein theAgaricus bioactive agent comprises or consists of the ergosteroldescribed by Takaku et al., (Isolation of an antitumor compound fromAgaricus blazei Murill and its mechanism of action. J Nutr. 2001 May;131(5):1409-13).
 143. The kit according to claim 119, wherein theAgaricus bioactive agent comprises or consists of ATOM(glucomannan-protein, isolated from submerged cultured mycelial biomass)described by Ito et al., “Antitumour effects of a newpolysaccharide-protein complex (ATOM) prepared from Agaricus blazei(Iwade strain 101) “Himematsutake” and its mechanisms in tumor-bearingmice”, Anticancer research 17:277-284 (1997).
 144. The kit according toclaim 119, wherein the Agaricus bioactive agent comprises or consists ofthe FIII-2-b ((1-6)-beta-D-glucan complex) described by Kawagishi et al.(“Formolysis of a potent antitumor (1-6)-beta-D-glucan-protein complexfrom Agaricus blazei fruiting bodies and antitumor activity of theresulting products. Carbohydr polymers 12:393-403, 1990).
 145. The kitaccording to claim 119, wherein the Agaricus bioactive agent comprisesor consists of the Isoflavone-beta-D-glucan, produced by culturingAgaricus blazei mycelia in isoflavone-containing liquid medium describedin US2005069989.
 146. The kit according to claim 119, wherein theAgaricus bioactive agent comprises or consists of the Glucomannan havinga mannose chain of −1, −2 bonds as its primary chain described in JP11080206.
 147. The kit according to claim 119, wherein the Agaricusbioactive agent comprises or consists of the polysaccharide described byFan et al., “Production of polysaccharide by culinary-medicinal mushroomAgaricus brasiliensis S Wasser et al. LPB 03 (Agaricomycetideae) insubmerged fermentation and its antitumor effect”, International Journalof Medicinal Mushrooms 2003), 5(1), 17-23.
 148. The kit according toclaim 119, wherein the Agaricus bioactive agent comprises or consists ofthe Linoleic acid; and/or 13-hydroxy cis-9, trans-11-octadecadienoicacid (13ZE-LOH) described in “Fruit body of a basidiomyceteAgaricus-Blazei”, Yakugaku Zasshi-Journal of the Pharmaceutical Societyof Japan
 1994. 149. The kit according to claim 119, wherein the Agaricusbioactive agent comprises or consists of the Ab-FP described by Liu etal., (“Fractionation of extracellular polysaccharide from Agaricusblazei murill and its antitumor activity”, Shipin Yu Fajiao Gongye(2001), 27(11), 27-29).
 150. The kit according to claim 119, wherein theAgaricus bioactive agent comprises or consists of the Glucan-proteincomplex described by Gonzaga et al., (“Isolation and characterisation ofpolysaccharides from Agaricus blazei Murill”, Carbohydrate polymers2005, Vol. 60, Iss 1, p 43-49).
 151. The kit according to claim 119,wherein the Agaricus bioactive agent comprises or consists of the Ap-MP(water-soluble mycelia polysaccharide) described by Liu et al., “Studyon antitumor activity of Agaricus blazei”.
 152. The kit according toclaim 119, wherein the Agaricus bioactive agent comprises or consists ofthe 1SY16 described by Lee et al. (“1SY16 isolated from Agaricus blazeiMurill K as a potent multipotential chemopreventative agent”, CancerEpidemiology Biomarkers and Prevention 2004, Vol 13, Iss 11, p 1861S).153. The kit according to claim 119, wherein the Agaricus bioactiveagent comprises or consists of the Sodium pyroglutamate described byKimura et al. (“Isolation of an anti-angiogenic substance from Agaricusblazei Murill: Its antitumor and antimetastatic actions”, Cancer Science2004, Vol 95, Iss 9, p758-764)
 154. The kit according to claim 119,wherein the Agaricus bioactive agent comprises or consists of theBlazeispirane derivatives described by Hirotani et al., (“Blazeispiraneand protoblazeispirane derivatives from the cultured mycelia of thefungus Agaricus blazei”, Phytochemistry 2002, Vol. 61, Iss 5, p589-595).
 155. The kit according to any of claims 1-119, wherein theAgaricus bioactive agent comprises or consists of any of thebasidiolipids BI-1, BI-2, BI-3 or BI-4 as described by Jennemann et al.,“Novel glycoinositolphosphosphingolipds, basidiolipds, from Agaricus”,Eur. J. Biochem. 259, 331-338 (1999).
 156. The kit according to any ofthe preceding claims, wherein the bioactive agent stimulates the immunesystem of an animal or a human when administered to said animal or humanin a pharmaceutically active amount.
 157. The kit according to claim156, wherein the immune stimulating agent is capable of stimulating inan individual in need of such stimulation, the production of one or moreof antibodies, such as IgG, IgA, and IgE, T helper cells, interleukins,such as IL-1 and IL-2, interferon, such as IFN-gamma, natural killercells, and macrophages.
 158. The kit according to any of the precedingclaims, wherein the bioactive agent is precipitated by alcoholprecipitation.
 159. The kit according to any of the preceding claims,wherein the bioactive agent is precipitated by ultracentrifugation. 160.The kit according to any of the preceding claims, wherein the bioactiveagent is size fractionated prior to precipitation or centrifugation.161. The kit according to any of the preceding claims, wherein thebioactive agent is further purified by one or more steps involvingwashing, desalting, size fractionation, and affinity chromatography,such as ion-exchange chromatography.
 162. The kit according to any ofthe preceding claims, wherein the bioactive agent is further purified bywashing and ion-exchange chromatography.
 163. The kit according to anyof the preceding claims, wherein the precipitated immune stimulatingagent is further purified by size exclusion chromatography or gelfiltration.
 164. The kit according to any of the preceding claims,wherein the bioactive agent is extracellularly located and can beisolated from the liquid growth medium and optionally is also producedintracellularly in said Basidiomycete sp.
 165. The kit according to allyof the preceding claims, wherein the bioactive agent is extracellularlylocated and immunologically distinct from an intracellularly producedbioactive variant of the agent having the same activity.
 166. The kitaccording to any of the preceding claims, wherein the liquid growthmedium comprises one or more of malt extract, yeast extract, peptone,glucose, sucrose, salts providing phosphate, magnesium and potassium,corn-steep liquor and vitamins, such as thiamine.
 167. The kit accordingto any of the preceding claims, wherein the Basidiomycete sp. is grownin a liquid growth medium comprising malt extract, yeast extract,peptone, and glucose.
 168. The kit according to any of the precedingclaims, wherein the Basidiomycete sp. is grown in a liquid growth mediumwhich is agitated and supplied with an oxygen source.
 169. The kitaccording to any of the preceding claims, wherein the Basidiomycete sp.is grown at a temperature in the range of from 23° C. to 32° C.
 170. Thekit according to any of the preceding claims, wherein Basidiomycete sp.mycelium is removed from the liquid growth medium prior to the isolationof the immune stimulating agent.
 171. The kit according to any of thepreceding claims, wherein the fungal mycelium is removed from theinitial culture by filtration or centrifugation.
 172. The kit accordingto any of the preceding claims, wherein said anti-cancer medicament issuitable for administration simultaneously with the administration ofthe bioactive agent, such as in a co-formulation.
 173. The kit accordingto any of the preceding claims, wherein said anti-cancer medicament andthe bioactive agent are suitable for sequential administration, in anyorder, such as first the bioactive agent and then the anti-cancermedicament.
 174. The kit according to any of the preceding claims,wherein said medicament and/or agent are suitable for subcutaneousadministrationn.
 175. The kit according to any of the preceding claims,wherein said medicament and/or agent are administered nasally.
 176. Thekit according to any of the preceding claims, wherein said medicamentand/or agent are suitable for administration via the pulmonary route,such as via aerosol administration.
 177. The kit according to any of thepreceding claims, wherein said medicament and/or agent are suitable foradministration via the parenteral route.
 178. The kit according to anyof the preceding claims, wherein said medicament and/or agent aresuitable for oral administration.
 179. The kit according to any of thepreceding claims, wherein said medicament and/or agent are suitable fortopical administration.
 180. The kit according to any of the precedingclaims, wherein said medicament and/or agent are co-formulated in acomposition.
 181. Use of an anti-cancer medicament and an Basidiomycetesp. bioactive agent for the manufacture of a kit of parts suitable foradministration to an individual in need thereof.
 182. The use accordingto claim 181, wherein the individual is a mammal, such as a human being.183. The use according to any of claims 181-182, wherein said individualis immunocompromised.
 184. The use according to any of claims 181-183,wherein said individual is elderly, such as 60-120 years old, forexample 70-120 years old, such as 80-120 years old, for instance 90-120years old
 185. The use according to any of claims 181-183, wherein saidindividual is 20-60 years old, such as 30-50 years old.
 186. The useaccording to any of claims 156-183, wherein said individual is a child,such as from 0-20 years old, for example 0-15 years old, such as 0-10years old, for example 0-5 years old, such as 0-1 years old, such as anewborn child less than 2 months old.
 187. The use according to any ofclaims 181-186, wherein said neoplastic disease is benign.
 188. The useaccording to any of claims 181-187, wherein said neoplastic disease ismetastatic.
 189. The use according to any of claims 181-188, whereinsaid neoplastic disease is stage 3-4 metastatic disease.
 190. The useaccording to any of claims 81-189, wherein said neoplastic disease isselected from the group consisting of: Acute Lymphoblastic Leukemia,Acute Myeloid Leukemia, Adrenocortical Carcinoma, AIDS-Related Cancers,AIDS-Related Lymphoma, Anal Cancer, Astrocytoma (e.g. ChildhoodCerebellar or Childhood Cerebral), Basal Cell Carcinoma, ExtrahepaticBile Duct Cancer, Bladder Cancer, Bone Cancer, Osteosarcoma/MalignantFibrous Histiocytoma, Brain Stem Glioma, Brain Tumor, Breast Cancer,Male Breast Cancer, Bronchial Adenomas/Carcinoids, Burkitt's Lymphoma,Carcinoid Tumor, Carcinoma of Unknown Primary, Primary Central NervousSystem Lymphoma, Cerebral Astrocytoma/Malignant Glioma, Cervical Cancer,Childhood Cancers, Chronic Lymphocytic Leukemia, Chronic MyelogenousLeukemia, Chronic Myeloproliferative Disorders, Colon Cancer, CutaneousT-Cell Lymphoma, Endometrial Cancer, Ependymoma (such as ChildhoodEpdndymoma), Esophageal Cancer, Ewing's Family of Tumors, ExtracranialGerm Cell Tumor (such as Childhood Extracranial Germ Cell Tumor),Extragonadal Germ Cell Tumor, Eye Cancer (Intraocular Melanoma orRetinoblastoma), Gallbladder Cancer, Gastric (Stomach) Cancer,Gastrointestinal Carcinoid Tumor, Gestational Trophoblastic Tumor,Glioma, Hairy Cell Leukemia, Head and Neck Cancer, Hepatocellular(Liver) Cancer, Hodgkin's Lymphoma, Hypopharyngeal Cancer, Hypothalamicand Visual Pathway Glioma (such as Childhood Hypothalamic and VisualPathway Glioma), Intraocular Melanoma, Islet Cell Carcinoma (EndocrinePancreas), Kaposi's Sarcoma, Kidney (Renal Cell) Cancer, LaryngealCancer, Lip and Oral Cavity Cancer, Lung Cancer (Non-Small Cell or SmallCell), Lymphoma (such as AIDS-Related Lymphoma, Burkitt's Lymphoma,Cutaneous T-Cell Lymphoma, Non-Hodgkin's Lymphoma), Macroglobulinemia(such as Waldenstrom's Macroglobulinemia), Malignant FibrousHistiocytoma of Bone/Osteosarcoma, Medulloblastoma (such as ChildhoodMedulloblastoma), Melanoma, Merkel Cell Carcinoma, Mesothelioma (such asAdult Malignant Mesothelioma or childhood Mesothelioma), MetastaticSquamous Neck Cancer with Occult Primary, Multiple Endocrine NeoplasiaSyndrome (such as occurring in childhood), Multiple Myeloma/Plasma CellNeoplasm, Mycosis Fungoides, Myelodysplastic Syndromes,Myelodysplastic/Myeloproliferative Diseases, Myeloma (such as MultipleMyeloma), Chronic myeloproliferative disorders, Nasal Cavity andParanasal Sinus Cancer, Nasopharyngeal Cancer, Nasopharyngeal Cancer(such as Childhood Nasopharyngeal Cancer), Neuroblastoma, OropharyngealCancer, Osteosarcoma/Malignant Fibrous Histiocytoma of Bone, OvarianCancer (such as Childhood Ovarian Cancer), Ovarian Epithelial Cancer,Ovarian Germ Cell Tumor, Ovarian Low Malignant Potential Tumor,Pancreatic Cancer, Pancreatic Cancer, Paranasal Sinus and Nasal CavityCancer, Parathyroid Cancer, Penile Cancer, Pheochromocytoma,Pineoblastoma and Supratentorial Primitive Neuroectodermal Tumors,Pituitary Tumor, Pleuropulmonary Blastoma, Prostate Cancer, Renal Pelvisand Ureter Transitional Cell Cancer, Retinoblastoma, Rhabdomyosarcoma(such as Childhood Rhabdomyosarcoma), Salivary Gland Cancer, Adult-onsetsoft tissue Sarcoma, Soft Tissue Sarcoma (such as Childhood Soft TissueSarcoma), uterine Sarcoma, Sezary Syndrome, Skin Cancer (such asnon-Melanoma skin cancer), Merkel Cell Skin Carcinoma, Small IntestineCancer, Supratentorial Primitive Neuroectodermal Tumors (such asoccurring in Childhood), Cutaneous T-Cell Lymphoma, Testicular Cancer,Thymoma and Thymic Carcinoma, Thyroid Cancer, Transitional Cell Cancerof the Renal Pelvis and Ureter, Trophoblastic Tumor (such as GestationalTrophoblastic Tumor), Urethral Cancer, Endometrial uterine cancer,Uterine Sarcoma, Vaginal Cancer, Visual Pathway and Hypothalamic Glioma(such as Childhood Visual Pathway and Hypothalamic Glioma),Waldenström's Macroglobulinemia or Wilms' Tumor.
 191. The use accordingto any of claims 181-190, wherein said Basidiomycete sp. bioactive agentis administered in a dosage from about 0.001 to about 100 mg/kg.
 192. Amethod for the treatment of a neoplastic disease in an individual, saidmethod comprising the steps of a. providing the kit of parts accordingto any of claims 1 to 180, and b. administering the anti-cancermedicament and a Basidiomycete sp. bioactive agent to said individual.193. The method according to claim 192, comprising any of the aspectsspecified in claims 1-191.
 194. A method for enhancing the therapeuticeffect of an anti-cancer drug, comprising co-administering with saidanti-cancer drug a Basidiomycete sp. bioactive agent.
 195. The methodaccording to claim 194, comprising any of the aspects specified inclaims 1-191.